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Increasing pre-clinical evidence supports a role of neuronal-immune interactions in chronic 
pain. Here, we investigated the involvement of G-protein receptor 84 (GPR84), an immune 
cell receptor that is markedly induced in monocytes/macrophages and microglia under 
inflammatory conditions, in chronic pain signalling.  
 
GPR84 knock-out (KO) mice exhibited normal acute pain thresholds but showed deficits in 
neuropathic and inflammatory pain responses. Thus, in contrast to wild-type (WT) mice, 
KOs did not develop mechanical allodynia or thermal hyperalgesia subsequent to partial 
sciatic nerve ligation (PNL) and exhibited attenuated mechanical, thermal and cold 
hyperalgesia after intraplantar injection of complete Freund’s adjuvant (CFA). Nerve injury 
or inflammation also resulted in increased Iba1 and phosphorylated p38 mitogen-activated 
protein kinase (MAPK) immunoreactivity in spinal microglia, as well as increased Iba1 
expression in macrophages of the sciatic nerve post PNL, with no difference between 
genotypes. 
 
In WT mice, GPR84 mRNA expression was up-regulated in the spinal cord and sciatic nerve 
at 7 and 21 days post PNL, as well as in microglia or macrophage cultures at 3 hours post 
lipopolysaccharide (LPS) stimulation. Concurrent with these changes, we identified 86 
dysregulated genes in the sciatic nerve and spinal cord following injury and 30 dysregulated 
mediators in macrophages following treatment. Interestingly, expression of arginase-1 
(ARG1), a marker for anti-inflammatory macrophages, was considerably up-regulated by 
20.8-fold in KO sciatic nerve at 7 days post PNL. In addition, forskolin-induced levels of 3'-
5'-cyclic adenosine monophosphate (cAMP) were greater in KO than WT macrophages. 
Together these data are indicative of an anti-inflammatory macrophage phenotype in KO 
mice under pathological conditions.  
 
We suggest that GPR84 is a pro-inflammatory receptor involved in nociceptive signalling in 
animal models of persistent pain, possibly mediating its effects via the modulation of 
peripheral macrophages. Based on these results GPR84 may be a promising new target with 
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HIV - Human immunodeficiency virus 
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HSP - Heat shock protein 
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IASP - International Association for the Study of 
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Iba1 - Ionised calcium binding adaptor molecule 1  
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IFN - Interferon 
IKK - Kinase complex  
IL - Interleukin 
IL-1ra - Interleukin-1 receptor antagonist 
iNOS - Inducible nitric oxide synthase  
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IP3 - Inositol 1, 4, 5-triphosphate 
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IRAK4 - IL-1 receptor-associated kinase 4  
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KO - Knock-out 
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MKK - MAPK kinase 
MMP - Matrix metalloproteinase  
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MS - Multiple sclerosis 
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MyD88 - Myeloid differentiation primary 
response gene 88  
 
Na+ - sodium  
NADPH - Nicotinamide adenine dinucleotide 
phosphate  
NCX - Sodium/calcium exchanger 
ND - Non-detectable 
NeuN - Neuronal nuclei  
NF200 - Neurofilament 200  
NF-κB - Nuclear factor kappa-light-chain-
enhancer of activated B cell 
NGF - Neurotrophin growth factor 
NK1 - Neurokinin 1 
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PAMP - Pathogen associated molecular pattern 
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PG - Prostaglandin 
PGE2 - prostaglandin E2 
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PUFA - polyunsaturated 
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RA - rheumatoid arthritis  
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TXA2 - Thromboxane 
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1.1 The clinical problem of chronic pain 
 
The nervous system is a specialised network of cells that integrates sensory information 
from an organism’s internal and external environment and coordinates an appropriate 
response. The sensation of pain is mediated by a complex system of neuronal activity, 
providing a protective mechanism against potential tissue injury and facilitating the process 
of healing in the event of damage. According to the International Association for the Study of 
Pain (IASP), pain is defined as ‘an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage, or described in terms of such damage’. The 
importance of pain as a survival mechanism is particularly evident when considering 
individuals born with genetic abnormalities that affect the normal function of this system. 
For example, congenital insensitivity to pain is a rare disorder characterised by the inability 
to detect and thus respond to a painful stimulus. It can be caused by mutations in the 
tropomyosin receptor kinase A (TrkA) gene, which render the encoded neurotrophin 
growth factor (NGF) receptor unresponsive to NGF (Pezet and McMahon, 2006), or by 
mutations in the SCN9A gene encoding the α-subunit of the voltage-gated sodium (Na+) 
channel, Nav1.7 (Cox et al., 2006). As a result these individuals tend to have extensive burns, 
bruises and lacerations, particularly during childhood, and often die prematurely from 
repetitive illness (Verpoorten et al., 2006). 
 
On the other hand, when pain becomes maladaptive and outlasts healing of the underlying 
tissue damage it surpasses its usefulness as a protective mechanism. Such pain chronicity 
may be broadly classified into three categories: pain caused by tissue disease or damage 
(inflammatory pain), pain owing to disease or damage of the somatosensory system 
(neuropathic pain) and the coexistence of the former two (mixed pain) (Baron et al., 2010). 
Currently chronic pain is a major public health concern, impacting on millions of people 
with epidemiological studies reporting a prevalence of 7-8% in the European population 
(Bouhassira et al., 2008). Symptoms of chronic pain are severely debilitating and inflict 
considerable personal suffering in relation to ensuing co-morbidities such as insomnia, 
depression and social isolation. In one study it was reported that around 60% of patients 
were less able or unable to work and that 20% had lost their jobs as a result of their medical 
condition (Breivik et al., 2006). In Europe it is estimated that chronic pain results in 
enormous socioeconomic costs in lost productivity that amounts to 1.5% of the total gross 
domestic product (Phillips, 2006). 
 





Many patients report a lack of satisfaction with currently available pain treatments, with 
less than 50% experiencing effective pain relief and 64% reporting that their treatment 
inadequately controls their pain (Breivik et al., 2006). Furthermore, many prescription 
drugs require long-term use due to a lack of disease-modifying capabilities and as a result 
are accompanied by adverse and intolerable side effects. Despite the increase in the number 
of clinical trials, many drugs have failed to show efficacy, most likely due to the underlying 
heterogeneity of chronic pain and the complex contribution of psychological and emotional 
factors. This poor prognosis indicates the continuing challenge of chronic pain and the need 
for better understanding of its pathology. In addition, the implementation of ‘tailor-made’ 
therapeutic approaches where specific drugs are targeted at particular groups of patients 
may provide a promising approach towards the development of safer and more effective 
treatments (Baron et al., 2010). 
 
For a long time non-steroidal anti-inflammatory drugs (NSAIDs), weak opioids, 
anticonvulsants and anti-depressants have been the mainstay of conventional chronic pain 
treatment. NSAIDs such as aspirin, ibruprofen and the related compound, paracetamol, are 
amongst the most widely used, with more than 50 types currently available on the market. 
NSAIDs generally provide pain relief and alleviation of swelling in chronic inflammatory 
joint diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA) as well as in acute 
inflammatory conditions such as fractures and soft tissue damage. The primary mode of 
action of this class of drugs is inhibition of cyclooxygenase (COX) enzymes and resultant 
reductions in the synthesis of prostaglandins (PGs), which are nociceptor sensitisors 
(Ferreira, 1980). Most NSAIDs share similar anti-inflammatory, analgesic and antipyretic 
effects and thus also tend to induce similar adverse reactions typically involving irritation of 
the gastric system.  
 
Opioids are currently commonly used analgesics by chronic pain patients due to their 
proven efficacy in several types of peripheral and central neuropathic pain disorders 
(Dworkin et al., 2010). Opioids such as morphine, oxycodone, methadone, levorphanol and 
tramadol exert their effects at pre- and post-synaptic μ-opioid receptors. Oxycodone also 
antagonises the κ-receptor and tramadol inhibits the uptake of monoamines (Baron et al., 
2010). The downstream effect of opioids is the closure of voltage-gated calcium (Ca2+) 
channels (VGCCs) and the opening of potassium (K+) channels, resulting in reduced neuronal 
excitability and neurotransmission. Although opioids are amongst the most effective 
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analgesics available, they are associated with many adverse side effects including 
constipation, nausea and sedation. Furthermore, there are still major concerns related to 
long-term use, such as misuse and addiction as well as complications such as immunologic 
changes, hypogonadism and opioid-associated hyperalgesia. Therefore, routine use of this 
class of drugs is strongly discouraged except in exceptional circumstances where immediate 
pain relief is necessary (O'Connor and Dworkin, 2009). For example, patients who are 
waiting upon first-line medications or have acute neuropathic pain symptoms or patients 
with chronic neuropathic pain suffering from bouts of exacerbated pain symptoms will be 
treated with opioids.  
 
The anticonvulsants gabapentin and pregabalin, are routinely used for treating neuropathic 
pain, both of which act by binding to the α2-δ1 subunit of T-type Ca2+ channels on primary 
afferent nociceptors and in CNS neurons. This consequently reduces the release of 
excitatory neurotransmitters including glutamate and substance P (SP). These drugs are 
well characterised in animal models of chronic pain and have exhibited efficacy in several 
clinical trials across various peripheral and central neuropathic pain conditions. However 
pregabalin has failed to relieve HIV neuropathy and there is no conclusive evidence for 
superior efficacy of either of these α2-δ1 binding agents (Finnerup et al., 2010). Gabapentin 
was originally developed for the treatment of epilepsy and designed as a blood brain 
barrier–penetrating γ-aminobutyric acid (GABA) analogue, but was later found to also be an 
effective analgesic. Both gabapentin and pregabalin have moderate drug interactions but 
patients do exhibit some side-effects such as sedation, dizziness and peripheral oedma 
(Baron et al., 2010; Dworkin et al., 2010). 
 
Anti-depressant drugs such as the tricyclic antidepressants (TCAs; amitriptyline, 
desipramine, nortriptyline) and selective serotonin and norepinephrine reuptake inhibitors 
(SSNRIs; duloxetine, venlafaxine) constitute first-line treatments for neuropathic pain 
patients. TCAs have demonstrated efficacy in central pain but amitriptyline was ineffective 
in patients with HIV or chemotherapy-induced neuropathies. Duloxetine and venlafaxine are 
particularly efficacious in painful poly-neuropathy, however, in a single study venlafaxine 
failed to relieve neuropathic pain of various aetiologies (Finnerup et al., 2010). Generally, 
their mode of action involves the inhibition of serotonin and norepinephrine uptake by 
monoaminergic nerve terminals, leading to increased extracellular concentrations of these 
transmitters. Besides providing pain relief, the anti-depressant effect is an additional benefit 
for patients who frequently suffer from chronic pain-associated depression. Like opioids, 
antidepressants have demonstrated efficacy in various types of neuropathic pain disorders 
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but also elicit a number of unwanted side effects, such as mouth dryness, blurred vision, 
constipation and urinary retention (Dworkin et al., 2010).  
 
Patients with postherpetic neuralgia or focal neuropathy who require localised peripheral 
pain relief can be treated with topical application of 5% lidocaine (non-specific Na+ channel 
blocker) in a patch or gel form. The lidocaine patch is recommended as a first-line drug 
treatment for such patients based on three published positive trials. Besides providing 
satisfactory pain relief in these cases, another advantage of this treatment is the minimal 
adverse side effects (erythema or rash) due to limited systemic absorption. Furthermore, 
since the risk of neuropathic pain is greater in the increasingly aging population, the use of 
topical drugs with fewer side effects is well suited for this group of patients. However, two 
trials have failed to demonstrate efficacy of the lidocaine patch/cream in patients with 
peripheral nerve injury or mixed neuropathic pain. Therefore results for this treatment 
option in placebo-controlled trials remain conflicting (Finnerup et al., 2010). 
 
Meta-analysis studies and systematic reviews are particularly informative for comparing the 
efficacy and safety of compounds used for different neuropathic pain conditions. Here, 
measurements such as numbers needed to treat (NNT) or numbers needed to harm (NNH) 
can be used in conjunction with the National Institute for Health and Care Excellence 
guidelines to provide appropriate treatment recommendations for individual patients. 
Whilst NNT is the number of patients treated with a drug until one experiences 50% pain 
relief, NNH is the number of patients needed to treat until one drops out as a result of 
adversive effects. Table 1 summarises combined NNT and NNH values across different 
neuropathic conditions. However, one must consider that such head-to-head comparisons 
can be misleading due to the heterogeneity of the studies involved (e.g. different drug doses, 
study design and placebo responses). Likewise, adverse side effects differ in severity and 
relevance, depending on a patient’s condition and dropout rates may also be influenced by 
trial duration. Therefore NNH values do not necessarily provide a definitive measure of 
long-term side effects (Finnerup et al., 2010).  
 
 





Table 1.1: Combined NNT and NNH for different classes of drugs commonly used for the 
treatment of several types of neuropathic pain conditions 
 
The data presented here is from a systematic review of 174 randomized, double-blind, placebo 
controlled trials showing combined NNT and NNH values for drugs used for neuropathic pain 
treatment (95% confidence interval). Ns, relative risk not significant (Finnerup et al., 2010). 
 
Besides the aforemented drug classes that are commonly used for various neuropathic pain 
conditions, in many acute and chronic inflammatory diseases such as RA, irritable bowel 
syndrome (IBS), multiple sclerosis (MS) and psoriasis, natural and synthetic glucocorticoids 
are at the forefront of available therapies. The anti-inflammatory and immunosuppressive 
actions of these drugs are mainly attributed to the suppression of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) mediated transcription of pro-
inflammatory chemokines/cytokines in leukocytes (Coutinho and Chapman, 2011). 
However, their excellent clinical efficacy is compromised by serious metabolic side effects 
associated with long term use.  
 
Although a diverse range of pharmacological treatments are available for a number of 





















Gabapentin 6.4 4.3 32.5









Opioids 2.6 2.6 5.1 2.1 17.1
Tramadol 4.9 4.8 13.3
Various
Cannabinoids 3.4 8.3 ns
Topical lidocaine ns
NMDA antagonists 3.5 12.5
Topical/NGX capsaicin 11.0 3.2 6.5 11.5
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patient satisfaction. This suggests that pain management requires further improvement via 
the development of new drugs with better efficacy, tolerability and safety. Despite this 
pessimistic outlook, treatment strategies have profoundly changed over the years and are 
continuing to evolve. This is particularly illustrated by the great wealth of research over the 
past two decades on the contribution of the immune system and its multiple pro-
inflammatory mediators in nociceptive transmission, which has subsequently led to more 
recent biological therapies. These include receptor antagonists of the cytokines, interleukin 
(IL)-1β (Anakinra), tumor necrosis factor (TNF)-α (Etanercept) and IL-6 (Tocilizumab), 
which have proven to be particularly efficacious in patients with RA. However, as with all 
forms of treatment, biological inhibitors are associated with some side effects related to 
their immunosuppressive actions such as increased susceptibility to infections. Regardless 
of this, they are generally well tolerated and form a promising new approach as disease-
modifying agents from the conventional symptomatic relieving medications (Upchurch and 
Kay, 2012).  
 
1.3 Pain transmission 
 
1.3.1 Sensory neurons 
 
Over a century ago, Charles Sherrington proposed the existence of primary sensory neurons 
(nociceptors), which are activated by stimuli deemed as potentially tissue damaging 
(Sherrington, 1906). This view was later reinforced by Ed Perl, who postulated that pain is 
mediated by specialised high threshold nociceptive sensory neurons (Bessou and Perl, 
1969), in strong opposition to Patrick Wall’s and Ron Melzack’s argument for a central 
origin of pain (Melzack and Wall, 1965). Today, we recognise that nociceptors do indeed 
form a peripheral pathway for pain detection and that altered processing in the central 
nervous system (CNS) may contribute to hypersensitivity. 
 
Sensory neurons are located within the dorsal root ganglion (DRG) and originate from 
multipotent neural crest stem cells that delaminate from the neural tube during the third 
wave of neurogenesis. DRG neurons consists of four main functional components; the 
peripheral terminal which transduces external inputs via action potential generation; the 
axon whereby these action potentials are propagated; the soma which maintains neuronal 
function and integrity and the central terminals, which engage in synaptic communication 
with central post-synaptic neurons via the release of neurotransmitters across the synaptic 
cleft (Marmigere and Ernfors, 2007). 
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1.3.2 Anatomical and electrophysiological properties of sensory neurons 
 
There are three main classes of sensory neurons. The first class are the thinly myelinated, 
medium diameter Aδ-fibre afferents, some of which convey acute well-localised ‘fast/sharp’ 
pain, and coduct at a velocity of approximately 2.2-8 m/s in rats. The second class are the 
unmyelinated small diameter C-fibre afferents, which conduct poorly localised ‘slow/dull’ 
pain at a velocity of < 1.4 m/s (Harper and Lawson, 1985b, a). Due to their cutaneous 
innervation and role in mediating painful sensations, together these two classes have been 
historically termed as nociceptors and constitute 70% of all neuronal cell bodies in the DRG 
(Ralston et al., 1984). Aδ nociceptors may be further categorised into type I high threshold 
mechanical nociceptors, which respond to mechanical, chemical and high threshold thermal 
stimuli ( > 50C) and type II low thermal threshold / high mechanical threshold nociceptors 
(Basbaum et al., 2009). Similarly, C-fibres consist of a heterogenous population of polymodal 
afferents that include mechano-heat-responsive, heat-responsive, and mechanically 
insensitive ‘silent’ nociceptors that develop mechanical sensitivity subsequent to injury 
(Schmidt et al., 1995). Notably, some C-fibres respond to cooling or innocuous stroking and 
thus not all C-fibres are involved in mediating noxious stimuli (Olausson et al., 2008). Lastly, 
the thickly myelinated large diameter Aβ-fibre afferents rapidly conduct stimuli at 14-30 
m/s and belong to large DRG neurons (constituting approximately 12% of DRG neurons) 
(Harper and Lawson, 1985a). Under normal conditions these fibres are predominantly low-
threshold mechanoreceptors that are responsive to innocuous stimulation of the skin, 
muscle and joint. However, approximately 20% of A-fibre nociceptors appear to conduct 
within the Aβ- conduction velocity range, and may be referred to as the ‘Aβ-nociceptors’ 
(Djouhri and Lawson, 2004).  
 
1.3.3 Biochemical and molecular properties of sensory neurons 
 
Nociceptors have also been classified according to their neurochemical properties, which 
encompasses an extensive list of cell markers utilised for the study of these neurons. 
Immunohistochemical studies have revealed two large groups of C-fibre neurons. The 
peptidergic population makes up 40% of DRG neurons and characteristically contain the 
neuropeptides SP and calcitonin-gene related peptide (CGRP) and express TrkA receptors 
(McCarthy and Lawson, 1989; Averill et al., 1995; Lawson, 2002). The non-peptidergic 
population makes up 30% of DRG neurons and express the glial-derived neurotrophin 
factor (GDNF) sensitive receptors, receptor tyrosine kinase (RET) in complex with GDNF 
family receptor α1/α2. Many RET-positive neurons also bind Bandeiraea simplicifolia 
isolectin B4 (IB4) and express the ionotropic purinergic receptor, P2X3 as well as Mrg class 
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G-protein-coupled receptors (GPCRs) (Molliver et al., 1997; Bradbury et al., 1998; Snider 
and McMahon, 1998; Vulchanova et al., 1998; Bennett et al., 2000). Lastly, the Aβ-fibres can 
be immunohistochemically labelled for phosphorylated neurofilament 200 (NF200) and 
express both tyrosine kinase receptor B (TrkB) and tyrosine kinase receptor C (TrkC) 
receptors, which are responsive to the neurotrophins, brain derived neurotrophic factor 
(BDNF), neurotrophin (NT) -3, 4, 5, respectively (McMahon et al., 1994).   
 
In addition, molecular studies have identified selective expression of receptors and ion 
channels that are involved in the modulation of pain transmission in nociceptors (Basbaum 
et al., 2009). For example, most C-fibres express transient receptor potential (TRP) channels 
sensitive to thermal stimuli (TRPV1) (Caterina et al., 1997; Michael and Priestley, 1999) and 
Aδ-fibres express both TRPV1 and TRPV2 (Bridges et al., 2003). Differential expression of 
other ion channels such as those responding to cold stimuli (TRPM8) (Bautista et al., 2007) 
or chemical irritants (TRPA1) (Bautista et al., 2006) as well as the acid sensing ion channels 
(ASICs) can potentially be used to distinguish between sensory neuron sub-populations 
(Garcia-Anoveros et al., 2001; Julius and Basbaum, 2001).  
 
1.4  The dorsal horn of the spinal cord 
 
DRG neurons relay sensory information to the spinal cord where their primary afferent 
terminals synapse with second order dorsal horn neurons. Work pioneered by Bror Rexed 
in the cat led to the establishment of an organised system of 10 laminae, which constitute 
the grey matter of the spinal cord according to the size and packing density of neurons 
(Rexed, 1952). A majority of dorsal horn neurons (laminae I – VI) are interneurons that are 
confined to the spinal cord and innervate localised regions. Interneurons may be 
electrophysiologically or immunohistochemically classified as excitatory (glutamatergic) or 
inhibitory (GABA-ergic). Many inhibitory neurons may also express glycine suggesting that 
in some cases both GABA and glycine are co-released (Todd, 2010). The dorsal horn also 
contains ascending and descending projection neurons to and from supraspinal sites. 
Lamina I, also referred to as the marginal layer, is a thin cell layer that covers the top of the 
dorsal horn. This lamina has the greatest number of projection neurons in the dorsal horn 
but mainly consists of interneurons, 45% of which are positive for the SP receptor, 
neurokinin 1 (NK1) (Todd et al., 1998). The interneurons are smaller than the projection 
neurons and hence there is some variation in size and shape within this layer. Lamina II 
(substantia gelatinosa) is much wider than lamina I and is divided into two parts; lamina II 
inner (IIi) or outer (IIo). Lamina II consists of densely packed interneurons in the outer 
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region and together laminae I and II are collectively referred to as the superficial dorsal 
horn and are mainly targeted by nociceptive afferents (Light and Perl, 1979a, b). The 
neurons in this region respond to noxious input and many are electrophysiologically 
classified as nociceptor specific. Lamina III is densely packed with interneurons that are 
larger than the ones that constitute lamina II and the border between these laminae can be 
clearly identified by the characteristic presence of myelinated axons in lamina III.  Deeper 
laminae (III - VI) receive both innocuous and noxious input (Light and Perl, 1979a, b) and 
are thus electrophysiologically classified as wide dynamic range neurons (WDR), 
responding to a broad range of stimulus intensities. Lastly, laminae VII - IX comprise the 








Figure 1.1: Anatomical characterisation of primary afferent fibres, their DRG neurons and 
connections with the spinal cord 
 
Simplified schematic illustrating anatomical features of the three main classes of primary afferent 
sensory neurons. Thickly myelinated Aβ-fibres, with large neuronal cell bodies terminate in laminae 
III - V and also have some extensions into lamina II. Thinly myelinated Aδ-fibres with medium sized 
neuronal cell bodies aborize laminae I, IIo and V. A-fibres may be identified with the neurochemical 
marker NF200. Unmyelinated C-fibres with small sized neuronal cell bodies are further categorised 
as peptidergic (SP, CGRP) or non-peptidergic (IB4, P2X3) and terminate superficially in lamina I/IIo 
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The functional class of primary afferents determines their specific termination patterns. 
Cutaneous nociceptors (Aδ- and C-fibres) generally innervate laminae I and II. However, 
there are some subclass differences; for instance Aδ- nociceptors primarily terminate in 
lamina I, whilst Aδ- hair follicle afferents innervate the border region between lamina II and 
III (Light and Perl, 1979a). Likewise, non-peptidergic C-fibres terminate centrally in lamina 
IIi, whereas peptidergic heavily arborize laminae I and IIo. C-fibres may also 
polysynaptically innervate lamina III - V (Light and Perl, 1979a, b; Todd, 2010). Finally the 
Aβ-fibres, arborize laminae III - V but also have some extensions into lamina II (Light and 
Perl, 1979a). Termination patterns and neurochemical markers for the different sensory 
neuron classes is presented in Fig. 1.1.  
 
1.5 Supraspinal centres and pain 
 
Information regarding noxious stimuli is transmitted from the dorsal horn of the spinal cord 
along ascending neuronal pathways to higher centres located in the brain. These projection 
neurons are particularly concentrated in lamina I and dispersed throughout laminae III – VI 
(Todd, 2010). Retrograde and anterograde tracing approaches have been valuable in 
enhancing our understanding of neuronal networks between the spinal cord and the brain. 
Lamina I ascending pathways, also referred to as the spinoparabrachial tract, target 
supraspinal areas such as the periaqueductal grey matter (PAG), the parabrachial (PB) and 
nuclei of the thalamus. Eighty percent of these projection neurons are NK1 positive (Hunt 
and Mantyh, 2001) and may project onwards to areas such as the amygdala and 
hypothalamus, which are involved in the affective/emotional aspects of the pain experience 
(Hunt and Mantyh, 2001). The NK1 receptor has attracted considerable attention due to its 
nociceptor-specific anatomical location. Studies in rodents using antagonists or the SP-
conjugated neurotoxin saporin, which selectively ablates NK1 positive cells, have 
demonstrated analgesic effects in experimental models of neuropathic and inflammatory 
pain (Mantyh, 1997; Ma and Hill, 1999). However, despite their success in animals, NK1 
antagonists failed to show efficacy in clinical trials, perhaps due to physiological species 
differences (Hill, 2000). This failure shed some doubt on the relevance of SP/NK1 signalling 
in pain pathways and brought forward the hypothesis that ablating NK1 positive cells 
produces analgesic effects due to loss of projection neurons rather than diminished 
nociceptor transduction.  
 
Arising from the deeper laminae (III - VI) of the dorsal horn is the spinothalamic pathway, 
which predominantly projects to the thalamus and carries information regarding the 
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sensory/discriminative aspects of the pain experience (Doyle and Hunt, 1999). In addition, a 
third pathway originating from lamina II interneurons that are in contact with IB4 positive 
C-fibres, primarily targets the amygdala, hypothalamus and globus pallidus through contact 
with lamina V projection neurons. This ascending pathway is connected to non-peptidergic 
nociceptors and parallels lamina I projection neurons that are connected to peptidergic 
nociceptors, indicating that the two nociceptive classes may possess their own pain 
pathways (Braz et al., 2005).  
 
Amongst the various pathways descending from the brain to the spinal cord are the two 
main monoamine-containing pathways: the serotonergic system, originating in the nucleus 
raphe magnus and the noradrenergic system, derived from the locus coeruleus and adjacent 
pontine regions. These descending axons terminate diffusely throughout the dorsal horn but 
mainly in superficial laminae I and II. Monoaminergic descending pathways projecting from 
the rostral ventromedial medulla (RVM) critically modulate nociceptive spinal cord activity 
and exert both facilitatory (Serotonin/5-hydroxytryptamine (5HT)3 receptors) and 
inhibitory (α2 adrenoceptors) control (Suzuki and Dickenson, 2005; D'Mello and Dickenson, 
2008; Todd, 2010).  
 
1.6 Peripheral sensitisation 
 
Abnormal pain sensations such as hyperalgesia, allodynia and spontaneous pain may be 
caused by tissue inflammation and nerve injury. According to IASP, hyperalgesia is defined 
as an increased pain response to normally noxious stimuli.  The change in threshold within 
the proximity of the injury site is referred to as primary hyperalgesia, whereas secondary 
hyperalgesia defines threshold changes in the surrounding undamaged tissue. Allodynia is 
defined by IASP as a noxious response to a normally innocuous stimulus. However, this 
terminology was recently clarified so that unless a pain response is known to be evoked by 
low-threshold fibres it is referred to as hyperalgesia (Sandkuhler, 2009). Thus with regards 
to the peripheral nervous system (PNS), hypersensitivity refers to a decrease in thresholds 
so that a previously innocuous stimulus can now recruit nociceptors, as well as an increase 
in neuronal excitability so that a noxious stimulus elicits a greater response; this augmented 
activity is a phenomenon referred to as peripheral sensitisation. 
 
Peripheral sensitisation is typically a result of changes in the chemical milieu caused by cell 
damage and mediator release from keratinocytes, fibroblasts, endothelial cells, peripheral 
nerve terminals glial and immune cells (see Chapter 3). These locally released mediators 
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facilitate the inflammatory process, and are commonly referred to as an ‘inflammatory soup’ 
consisting of prostanoids, kinins, histamine, neuropeptides (SP, CGRP), 5HT, adenosine 
triphosphate (ATP), adenosine, growth factors, protons, cytokines and chemokines 
(Marchand et al., 2005; Woolf and Ma, 2007; Basbaum et al., 2009). Subsequent to release 
these agents may act directly on nociceptor terminals or indirectly on other target cells via 
their cognate membrane ion channels/receptors, resulting in the induction of multiple 
intracellular signalling pathways including protein kinase A (PKA), protein kinase C (PKC), 
phosphoinositide 3-kinase (PI3K), and the MAPKs: extracellular signal-regulated kinase 
(ERK), p38, c-Jun N-terminal (JNK). This leads to the phosphorylation of various proteins 
and a substantial increase in the transcription of neuropeptides, growth factors and 
receptors/ion channels in the somata of nociceptors (Costigan et al., 2002; Xiao et al., 2002). 
Consequentially, primary sensory neurons undergo a phenotypic switch that alters their 
neurochemical characters and properties. This results in raised basal sensitivity to noxious 
and innocuous stimuli and a subsequent increase in excitability and action potential firing. 
Voltage-gated Na+ channels are responsible for the initiation of action potentials and 
together with K+ channels regulate the excitability of sensory neurons and communicate 
amplified sensory information from the periphery to the spinal cord. Thus the combination 
of phosphorylation- and transcriptional-dependent events drives peripheral sensitisation 
and contributes to enhanced central transmission (Woolf and Ma, 2007). These mechanisms 
are summarised in Fig. 1.3. 
 
The receptors of inflammatory mediators fall into three broad classes: ionotropic 
receptors/ion channels (ATP receptors, P2X2 and P2X3; TRP channels); receptor tyrosine 
kinases (NGF and BDNF receptors, TrkA and TrkB, respectively) and GPCRs (bradykinin 
receptors 1 and 2 (B1 and B2); chemokine receptors e.g. chemokine (C-C motif) receptor 2 
(CCR2), chemokine (CX3C-motif) receptor 1 (CX3CR1)). These receptor classes shall be 
addressed below. 
 
1.6.1 Ionotropic receptors/ion channels 
 
Thermal hyperalgesia is a key sensory maladaptation associated with inflammation and is 
mediated by TRPV1, which is one of the most studied vanilloid receptors in pain research. 
TRPV1 is a six transmembrane domain non-selective cation channel and its activation 
produces an influx of Na+ and Ca2+, which depolarises the neuron and activates downstream 
signalling molecules (Caterina et al., 1997). TRPV1 is expressed by small- to medium- sized 
DRG neurons and is activated by noxious temperatures (> 42 C), capsaicin (extract from 
hot chilli peppers) and protons. The most compelling evidence for a role of this ion channel 
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in nociception is the reported alleviation of CFA or mustard oil-induced thermal 
hyperalgesia in the TRPV1 null mouse. In contrast, nerve injury induced thermal and 
mechanical hypersensitivity was normal in TRPV1 KOs as well as responses to acute 
thermal stimuli in intact animals, except at high temperatures (Caterina, 2000). The 
participation of TRPV1 in inflammatory pain is well documented but in neuropathic pain the 
role of this receptor is less understood. TRPV1 expression up-regulates in models of 
inflammatory pain but contrastingly down-regulates in a number of models of neuropathic 
pain, except for some up-regulation in surviving DRG somata (Hudson et al., 2001; Rasband 
et al., 2001; Schafers et al., 2003a). These polymodal signal integrators can be substantially 
modulated by components of the inflammatory soup, which may involve the lowering of 
temperature- or agonist-dependent thresholds required for activation. This results in the 
firing of neurons to a stimulus that was previously innocuous, which correlates with acute 
hyperalgesia. Concurrently, long-term changes encompass increased protein expression and 
insertion of TRPV1 channels into the plasma membrane of nociceptor terminals (Ji et al., 
2002; Linley et al., 2010).  
 
Extracellular protons and lipids behave as direct allosteric modulators of the channel, 
whereas bradykinin, ATP and NGF can indirectly modulate TRPV1 through the mobilisation 
of down-stream intracellular signalling cascades (Basbaum et al., 2009). NGF/TrkA and 
bradykinin/B2 mediated sensitisation was previously proposed to be via phospholipase C 
(PLC) mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2), which is a tonic 
inhibitor of TRPV1 (Chuang et al., 2001; Prescott and Julius, 2003). However, later findings 
opposed this accepted model and demonstrated that in fact PIP2 promotes the activation of 
TRPV1. Instead it was proposed that NGF mediated activation of PI3K subsequently 
activates Src kinase, which phosphorylates tyrosine residues on the N-terminus of TRPV1 
and promotes trafficking of the receptor to the plasma membrane (Zhang et al., 2005d; Stein 
et al., 2006). This enhanced expression at the plasma membrane is thought to be the main 
contributor to thermal hyperalgesia. NGF/TrkA is also retrogradely transported in 
endosomes to the cell bodies of sensory neurons, where it activates p38 MAPK, leading to 
increased translation and transport of TRPV1 to peripheral nociceptor terminals (Ji et al., 
2002). However, NGF may also mediate transcriptional-dependent effects, and in a model of 
CFA, up-regulation in the expression of TRPV1 was dependent on both NGF and GDNF in 
Trk-A and IB4/RET positive neurons, respectively (Amaya et al., 2004). In addition, PKA 
and/or PKC have been documented to facilitate TRPV1 signalling possibly via increasing the 
open probability of the channel, which consequently augments TRPV1 currents (Lopshire 
and Nicol, 1998; Bhave et al., 2003). For example, prostaglandin E2 (PGE2) sensitises TRPV1 
channels through both PKA (EP4) and PKC (EP1) dependent signalling pathways (Lopshire 
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and Nicol, 1998; Moriyama et al., 2005). In addition to the mediators mentioned above, a 
number of other pro-algesic substances may exert sensitising effects on TRPV1 channels 
during peripheral inflammation including glutamate, 5HT, adenosine, histamine, 
chemokines and cytokines (Ma and Quirion, 2007). 
 
Tissue injury results in local acidosis and the production of hydrogen ions, which is a 
hallmark of a physiological inflammatory response that can be detected by TRP and ASIC 
channels. TRPA1 mediates sensory responses to many chemical irritants such as mustard 
oil, garlic and membrane permeable electrophiles (allyl isothiocyanate from wasabi or 
allicin from garlic) as well as endogenous proalgesic agents that are produced in response to 
damage or stress. Like TRPV1, these channels are expressed by peptidergic C-fibres and 
consist of six transmembrane domains with a non-cation selective central pore (Nilius et al., 
2012). Pharmacological blockade of TRPA1 was shown to inhibit formalin responses and 
attenuate mechanically evoked C-fibre firing in rodents, indicating a role in the transduction 
of both noxious chemical and mechanical stimuli (Kerstein et al., 2009). Interestingly, in a 
study utilising TRPA1 null mice, the channel was demonstrated to be a target of pro-
inflammatory factors such as bradykinin, which elicit hypersensitivity in pain pathways via 
PLC signalling (Bautista et al., 2006). Bradykinin is a peptide cleaved by enzymes 
(kallikreins) from circulating plasma proteins upon tissue injury and directly activates 
nociceptive DRG neurons causing pain in animals and humans (Levine et al., 1993). 
Subsequent to activation of the bradykinin B2 receptor, mobilisation of PLC and cAMP-
induced PKA contributes to TRPA1 sensitisation, probably via a phosphorylation dependent 
mechanism (Wang et al., 2008). Conversely, in a number of nerve injury models of 
neuropathic pain the expression of TRPA1 is down-regulated (Andrade et al., 2012). 
Although one study showed that whilst TRPA1 mRNA was down-regulated in the injured-L5 
DRG, it was up-regulated in the un-injured L4 DRG and was found to contribute to the 
development of cold hyperalgesia (Katsura et al., 2006).  
 
 ASICs are sodium selective cation channels that are activated by low extracellular pH and 
are thought to play a role in sensing tissue acidosis during inflammation, where pH values 
may drop as low as 5.4 (Jacobus et al., 1977; Wang et al., 2013).  ASIC channels consist of 
two transmembrane domains and are located in sensory neurons innervating the skin and 
in DRG somas of variable sizes (Wemmie et al., 2006). Similar to the TRPA1s, ASIC channels 
exhibit changes in activity subsequent to exposure to inflammatory mediators. For example, 
application of NGF, bradykinin, 5HT and IL-1β enhanced ASIC3 mRNA expression in 
cultured DRG neurons, which showed some correlation with augmented channel activity 
and increased sensory neuron excitability (Mamet et al., 2002). It was also previously 
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reported that ASIC expression in small DRG neurons increases in CFA treated rats (Voilley et 
al., 2001). A recent study demonstrated that 5HT-induced nociceptive behaviours are 
attenuated in ASIC3 KO mice and inhibited by the non-selective antagonist, amiloride, in WT 
mice. It was proposed that 5HT enhances proton-evoked currents of ASIC3 channels by 
binding to the non-proton ligand sensing domain and sensitising the channel to respond to 
extracellular mild pH (Wang et al., 2013).   
 
Enhanced activity of voltage-gated Na+ and Ca2+ channels and suppression of voltage-gated 
K+ channels is also implicated in the establishment of hyperalgesia. For example, the Kv7 
family of K+ channels are inhibited via the activation of PLC coupled receptors as a result of 
PIP2 depletion (Li et al., 2005) or inositol triphosphate (IP3) -mediated increases in 
intracellular Ca2+ levels (Gamper and Shapiro, 2003). Kv7 channels are involved in the 
regulation of neuronal excitability and so inhibition results in augmented neuronal activity. 
Similarly, in the setting of nerve injury and inflammation several voltage gated K+ channels 
have been reported to be down-regulated (Kv4.3, Kv3.4, Kv9.1 and the Kv2 subunit), which 
has been linked to a heightened neuronal excitability (Takeda et al., 2006; Chien et al., 2007; 
Takeda et al., 2008; Tsantoulas et al., 2012; Tsantoulas and McMahon, 2014; Tsantoulas et 
al., 2014). Small DRG neurons express a combination of tetrodotoxin (TTX) -sensitive fast 
kinetics (Nav1.7) and TTX-resistant slow kinetics (Nav1.8, Nav1.9) Na+ channels. Evidence 
from multiple KO studies support the considerable contribution of these Na+ channels to 
inflammation-induced hypersensitivity (Kerr et al., 2001; Nassar et al., 2004; Amaya et al., 
2006), as well as studies utilising animal models of inflammation. For example, intraplantar 
CFA was shown to evoke an increase in the expression of Nav1.7 and Nav1.8 in the DRG 
(Gould et al., 2004) and sensitising agents released during inflammation such as PGE2, 
adenosine and 5HT enhanced Na+ conductance, induced a hyperpolarising shift and 
accelerated current activation (Gold et al., 1996). Likewise, Nav1.9 currents were 
potentiated by a combination of pro-inflammatory mediators in rat DRG neurons (Maingret 
et al., 2008) possibly via PKC mediated phosphorylation (Liu and Wood, 2011). In contrast, 
TTX-resistant Na+ channels seem unlikely to participate in neuropathic pain. Both Nav1.8 
and Nav1.9 are down-regulated in injured neurons and KO studies show little impact on pain 
thresholds (Dib-Hajj et al., 1999; Priest et al., 2005; Amaya et al., 2006). For example, Nav1.7 
and Nav1.8 double KO mice continue to develop neuropathic pain behaviours after nerve 
injury (Nassar et al., 2005). In addition to changes in the properties of voltage-gated Na+ and 
K+ channels, Ca2+ channels are also altered by inflammatory mediators. Low voltage 
activated T-type Ca2+ channels expressed in nociceptors are activated by weak 
depolarisation and facilitate the initiation of action potentials (Coste et al., 2007). Increases 
in their density as a result of exposure to inflammatory mediators such as hydrogen 
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sulphide, enhances their currents (Kawabata et al., 2007). C-fibre expressed N- and T-type 
Ca2+ channels are also up-regulated in models of nerve injury, and Cav2.2 or 3.2 deficient 
mice exhibit attenuated pain behaviours after inflammation or nerve injury, respectively 
(Cao, 2006). 
 
ATP released from damaged cells, skin keratinocytes exposed to mechanical or chemical 
stimuli, or sensory neurons, activates ionotropic purinergic receptors such as P2X2 and P2X3 
(Linley et al., 2010). These non-cation selective receptors are expressed in small DRG 
neuronal cell bodies and their axons, and the opening of these receptors results in an influx 
of Na+ and Ca2+ and an efflux of K+ (Lewis et al., 1995). This initiates depolarisation and a 
secondary influx of Ca2+ via VGCCs. The substantial rise in intracellular Ca2+ and subsequent 
activation of kinases such as ERK leads to the release of secondary mediators (Dai et al., 
2004). Intraplantar injection of ATP has exhibited dose-dependent pro-nociceptive effects, 
and was reported to enhance pain behaviours in three independent paradigms of peripheral 
sensitisation (Hamilton et al., 1999). Notably, P2X3 expression falls by ∼ 50% in the DRG 
following nerve transection (Bradbury et al., 1998) but increases following intraplantar CFA 
(Xu and Huang, 2002) possibly due to an NGF/GDNF mediated effect (Ramer et al., 2001). 
Furthermore, P2X2 and P2X2/P2X3 KO mice exhibit attenuated pain-related behaviours in 
response to intraplantar formalin, and DRG neurons from these mice show minimal ATP 
responses, indicating that these subunits account for virtually all ATP responses in sensory 
neurons (Cockayne et al., 2005). 
 
1.6.2 Receptor tyrosine kinases 
 
The neurotrophins NGF and BDNF and their cognate receptors TrkA and TrkB, respectively, 
form a well-documented pro-nociceptive signalling system (Pezet and McMahon, 2006). The 
Trk receptors are tyrosine kinase receptors that dimerise and autophosphorylate upon 
ligand binding to initiate two major biochemical pathways involving PI3K and MAPK. These 
signalling pathways contribute to transcriptional and post-translational regulation of 
neuropeptides/neuromodulators (CGRP, SP, BDNF), receptors (TRPV1, ASIC, P2X3, μ-opioid) 
and voltage-gated ion channels (TTX -sensitive and -resistant Na+ channels) in nociceptive 
neurons (Pezet and McMahon, 2006). As aforementioned, NGF/TrkA-induced hyperalgesia 
through TRPV1 sensitisation has been demonstrated to occur through a number of 
downstream second messengers including, PKA, PKC, PLC, PI3K and MAPK (Chuang et al., 
2001; Ji et al., 2002; Zhang et al., 2005d; Stein et al., 2006; Zhu and Oxford, 2007). 
 





The purpose of this thesis was to examine the role of GPR84 in chronic pain mechanisms. 
Therefore, a more in depth discussion about the GPCR class of receptors is appropriate with 
regards to the aim of this thesis. 
 
GPCRs are the largest family of membrane proteins with more than 800 genes and 
remarkably orchestrate a diverse range of biological processes from hormonal and 
neurotransmitter signalling, to mediating sensory responses such as sight and smell. Thus it 
isn’t surprising that the majority of currently used drugs in the clinic target these receptors. 
Pioneering work by Rall and Sutherland in the 1950’s lead to the establishment that a series 
of hormones bind to specific heptahelical receptors linked to highly specialised intracellular 
transducer systems. These receptors generically consist of 7 transmembrane domains 
connected by 3 intracellular and extracellular loops, in addition to a cytoplasmic domain 
which interacts with G-proteins. GPCRs are grouped into three families according to 
sequence similarity within the transmembrane core or the presence of certain conserved 
residues or motifs (Pierce et al., 2002). Family A constitutes the largest group of these 
receptors and includes the rhodopsin, adrenergic and olfactory receptors. Family B is 
considerably smaller and includes gastrointestinal peptide hormone receptors, such as 
vasoactive intestinal peptide. Lastly, family C is the smallest class and consists mainly of the 
metabotropic glutamate and GABA receptor families. This group characteristically possesses 
very large extracellular amino terminals that are important for the binding of ligands and 
subsequent activation (Pierce et al., 2002). Once activated, the GPCR initiates signal 
transduction by interacting with a heterotrimeric G protein (α, β, γ) and so in effect acts as a 
guanine nucleotide exchange factor (GEF) for Gα subunits and facilitates the exchange of 
guanosine diphosphate (GDP) for guanosine triphosphate (GTP) (Siderovski and Willard, 
2005). This leads to the dissociation of the Gα-GTP complex from the inhibitory βγ subunit 
(Hamm, 1998), enabling Gα-GTP and the βγ dimer to interact with downstream effectors 
which drive further intracellular signalling cascades (see Fig. 1.2). The duration of these 
signalling events is determined by the rate of guanosine triphosphatase (GTPase) mediated 
hydrolysis of the Gα-subunit and consequential re-association of Gα-GDP with Gβγ (Hamm, 
1998). This process is accelerated in heterotrimeric G-proteins by regulator of G-protein 
signalling (RGS) proteins, which stimulate signal termination by acting as GTPase-
accelerating proteins (GAPs) for Gα (Siderovski and Willard, 2005). 
 






Figure 1.2: Generic heterotrimeric GPCR activation model 
 
Ligand binding to a hepathelical GPCR leads to a conformational change and the interaction of the 
receptor with the αβγ complex bound to GDP. GDP is subsequently exchanged for GTP, initiating the 
dissociation of Gα-GTP and Gβγ, which go on to activate down-stream second messengers such as 
cAMP and Ca2+. RGS proteins stimulate signal termination by acting as GAPs. Here GTP is rapidly 
hydrolysed into GDP and inorganic phosphate.  
 
 
Based on the homology of the α-subunit sequences, G-proteins are classically divided into 
four main families: Gαs (activates adenylate cyclase (AC)), Gαi/o (inhibits AC), Gαq/11 
(activates PLC) and Gα12/13 (activates Rho-GEFs) (Hamm, 1998; Cabrera-Vera et al., 2003). 
The Gα-subunits are comprised of two specific domains, a GTPase domain that mediates 
binding and hydrolysis of GTP and a helical domain that buries GTP within the protein core. 
The Gγ-subunit extensively interacts with the Gβ-subunit through N-terminal coiled coils 
(Lambright et al., 1996) and is bound to Gα-GDP via a hydrophobic pocket. Upon GTP 
binding to Gα the hydrophobic pocket is removed, causing loss of affinity for Gβγ (Cabrera-
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 Gαs family 
 
An important aspect of the regulation of receptors/ion channels in the context of peripheral 
hypersensitivity is the mechanisms by which the channels become sensitised or 
desensitised as a result of alterations in the surrounding chemical milieu of nociceptive 
terminals. GPCRs are of particular interest as their various secondary pathways have been 
implicated in nociceptor sensitisation. Furthermore, many of the mediators released during 
an inflammatory response act via GPCRs and initiate many intracellular signalling cascades 
that contribute to the modulation of ion channels and the generation of hyperalgesia. For 
instance, the prostaglandin (EP2, EP4, IP and DPI) (Smyth et al., 2009) and 5HT receptors 
(5HT4,6,7) (Cardenas et al., 2001) are coupled to the Gαs family, which stimulate the enzyme 
AC to catalyse the formation of cAMP from ATP. Newly synthesised cAMP subsequently 
binds to PKA, initiating the dissociation of the PKA regulatory and catalytic subunits and 
passive diffusion into the nucleus (Taylor et al., 1992). In turn, activated PKA 
phosphorylates numerous targets such as cAMP response element-binding protein (CREB), 
which binds to the conserved cAMP response element expressed within the promoter 
region of many cAMP-responsive genes. CREB may then form a complex with its 
transcription co-activator, CREB binding protein (CBP), subsequent to phosphorylation and 
translocate to the nucleus to initiate RNA synthesis (Mayr and Montminy, 2001; Racioppi 
and Means, 2008). 
 
PGE2/EP4 signalling induces the sensitisation of TRP channels (Lopshire and Nicol, 1998) 
and TTX-resistant Na+ channels (Gold et al., 1996) and suppresses K+ channels (Nicol et al., 
1997) probably via PKA mediated phosphorylation. As previously mentioned, Lopshire and 
Nicol (1988) demonstrated that PGE2 or cAMP analogs transiently increase capsaicin-gated 
channel activity in embryonic rat sensory neurons by enhancing the amplitude of whole cell 
currents. They also demonstrated that this sensitising effect could be blocked by a PKA 
inhibitor, leading to the suggestion that capsaicin-gated ion channels may be modulated by 
PKA-mediated phosphorylation of the serine residue S116 (Lopshire and Nicol, 1998; Bhave 
et al., 2002). Cyclic AMP was in fact one of the first second messengers implicated in pain 
and nociceptor sensitisation, and elevated levels of this signalling molecule is associated 
with increased neuronal excitability. This is illustrated by a study showing that intradermal 
injection of cAMP-inducing agents such as forskolin in rats produces dose-dependent 
hyperalgesia that can be blocked via the cAMP analog, RP-cAMP (Taiwo and Levine, 1991). 
Furthermore, transgenic mice that do not express particular isoforms of AC exhibit 
attenuated pain behaviours and correspondingly pre-treatment with AC inhibitors 
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decreases PGE2-induced behavioural hyperalgesia (Aley and Levine, 1999; Wei et al., 2002; 
Kim et al., 2007b). 
 
 Gαq/11 family  
 
The histamine (H1), bradykinin (B2), prostaglandin (EP1) and SP (NK1) receptors are 
coupled to the Gαq/11 family of G-proteins, which activate PLC. The PLC family consists of a 
diverse group of enzymes that are divided into 3 subtypes. There are 4 members of the PLCβ 
family, 2 members of the PLCγ family and 4 members of the PLCδ family. The Gα subunits 
(αq, α11, α14, α16) belonging to the Gq subfamily selectively activate PLC-β isozymes via 
interaction with its COOH-terminal. Activation of PLC results in the biosynthesis of diacyl-
glycerol (DAG) and IP3 from the membrane-bound lipid precursor, PIP2. DAG may then 
activate PKC, whilst IP3 binds to its IP3 receptors (IP3Rs), expressed by intracellular stores. 
This leads to the mobilisation of a Ca2+ response and consequently activates an array of Ca2+ 
dependent kinases. PKC has a well documented role in nociceptor activation and 
sensitisation, which is thought to be mainly via the direct phosphorylation of receptors and 
ion channels (Hucho and Levine, 2007). For example, PKCε is able to augment TRPV1 
channel activity and restore currents subsequent to desensitisation by directly 
phosphorylating S800 residues (Mandadi et al., 2006). PKC also promotes soluble N-
ethylmaleimide-sensitive factor attachment protein receptor (SNARE) -dependent 
trafficking of TRPV1 to the membrane, which enhances channel currents and thus 
contributes to thermal hyperalgesia (Morenilla-Palao et al., 2004). As previously discussed it 
was thought that bradykinin-B2 signalling sensitised TRPV1 via PLC activation and 
subsequent PIP2 depletion (Chuang et al., 2001), however this mechanism has been 




Stimulation of the Gαi/o pathway in nociceptors usually involves the inhibition of AC and the 
activation of phosphodiesterases, which reduces cAMP levels and the activity of PKA.  Gαi/o 
activation also leads to an inhibition of presynaptic VGCCs and a consequential suppression 
of synaptic transmission. Therefore this pathway is associated with a state of reduced 
excitability and analgesia that is best illustrated by the activation of opioid receptors, which 
are expressed in 29-38% of C-fibre axons (Ingram and Williams, 1994; Coggeshall et al., 
1997). However, the most compelling evidence for the involvement of Gαi/o signalling in 
peripheral sensitisation is the direct and indirect effects of chemokines. Chemokine 
receptors are widely distributed in neurons, leukocytes and glial cells and signal via the 
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Gαi/o family of G-proteins (Kiguchi et al., 2012). Activation of these receptors leads to the 
mobilisation of Ca2+ via a PLC-β-dependent pathway and the subsequent initiation of various 
intracellular kinases such as the calmodulin-kinases (CAMKs) and MAPKs (Elzi et al., 2001; 
Sassone-Corsi, 2012). Ultimately, via a combination of phosphorylation and/or 
transcription-dependent events there is an increase in receptor/ion channel membrane 
density and currents in nociceptors as well as enhanced release of mediators; immune and 
glial cells may also show enhanced secretion and expression of cell surface receptors. The 
contribution of some chemokine receptors to peripheral sensitisation is well documented 
(Abbadie et al., 2009) and will be discussed more thoroughly later in this chapter.  
 
Termination of receptor activation is crucial for the tight regulation of intracellular 
signalling. One of the most widespread mechanisms for regulating GPCR activity is via G-
protein-coupled receptor kinase (GRK) driven receptor desensitisation. GRKs only 
phosphorylate the receptor in its agonist bound state and promote the binding of arrestin 
proteins, which act as sterical inhibitors of receptor/G-protein interaction. Second 
messenger kinases such as PKA and PKC may also serve as negative feedback regulators and 
promote G-protein uncoupling by phosphorylating receptors. Besides acute 
phosphorylation-dependent effects, dampening of receptor signalling may also entail slower 
regulatory mechanisms such as receptor degradation and gene transcription/translation, in 
addition to the intrinsic regulation of GTPase activity via RGS proteins. On the other hand, 
receptor internalisation serves as a mechanism by which receptors are resensitised and 
made ready to respond to a subsequent stimulus. This usually involves β-arrestin-
dependent mechanisms via clathrin coated or uncoated vesicles (Pierce et al., 2002). 
 





Figure 1.3: Signalling pathways involved in peripheral sensitisation 
 
Keratinocytes, fibroblasts, endothelial cells, peripheral nerve terminals, glial and immune cells 
release mediators such as PGs, histamine, bradykinin, SP, chemokines (CCL2, CCL3), ATP, cytokines 
(TNF-α, IL-1β), growth factors (NGF, BDNF), protons (H+). These mediators act via their cognate 
receptors (GPCR, ionotropic receptors, tyrosine kinase receptors) expressed by peripheral nerve 
terminals and activate multiple intracellular signalling pathways (PKA, PKC, PI3K, MAPK’s). This 
leads to the phosphorylation of various proteins and post-translational modifications such as 
increased trafficking/changes in properties of receptors/ion channels. There is also a substantial 
increase in the transcription of neuropeptides, growth factors and receptors/ion channels in the 
somatas of nociceptor neurons. The combination of phosphorylation-dependent and transcriptional-
dependent events sensitises nociceptors and drives peripheral sensitisation. 
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1.7 Central sensitisation 
 
Nociceptor afferents terminate in the superficial dorsal horn of the spinal cord and synapse 
with second-order neurons, transferring incoming peripheral information about the 
intensity and duration of a noxious stimulus to the CNS. Central sensitisation is manifested 
as a state of hyperexcitability of dorsal horn neurons, which can be electrophysiologically 
characterised as an elevation in spontaneous activity, a reduction in thresholds, heightened 
responses to incoming stimuli and an increase in receptive fields (Latremoliere and Woolf, 
2009). In contrast to peripheral sensitisation, central sensitisation contributes to 
hypersensitivity in unaffected areas (secondary hyperalgesia). Peripheral sensitisation is 
most certainly involved in changes in the nociceptive system and constitutes the trigger for 
central changes; this form of hypersensitivity is localised to the site of injury/damage 
(primary hyperalgesia) and plays a major role in thermal hyperalgesia. On the other hand, 
central sensitisation is thought to be the main driver of mechanical hyperalgesia as a result 
of CNS plasticity that alters responsiveness to stimulus inputs (Woolf and Salter, 2000; 
Latremoliere and Woolf, 2009). Evidence of this striking phenomenon in the context of pain 
was first shown by Woolf in 1983, who measured the flexor reflex withdrawal response of 
α-motorneurons as an output indicator to noxious stimuli. He reported that under normal 
conditions spontaneous activity was absent and that activation of motor neurons required a 
noxious input. However, after repeated application of a noxious heat stimulus to the paw, he 
observed an increase in motor neuron excitability, a reduction in thresholds and an increase 
in cutaneous receptive fields. This meant that a peripheral stimulus such as light touch was 
consequentially able to evoke a response. He verified that these findings were exclusively 
due to a central mechanism by showing that electric stimulation of Aβ-fibres elicited 
responses only after induction of inflammation, and that local administration of an 
anaesthetic at the site of injury bore no effect on the enlarged receptive fields. Importantly, 
he also confirmed that this central hypersensitive state could be recapitulated by repeated 
electrical stimulation at C-fibre strength (Woolf, 1983). 
 
Glutamate is the primary fast excitatory neurotransmitter of the CNS and mediates its 
effects via its ionotropic receptors: N-methyl-D-aspartate receptor (NMDAR), α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) and kainate receptors and 
metabotropic glutamate receptors (mGluR). AMPAR and NMDAR receptors are found at 
virtually every synapse in the superficial laminae, whereas mGluRs are more localised to 
extrasynaptic sites (Alvarez et al., 2000; Antal et al., 2008). Excitatory postsynaptic currents 
(EPSCs) are mainly generated via the activation of AMPA and kainate receptors expressed 
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by second order dorsal horn neurons whilst NMDARs are normally blocked by magnesium 
ions (Mg2+) (Mayer et al., 1984). In the setting of tissue damage or injury, the sustained 
release of neurotransmitters and neuromodulators such as glutamate, BDNF, SP and CGRP 
from nociceptor terminals into the superficial dorsal horn contribute to the summation of 
EPSCs in second order neurons. This eventually generates a sufficient level of depolarisation 
that removes the NMDAR Mg2+ block and opens the pore (Mayer et al., 1984; Mannion et al., 
1999; Woolf and Salter, 2000; Kawasaki et al., 2004; D'Mello and Dickenson, 2008). The 
activation of NMDARs produces a large inward Ca2+ current and the mobilisation of multiple 
downstream signalling cascades (MAPK, PKA, PKC, PI3K, Src) that facilitate C-fibre mediated 
central sensitisation of dorsal horn neurons (Latremoliere and Woolf, 2009). Essentially, 
these Ca2+-dependent protein kinases contribute to phosphorylation-dependent 
modifications of NMDAR and AMPAR, as well as numerous other receptors and ion channels. 
Such modifications may include changes in channel kinetics, as well as increased synaptic 
density caused by enhanced synthesis and trafficking of ion channels and scaffold proteins. 
These changes subsequently strengthen nociceptive transmission by increasing membrane 
excitability and synaptic efficacy (Costigan et al., 2009a; Latremoliere and Woolf, 2009). 
 
In addition to phosphorylation-dependent modifications, longer-lasting transcription-
dependent (phosphorylation-independent) processes contribute to the establishment of 
central hyperexcitability. A body of literature supports a key role of the MAPK, ERK, in 
neuronal plasticity. One of the earliest studies demonstrated that MAPK phosphorylation in 
the dorsal horn was very much dependent on nociceptive activity (Ji et al., 1999; Ji et al., 
2009). This was shown to depend on the intensity and duration of the noxious stimulus i.e. 
only noxious stimuli of a duration greater than ten seconds was capable of activating ERK; 
however, this may well change in the setting of injury (Ji et al., 1999; Wang et al., 2004; Wei 
et al., 2006). As the ERK pathway integrates multiple protein kinases that are triggered by 
various receptors (NMDARs, mGluRs, TrkB, NK1 or CGRP), many signalling pathways 
converge to activate ERK. In addition, raised intracellular Ca2+ levels via the glutamatergic 
receptors critically mobilises several Ca2+ dependent kinases (PKC, PI3K) that 
phosphorylate ERK in dorsal horn neurons (Pezet et al., 2008). Correspondingly, the 
distribution of phosphorylated ERK reveals neurons that have been stimulated with 
nociceptive input. The activation of ERK is necessary for the phosphorylation of CREB and 
other transcription factors that drive the expression of genes such as c-Fos, NK1, COX-2 and 
TrkB (Latremoliere and Woolf, 2009). Such transcriptional regulation is critical for long-
term changes that drive the maintenance of central sensitisation, whereas posttranslational 
regulation is only sufficient for inducing central sensitisation. 
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Another mechanism which contributes to central sensitisation is the loss of inhibitory 
control. GABAergic or glycinergic inhibitory interneurons are densely found in the 
superficial dorsal horn. Experimentally induced inhibition of GABAA or glycine receptors via 
spinal administration of bicuculline or strychnine, respectively, generates behavioural 
hypersensitivity in rats similar to that seen after peripheral nerve injury (Sivilotti and 
Woolf, 1994). In accordance with these findings, nerve injury results in diminished 
GABAergic currents and suppressed glycinergic currents, suggested to be a result of 
inhibitory neuron cell death (Moore et al., 2002). Other studies have shown that BDNF 
release from microglial cells may contribute towards a state of disinhibition in the spinal 
cord. Under physiological conditions the potassium chloride co-transporter 2 (KCC2) drives 
chloride (Cl-) out of the cell. Therefore the opening of Cl- channels causes hyperpolarisation 
of neurons due to the influx of Cl- along the electrochemical gradient. However, after 
peripheral nerve injury microglial derived BDNF induces a down-regulation of KCC2 in 
lamina I projection neurons (Coull et al., 2003). The decrease in expression of KCC2 
produces a rise in the intracellular Cl- concentration and a depolarising shift in the anion 
reversal potential, hence impeding the inhibitory tone of GABA and glycine channels (Coull 
et al., 2005). In addition, disinhibition may occur via PGE2/EP2 -induced activation of the 
cAMP/PKA pathway, where the phosphorylation of glycine receptors consequently inhibits 
the responsiveness of neurons to glycine (Harvey et al., 2004). 
 
Finally, glial cells may also contribute to the development and maintenance of central 
sensitisation, which will be discussed below. 
 
1.8 Immune cells and pain 
 
Tissue or peripheral nerve damage is accompanied by an immune cell response, which 
encompasses the activation of resident immune cells, infiltration of inflammatory cells and 
the release of immune mediators. This response is evident in damaged tissues or nerves, the 
DRG and spinal cord as well as supraspinal sites. Accumulating evidence has supported the 
critical involvement of immune cells and immune mediators in the development of 
hyperalgesia. Microglia and macrophages are the key phagocytic cells of the innate immune 
system in CNS and PNS, respectively, and are the most studied immune cells in the field of 
pain with a wealth of literature supporting their contribution to nociceptive transmission. 
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1.8.1 Mast cells 
 
Bone marrow derived mast cells are a heterogenous population originating from 
haematopoietic progenitors and are easily recognised by their distinctive heavily granulated 
appearance. These cells are typically found in body tissues exposed to the external 
environment such as the skin and mucosal layers of the airways and intestines, but are also 
found in nerves. Like other immune cells, mast cells engage in numerous immunological 
activities ranging from phagocytosis and antigen processing to the synthesis and secretion 
of cytokines (Metcalfe et al., 1997; Galli et al., 2005; Urb and Sheppard, 2012). Mast cells are 
major players in inflammatory responses and are considered as effector cells in allergic 
disorders. As one of the resident classes of immune cells in peripheral nerves they are 
thought to play a role in the development of inflammation and the establishment of a 
hypersensitive state. The most characterised mechanism of activation of these cells is via 
their high-affinity immunoglobulin E receptors (FCεRI). However, mast cells may also be 
activated via the engagement of their pattern recognition receptors (PRRs) in a similar 
fashion to other leukocytes. Upon activation mast cells rapidly degranulate releasing 
histamine, heparin, 5HT and proteases (e.g. tryptase) in addition to secreting prostaglandins 
and a number of chemokines and cytokines (Urb and Sheppard, 2012). Several of the 
mediators released have demonstrated pro-nociceptive properties that contribute to 
hyperalgesia. For example, histamines, TNF-α, 5HT and tryptase are able to both activate 
and sensitise nociceptors, and TNF-α has been shown to directly increase firing rates of 
sensory axons (Rueff and Dray, 1993; Sorkin et al., 1997; Herbert et al., 2001; Kawabata et 
al., 2001). Correspondingly, treatment of neuropathic rats with histamine inhibitors has 
been shown to alleviate the development and maintenance of mechanical and thermal 
hyperalgesia (Zuo et al., 2003). However, as expected, this method of treatment only 
provided partial relief as multiple mediators contribute to neuropathic pain. Many mast cell 
derived mediators also possess chemoattractant properties and thus are able to recruit 
other immune cell types, particularly neutrophils that release further algogenic and pro-
inflammatory mediators at the site of injury (Moalem and Tracey, 2006). 
 
One of the most striking studies supporting the involvement of mast cells in neuropathic 
pain demonstrated that the development of behavioural hyperalgesia was alleviated in rats 
treated pre and post PNL surgery with sodium cromoglycate, an agent that stabilises mast 
cells and prevents them from degranulating. This effect was also associated with a reduction 
in the recruitment of neutrophils and macrophages to the site of nerve injury (Zuo et al., 
2003). Cromoglycate treatment also exhibited analgesic effects in the second-phase of 
formalin evoked pain (Parada et al., 2001). Furthermore, depletion of mast cell granules via 
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chronic treatment with compound 48/80 results in attenuated CFA or zymosan and acetic 
acid-induced hyperalgesia (Woolf et al., 1996; Ribeiro et al., 2000). Conversely, 
subcutaneous injection of a single dose of 48/80 evoked acute nociceptive behaviours in 
rats (Parada et al., 2001).  
 
Interestingly, mast cell depletion results in a loss of NGF-induced thermal sensitisation in 
skin preparations of the saphenous nerve attached to dorsal skin of the hind paw (Rueff and 
Mendell, 1996). NGF indirectly augments an inflammatory response by exerting cytokine-
like action on TrkA-positive inflammatory cells such as mast cells, basophils, lymphocytes 
and neutrophils. This results in proliferation and the synthesis of cytokines that contribute 
to the sensitisation of peripheral nerve terminals. In addition, NGF promotes mast cell 
survival and degranulation. Depletion of mast cells results in a reduction in the NGF 
sensitising effect and prevents an increase in NGF from baseline levels in CFA treated rats. 
This is not only because mast cell depletion eliminates the indirect effect of NGF in evoking 
mediator release (which in turn induces NGF production in other cell types), but also 




Neutrophils, also referred to as polymorphonuclear leukocytes (PMNs), are the most 
abundant type of white blood cell in mammals, comprising 60-70% of the total white blood 
cell pool. These short-lived (24 hours) cells form a crucial component of the inflammatory 
response by orchestrating the recruitment, activation and programming of antigen 
presenting cells (Witko-Sarsat et al., 2000; Nathan, 2006; Caielli et al., 2012). Under normal 
conditions neutrophils are in a circulating non-adherent state and are undetectable in 
peripheral nerves. However, subsequent to nerve injury/tissue damage, the local 
appearance of inflammation-induced adhesion molecules enables the extravasation and 
migration of these cells to the site of inflammation where their numbers become 
considerably greater (Clatworthy et al., 1995; Perkins and Tracey, 2000; Zuo et al., 2003; 
Nathan, 2006; Cunha et al., 2008a). For example, a 3-fold increase in neutrophils was 
reported in the rat ipsilateral DRG at 7 days post chronic constriction injury (CCI) surgery 
(Morin et al., 2007).  
 
As neutrophils migrate towards a stimulus along the concentration gradient of 
chemoattractants such as NGF-β, chemokine (C-X-C motif) ligand (CXCL)1 and leukotriene-
B4 (LTB4) (Scholz and Woolf, 2007) they discharge two distinctive sets of granules, the 
peroxidase-negative and the peroxidise-positive granules (Nathan, 2006). Peroxidase-
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negative granules are secreted first and contain large amounts of lactoferrin, lipocalin, 
lysozymes and the chemotactic antimicrobial peptide LL37. They also contain matrix 
metalloproteinase (MMP) 8, 9 and 25, which facilitate neutrophil recruitment and tissue 
break-down. The second group of granules released are peroxidase-positive and contain 
small α-defensins, myeloperoxidase and a selection of potent antibiotics (Nathan, 2006). 
The release of these factors, particularly superoxides and other reactive oxygen species as 
well as many pro-inflammatory cytokines (IL-1β, TNF-α, IL-6), contribute to inflammation 
by directly or indirectly exciting sensory neurons (Cunha et al., 1992; Schafers et al., 2003b; 
Zelenka et al., 2005; Nathan, 2006). In addition, the release of CCL3, CCL4 and defensins co-
ordinates the recruitment of macrophages, which perpetuate the inflammatory response 
once neutrophil numbers begin to dwindle subsequent to their initial peak at 24 hours post 
injury (Scapini et al., 2000; Witko-Sarsat et al., 2000; Zuo et al., 2003).  
 
The most convincing evidence for the involvement of neutrophil invasion in neuropathic 
pain is derived from studies examining the effects of neutrophil recruitment/depletion on 
pain behaviours. For example, it was shown that the hypernociceptive effects of the potent 
neutrophil chemoattractants, LTB4 and complement 5a (C5a), were dependent on 
neutrophil migration (Levine et al., 1984; Levine et al., 1985). Administration of PMX53, 
which is a C5a receptor antagonist, exerted analgesic effects in the zymosan, carrageenan 
and LPS models of peripheral inflammation (Ting et al., 2008). Similarly, a single study 
showed that inhibition of neutrophil migration via orally administered DF 2162, a selective 
inhibitor of the CXC chemokine receptors 1 and 2 (CXCR1 and CXCR2), prevented pro-
nociceptive behaviours induced by LPS, CFA or zymosan in rats (Cunha et al., 2008b). Cunha 
et al. (2008) also showed that this compound could reduce neutrophil infiltration, oedema 
and behavioural hypersensitivity in a model of collagen-induced arthritis. Accordingly, early 
depletion of neutrophils in rats with a PNL injury was reported to considerably attenuate 
the development of hyperalgesia (Perkins and Tracey, 2000; Zuo et al., 2003).  
 
Integrin α4β1, is expressed by human and rat neutrophils as well as other immune cell types 
and mediates the process of extravasation, including neutrophil tethering, rolling and firm 
adhesion, by binding to vascular cell adhesion molecule-1. Early treatment with a 
neutralising antibody against α4β1 produced a reduction in neutrophil infiltration at the site 
of injury and alleviated mechanical allodynia in spinal cord injured rats (Fleming et al., 
2009). In a related study, pre-treatment with a leukocyte adhesion inhibitor (fucoidin), 
which prevents neutrophil infiltration, alleviated carrageenan-induced hyperalgesia in a 
dose-dependent manner but bore no effect on the induction of inflammatory cytokines (IL-
1β, TNF-α, CXCL1) (Cunha et al., 2008a). It was also found that in vitro stimulation of 
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neutrophils with IL-1β resulted in the production of PGE2, whilst intraplantar IL-1β elicited 
PGE2 production in the hind paw that was abolished via pre-treatment with fucoidin. 
Furthermore, depletion of the neutrophil population at a later stage of nerve injury-induced 
pathology (8 days post PNL) had no effect on behavioural hypersensitivity (Zuo et al., 2003). 
Thus together these data indicate that neutrophils are important in the induction of 
inflammatory hyperalgesia via the release of numerous pro-nociceptive mediators such as 
PGE2 and chemoattractant cytokines. However, neutrophils are unlikely to contribute 
significantly at later stages of neuropathic pain, which corresponds with their succeeding 
decrease in numbers subsequent to the initial peak. 
 
Early on in the inflammatory response, neutrophils may also release opioid peptides, which 
exert anti-nociceptive effects via their neuronally expressed opioid receptors (Brack et al., 
2004). This adds to the complexity of an inflammatory response and may be a mechanism 
which is lost or outweighed in the pathology of neuropathic pain.  Netherless, what we can 
gather from these experimental studies is that although the neutrophil response is limited 
and relatively short-lived, these cells release important mediators that attract other immune 
cell types, particularly macrophages, which surpass the initial contribution of neutrophil 




Macrophages are large phagocytic cells of the innate immune system that are distributed 
throughout the body and can be broadly categorised into tissue or circulating macrophages. 
Under normal conditions macrophages closely survey their microenvironment for 
pathogens or tissue injury and maintain homeostasis by phagocytosing necrotic cells and 
rapidly responding to local disturbances. In the bone marrow, myeloid progenitor cells give 
rise to monoblasts, pro-monocytes and eventually monocytes, which are subsequently 
released into the bloodstream where they are thought to continue developing and maturing 
(Mosser and Edwards, 2008). In mice and humans there are two main subsets of monocytes 
that exhibit specific migration and functional differences, the ‘inflammatory’ and ‘resident’ 
monocytes. These subsets are thought to be derived from macrophage dendritic cell 
precursors and whilst inflammatory monocytes may further differentiate into dendritic 
cells, resident monocytes give rise to macrophages upon migration from the blood into the 
tissue (Zhang and Mosser, 2008; David and Kroner, 2011). Resident monocytes are CD115+ 
(cluster of differentiation 115; macrophage colony stimulating factor receptor) and possess 
high levels of CX3CR1 but lack expression of C-C chemokine receptor type (CCR)2,  GR1 
(Ly6C) and CD62L (L-selectin). On the other hand, inflammatory monocytes are 
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characterised as CD115+ and GR1+ (Ly6C), express high levels of CCR2 and CD62L and low 
levels of CX3CR1 (Zhang and Mosser, 2008; David and Kroner, 2011). 
 
Macrophages are also classified according to their functional characteristics as either M1 
(classically activated pro-inflammatory macrophages) or M2 (alternatively activated anti-
inflammatory macrophages). M1 macrophages, which are associated with the inducible 
nitric oxide synthase (iNOS) marker, are produced during a cell-mediated immune response. 
These macrophages are induced by interferon (IFN)-γ released from other immune cell 
types (natural killer cells and Th-1 lymphocytes), exhibit greater microbiocidal capacity and 
secrete higher levels of the pro-inflammatory mediators IL-1β, IL-6 and IL-23 compared to 
the M2 class (Mosser and Edwards, 2008; David and Kroner, 2011). In contrast, M2 
macrophages express higher levels of some anti-inflammatory cytokines such as IL-10 and 
transforming growth factor (TGF)-β and up-regulate ARG1 whilst down-regulating pro-
inflammatory mediators during a response. This subtype may be further subdivided into 
M2a (immunity against parasites), M2b (pro- and anti-inflammatory function) and M2c 
(pro-healing/regulatory) (David and Kroner, 2011). 
 
Subsequent to injury or infection, macrophages form one of the first lines of defence of the 
immune system and become rapidly activated in response to various exogenous and 
endogenous ‘danger signals’ such as pathogen associated molecular patterns (PAMPs), 
alarmins and heat shock proteins (HSP) (Zhang and Mosser, 2008). Macrophages also 
respond to the release of mediators from other innate immune cells. One of the most well 
established modes of activation is via a family of highly conserved PRRs such as the toll-like 
receptors (TLRs) which are able to recognise PAMPs, including the typical LPS and 
lipoteichoic acid (LTA) outer membrane components of Gram-negative and -positive 
bacteria, respectively. Once activated macrophage cells undergo profound physiological 
changes and up-regulate a number of cell surface receptors, secrete a range of mediators 
and exhibit enhanced phagocytic activity (Zhang and Mosser, 2008). 
 
Macrophages also play a key role in the process of Wallerian degeneration (WD) by 
phagocytosing damaged axons, myelin sheaths, debris and necrotic cells distal to the site of 
injury (Perrin et al., 2005). As previously discussed, peripheral macrophages consist of a 
heterogenous population of resident and infiltrating cells. The faster responding resident 
macrophages are important in initiating the clearance response and are assisted by a large 
influx of the hematogenous derived infiltrating population (Ton et al., 2013). The clearance 
process is orchestrated by a number of chemokines including CCL2, CCL3 and IL-1β and is 
necessary for axonal regeneration. In the PNS, this process occurs rapidly within a matter of 
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days, in the CNS, WD is much slower and can take as long as months (Perry et al., 1987; 
Perrin et al., 2005). Interestingly, WD may be interrupted by the application of CCL2, CCL3 
or IL-1β neutralising antibodies (Perrin et al., 2005), which prevents the infiltration of 
macrophages, or enhanced by the application of TLR2 or TLR4 ligands (zymosan and LPS, 
respectively) (Boivin et al., 2007). Furthermore, mice pre-treated with the glucocorticoid 
dexamethasone, or deficient in TLR signalling exhibit reduced recruitment/activation of 
macrophage cells and a delayed clearance of myelin debris and regeneration of the injured 
nerve (Boivin et al., 2007). TLR signalling is coupled to the activation of NF-κB, which 
orchestrates the transcription of many pro-inflammatory mediators in response to PAMPs 
such as HSP60 and 70, necrotic cells and components of the extracellular matrix (ECM) that 
are abundantly found at sites of injury (Nguyen et al., 2002; Willis et al., 2005). Based on 
these studies it is evident that TLRs do indeed contribute to the process of WD and in this 
setting are activated by a number of endogenous ligands.  
 
The findings of Perrin et al. (2005) and Boivin et al. (2007) are particularly interesting as 
they implicate impairment of WD and the macrophage response in the alleviation of pain-
related behaviours. Their work is supported by a previous study that used C57BL/WLD 
mice, which exhibit reduced rates of WD as a result of over-expression of the nicotinamide 
mononucleotide adenylyltransferase gene (Myers et al., 1996; Mack et al., 2001). These mice 
displayed delayed macrophage recruitment and WD that correlated with attenuated nerve 
injury-induced thermal hyperalgesia compared to WT controls (Myers et al., 1996). In 
addition, macrophage depletion via systemic administration of clodronate-containing 
liposomes not only reduced axonal degeneration but also alleviated mechanical and thermal 
hyperalgesia (Liu et al., 2000; Barclay et al., 2007). Correspondingly, mechanical thresholds 
increased by the time the macrophage population recovered at 8 days post injury, as 
revealed by ED1 and ED2 immunoreactivity in the spleen (Barclay et al., 2007). Notably, 
macrophages have been shown to play a limited role in mechanical allodynia and neither 
systemic/perineural administration of a macrophage inihibitor nor depletion or transfer of 
activated macrophages to the perineurium can alter mechanical thresholds (Rutkowski et 
al., 2000; Barclay et al., 2007).  
 
Interestingly, evidence from pain models of disease associated pathologies suggests that 
macrophages play a modality specific role in neuropathic pain mechanisms that is very 
much dependent on aetiology. For example, in a model of streptozotocin (STZ) -induced 
diabetes (where macrophages infiltrate L4/L5 DRGs by 1 week and diabetic nerves by 
weeks 2 and 3) depletion via clodronate treatment alleviated beta cell damage and 
mechanical allodynia, but not thermal hyperalgesia (Conti et al., 2002; Mert et al., 2009; Ton 
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et al., 2013). Similarly, in rat models of HIV-1 or chemotherapy-induced neuropathy, the 
infiltration of peripheral macrophages into the sciatic nerve and DRG correlated with 
mechanical allodynia (Peters et al., 2007b; Peters et al., 2007a; Wallace et al., 2007b; Liu et 
al., 2010; Kamerman et al., 2012). Accordingly, pre-treatment with minocycline diminished 
paclitaxel-evoked allodynia and attenuated macrophage infiltration (Liu et al., 2010). In a 
model of vincristine-induced pain it was reported that expression of IL-6 was co-localised 
with infiltrating macrophages in the sciatic nerve and lumbar DRG. Correspondingly, 
administration of an IL-6 neutralising antibody to the sciatic nerve attenuated mechanical 
allodynia and IL-6 KO mice showed reduced behavioural hypersensitivity (Kiguchi et al., 
2008b).  
 
Attenuation in neuropathic pain-associated behaviours in TLR2, 3 and 4 null mice has 
mainly been attributed to an impaired microglial response (Tanga et al., 2005; Kim et al., 
2007a; Obata et al., 2008). However, a recent study using TLR2 null mice supported a 
prominent role of peripheral macrophages in behavioural hypersensitivity and found no 
evidence of microglial involvement (Shi et al., 2011). Here, it was reported that thermal 
hyperalgesia was abolished in nerve-injured TLR2 KO mice whilst mechanical allodynia was 
partially attenuated. This correlated with a reduction in macrophage infiltration as well as a 
decrease in the expression of IκB-α and TNF-α in the injured sciatic nerve of KO mice at 14 
days post injury. In contrast, WT mice exhibited normal thresholds and an increase in these 
markers, which co-localised with ED1+ cells (Shi et al., 2011). In contradiction with previous 
findings (Kim et al., 2007a), Shi et al. (2011) found no evidence of a microglial phenotype 
and reported that expression of TLR2 and IκB-α mRNA was undetectable in the spinal cords 
of WT mice, but strikingly induced along with TNF-α in injured sciatic nerves. 
   
Peripheral inflammatory models such as carrageenan and CFA are thought to mediate their 
effects in a TLR-dependent manner (Bhattacharyya et al., 2008) and evoke the release of 
ATP from monocytes, which in turn activates P2X4 receptors via autocrine signalling. This 
leads to the mobilisation of Ca2+ and subsequent phosphorylation of p38 and the release of 
pro-inflammatory PGE2. Mice deficient in the expression of P2X4 show attenuated formalin, 
CFA or carrageenan-induced pain behaviours due to a reduction in PGE2-driven neuronal 
hyperexcitability (Ulmann et al., 2010). This effect is attributed to resident macrophages in 
the paw, as the expression of P2X4 is restricted to this cell type. In support of this, transfer of 
ATP-primed WT but not KO macrophages to the hind paws of naïve mice recapitulated pain 
behaviours (Ulmann et al., 2010). Interestingly, CCR2 null mice also exhibit marked 
reductions in inflammatory and neuropathic pain behaviours, linked to a diminished 
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microglial response and evidence of reduced monocyte recruitment (Izikson et al., 2000; 
Abbadie et al., 2003). 
 
Macrophages contribute significantly to inflammatory pain by releasing many inflammatory 
mediators (Marchand et al., 2005). Intraperitoneal administration of zymosan and acetic 
acid elicited dose-dependent writhing responses which could be enhanced by peritoneal 
pre-treatment with thioglycollate, or reduced by macrophage removal via saline lavage 
(Ribeiro et al., 2000). The aforementioned experiments illustrate that the pain response is 
dependent on the number of macrophages present in the peritoneal cavity. Furthermore, it 
was also shown that this response was dependent on the release of TNF-α, IL-1β and IL-
8/CXCL8, as pre-treatment with corresponding neutralising antibodies attenuated 
nociceptive behaviours, whereas administration of all three recombinant cytokines induced 
hypernociception in mice (Ribeiro et al., 2000). These findings are further supported by a 
study that demonstrated that intraperitoneal administration of LPS-stimulated macrophage 
supernatants produced nociceptive writhing responses in rats that could be inhibited via 
pre-treatment with dexamethasone, paracetamol or indomethacin (Thomazzi et al., 1997). It 
was also shown that pre-incubation of LPS stimulated macrophage supernatants with 
neutralsing antibodies for TNF-α, IL-1β and IL-8/CXCL8 produced some alleviation of pain 
behaviours (Thomazzi et al., 1997). Accordingly, intraplantar administration of LPS or 
carrageenan evoked mechanical hyperalgesia and an increase in TNF-α and IL-1β 
immunoreactivity in the skin of treated paws (Cunha et al., 2000). 
 
Macrophage-derived mediators such as TNF-α, IL-1β, IL-6, CCL3, PGs and nitric oxide (NO) 
may directly or indirectly contribute to the development of hyperalgesia (Woolf and Ma, 
2007; Austin and Moalem-Taylor, 2010). For example, PGs are up-regulated in macrophages 
located in the peripheral nerve and contribute to the development of pain behaviours by 
directly sensitising nociceptors and increasing neuronal excitability (Samad et al., 2002; Ma 
and Eisenach, 2003b). TNF-α and IL-1β have been documented to increase in the sciatic 
nerve and spinal cord of STZ-treated rats, and IL-1β was co-localised with ED-1 positive 
macrophages in the nerve (Conti et al., 2002; Drel et al., 2010; Bishnoi et al., 2011). TNF-α 
has also been reported to co-localise with ED-1 positive macrophages in the sural nerves of 
patients with established diabetic neuropathy, though this was not a model of pain 
(Kawamura et al., 2008). In the injured sciatic nerves of mice, the dramatic up-regulation of 
CCL3 is thought to contribute to macrophage recruitment and hence the development of 
neuropathic pain (Kiguchi et al., 2010a). Perineural administration of anti-CCL3 delays the 
onset of hypernociception, whereas intraneural or perineural application of recombinant 
CCL3 evokes allodynia and thermal hyperalgesia. Furthermore, perineural application of 
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nicotine, which acts at nicotinic acetylcholinergic receptors to suppress cell migration and 
cytokine expression, reduces both pain behaviours and the expression of CCL2 and IL-1β 
(Cloez-Tayarani and Changeux, 2007; Kiguchi et al., 2010a).   
 
1.8.4 T cells 
 
T lymphocytes are effector cells of the adaptive immune system and are derived from 
haematopoietic stem cells in the bone marrow. Later these cells transit into the blood 
stream and populate the thymus where they mature into thymocytes (Schwarz and 
Bhandoola, 2006). T cells are a heterologous population of immune cells comprising of CD4+ 
T-helper (Th) cells, CD8+ cytotoxic T (Tc) cells or CD4+ regulatory T cells (Tregs) and upon 
maturation and selection they exit the thymus and enter the blood circulation. Th cells may 
be further subdivided into pro-inflammatory Th1 cells or anti-inflammatory Th2 cells, 
which depends greatly on the transcription factors they induce and a number of external 
cues (cytokines). A Th1 phenotype is directed by IL-12 and these cells produce INF-γ 
through a STAT 4 dependent pathway, whereas a Th2 phenotype is directed by IL-4 and 
these cells also produce IL-4 along with IL-5 through a STAT 6 dependent pathway (O'Garra 
and Arai, 2000). Th1 cells promote cellular immunity and play an important role in the 
removal of various types of pathogens such as bacteria, parasites, yeasts and viruses. 
Characteristically, this T cell phenotype produces INF-γ and TNF-α and tends to be 
associated with the recruitment of NK cells and cytotoxic CD8+ T cells. On the other hand 
Th2 cells mainly mediate humoral immunity and typically produce IL-4, IL-5 and IL-13. This 
class of T cells engage mast cells and eosinophils in the removal of parasites and suppress 
macrophage activation and the production of pro-inflammatory cytokines (O'Garra and Arai, 
2000). (Moalem et al., 2004) 
 
The first implication of T cells in nociception came from a study examining the inflammatory 
response in three models of neuropathic pain in rats. Here it was found that after CCI, PNL 
or ischaemic lesion/transection injury, there was a considerable increase in T cells in the 
injured sciatic nerve compared to sham controls (Cui et al., 2000). Moalem and Yu (2004) 
later reported that T cell infiltration into the sciatic nerve occurs as soon as 3 days post CCI, 
which peaks at day 21 and remains present for 5-6 weeks. They also demonstrated that 
nerve-injured congenitally athymic nude rats, which lack mature T cells, exhibit attenuated 
mechanical allodynia and thermal hyperalgesia. To further elucidate the role of T cells in 
neuropathic pain, Moalem and Yu (2004) subsequently showed that the application of Th 
cells polarised to either a pro-inflammatory Th1 phenotype or anti-inflammatory Th2 
phenotype elicited behavioural hypersensitivity in nude rats or modestly attenuated pain 
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behaviour in littermate controls, respectively. These findings were later confirmed in nude 
and recombinant activating gene-1 null mice (Rag-1; encodes an enzyme essential for T-cell 
maturation) that again exhibited attenuated mechanical hypersensitivity after nerve injury, 
which was reversed by adoptive transfer of CD4+ leukocytes (Cao and DeLeo, 2008; Costigan 
et al., 2009b). It has also been reported that T cells infiltrate the dorsal horn, peaking at 7 
days post injury. Interestingly, nude rats exhibited reduced GFAP immunoreactivity in the 
spinal cord, which is suggestive of a possible T cell-glial interaction in nociceptive 
transmission (Cao and DeLeo, 2008).   
 
In contrast to adult rats, nerve-injured neonatal rats do not develop neuropathic pain, which 
is a striking phenomenon also observed in humans. One of the most important studies 
illustrating the T cell contribution to neuropathic pain delineated the transcriptional profile 
differences in the dorsal horn between adult and neonatal rats. It was identified that in the 
setting of nerve injury a greater microglial and T cell response occurred in adult rats 
compared to younger animals. Central chemokine profiles were also different between these 
two age groups and INF-γ was particularly up-regulated in the dorsal horns of adults but not 
neonates (Costigan et al., 2009b). Furthermore, it has also been shown that although 
neonates have a limited Th population, they possess a relatively larger Th2 population, 
which may account for the differences in pain responses compared to adults (Morein et al., 
2007). 
 
Despite the selection process which only allows functional, non self-reactive T cells into the 
periphery, some autoreactive T cells escape thymic censorship and are released into the 
circulation. T cells are associated with many autoimmune diseases that are accompanied by 
debilitating pain symptoms, such as Guillain-Barré Syndrome (GBS). In a model of 
experimental autoimmune neuritis (EAN) that mimics acute inflammatory demyelinating 
polyradiculoneuropathy in GBS, rats exhibited neuropathic pain-associated behaviours that 
coincided with significant T cell infiltration into the sciatic nerve (Moalem-Taylor et al., 
2007). Similarly, in experimental autoimmune encephalomyelitis (EAE; model of MS) mice 
developed mechanical allodynia during the early disease stages, where significant T cell 
infiltration into the superficial dorsal horn was accompanied by increased glial reactivity 
(Olechowski et al., 2009).  
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1.9 Glia and pain 
 
In the CNS, glial cells (astrocytes, oligodendrocytes and microglia) account for 
approximately 70% of the total cell population and are involved in the formation of the 
blood brain barrier, the development of the myelin sheath and defence against invading 
pathogens or damage. Glial cells also regulate neuronal function via neurotransmitter 
release and express an array of receptors/ion channels that allow them to directly respond 
to neuronal signals. In the PNS, glial cells (satellite cells and Schwann cells) also undertake 
numerous roles in metabolic and ionic homeostasis, myelin sheath development and trophic 
support. 
 
Over the past two decades glial cells, particularly microglia and astrocytes, have received 
considerable attention for their involvement in chronic pain, stemming from some of the 




Del Rίo-Hortega was the first to introduce the concept of microglia with a series of 
published studies between 1919 and 1927, which adopted the classic silver carbon labelling 
technique. The origin of these cells has long been the subject of great controversy within the 
glial field. Initially it was believed that microglia were of mesodermal origin and Rio-
Hortega postulated that these cells invaded the brain early during development where they 
matured into amoeboid cells. Although this view was widely accepted, others disagreed and 
proposed that glioblasts of the neuroectoderm were the precursors of microglial cells and 
thus argued that all glial cells shared a common stem cell population (Paterson et al., 1973; 
Kitamura et al., 1984). The third view, which was originally proposed by Leblond and 
colleagues in the 1930s was that microglia are of the monocytic lineage. This theory was 
later verified using autoradiography, which showed that amoeboid microglia exhibiting 
monocytic characteristics later transformed into ramified microglia (Imamoto and Leblond, 
1978; Ling et al., 1980). These findings were further validated by subsequent studies and 
the use of newly developed immunohistochemical markers (Perry et al., 1985; Graeber et al., 
1988). 
 
It is now generally accepted that microglial cells are of the monocytic lineage and share 
many functional similarities of peripheral monocytes/macrophages. Recent findings suggest 
that these cells originate from the foetal yolk sac and migrate into the CNS during early 
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embryonic development; however microglia are also thought to differentiate from 
circulating monocytes entering the CNS during the early stages of postnatal development 
(Perry et al., 1985; Saijo and Glass, 2011). Under normal conditions microglia are in a 
‘quiescent’ state and are involved in immune surveillance and CNS homeostasis. In this state 
microglia morphology is typically ramified with a small cell body and fine long projections 
that continuously survey the local microenvironment. However, subsequent to infection or 
injury microglia undergo considerable morphological changes; their processes shorten and 
thicken and their distal branches become de-ramified. Their cell bodies also increase in size 
and adopt a more rounded ‘amoeboid’ shape. Microglia also up-regulate multiple cell 
surface glycoproteins (MHC-II, CD45), considerably increase in numbers by means of 
proliferation and enhanced migratory capacity, become more phagocytic and release a 
range of pro-inflammatory substances. This response is collectively referred to as 
microgliosis (Ransohoff, 2007; Ransohoff and Perry, 2009). As microglia express a 
repertoire of ionotropic and metabotropic receptors, it is apparent that a single mechanism 
of activation is unlikely, and that these cells are engaged by various signals that lead to 
different morphological and secretory responses. Such signals include invading pathogens 
or nerve/tissue damage, which is accompanied by the release of a number of mediators such 
as ATP, glutamate, cytokines, chemokines, PGs, neuropeptides and NO. In turn microglia 
release a repertoire of neuroexcitatory substances, which directly/indirectly excite and 
sensitise dorsal horn neurons and thus enhance nociceptive transmission, leading to 
hyperalgesia and allodynia (DeLeo and Yezierski, 2001; Watkins et al., 2001; Watkins and 
Maier, 2003). 
 
The role of microglia in chronic pain mechanisms has been well characterised in a number 
of neuropathic and inflammatory pain paradigms. Many of the initial findings were based on 
studies using general glial inhibitors, which proved to be effective in reducing/preventing 
hyperalgesia and allodynia in animal pain models (Meller et al., 1994; Watkins et al., 1997; 
Sweitzer et al., 2001; Raghavendra et al., 2003a; Raghavendra et al., 2003b; Hua et al., 2005; 
Ledeboer et al., 2005; Clark et al., 2007a). Fluorocitrate attenuates metabolic activity 
specifically in glial cells by inhibiting the enzyme aconitase and consequently blocking the 
citric acid cycle (Goncharov et al., 2006). Propentofylline is a derivative of methyl xanthine 
and mediates its glia suppressing effects via the inhibition of adenosine transporters and 
phosphodiesterases, which leads to a reduction in cAMP (Tawfik et al., 2008). Minocycline 
belongs to the tetracycline class of antibiotics and exerts a number of inhibitory effects on 
microglial cells, including the suppression of iNOS and IL-1 as well as the phosphorylation of 
p38 MAPK (Lai and Todd, 2006). Although much of the work using propentofylline and 
fluorocitrate illustrated the involvement of glial cells in the regulation of pain sensitivity, 
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these inhibitors failed to distinguish which glial cell type is involved. Furthermore, their 
biological actions lacked the necessary selectivity to be entirely convincing, with even 
suspected effects on neuronal function. On the other hand, the literature supports a selective 
mode of action of minocycline in microglial cells. In one study minocycline reduced the 
development of nerve injury induced neuropathic pain but failed to attenuate existing 
mechanical allodynia and hyperalgesia (Raghavendra et al., 2003a), indicating that microglia 
may play a more important role in the initiation rather than maintenance of chronic pain. 
Conversely, it has also been demonstrated that administration of agents capable of directly 
activating microglia, including LPS and the HIV glycoprotein 120, evoke nociceptive 
behaviours in naïve rats (Milligan et al., 2000; Cahill et al., 2003; Clark et al., 2006). 
 
Out of the three glial inhibitors discussed, propentofylline is the only one that has been 
taken to a high-profile clinical trial and failed to show efficacy in alleviating pain associated 
with post-herpetic neuralgia. In cases like this, the lack of translation from pre-clinical 
rodent models of pain to humans is thought to be due to a number of reasons such as the 
lack of predictability of animal models, functional differences between rodent and human 
microglia and different methods of pain measurement (evoked pain vs spontaneous pain). 
Such failures highlight the limitations of preclinical research and emphasise the importance 
of using human tissues and primary cells to improve translation to the human condition 
(Landry et al., 2012). 
 
Progression on to more targeted interventions has led to a wealth of literature exploring 
specific microglial receptors using pharmacological tools and transgenic technology. Like 
peripheral macrophages, microglia express a number of TLRs, which initiate a cellular 
response upon detection of numerous endogenous and exogenous danger signals, as 
previously described (section 1.8.3). The expression of TLR4 is exclusive to microglia in the 
CNS, which has been shown to up-regulate in the spinal cord of nerve-transected rats as 
soon as 4 hours post surgery up until day 14 (Tanga et al., 2004). In a later study, Tanga et 
al. (2005) showed that nerve-injured TLR4 KO mice exhibited attenuated mechanical 
allodynia and thermal hyperalgesia compared to WT controls, which correlated with 
reduced microglia reactivity in the spinal cord as revealed by OX-42 (cluster of 
differentiating molecules 11b; CD11b) staining. These studies suggest that TLR4 signalling 
contributes to the activation of microglia during the induction of neuropathic pain. 
Moreover, as reduced microglia activity is associated with attenuated pain behaviours it is 
evident that these cells are important in chronic pain pathways. This is further supported by 
studies examining the function of other microglial receptors in models of neuropathic pain, 
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such as CX3CR1, P2X4, P2X7 and CCR2 (Abbadie et al., 2003; Tsuda et al., 2003; Chessell et al., 
2005; Tanga et al., 2005; Clark et al., 2010b; Staniland et al., 2010). 
 
In contrast to neuropathic models of traumatic nerve injury, evidence for microglial 
involvement in models of peripheral inflammatory pain is circumstantial (McMahon et al., 
2005; McMahon and Malcangio, 2009). Intraplantar administration of various inflammogens 
such as zymosan, formalin, carrageenan and CFA elicit hypersensitivity of the ipsilateral 
hind paw. However, the extent of the glial response is notably moderate and discrepancies 
between groups are evident throughout the literature. For instance, many studies have 
reported contradictory observations on the regulation of glial cell markers in numerous 
inflammatory models; whilst some failed to observe any change in the microglial response 
(Molander et al., 1997; Honore et al., 2000; Zhang et al., 2003; Clark et al., 2007a) others 
have reported clear changes (Fu et al., 1999; Sweitzer et al., 1999; Sweitzer et al., 2001; Yeo 
et al., 2001; Aumeerally et al., 2004; Raghavendra et al., 2004), which is supported by 
studies using glial inhibitors, particularly minocycline (Meller et al., 1994; Watkins et al., 
1997; Hua et al., 2005). It should be noted, however, that differences between inflammatory 
models and time points examined may account for some of the discrepancies. Furthermore, 
many of these studies have used markers such as OX-42 and ionised calcium binding 
adaptor molecule 1 (Iba1) to illustrate microglia activation but it remains unclear whether 
these markers are associated with pain hypersensitivity. Nevertheless, certain microglial 
markers such as P2X4, CX3CR1 and TLR4 are up-regulated in the context of 
injury/inflammation and inhibition of these receptors attenuates neuropathic/ 
inflammation-induced pain (Tsuda et al., 2003; Tanga et al., 2004; Zhuang et al., 2007; Clark 
et al., 2012). In addition to these exclusive markers, strong evidence for microglial 
involvement in inflammation-induced pain has been demonstrated using p-p38 MAPK as a 
marker of microglia activation, which is a nociceptive specific kinase (Kim et al., 2002; 
Kumar et al., 2003; Svensson et al., 2003a; Svensson et al., 2003b; Ji and Suter, 2007; Ji et al., 
2009; Clark et al., 2012). 
 
MAPKs are an evolutionally conserved family of molecules that possess various roles in gene 
expression and cell signalling. MAPKs are comprised of three main members: ERK (1 and 2), 
p38 (α,β,γ,δ) and JNK (1-3), which are activated via MAPK kinase mediated phosphorylation 
and exert a range of transcriptional-dependent and independent effects (Ji et al., 1999). 
Phosphorylated p38 is induced by pro-inflammatory cytokines and a number of cell 
stressors, and has a crucial role in inflammatory responses. Accordingly, the administration 
of p38 inhibitors in models of inflammatory and neuropathic pain confers analgesia (Ji and 
Woolf, 2001; Ji et al., 2002; Kumar et al., 2003; Svensson et al., 2003a; Svensson et al., 
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2003b; Tsuda et al., 2004; Clark et al., 2006; Ji and Suter, 2007). Activated microglia produce 
numerous inflammatory mediators such as IL-1β, IL-6, TNF-α, PGE2, NO and BDNF (Ji and 
Suter, 2007), some of which can induce the activation of p38 (Ji and Woolf, 2001; Abbadie et 
al., 2003; Svensson et al., 2005). In turn, p38 regulates the transcription of many mediators 
in an NF-κB dependent manner, particularly IL-1β, IL-6 and TNF-α (Ji and Woolf, 2001; 
Svensson et al., 2003a; Sung et al., 2005; Clark et al., 2006). These cytokines contribute to 
central sensitisation via a combination of modulatory effects on excitatory and inhibitory 
synaptic transmission, which involve the phosphorylation of CREB and transcription of pro-
nociceptive genes (Kawasaki et al., 2008).  
 
The modulation of microglial activation has also proven to be efficacious in some pain 
models of disease-associated pathologies. For example, inhibition of p-p38, pERK1/2, p-Src 
and p-JNK via the administration of gabapentin, minocycline, lidocaine or MAPK inhibitors 
prevented/reversed microglial activation and hence alleviated the development of diabetic 
and paclitaxel-induced neuropathic pain in rats (Sweitzer et al., 2004; Daulhac et al., 2006; 
Tsuda et al., 2008; Wodarski et al., 2009; Pabreja et al., 2011; Suzuki et al., 2011; Burgos et 
al., 2012). Correspondingly, the inhibition or modulation of mediators released by activated 
microglia also attenuates behavioural hypersensitivity. Intrathecal administration of a TNF-
α neutralising antibody or an IL-1 receptor antagonist reduced vincristine or paclitaxel-
induced mechanical allodynia, respectively, whilst  IL-10 gene therapy prevented and 
reversed the allodynic state in paclitaxel-treated rats (Ledeboer et al., 2007; Kiguchi et al., 
2008a). Similarly, gp120-treated rats exhibited spinal microgliosis that correlated with the 
development of behavioural hypersensitivity, whereas treatment with minocycline or a 
TNF-α neutralising antibody attenuated these behaviours (Herzberg and Sagen, 2001; 
Wallace et al., 2007b; Wallace et al., 2007a; Zheng et al., 2011b; Blackbeard et al., 2012). 
Microglial activation is also documented to contribute to bone cancer-induced neuropathic 
pain (Zhang et al., 2005b; Mao-Ying et al., 2012). Early minocycline treatment prevented 
bone cancer-induced behavioural hypersensitivity by inhibiting the release of BDNF from 
microglial cells. Concurrent treatment with fluorocitrate or an ERK kinase inhibitor reduced 
spinal p-ERK expression and attenuated mechanical allodynia (Wang et al., 2011; Wang et 
al., 2012a; Wang et al., 2012b). Furthermore, intrathecal administration of a CCL2 
neutralising antibody attenuated bone cancer-induced pain possibly by inhibiting 
microglial-neuronal communication (Hu et al., 2012). 
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1.9.2 Astrocytes, Schwann cells and satellite cells 
 
Astrocytes are the most abundant cell population of the CNS and arise from neuroepithelial 
stem cells, sharing the same origin as oligodendrocytes and neurons. These cells form close 
connections with neurons and capillaries and are active cells that are normally involved in 
regulating most aspects of neuronal function (Butt, 2011). Garrison et al. (1991) were 
amongst the first to propose a role for astrocytes in neuropathic pain by describing 
astrocytic hypertrophy in the spinal cord of nerve-injured rats, which was evident by an 
increase in glial fibrillary acidic protein (GFAP) immunoreactivity. This result triggered 
many more studies that confirmed the reactive astrocytic phenotype in a number of models 
of inflammatory and neuropathic pain (Sweitzer et al., 1999; Ma and Quirion, 2002; Gao et 
al., 2009).  
(Garrison et al., 1991) 
Astrocytes are believed to play a prominent role in the maintenance of neuropathic pain, as 
illustrated by studies that show astrocytic activation succeeding microglial activation at 4 
days and lasting up to 12 weeks post peripheral nerve injury in rats (Tanga et al., 2004). 
This temporal dissociation between microglia and astrocytes is supported by the fact that 
neuropathic GFAP null mice exhibit initial development of behavioural hypersensitivity but 
the duration of these pain behaviours is considerably shorter (Kim et al., 2009). In the 
context of injury/tissue damage, astrocytes, like microglia, are engaged by a wide range of 
neurotransmitters that initiate the transition into a reactive astrocytic state. Once activated, 
these cells may in turn release many mediators including PGs, NO, glutamate, ATP, cytokines 
and chemokines (Hansen and Malcangio, 2013; Mika et al., 2013) that directly or indirectly 
contribute to pain hypersensitivity.  
 
In the PNS there are two main types of glial cells, the Schwann and satellite cells. Schwann 
cells are derived from the neural crest and comprise of two main phenotypes: the 
myelinating Schwann cell and the ensheathing/non-myelinating Schwann cell (Campana, 
2007). Myelinating Schwann cells wrap around medium and large diameter axons and 
provide a lipid rich membrane that facilitates axonal conduction, whereas non-myelinating 
Schwann cells ensheath unmyelinated small diameter axons in small bundles known as 
Remak bundles (Murinson and Griffin, 2004). Satellite cells surround neuronal somas within 
the DRG and are thought to exert similar metabolic homeostasis functions as astrocytes (Lu 
and Richardson, 1991). In the context of nerve injury, Schwann cells mediate the process of 
WD by orchestrating demyelination and nerve regeneration (Campana, 2007). Shortly after 
nerve injury Schwann cells undergo a phenotypic switch and stop producing myelin 
proteins, proliferate, migrate and release multiple mediators such as cytokines (IL-1β, TNF-
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α, IL-6, CCL2), growth factors (NGF, BDNF, GDNF), PGE2 and ATP. These mediators sensitise 
nociceptors through direct or indirect mechanisms and promote the recruitment of other 
immune cells, namely via CCL2-mediated recruitment of macrophages (Shamash et al., 
2002; Tofaris et al., 2002; Muja and DeVries, 2004; Austin and Moalem-Taylor, 2010; Gaudet 
et al., 2011). In the DRG, satellite cells also become activated and proliferate extensively (Lu 
and Richardson, 1991), leading to an increase in GFAP immunoreactivity and the release of 
pro-inflammatory cytokines (IL-1β, TNF-α), which contribute to enhanced neuronal firing 
(Takeda et al., 2007).  
 
From the literature it is clear that the release of mediators from immune cells significantly 
contributes to the development and maintenance of hypersensitivity. Therefore it is 
plausible that blocking the release of these signalling molecules or their receptors may 
alleviate pain. For example, anti-NGF treatment effectively reverses established 
hyperalgesia in rodent models of inflammatory and neuropathic pain (Wild et al., 2007), 
whilst anti-TNF-α therapy is a clinical success in the treatment of RA (Haraoui, 2005). 
 
1.10 Cytokines and chemokines 
 
The contribution of pro-inflammatory cytokines and chemokines to the exacerbation of 
inflammatory and neuropathic pain is supported by a wealth of studies. These signalling 
molecules are released by resident dendritic cells, macrophages, lymphocytes and mast cells 
as well as other cell types of the nervous system in response to various stimuli. 
Cytokines/chemokines signal in an autocrine, paracrine or hormonal fashion and have 
multiple roles in the modulation of the immune system and the inflammatory response 
(Sommer and Kress, 2004; Wells et al., 2006; Kiguchi et al., 2012).  
 
Cytokines are small polypeptides (5-140kDa) with diverse molecular structures and 
relatively short half-lives and can be categorised into four main groups: growth factors, 
interleukins, interferons and TNF. The members of these groups can also be further 
classified as pro- or anti-inflammatory, depending on their primary function. Pro-
inflammatory cytokines (IL-1β, TNF-α, IL-6, IL-12, IL-15, IL-17, IL-18, IFN-γ) promote an 
inflammatory response and are implicated in nociception by facilitating neurogenic 
inflammation (Opree and Kress, 2000). In contrast, anti-inflammatory cytokines (IL-4, IL-10, 
TGF-β) suppress the immune response. On the other hand, chemokines form a distinct 
group of chemotactic cytokines that possess exclusive chemical properties. They are 
typically much smaller than cytokines with a molecular weight ranging from 8-10kDa and 
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act on cell membrane expressed GPCRs coupled to the inhibitory Gαi/o family of G-proteins. 
Functionally, this group of approximately 50 signalling molecules exhibits great redundancy 
and overlap, as there are several ligands for each of the 20 receptors. Likewise, single 
chemokines are recognised by multiple receptors expressed by a range of cell types 
including leukocytes, neurons and glial cells (Ubogu et al., 2006). Generally, chemokines 
consist of four or more cysteine residues that form disulphide bonds, and are thus classified 
into 4 main groups according to the position of the first two conserved cysteine residues 
near the N-terminus (see Fig. 1.4). The CC group constitutes the largest family of 
chemokines and possesses 2 adjacent cysteines (CCL2, CCL3, CCL4, CCL5). This chemokine 
group predominantly attracts macrophages and eosinophils. The CXC group has a single 
amino acid between the two cysteine residues and may be further divided based on the 
presence or absence of an ELR motif (glutamic acid-leucine-arginine) on the N-terminus just 
before the CXC (CXCL5, CXCL8). These chemokines primarily recruit neutrophils, while the 
non-expressing ELR motif chemokines are involved in lymphocyte recruitment (CXCL9, 
CXCL10, CXCL12, CXCL13) (Clark-Lewis et al., 1991; Ubogu et al., 2006; Verri et al., 2006). 
The CX3C group features 3 amino acids between the two cysteine residues and has currently 
a single member (CX3CL1 (fractalkine)) that acts on multiple cell types including monocytes, 
T lymphocytes and natural killer cells. Unlike the other groups, chemokines of the C family 
only have a total of 2 cysteines (Chemokine (C motif) ligand (XCL) 1 and 2) and 
preferentially recruit lymphocytes (Zlotnik and Yoshie, 2000; Verri et al., 2006). 
 
A number of groups have demonstrated the onset of mechanical and thermal hyperalgesia 
subsequent to local, intraneural, systemic or intrathecal injection of cytokines and 
chemokines, which can be reversed via neutralising antibodies or inhibitors (Ferreira et al., 
1988; Follenfant et al., 1989; Cunha et al., 1992; Safieh-Garabedian et al., 1995; Woolf et al., 
1997; Sung et al., 2004; Zelenka et al., 2005). Furthermore, in experimental models of 
neuropathic and inflammatory pain these cytokines and their receptors are up-regulated in 
the sciatic nerves and DRG neurons of rodents. Accordingly, pre-treatment with neutralising 
antibodies or inhibitors exhibits analgesic effects (Ferreira, 1980; Cunha et al., 1991; Cunha 
et al., 1992; Murphy et al., 1995; Safieh-Garabedian et al., 1995; DeLeo et al., 1996; Woolf et 
al., 1997; Cunha et al., 2000; Ribeiro et al., 2000; Shubayev and Myers, 2000; Okamoto et al., 
2001; Homma et al., 2002; Sommer and Kress, 2004; Svensson et al., 2005; Marchand et al., 
2009). Some of these experiments are discussed in more detail in Chapters 2 and 3.  
 
Cytokines generate a state of hypersensitivity by exerting a combination of direct and 
indirect effects. This is supported by evidence of the expression of cytokine receptors on 
peripheral axons, suggesting that their ligands are able to directly mediate sensitising 
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effects on nociceptors (Sommer and Kress, 2004). For example, subsequent to nerve injury 
there is a marked increase in the expression of the TNF-α receptors, TNF 1 and 2, in 
peripheral nerve axons, DRG somata, peripheral immune cells and spinal microglia (Ohtori 
et al., 2004; George et al., 2005). Therefore, it is likely that TNF-α signalling can directly 
induce the excitation of sensory neurons and contribute to the development of 
hypersensitivity. The IL-1β receptor, IL-1R, is also expressed by DRG neurons indicating that 
IL-1β may mediate direct sensitising effects via an IL-1R/tyrosine kinase/PKC-dependent 
pathway (Sommer and Kress, 2004). However, in most cases the algesic effects of cytokines 
are mediated indirectly via the induction of other mediators such as PGE2, which directly 
bind to their cognate receptors on nociceptor afferents and sensitise them. Evidence of this 
was shown in earlier studies, where pre-treatment with intraplantar indomethacin (COX 
inhibitor) attenuated IL-1β or IL-6 evoked behavioural hyperalgesia, whilst pre-treatment 
with atenolol (B1 blocker) attenuated IL-8/CXCL8 evoked hyperalgesia (Cunha et al., 1991; 
Cunha et al., 1992), indicating that these cytokines can elicit their effects indirectly via the 
COX pathway or the sympathetic nervous system, respectively. In accordance with these 
findings, later studies showed that IL-1β and TNF-α signalling induces NF-κB mediated 
transcription of a number of genes including COX-2, NO, IL-1β, TNF-α and IL-6 (Pahl, 1999; 
Moalem and Tracey, 2006). IL-1β has also been shown to mediate thermal hyperalgesia via 
activating the iNOS-NO cascade in the spinal cord (Sung et al., 2004). Furthermore, IL-6 
promotes the induction of BDNF in rat DRG neurons, which is attenuated in IL-6 KO mice 
(Murphy et al., 2000). These mice also exhibited attenuated pain hypersensitivity after 
injury, suggesting that IL-6 contributes to sensitisation via BDNF synthesis (Murphy et al., 
2000). IL-6 also promotes OX-42 expression in spinal microglia as well as the up-regulation 
of the chemokine CX3CR1 (Latremoliere et al., 2008; Lee et al., 2010). 
 
In the spinal cord, pro-inflammatory cytokines secreted by microglia and astrocytes 
enhance neuronal excitability and synaptic transmission, which are characteristic features 
of central sensitisation (Woolf and Salter, 2000; DeLeo and Yezierski, 2001; Watkins et al., 
2001). IL-1β, TNF-α and IL-6 perfusion can augment excitatory AMPAR and NMDAR-
induced currents, while IL-1β can inhibit GABAergic and glycinergic currents in lamina II 
neurons (Kawasaki et al., 2008). These modulatory effects are possibly via the induction of 
protein kinases, which phosphorylate excitatory and inhibitory receptor subunits and 
mediate transcriptional-dependent changes that contribute towards long-term neural 
plasticity (Ji et al., 2003; Kawasaki et al., 2008). 
 
During inflammation the most important role of chemokines is the promotion of leukocyte 
migration and recruitment to the site of damage. Experimental evidence suggests that these 
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signalling molecules contribute to nociception mainly by activating immune cells in the 
periphery or spinal microglia. However, chemokines may also be able to exert direct effects 
via chemokine receptors expressed by primary afferent neurons or second order dorsal 
horn neurons. Similar to previous studies on cytokines; peripheral or central administration 
of chemokines elicits pain behaviours in rodents, which can be reversed via the 
administration of neutralising antibodies (Clark et al., 2007b; Thacker et al., 2009; Kiguchi et 
al., 2010b; Kiguchi et al., 2010a; Dawes et al., 2011). In addition, the development of pain 
behaviours is abolished in CCR2 and CX3CR1 (CX3CL1/fractalkine receptor) KO mice in 
various pain models (Abbadie et al., 2003; Staniland et al., 2010). 
 
In response to nerve injury macrophages infiltrate the peripheral nerve and DRG and up-
regulate the expression of the fractalkine receptor CX3CR1 and the production of the 
protease cathepsin S (CatS) and the chemokine IL-8/CXCL8 (Barclay et al., 2007; Holmes et 
al., 2008). CXCL8 was one of the first chemokines implicated in nociceptive transmission as 
intradermal injection produces hypersensitivity in rats, as previously discussed (Cunha et 
al., 1991). Similarly fractalkine is also pro-nociceptive when administered intrathecally and 
CX3CR1 null mice exhibit attenuated pain behaviours after nerve injury (Milligan et al., 2005; 
Clark et al., 2007b; Staniland et al., 2010). In the spinal cord the membrane-bound form of 
fractalkine is cleaved from neurons by the microglial-derived CatS and may subsequently 
bind to CX3CR1, which is exclusively expressed by spinal microglia (Clark and Malcangio, 
2012). This feedback mechanism initiates the activation of the p38 MAPK pathway and 
subsequent release of pro-inflammatory mediators that contribute to pain hypersensitivity 
(Clark et al., 2007b; Clark et al., 2011). In addition, intraplantar injection of CatS elicited 
transient mechanical hyperalgesia in naïve rats, whereas systemic administration of an 
irreversible CatS inhibitor reversed mechanical hyperalgesia in nerve-injured rats (Barclay 
et al., 2007).  
 
Other chemokines suggested to contribute to neuron-glia nociceptive transmission are CCL2 
and CCL3. Spinally released CCL2 and CCL3 from sensory neurons may recruit and activate 
CCR2+ and CCR1/CCR5+ microglia cells, respectively. This is supported by studies 
demonstrating that the exogenous application of CCL2 or CCL3 to the spinal cord induces 
microglia activation and hyperalgesia in rodents, which is abolished in CCR2 null mice or via 
the administration of CCL2 or CCL3 neutralising antibodies (Zhang et al., 2007; Kiguchi et al., 
2010b). In the periphery CCL2 is released in large amounts from Schwann cells and 
constitutes a crucial chemoattractant for infiltrating CCR2+ macrophages. The migration of 
macrophages occurs 2-3 days post injury, in accordance with the onset of WD (Gaudet et al., 
2011). Thus it is not surprising that CCR2 null mice show attenuated macrophage 
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recruitment and WD as well as reduced behavioural hypersensitivity (Siebert et al., 2000; 
Abbadie et al., 2003). CCL3-CCR1 signalling has also been proposed to elicit some 
interesting peripheral actions that contribute to pain hypersensitivity, such as the 
sensitisation of TRPV1 receptors in DRG neurons. CCR1 and TRPV1 are co-expressed in 
small to medium sized DRG neurons. Activation of CCR1 initiates PLC mediated hydrolysis of 
PIP3 and Ca2+ mobilisation. This leads to the activation of PKC, which is proposed to 
phosphorylate TRPV1 and remove inhibitory PIP2, leading to thermal hyperalgesia (Zhang 




Figure 1.4: Chemokine ligands and their receptors 
  
Chemokines are classified into 4 main groups (CC, CXC, CX3C, XC) according to the position of the first 
two conserved cysteine residues near the N-terminus. Functionally, this group of approximately 50 
signalling molecules exhibits great redundancy and overlap, as there are several ligands for each of 
the receptors. Likewise, single chemokines are recognised by multiple receptors expressed by a range 
of cell types including leukocytes, neurons and glial cells (Wells et al., 2006). 
 
Ligand Receptor
CCL3, 5, 6, 7, 8, 9, 13, 14, 15, 16, 23 CCR1
CCL2, 7, 8, 12, 13, 14, 16 CCR2
CCL5, 7, 8, 11, 13, 15, 24, 26, 28 CCR3
CCL17, 22 CCR4
CCL3, 4, 5, 6, 8, 11, 14, 16 CCR5
CCL20 CCR6
CCL19, 21 CCR7
CCL1, 4, 17 CCR8
CCL25 CCR9
CCL18, 26, 27, 28 CCR10
CXCL1, 5, 6, 8 CXCR1
CXCL1, 2, 3, 5, 6, 7, 8 CXCR2
CXCL9, 10, 11 CXCR3a
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Although only some of the literature concerning cytokines and chemokines in pain has been 
discussed, it is evident that these signalling molecules play a crucial and complex role in the 
development and maintenance of chronic pain in the nervous system. The immune system 
and its array of signalling molecules have been implicated in various diseases associated 
with chronic pain such as diabetes, MS, RA, fibromyalgia, Crohn’s disease and IBS (Sommer 
and Kress, 2004; Abbadie, 2005; McMahon et al., 2005; Austin and Moalem-Taylor, 2010; 
Calvo et al., 2012). In the clinic, evidence of elevated levels of chemokines and cytokines as 
well as increased leukocyte counts in diseased tissues have been reported in patients with 
various pain associated pathologies. For example, in patients with inflammation of the 
connective tissue, the severity of reported pain correlates with levels of TNF-α in the 
synovial fluid (Nordahl et al., 2000). Similarly, raised levels of CXCL8 or CCL2 were found in 
the cerebral spinal fluid (CSF) of patients with back pain and demyelinating polyneuropathy 
(Brisby et al., 2002; Ochi et al., 2003). In cohorts of patients with complex regional pain 
syndrome (CRPS), painful neuropathy or spinal cord injury, levels of pro-inflammatory TNF-
α, IL-2 and IL-6 were raised, whilst levels of anti-inflammatory IL-4 and IL-10 were reduced. 
Conversely, patients with painless neuropathy exhibited increased levels of anti-
inflammatory cytokines (Davies et al., 2007; Uceyler et al., 2007b; Uceyler et al., 2007a). In 
addition to raised expression of cytokines, evidence of increased inflammatory cell 
recruitment has been reported in patients. For example, patients with CRPS showed an 
enhanced pro-inflammatory monocyte phenotype, in contrast to healthy control patients 
(Ritz et al., 2011) and in nerve biopsies from neuropathic pain patients the severity of 
immune cell infiltration correlated with the extent of experienced pain (Lindenlaub and 
Sommer, 2003). Microgliosis in the thalamus of patients suffering from chronic phantom-
limb pain has also been documented in a PET scan study (Banati et al., 2001) and evidence 
of gliosis in the spinal cord has been reported in a post-mortem examination of a CRPS 
patient (Del Valle et al., 2009). Furthermore, patients with inflammatory diseases such as 
interstitial cystitis and chronic pancreatitis, where pain is a cardinal sign, have increased 
levels of mast cells compared to patients without pain (Oberpenning et al., 2002; 
Hoogerwerf et al., 2005). Approximately 90% of MS patients exhibit elevated levels of 
immunoglobulin G in the brain or cerebrospinal fluid, which is indicative of CNS 
inflammation (Gilden, 2005). Unsurprisingly CNS diseases such as Parkinson’s disease, 
Alzheimer’s disease and stroke may also be associated with a pro-inflammatory component 
and an altered immune cell presence (DeLeo and Yezierski, 2001), however further research 
is required to fully understand the mechanisms and implications of this. 
 
In conclusion, it is apparent that basic research as well as some clinical evidence strongly 
supports the role of immune cells and pro-inflammatory cytokines/chemokines in chronic 
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pain mechanisms. Therefore, the development of novel immunomodulatory analgesics that 
are selective for particular receptors could provide a successful approach in the treatment 
of chronic pain. Moreover, as chemokines signal via GPCRs, they are plausible targets for 
pharmacological manipulation with regards to the immense success of current drugs on the 
market that largely act on this class of receptors.  
 
1.11 GPR84 (EX33) 
 
In a series of screening studies GlaxoSmithKline identified the orphan GPR84 as a promising 
immune cell target in chronic pain pathways. Therefore, this thesis examines GPR84 as a 
novel candidate for the treatment of chronic pain.  Despite being discovered well over a 
decade ago, very little is known about GPR84 and its functional role. However, some groups 
have utilised transgenic mice and heterologous in vitro systems to elucidate the contribution 
of GPR84 in neuroimmune and neuroinflammatory processes. 
 
GPR84 consists of a generic heptahelical structure of a typical GPCR and is thought to belong 
to the rhodopsin superfamily, with little similarity to other known receptors. Expression 
analysis has revealed that this receptor is predominantly expressed in hematopoietic tissues 
in both humans and mice, and that particularly high levels of GPR84 mRNA are found in 
bone marrow. In the mouse there is also some expression in the spleen, lung and lymph 
nodes (Wittenberger et al., 2001; Yousefi et al., 2001; Wang et al., 2006a). Strikingly, GPR84 
expression is restricted to immune cells and exclusive to microglia in the CNS, while upon 
appropriate immune stimulation such as LPS exposure, GPR84 expression is considerably 
up-regulated. TNF-α and IL-1β can also induce GPR84 expression and accordingly, LPS-
induced GPR84 expression was attenuated in TNF-α and IL-1β null mice (Wang et al., 2006a; 
Bouchard et al., 2007; Lattin et al., 2008). This finding is consistent with the up-regulation of 
GPR84 mRNA in cortical and spinal microglia in a model of endotoxemia (systemic 
administration of LPS) and EAE and perhaps indicates a role in neuroinflammation 
(Bouchard et al., 2007). Furthermore, its restricted expression and up-regulation only upon 
immunostimulation makes it an appealing target for selective pharmacological 
manipulation. A selective ligand for GPR84 is yet to be identified. However, free fatty acids 
(FFAs) of a medium chain length of C9-C14, including undecanoic acid (C11:0), capric acid 
(C10:0) and lauric acid (C12:0), have exhibited efficacy in GPR84 transfected Chinese 
hamster ovary (CHO) cells (Wang et al., 2006a). Little is known about the signalling pathway 
of this receptor, although in one study Wang et al. (2006) showed that capric acid inhibited 
forskolin-induced cAMP in CHO cells with greater efficacy than other screened ligands. It 
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was also shown that this effect was Bordetella pertussis toxin-sensitive, indicating that 
GPR84 may be coupled to the Gαi/o family (Wang et al., 2006a; Suzuki et al., 2013). However, 
these findings were opposed by a later study that demonstrated that medium chain free 
fatty acids (MCFFAs) do not signal via a Gαi/o coupled pathway in neutrophils (Versleijen et 
al., 2009). FFAs have diverse actions on a number of different tissues and are associated 
with diseases such as diabetes, obesity and dyslipidemia (Hwang, 2000; Evans et al., 2004). 
Therefore, it is possible that FFAs have an immunomodulatory role via GPR84 mediated 
signalling, providing a feasible link between obesity-related metabolic syndromes and 
inflammation. Intriguingly, GPR84 has been reported to be up-regulated in adipocytes of 
high fat chow induced obese mice in response to TNF-α release from infiltrating 
macrophages, suggesting a potential link between GPR84 signalling and inflammation-
induced adiposity and diabesity (Nagasaki et al., 2012). 
 
There is some evidence suggesting that GPR84 may be involved in the regulation of a subset 
of chemokines and cytokines. Wang et al. (2006) showed that undecanoic acid, capric acid 
and lauric acid were able to dose-dependently increase the secretion of IL-12p40 from 
macrophages under LPS stimulated conditions.  Pro-inflammatory IL-12 plays a key role in 
promoting Th1-driven immunity and inhibiting Th2 anti-inflammatory responses. This 
indicates that activation of GPR84 promotes Th1 differentiation and the production of Th1-
associated cytokines such as INF-γ and IL-2. In accordance with this finding, Venkataraman 
and Kuo (2005) found that when stimulated under Th1 or Th2 differentiation conditions, 
GPR84 null T-cells exhibited enhanced production of Th2 cytokines IL-4, IL-5 and IL-13. 
Interestingly, Th1-driven immunity is associated with many autoimmune and inflammatory 
diseases such as MS, IBS and RA (Verri, 2005). However, despite a hyper Th2 cytokine 
phenotype and augmented anti-CD3 induced production of IL-4, GPR84 null mice exhibit 
normal T and B cell proliferation (Venkataraman and Kuo, 2005).  
 
More recent studies using modified medium chain FFAs with additional hydroxyl groups or 
the surrogate agonist, 6-n-octylamino uracil (6-OAU), revealed that GPR84 promotes 
leukocyte and macrophage chemotaxis. It was also found that under LPS-stimulated 
conditions GPR84 activation via these ligands resulted in the production of pro-
inflammatory IL-8/CXCL8 from leukocytes and TNF-α from macrophages (Suzuki et al., 
2013). In addition, systemic administration of 6-OAU in rats increased plasma levels of the 
potent neutrophil and macrophage chemoattractant, CXCL1 (Suzuki et al., 2013).   
 
Owning to the compelling body of evidence on the interaction between neurons, immune 
and glial cells, it is now recognised that the pathogenesis of chronic pain is not limited to the 
Chapter 1 - General Introduction 
 
67 
aberrant activity of neurons but also depends on a self-perpetuating neuro-immune 
component (Marchand et al., 2005; Scholz and Woolf, 2007; Thacker et al., 2007; Austin and 
Moalem-Taylor, 2010; Calvo et al., 2012). Therefore, researchers are challenged with the 
diversity of neuronal-immune-glial interactions in their quest to identify novel exploitable 
targets for the treatment of neuropathic pain. Pro-inflammatory GPR84 is an exciting new 
candidate in the field of chronic pain, not only because it is restricted to immune cells but 
also due to the fact that it is only up-regulated upon appropriate immunostimulation. Thus 
pharmacological manipulation of this receptor is likely to have limited side effects, which is 
always a detrimental set back in patient health care treatment. Although there is currently 
no evidence for a role of this receptor in nociceptive transmission, up-regulation of GPR84 
has been observed in clinically relevant animal models of diabesity and EAE, which feature 
pain-associated pathologies (Bouchard et al., 2007; Nagasaki et al., 2012). Furthermore, the 
current literature indicates that GPR84 promotes a pro-inflammatory T cell phenotype and 
the release of a subset of cytokines known to contribute to inflammation and nociceptive 
signalling. Therefore, GPR84 is a promising and relevant target to examine in the context of 
chronic pain. 
 
1.12 Aims of thesis 
 
The aim of this thesis is to investigate the role of GPR84 in chronic pain mechanisms. In 
Chapters 1 and 2 we characterise mechanical and thermal thresholds of GPR84 transgenic 
mice using a range of behavioural tests in a model of nerve injury (PNL) and in two models 
of inflammation (CFA, LPS). We immunohistochemically examine the spinal microglial and 
peripheral macrophage responses in these models, as GPR84 is an immune cell expressed 
receptor and these cells are well documented to play a prominent role in persistent pain 
mechanisms. To gain an understanding of the functional role of GPR84 in pain pathways, we 
investigate the transcriptional regulation of 92 different chemokines, cytokines, growth 
factors and cell markers known to be immune-regulated in the sciatic nerve and spinal cord 
tissues of nerve injured GPR84 WT and KO mice. Similarly, we profile LPS-induced gene 
transcription in GPR84 WT and KO macrophages to investigate whether GPR84 regulates 
the pro-inflammatory response of these immune cells. Lastly, Chapter 3 entails a screening 
study of three potential GPR84 ligands, examining their selectivity and efficacy using Ca2+ 
and cAMP signalling assays. Here the aim is to identify a selective agonist that could be 
utilised in further studies to facilitate our understanding of the role of GPR84 in chronic pain 
mechanisms. 
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To summarise, in this thesis we have used a combination of behavioural testing, molecular 
and biochemical techniques to test the hypothesis that pro-inflammatory GPR84 contributes 
















The Role of GPR84 in Neuropathic Pain 
 
Chapter 2 The Role of GPR84 in Neuropathic Pain 
  






2.1.1 Neuropathic pain 
 
Neuropathic pain is defined as ‘‘pain arising as a direct consequence of a lesion or disease 
affecting the somatosensory system” (Treede et al., 2008). Aside from traumatic nerve 
injuries such as mechanical damage during surgery or compression injury in carpal tunnel 
syndrome, neuropathic pain is associated with a wide spectrum of neuropathologies. Such 
diverse aetiologies include metabolic diseases (diabetic polyneuropathy); viral infections 
(Human Immunodeficiency Virus (HIV), Varicella zoster virus (VZV)); neurotoxicity 
(chemotherapeutic drugs or anti-viral therapy); autoimmune diseases (MS) and 
sympathetic nervous system dysfunction (CRPS) (Zimmermann, 2001). Symptoms of 
neuropathic pain are typically associated with sensory abnormalities that clinically manifest 
as a combination of paraesthesias (tickling, tingling, burning, pricking, numbing); 
dysaesthesias (electrical, ‘pins and needles’, itching); evoked pain (mechanical allodynia, 
thermal hyperalgesia) and spontaneous pain. While these are considered as positive 
symptoms that are caused by hyperexcitability of the nervous system, patients also 
experience negative symptoms (hypoesthesia and hypoalgesia) as a result of axonal 
degeneration and neuronal necrosis. Due to treatment side effects and accompanying co-
morbidities such as poor sleep, depression and anxiety, neuropathic pain severely 
debilitates the lives of patients. Despite the overwhelming number of analgesics available, 
therapeutic treatment is still considered to be insufficient and many patients report lack of 
adequacy in the management of their pain. Therefore, optimal pain care continues to remain 
elusive (Breivik et al., 2006).   
 
2.1.2 Animal models of neuropathic pain 
 
Due to difficulties in studying the underlying pathophysiological mechanisms of neuropathic 
pain in humans, several animal pain models have been developed as tools to assist research 
for more effective treatments. Many of these involve surgical injury to the sciatic nerve to 
induce sustained pain-related behaviours of the hind paw (see Fig. 2.1). Complete sciatic 
nerve transection (CST) was one of the first models employed to study neuropathic pain 
mechanisms and closely simulates symptoms of phantom limb pain seen after complete 
axotomy in humans (Wall et al., 1979). As a result of motor dysfunction caused by complete 
deinnervation of the limb, the assessment of pain behaviours to an applied stimulus is not  






Figure 2.1: Commonly used traumatic nerve injury models of neuropathic pain 
 
possible in this model. However, animals do show autotomy (self-mutilation), which is 
thought by many to reflect a level of spontaneous activity in the damaged sensory neurons 
and has thus been used to quantify the degree of neuropathic pain. Although in similar 
models of nerve lesions this autotomic behaviour is absent due to the presence of some 
sensory innervation. Therefore the self-mutilating response in the CST model may be 
attributed to excessive grooming in the absence of sensory feedback from the affected hind 
paw rather than representing an abnormal pain state (Rodin and Kruger, 1984).  
 
The CCI model, entails loosely tying the sciatic nerve with four chromic catgut ligatures to 
simulate a chronic nerve compression injury and is accompanied by an inflammatory 
response and a subsequent degree of peripheral nerve axotomy (Bennett and Xie, 1988). 
Simulation of partial injuries encountered in the clinic is achieved by the PNL model (Seltzer 
et al., 1990). This model involves the tight ligation of 1/3 to 1/2 of the sciatic nerve, which 
keeps some fibres intact so that painful sensory information can still be detected from the 
periphery. In this model a greater number of axons are injured, and these consist of a 
random subset of damaged and intact L4 and L5 fibres. Due to inconsistencies in 
constriction, both the PNL and CCI models exhibit some variability.  
 
The spinal nerve ligation (SNL) (Kim and Chung, 1992) and spared nerve injury (SNI) 
(Decosterd and Woolf, 2000) models are popular for their accuracy and minimal variability. 
1) Spinal nerve ligation
2) Complete nerve transection
3) Chronic constriction injury
4) Partial sciatic ligation






















SNL is performed via the tight ligation of both or either of the L5 or L6 spinal nerves so that 
whilst the primary sensory neurons of the L5/L6 DRG are axotomised, L4 is left uninjured. 
This allows the investigator to determine the relative contribution of injured and intact 
neurons in the development of pain associated behaviours. SNI entails the sectioning of the 
tibial and peroneal nerves while the sural nerve is left intact, thus enabling the study of 
injured and non-injured neuronal populations. These models of traumatic peripheral nerve 
injury (schematically presented in Fig. 2.1) have been shown to produce neuropathic 
symptoms such as allodynia and hyperalgesia (except CST). However, the duration and 
magnitude of these pain components vary considerably (Kim et al., 1997; Dowdall et al., 
2005).  
 
In addition to traumatic nerve injury models there are also disease-based models that are 
considered to be more clinically relevant and representative of the diverse human 
neuropathic pain condition. These include models of painful diabetic neuropathy such as the 
streptozocin-induced diabetic neuropathy model (Wuarin-Bierman et al., 1987); models of 
viral infections such as HIV associated neuropathy (Wallace et al., 2007b) and post-herpetic 
neuralgia (Fleetwood-Walker et al., 1999); neuropathy induced by chemotherapy and 
antiretroviral  therapy (Aley et al., 1996; Polomano et al., 2001; Wallace et al., 2007a), and 
bone cancer pain models (Medhurst et al., 2002), although in the latter model there is 
debate about the degree of nerve injury.  
 
A majority of work published on pain testing in rodents involves the application of 
mechanical or thermal stimuli to the affected hind paw. This initiates a spinally mediated 
reflex flexion withdrawal response as a result of the activation of peripheral nociceptors. 
The application of graded filaments to the plantar surface of the hind paw as a measure of 
sensitivity to punctuate mechanical stimuli was first described by von Frey (1986). This 
method was later adapted to enable the calculation of the 50% paw withdrawal threshold 
(PWT) (Chaplan et al., 1994). Likewise, the application of a heat source in the form of 
radiant light to the plantar hind paw surface can be used to examine sensitivity to thermal 
stimuli. This method was developed by Hargreaves and colleagues (1988) and the latency of 
the withdrawal reflex is measured as an indicator of sensitivity. In addition to these two key 
methods, the paw-pressure test as a measure of mechanical hypersensitivity, hot-plate and 
tail-flick tests as measures of thermal sensitivity and cold-plate and acetone tests as 
measures of cold sensitivity are also regularly used. Whilst these forms of behavioural pain 
assessment in rodent models are well established in the literature, they do not account for 
the presence of spontaneous pain or the global impact of pain and poorly address 




ethological validity (Andrews et al., 2012). As previously mentioned, the behaviours 
typically measured are spinal reflexes (paw withdrawal), spino-bulbospinal reflexes 
(jumping) or innate behaviours (biting, licking, scratching, vocalization and guarding). 
Importantly, one must note that evoked withdrawal responses are a measure of 
hypersensitivity (allodynia and hyperalgesia) rather than the pain itself (Mogil, 2009). 
Furthermore, in the clinical setting spontaneous pain is a much better indicator of a 
patient’s pain rating than measures of hypersensitivity. Moreover, while von Frey fibres are 
generally used for testing static/punctate allodynia, the most problematic symptom in 
patients is dynamic allodynia. Consequentially, the clinical reality is poorly reflected by the 
behavioural measures adopted in animal experiments (Mogil, 2009), an issue that needs 
careful consideration when interpreting animal pain studies and their translation to the 
human condition. Hence some research groups are now attempting to establish alternative 
animal pain paradigms focused on operant measures (Rice et al., 2008; Mogil, 2009; 
Andrews et al., 2011; Andrews et al., 2012), which can also be used in conjunction with 
conventional behavioural tests. 
 
2.1.3 Mechanisms of Neuropathic pain: Immune and glial cells 
 
Traumatic nerve injury animal models have been used by many research groups to study 
peripheral and central neuronal mechanisms in neuropathic pain. However, as a result of 
tissue damage caused by nerve injury, an inflammatory response generated by the immune 
system undoubtedly marks the contribution of these non-neuronal cells to neuropathic pain 
mechanisms (Bennett, 1999). Therefore, it is now recognised that the pathogenesis of 
neuropathic pain is not limited to the aberrant activity of neurons but also depends on a 
self-perpetuating neuro-immune component (Marchand et al., 2005; Scholz and Woolf, 
2007; Thacker et al., 2007; Austin and Moalem-Taylor, 2010; Calvo et al., 2012).  
 
Nerve injury results in immediate and irreversible interruption of electrical nerve 
conduction and the intrinsic degeneration of damaged axons in a process referred to as WD, 
which triggers a vigorous cascade of non-neuronal responses (Gaudet et al., 2011). Schwann 
cells, the principle glial cells of the PNS that support neuronal function, rapidly undergo a 
phenotypic switch which involves the secretion of numerous pro-inflammatory cytokines, 
including  IL-1β, TNF-α, IL-6 and PGE2 as well as MMPs, which coordinate WD and immune 
cell recruitment (Campana, 2007). In juxtaposition, growth factors such as BDNF and GDNF 
are also released and transported retrogradely to promote axonal growth and re-
myelination (Ramer et al., 2003; Scholz and Woolf, 2007; Austin and Moalem-Taylor, 2010). 




One of the first responders to a peripheral insult are the resident mast cells, which 
degranulate at the site of injury releasing histamine, serotonin, proteases, PGs and 
chemokines that mediate sensitisation of primary afferent axons and attract neutrophils and 
macrophages (Austin and Moalem-Taylor, 2010). Experimental evidence has shown that 
inhibition of mast cell degranulation reduces the infiltration of neutrophils and 
macrophages, attenuating nerve injury induced hyperalgesia (Zuo et al., 2003).   
 
Subsequent to nerve injury, resident macrophages (the primary phagocytic cells of the PNS) 
proliferate extensively and circulating monocytes are attracted to the lesion site via 
chemokines, resembling a ‘rapid-response team’. These later acting cells play a crucial role 
in WD and the phagocytosis of necrotic tissue, cellular debris and axotomised processes 
(Perry et al., 1987; Austin and Moalem-Taylor, 2010). Inhibition of macrophage infiltration 
or activation has been experimentally demonstrated to interrupt WD. Here, Perrin et al. 
(2005) showed that application of neutralising antibodies for the chemokines CCL2 and IL-
1β interrupts macrophage recruitment and suppresses myelin clearance, whereas 
administration of recombinant forms of these chemokines elicits a rapid macrophage 
response (Perrin et al., 2005). Boivin et al. (2007) demonstrated that mice deficient in TLR 
signalling exhibited a significant attenuation in the recruitment/activation of macrophage 
cells and the persistence of myelin debris, delaying regeneration of the injured nerve. In 
contrast, WD was accelerated via the administration of TLR ligands, and this effect was 
thought to be partially mediated by macrophages as glucocorticoid treatment resulted in 
delayed clearance and functional recovery (Boivin et al., 2007). In addition to their role in 
phagocytosis and regeneration of injured nerves, macrophages have also been implicated in 
pain-associated behaviour. The most compelling evidence for the role of these cells in 
neuropathic pain mechanisms comes from a study on C57BL/WLD mice, which have an 
intrinsic genetic defect in peripheral axons that causes an abnormal rate of WD and delayed 
macrophage recruitment (Myers et al., 1996). Here it was observed these mice exhibited 
delayed macrophage recruitment and WD that correlated with reduced CCI-induced thermal 
hyperalgesia (Myers et al., 1996). Furthermore, it has been demonstrated that systemic 
depletion of macrophages in a range of animal models of nerve injury not only reduced 
axonal degeneration but alleviated mechanical and thermal hyperalgesia (Liu et al., 2000; 
Barclay et al., 2007). Notably, other groups have reported the inability to relieve mechanical 
allodynia using this approach, hence highlighting the distinct mechanisms underlying 
different pain modalities (Rutkowski et al., 2000; Barclay et al., 2007).  
 




‘Activated’ macrophages release many algesic mediators such as TNF-α, IL-1β, IL-6, PGs and 
NO that directly or indirectly sensitise nociceptors by binding to their cognate receptors and 
activating various intracellular signalling pathways (Woolf and Ma, 2007). Aptly, this pro-
inflammatory macrophage phenotype has also been observed in patients with CRPS, who 
exhibit raised blood monocyte levels (Ritz et al., 2011). Furthermore, a number of gene 
profiling studies in rodents have illustrated a dramatic regulation of cytokines in the context 
of neuropathic pain, highlighting the importance of temporal and spatial expression 
patterns of pro-inflammatory (particularly IL-1β, IL-6 and TNF-α) and anti-inflammatory 
(IL-10) cytokines, in correlation with behavioural hypersensitivity and a delayed resolution 
component (Gillen et al., 1998; Okamoto et al., 2001; Costigan et al., 2002; Tanga et al., 
2005). Many of the cytokines and chemokines released following nerve injury modulate the 
transduction properties of nociceptive sensory axons and evoke ongoing activity in 
myelinated and unmyelinated axons. Ectopic firing is a crucial component underlying 
spontaneous activity in neuropathic pain and has been shown to arise in multiple locations, 
such as at the site of injury and in the DRG (Amir et al., 2005). Increased density of cytokine 
receptors in nociceptive afferents as a result of enhanced membrane trafficking means that 
these fibres also become more sensitised and hyper-responsive to inflammatory factors, 
which may contribute to ectopic firing. For example, raised TNF-α expression has been 
documented in the injured nerves of patients and rodents (Empl et al., 2001; George et al., 
2004). This cytokine is able to directly stimulate neurons, evoke action potential firing and 
elicit pain behaviours when injected intraneurally in rodents (Wagner and Myers, 1996; 
Schafers et al., 2003b). Conversely, pre-emptive pharmacological blockade studies using the 
competitive TNF-α inhibitor, Etanercept, have demonstrated attenuation of pain-associated 
behaviour in rodents (Sommer et al., 2001; Svensson et al., 2005) and thus this conceptual 
approach has progressed on to trials of anti-TNF-α therapy in humans.  
 
In addition to the mobilisation of the immune system and accumulation of a large 
‘inflammatory soup’ of mediators within the endoneurium, an immune response also occurs 
within the proximity of the cell bodies of injured and spared sensory neurons. In response 
to the release of ATP and perhaps other factors, satellite glial cells become activated, 
proliferate and release soluble molecules such as TNF-α and IL-1β (Ohara et al., 2009), 
accompanied by the rapid recruitment of neutrophils, macrophages and T lymphocytes. T 
lymphocytes have been shown to infiltrate the nerve at a much later stage than their innate 
immune system counterparts and enter the DRG via deep ganglionic blood vessels and cell 
surface meninges. This recruitment is perhaps driven by signals originating from neurons 
and satellite cells that project into the axons of damaged nerves (Hu and McLachlan, 2002; 




Moalem et al., 2004). T cells have also been implicated in nerve injury-induced neuropathic 
pain behaviour and a key study showed that congenetically athymic nude rats, which lack 
functional T cells, had attenuated mechanical allodynia and thermal hyperalgesia post CCI in 
contrast to their WT littermate controls (Moalem et al., 2004). Alongside the immune 
response, the DRG also undergoes cascades of transcriptional changes that encompass the 
up- and down-regulation of pro-inflammatory mediators, ionotropic and metabotropic 
receptors, neuropeptides, ion channels, signalling molecules and vesicular proteins 
(Costigan et al., 2002; Xiao et al., 2002). This extensive phenotypic change contributes to an 
increase in DRG neuronal excitability, which is synaptically communicated to first order 
dorsal horn neurons of the spinal cord. 
 
In the CNS, microglia are one of the first responders to disturbances in the homeostasis of 
the microenvironment by pathogens or damage and undergo a repertoire of morphological, 
immunophenotypic and gene expression changes (as described in Chapter 1). Their 
numbers increase drastically by means of proliferation and migration in a process defined 
as microgliosis, a phenomenon also observed in the thalamus of amputee patients with 
chronic phantom-limb pain and in a post-mortem study of a patient with CRPS where 
‘reactive’ microglia were observed in the spinal cord (Banati et al., 2001; Del Valle et al., 
2009). The transition from a normally ‘quiescent’ to a ‘pain-related’ enhanced response 
state (McMahon and Malcangio, 2009) is thought to be initiated by multiple endogenous 
signals from primary afferent nociceptive inputs, as well as mediators released from 
localised astrocytes, microglia and neurons. Such mediators are thought to include 
adenosine, ATP, glutamate, cytokines/chemokines, arachadonic acid, neuropeptides (SP, 
CGRP) and NO, some of which act on their respective ionotropic or metabotropic microglial 
expressed receptors (DeLeo and Yezierski, 2001; Watkins et al., 2001). This in turn drives 
signalling pathways involving the phosphorylation of the MAPKs, p38 and ERK and the 
subsequent initiation of several transcription factor cascades including NF-κB, which 
controls the expression of a plethora of pro-inflammatory mediators such as IL-1β, IL-6, 
TNF-α, PGE2, NOS, COX-2, ATP, BDNF and CatS (DeLeo and Yezierski, 2001; Watkins et al., 
2001; Coull et al., 2005; Ji and Suter, 2007; Kawasaki et al., 2008; Clark et al., 2009). The 
secretion of pro-inflammatory mediators contributes to central sensitisation via enhancing 
excitatory synaptic transmission and suppressing synaptic inhibition. IL-1β, IL-6 and TNF-α 
have been shown to augment EPSCs and suppress inhibitory post-synaptic currents (IPSCs) 
in the superficial dorsal horn of the spinal cord, inducing central sensitisation, hyperalgesia 
and long-term synaptic plasticity via the induction of CREB induced gene transcription 
(Kawasaki et al., 2008). Spinal blockade of pro-inflammatory cytokines is analgesic, whilst 




spinal injection of recombinant factors is pro-nociceptive (DeLeo et al., 1996; DeLeo and 
Yezierski, 2001; Watkins et al., 2001).  
 
TLR4 is also an important player in the activation of microglial cells, triggering a cascade of 
downstream signalling pathways that culminate to engage NF-κB (Baeuerle and Henkel, 
1994). In pathological states the TLRs respond to cell body damage, components of the ECM, 
HSPs 60 and 70, cations and proteoglycan fragments (Tanga et al., 2005). Importantly, data 
suggests that the TLRs co-ordinate WD in the injured nerve and neuroinflammation via the 
modulation of Schwann cells/macrophages or microglial cells, respectively (Aravalli et al., 
2007). Conversely, pharmacological or genetic manipulation of this single transmembrane 
receptor results in impairment of these processes and attenuation of behavioural 
hypersensitivity (Tanga et al., 2005; Boivin et al., 2007). Similar studies involving the 
manipulation of specific microglial receptors in the CNS: CX3CR1, P2X4, P2X7, CCR2 and TLR4 
(see Chapter 1) (Abbadie et al., 2003; Tsuda et al., 2003; Chessell et al., 2005; Tanga et al., 
2005; Clark et al., 2010b; Staniland et al., 2010) or the use of general glial inhibitors 
(Sweitzer et al., 2001; Ledeboer et al., 2005; Clark et al., 2007a) demonstrate inhibition or 
reversal of neuropathic pain behaviours and together form a wealth of evidence supporting 
the contribution of microglial cells to experimental pain states. Furthermore, the role of 
microglial cells in pain has also been explored in humans with post-mortem evidence of 
‘reactive’ microglia and astrocytes in the spinal cords of patients with CRPS (Del Valle et al., 
2009).  In addition to reports of raised pro-inflammatory and reduced anti-inflammatory 
cytokine profiles in the CSF of two CRPS patients compared to control patients, which 
correlated with pain intensity (Alexander et al., 2005). 
 
Microglia are also involved in the recruitment of T cells, which have been shown to infiltrate 
the spinal cord, peaking in cell numbers at 7 days post nerve injury (Cao and DeLeo, 2008). 
Cao and DeLeo (2008) reported a significant reduction in behavioural hypersensitivity in 
CD4+ KO mice that was reversed via the adoptive transfer of CD4+ leukocytes and 
hypothesised that T cells interact with both microglia and astrocytes to exacerbate 
inflammation and neuronal sensitisation (Cao and DeLeo, 2008). Subsequent to nerve 
injury, astrocytes proliferate and undergo considerable morphological and 
immunophenotypic changes, which was first documented by Garrison et al. (1991). These 
changes are characterised by hypertrophy and a dramatic increase in GFAP staining that 
parallels with the extent of behavioural hyperalgesia in rats (Garrison et al., 1991). 
Recruitment of reactive astrocytes is thought to be due an array of signals from 
neighbouring microglia, astrocytes and neurons. Once ‘activated’, astrocytes release many   






Figure 2.2: Neuroimmune interactions occuring subsequent to peripheral nerve injury 
 
At the site of peripheral nerve injury, Schwann cells and resident mast cells proliferate and release a 
combination of ATP, growth factors, histamines, cytokines, and TLR ligands, which sensitise axons or 
may be transported retrogradely to the DRG where they alter gene transcription. The release of 
mediators also activates resident macrophages and neutrophils and contributes to the recruitment of 
other immune cells, such as infiltrating monocytes and T-cells. These non-neuronal cells in turn 
release further algogenic substances that contribute to ectopic activity of the injured nerve. In the 
CNS, incoming signals from the periphery lead to the activation of dorsal horn neurons, microglia and 
astrocytes. Activated microglia proliferate and release cytokines such as IL-1β, TNF-α and IL-6, which 
activate intracellular signalling pathways and initiate further sustained release of mediators that 
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factors through JNK mediated cellular pathways and are essentially thought to play a role in 
the persistence of pain (Ji et al., 2006; Gao et al., 2009; Ji et al., 2009; Ransohoff and Perry, 
2009). Fig. 2.2 summarises the neuroimmune interactions that can occur subsequent to 
peripheral nerve injury. 
 
In conclusion, experimental evidence has pointed towards a critical role of immune and glial 
cells as well as pro-inflammatory mediators in the generation of neuropathic pain. It is 
apparent that specific roles of individual cells and molecules are regarded as particularly 
important. In terms of translational human research, the immune cell component in chronic 
pain is very much dependent on genetic and environmental factors as well as the nature of 
the associated pathology. Despite the growing amount of clinical evidence supporting 
immune cell involvement in chronic pain, neuro-immune interactions are complex and their 
role in the induction and maintenance of pain are not yet fully understood. In light of this 
credible evidence, scientists are challenged with the diversity of neuronal-immune-glial 
interactions to identify novel exploitable targets in the treatment of neuropathic pain.  
 
GPR84 was identified by GSK as a potential new target for the development of analgesics for 
chronic pain patients. GPR84 is an immune cell expressed receptor that is up-regulated 
upon appropriate immunostimulation and has some implications in neuroinflammation (see 
Chapter 1). Although there is currently no evidence for the role of this receptor in 
nociceptive transmission, an increase in GPR84 expression has been documented in animal 
models that feature pain-associated pathologies (Bouchard et al., 2007; Nagasaki et al., 
2012). Therefore GPR84 qualifies as a valid and interesting new target to examine within 




In this chapter we utilised the PNL model (Seltzer et al., 1990) in transgenic mice to examine 
GPR84 in neuropathic pain mechanisms. The PNL model is documented to produce 
consistent and reproducible pain-associated behaviours in rodents, which correlates with 
robust peripheral and central immune and glial reactivity. We assessed neuropathic pain 
behaviours of GPR84 WT and KO mice in conjunction with a prominent focus on the 
macrophage and microglia response. We also investigated mRNA transcript expression of 
92 different chemokines, cytokines, growth factors and cell markers known to be immune-
regulated in the sciatic nerve and spinal cord tissue of nerve injured WT and KO mice. This 




approach enabled us to identify putative mediators that are modulated by GPR84 and may 
thus contribute to neuropathic-pain behaviour via down-stream signalling of this receptor.  




2.2 Materials and methods 
 
2.2.1 Generation, Breeding and Genotyping of GPR84 knock-out Mice 
 
GPR84 (NM_030720, ENSMUSG00000063234) KO mice were provided by Deltagen Inc. 
under a GlaxoSmithKline license agreement (CA). Genomic DNA  from recombinant 
embryonic stem cells 129/OlaHsd was used for gene targeting and assayed for homologous 
recombination using long range polymerase chain reaction (PCR) analysis (Fig. 2.2A). PCR 
was used to confirm correctly targeted ES clones using one primer within the LacZ/Neo 
Cassette and another primer outside the targeting construct for both 5′ and 3′ ends of the 
targeted locus, as follows:  
5’ end: 5' external primer #28016; TGGTCAATCATTGTCCTCTCTGAACC and LacZ/Neo 
primer #2416; GGGATCTTGGCCATGGTAAGCTGAT; expected amplicon size 4.6kb. 3’ end: 3' 
external primer #28005 AAACCACAGTTTATCACTTACTAGCCC and LacZ/Neo primer 1431 
ACGTACTCGGATGGAAGCCGGTCTT; expected amplicon size 4.0kb.  
PCR cycling conditions were 96 C for 20 s; 30 cycles of 96 C for 8 s, 63 C for 10 s, 68 C for 
2 min 15 s; followed by 5 cycles of 96 C for 8 s, 63 C for 10 s and 68 C for 8 min. Those ES 
cells that were correctly targeted were injected into C57BL/6 host blastocyts to generate 
chimeric mice. Male chimaeras were crossed with C57BL/6 females to produce 
heterozygous (HET) N1F0 offspring. HET’s were repeatedly bred, or backcrossed, onto the 
C57BL/6 genetic background, which was later verified using 98 single nucleotide 
polymorphism markers (Markel et al., 1997; Wakeland et al., 1997).  Fully backcrossed mice 
exhibited > 98% coverage with the C57BL/6 marker. HET backcrossed mice were inter-
mated to produce F1 animals homozygous for the GPR84 mutation or WT littermate 
controls. Mice were genotyped by PCR using the following primers:  
GS(E) #35788 5’:-ACAGCTCAGATGCCAACTTCTCCTG ;-3’,  
GS (TE)#35789  5’:-TCCTAGAGCAATGAGACAGAGGGTG;-3’                                        
and Neo(T) #40610  5’:- GACGAGTTCTTCTGAGGGGATCGATC;-3’                                                   
Ear punched samples were lysed and the DNA was run with a Taq polymerase (Qiagen) mix. 
PCR cycling conditions were 95°C for 3 min, followed by 30 cycles—95°C for 30 s, 58°C for 
30 s, 72°C for 30 s, with a final extension at 72°C for 3 min and maintained at 4°C. The PCR 
products were run and visualised on a 2% agarose gel; the WT allele generated a 344-bp 
band using primers GS(E) 35788 and GS (TE) 35789, whereas the mutant allele generated a 
583-bp band from primers GS (TE) 35789 and Neo(T) 40610 (Fig. 2.2B). All experiments 
were conducted according to the requirements of the United Kingdom Animals (Scientific 
Procedures) Act (1986) and conformed to GlaxoSmithKline ethical standards. 






Figure 2.3: Generation of GPR84 KO mice 
 
(A) Schematic of single coding exon 2 is shown. Thicker lines indicate the relative positioning of the 
gene target. Targeting replaced 257 bp of coding sequence with an Internal Ribosome Entry Site - 
LacZ-polyA expression cassette and a positive selection cassette that contains the neomycin 
phosphotransferase gene driven by the PGK promoter (Neo). Correctly targeted ES clones were 
identified via the PCR primers indicated, which were also used to genotype F1 mice. The insertion of 
the LacZ IRESLacZ introduces a premature translational stop signal that deletes the first three 
predicted trans-membrane domain sequences of the seven transmembrane domain receptor 
molecule. (B) An example of GPR84 genotyping results from F1 intercross. The genotyping primers 
(GS(T) #35788, GS(TE) #35789, Neo(T) #40610) generate a 344 bp and 558 bp product for WT and 













































 Breeding and husbandry 
 
Mice forming the initial breeding pairs were supplied by GlaxoSmithKline, which consisted 
of HET F1 offspring from WT and KO breeding. HET pairs were bred from 8 weeks old to 
produce litters of mixed genotypes according to Mendelian genetics: 50% HETS, 25% 
homozygous WT and 25% homozygous KO.  Breeding pairs and their litters were delegated 
identity codes. From 10 days of age each mouse received an identity ear notch mark and a 
unique corresponding animal number and was genotyped as previously described. Breeding 
pairs had a maximum of 6 litters before the pair were retired. On average, litter sizes were 
around 4-12 pups and weaning occurred 21 days after birth. WT and KO mice were used for 




Experiments were conducted on randomly selected mixed sex and age-matched mice 
weighing 20-25 g (7-14 weeks old). Mice were housed individually or in groups (no more 
than 4 per cage) in standard environmental conditions (12 hour light/dark cycle) with ad 
libitum access to food and water. Animal husbandry and experiments were carried out in a 
non-sterile housing environment in accordance with the United Kingdom Animals (Scientific 
Procedures) Act 1986.  
 
To calculate the number of animals required for behavioural studies a priori power analysis 
was carried out using G*Power (v-3.1.7) software. Based on an estimated 60% reduction 
effect (deduced from previous experimental studies in our lab), the software estimated that 
a total sample size of 32 (n = 8 per group) would be required to detect statistical differences 
(α = 0.05, 1-β = 0.95, d = 7). Four groups of animals were tested including a control sham-
operated group and a nerve-injured group for each genotype. For all studies the 
experimenter was blinded to genotype and treatment. Allocation concealment was carried 
out by assigning individual animals with identification numbers (as previously mentioned) 
and by employing an independent investigator to re-blind animals after surgery. Blinding 
codes were broken after completion of behavioural experiments to determine if further 
anatomical assessment was necessary. According to pre-determined exclusion criteria, 
animals were excluded from experimental analysis if they died during surgery, if the surgery 




was flawed or if animals reached end points as specified by the project license e.g. excessive 
self-mutilation. 
 
2.2.3 Neuropathic pain model: PNL  
 
Animals were anesthetised with 2-3% isoflurane (Abbott Animal Health, UK) inhalation 
anaesthesia. The left hind paw was secured, shaved and sterilised. The sciatic nerve was 
carefully exposed and isolated from neighbouring connective tissue via a small incision 
midway of the left thigh. At a site within close proximity of the trochanter, distal to the 
posterior biceps semitendinosus nerve branch, a 5-0 vicryl suture (Ethicon, UK) was 
inserted into the nerve and ligated so that 1/3 to 1/2 of the nerve was held tightly within 
the ligature, as previously described (Seltzer et al., 1990). In sham operated mice the same 
procedure was carried out except that the nerve was not ligated. Mechanical (von Frey) and 
thermal (Hargreaves) withdrawal thresholds were examined pre-surgery (at least three 
baseline measurements) and post-surgery on days 4, 7, 11, 14, 18 and 21. 
 




Tactile mechanical thresholds of alert and unrestrained mice were examined via von Frey 
hair application (0.008-1 g, Touch Test, Stoelting, USA) to the plantar surface of the hindpaw 
via the ‘up-down’ method (Chaplan et al., 1994). Before testing mice were acclimatised for a 
period of 1 hr in individual acrylic testing cubicles (8 x 5 x 10 cm) on an elevated wire mesh 
floor. Placement in testing cubicles was selected at random for each testing day. This 
enabled access to the lateral paw surface. Calibrated von Frey hairs were applied starting 
with the 0.6 g filament, in an alternate fashion to the left and right hind paw. The flexible 
nylon hair was applied so that the fibre bent for a duration of 3 s or until a paw withdrawal 
reflex occurred that was not coupled with movement or grooming. A positive withdrawal 
response is followed by a lower force hair and vice versa for a negative response until a 
change in behaviour occurs. Using this ‘up-down’ sequence four subsequent hairs were 
assessed and the 50% PWT was calculated according to the method described by Dixon 
(1980). (Dixon, 1980) 
 






Noxious mechanical thresholds were examined in the hindpaws of restrained alert mice via 
an Analgesymeter (7200; Ugo Basile, Italy) (Randall and Selitto, 1957). Each hindpaw was 
tested separately; briefly, the plantar surface was placed on a pedestal with a probe resting 
on the dorsal surface. Increasing pressure was applied via the probe, up to a maximum of 
120 g to prevent tissue damage. The nociceptive threshold was taken as the force at which 
the mouse responded. 
 




Thermal thresholds in unrestrained and alert mice were determined with the Hargreaves 
method using the Plantar Test (7370; Ugo Basile, Italy) (Hargreaves et al., 1988). Prior to 
testing, mice were acclimatised for 1 hr in individual acrylic testing cubicles (8 x 5 x 10 cm) 
on a glass plate. Placement in testing cubicles was selected at random for each testing day. 
An infrared light source of an arbitrary intensity of 30 (calibrated to elicit a paw withdrawal 
latency (PWL) of 10-15 s in naïve mice) was directed onto the plantar surface of the hind 
paw through the glass plate. The PWL was automatically recorded in secs upon a 
withdrawal reflex. The left and right paws were tested alternately and responses were 
recorded for each paw on three separate occasions with at least 2 mins between assays. 




Thermal thresholds of the tails of lightly restrained mice were examined via the tail 
immersion-withdrawal test (Mogil et al., 1999). The distal third of the tail was directly 
immersed in water at a set temperature of either 49°C or 52°C ± 0.2°C (Grant SUB14; Grant 
Instruments Ltd, UK). The thermal withdrawal latency was recorded to the nearest 0.01 s as 
a characteristic abrupt tail reflex. A maximum latency of 20 s and 10 s was permitted at 
temperatures of 49°C and 52°C, respectively, to prevent tissue damage. 
 






Noxious thermal thresholds of the hind paws were examined via the hot plate test (Eddy 
and Leimbach, 1953) using a hot/cold plate (IITC Life Sciences, USA) set at a temperature of 
49°C ± 0.1°C. Unrestrained mice were placed on the hot plate in a 10 cm-diameter acrylic 
testing box. A jumping, licking and stamping reflex was taken as the latency to respond and 





Noxious cold thresholds of the hind paws of lightly restrained mice were examined using the 
cold plate (IITC Life Sciences, USA) set at a temperature of 10°C ± 0.1°C. Each paw was 
tested separately by being placed with the plantar surface touching the plate. The latency to 
withdraw was taken as the threshold and recorded to the nearest 0.01 s. A 20 s cut-off was 
implemented to prevent tissue damage. 
 
Locomotor function (RotaRod) 
 
Balance and co-ordination was examined via the locomotor test, using a RotaRod that 
accelerates from 2 to 40 rpm over a period of 300 s (7650; Ugo Basile, Italy). Mice were 
initially trained before testing. Unsuccessful test runs were trialled again and no mice 
remained on the apparatus after 100 s. 
 
2.2.6 Tissue preparation and immunohistochemistry 
 
On days 7 or 21 following PNL or sham surgery, GPR84 WT and KO mice were anaesthetised 
with sodium pentobarbital (0.2 g/mL intraperitoneal (i.p.); Euthatal, Merial Animal Health 
Ltd) and perfused transcardially with a 0.9% saline and 0.1% heparin solution (Leo 
Laboratories Ltd, UK) followed by fixation with 4% paraformaldehyde (PFA) (VWR, UK) in 
0.1 M phosphate buffer (PB). Lumbar spinal cord and sciatic nerve were dissected and post-
fixed for 2 hrs in PFA and cryoprotected in a 20% sucrose/0.1 M PB solution (VWR, UK) for 
a minimum of 3 days at 4°C. Subsequently, tissue was embedded in Optimum Cutting 
Temperature (OCT) medium (VWR, UK), snap frozen with liquid nitrogen and stored at -
80°C. Prior to embedding sutures were removed from injured sciatic nerves. Transverse 
spinal cord sections of the L4 and L5 lumbar region and longitudinal nerve sections were 




cut on the cryostat in sets of 8 series at 20 μm and 15 μm thickness, respectively, and 
subsequently thaw-mounted onto Superfrost plus microscope slides (VWR, UK). After 
drying, 7 day post-PNL or sham surgery spinal cord sections were incubated overnight with 
primary antibody solution for p-p38 (rabbit anti-p-p38; 1:100; Sigma, UK), and visualised 
with extra avidin-FITC following two stages of signal amplification with Avidin Biotin 
Complex (ABC; Vector Laboratories, USA) and biotinyl tyramide (PerkinElmer Life Sciences, 
UK) as previously shown (Clark et al., 2006). The sections were then incubated overnight 
with the second primary antibody, raised against rabbit anti-Iba1 (1:1000; Wako Chemicals, 
Germany). Spinal cord (21 day) and sciatic nerve sections were only incubated with Iba1. 
After anti-Iba1 incubation sections were incubated with the secondary antibody solution for 
2 hrs (1:1000; IgG conjugated Alexa Fluor 488 or 546; Invitrogen, USA). All antibodies were 
prepared in PBS supplemented with 0.1% Triton X-100 (VWR, UK) and 0.2% sodium azide 
(Sigma, UK). Slides were carefully cover slipped with Vectashield Mounting Medium 
containing 4',6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, UK), nail-varnished 
and dried.  
 
Quantification of immunoreactivity 
 
Images were visualised and captured using a Zeiss Axioplan microscope (Zeiss, UK) and for 
blinding purposes were labelled according to the identification code of the animal. Blinding 
codes were broken after study completion. Analysis of p-p38 and Iba1 immunoreactivity 
was performed by counting the number of positive profiles within three fixed 4x104 μm2  
boxes in the lateral, central and medial areas of the dorsal horn, using the nuclear marker 
DAPI to assist in determining positive cells, as previously described (Clark et al., 2007a). A 
mean value was obtained for both the ipsilateral and contralateral dorsal horns of a 
minimum of three sections per animal. For analysis of Iba1 staining in the sciatic nerves, 
four boxes of 4x104 μm2 area, two distal and two proximal to the nerve lesion, were placed 
randomly along the nerve.  The number of Iba1 positive cell profiles were counted within 
the boxes and a mean value was obtained for both the distal and proximal regions of the 
nerve. A minimum of three sections per animal were assessed. The experimenter was 
blinded to both the genotype and treatment throughout the analysis. 
 
2.2.7 RNA extraction and cDNA synthesis 
 
On days 7 or 21 following PNL or sham surgery, mice were anaesthetised with sodium 
pentobarbital (0.2 mg/mL i.p.); Euthatal, Merial Animal Health Ltd, UK). The lumbar regions 




of the spinal cord were quickly dissected, separated into the ipsilateral and contralateral 
sides and placed into separate 1.5 mL Eppendorf tubes.  The ipsilateral and contralateral 
sciatic nerves of approximately 1 cm in length were also collected and stored in separate 
Eppendorf tubes. The collected tissue was immediately snap frozen in liquid nitrogen and 
stored at -80°C for further processing. RNA was extracted via homogenising the tissue 
samples using a hybrid method of phenol extraction (Trizol, Invitrogen, UK) and column 
purification (RNeasy, Qiagen, UK). For injured sciatic nerves, the sutures were removed 
prior to RNA extraction and mini elute columns (Qiagen, UK) were used, which are 
optimized for samples with small RNA amounts. Sham nerves were pooled to increase the 
yield of RNA isolation. After purification the RNA was eluted using RNAse-free water and its 
concentration and purity were estimated using a NanoDrop ND-100 Spectrophotometer 
(Thermo Fischer Scientific, UK). All 260:280 absorbance ratios were in the range of 1.96-
2.15. Samples were also deoxyribonuclease (DNase; Qiagen, UK) treated during RNA 
isolation to prevent genomic contamination. RNA integrity was confirmed by running 
samples on a RNA 6000 Nano Chips Bioanalyzer (Agilent). Complementary deoxyribonucleic 
acid (cDNA) was subsequently synthesised from the ribonucleic acid (RNA) using the 
SuperScript II reverse transcriptase kit (Invitrogen, UK) according to the manufacturers 
protocol.   
 
2.2.8 Taqman array set-up and quantitative real-time PCR 
 
Taqman® PCR mouse mediator arrays cards were custom designed using the Applied 
Biosystem website (http://www.appliedbiosystems.com). The cards use micro-fluidic 
technology, comprising of 384 wells and 4 sets of 96 different primer/probe pairs against 
specific genes within the mouse genome, including four housekeeping (HK) genes: 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 18S ribosomal RNA, β-actin, and 
hypoxanthine phosphoribosyltransferase (HPRT). Spinal cord and sciatic nerve cDNA 
samples from 7 and 21 days post PNL or sham surgery were diluted and added in a 1:1 ratio 
to Taqman universal PCR master mix (Applied Biosystems, UK; contains DNA Taq 
polymerase and dNTPs). Dnase-free water was added to the sample mix producing a final 
[cDNA] of 2 ng/μl in a total volume of 20 μl. The sample mix was loaded into the appropriate 
port and the cards were centrifuged so that 1 μl was channelled into each well. Cards were 
then sealed and placed into a 7900 HT Fast Real-Time PCR system (Applied Biosystems, 
UK), where cDNA samples underwent 40 amplification cycles, and amplification products 
were analysed in real time with DSD 2.1 software. Real-Time PCR records fluorescence 
emitted from a reporter molecule upon the amplification of target DNA. Thus upon 




amplification the complementary Taqman probe is degraded releasing a reporter molecule 
from local proximity of the quencher, which produces fluorescent emissions during each 
amplification cycle. The number of cycles required to pass an arbitrary threshold of 
fluorescence (calculated for each individual card) is measured to quantify the amount of the 
target sequence present in the sample. Hence the lower the cycling time (CT) the greater the 
expression of a particular transcript. Relative expression values of gene transcripts using 
the delta delta cycling time (ΔΔCT) method as previously described (Schmittgen and Livak, 
2008) were calculated for each sample and normalised against the mean of the CT values of 
the four HK genes via the R packages ReadPCR and NormqPCR (Perkins et al., 2012). For 
each transcript the ΔΔCT values are presented as fold change (FC = PNL/sham for each 
genotype). Transcripts with undetermined values in more than 50% of the samples were 
assigned an average default CT value of 38. If this occurred in both PNL and sham sample 
groups, no FC value was calculated. Transcripts that were undetermined in less than 50% of 
samples obtained an average CT value based on the remaining data values.   
 
2.2.9 Data and statistical analysis 
 
All behavioural and immunohistochemical data were analysed using SigmaPlot 12.3 and 
SigmaStat software. For single comparisons between two groups, a paired student t-test was 
applied (behavioural data). For multiple comparisons, one-way (immunohistochemical 
data) or two-way (behavioural data) analysis of variance (ANOVA) was used, followed by 
Student-Newman-Keuls (SNK) post hoc test to determine individual group differences. For 
the Taqman mouse PCR array card data, two-sided Welch’s t-test were run in the R 
programme on the ΔCT values. The p values were adjusted using the false discovery rate 
(FDR) to correct for multiple hypothesis testing, as previously described (Benjamini et al., 
2001). Non-parametric tests were applied where the data was not normally distributed. In 
all cases the data is presented as the mean ± standard error of the mean (SEM) and p < 0.05 
was set as the statistical significance level.  






2.3.1 Acute pain thresholds and locomotor ability are normal in GPR84 KO mice 
 
In order to investigate whether deletion of the GPR84 gene impacts on acute pain thresholds 
of naïve mice, GPR84 WT and KO mice were behaviourally assessed following acute 
peripheral application of a range of mechanical and thermal stimuli (Fig. 2.4). GPR84 KO 
mice exhibited normal thermal pain thresholds to varying levels of intensity applied to the 
hind paw or tail compared to WT mice (A, WT: 10.5 ± 0.4 s, KO: 11.6 ± 0.4 s; B, WT: 5.2 ± 0.3 
s, KO 5.0 ± 0.3 s; C, WT: 2.2 ± 0.1 s, KO: 2.0 ± 0.2 s; D, WT: 14.0 ± 1.2 s, KO: 12.6 ± 2.0 s; Fig. 
2.4A-D). In addition, acute cold pain thresholds were unaffected (WT: 20.1  ± 2.1 s, KO: 20.3 
± 1.6 s; Fig. 2.4E). GPR84 KO mice also exhibited normal mechanical thresholds of low and 
high intensity (Fig. 2.4F & G) compared to WT mice and showed no deficits in locomotor 
function (F, WT: 0.72 ± 0.05 g, KO: 0.71 ± 0.1 g; G, WT: 104.8 ± 2.0 g, KO: 118.2 ± 4.4 g; H, 
WT: 87.6 ± 1.9 s, KO: 82.1 ± 2.6 s; Fig. 2.4H). There were no significant differences between 
the genotypes in any of the acute tests. These data indicate that naïve GPR84 KO mice 
exhibit normal thermal and mechanical acute thresholds and are equally capable as their 
WT littermate controls to elicit paw withdrawal responses to an applied stimulus. 
 
2.3.2 GPR84 KO mice do not develop pain-associated behaviours after nerve injury 
 
It is well established that peripheral nerve injury results in the development of evoked pain-
associated behaviours such as mechanical allodynia and thermal hyperalgesia in the 
ipsilateral, but not the contralateral hindpaw, which serves as a control. In our studies we 
utilised the PNL model, which is a well documented model of peripheral nerve injury. To 
demonstrate the reproducibility of this model and confirm that we were also able to induce 
a neuropathic pain state in mice, mechanical and thermal thresholds were examined before 
and after PNL or sham surgery. As expected, nerve injured mice showed a significant 
reduction in mechanical and thermal paw withdrawal thresholds (data not shown). 
 
Having demonstrated the ability to reiterate pain-associated behaviours using the PNL 
model as reported in the literature we then compared mechanical and thermal thresholds of 
nerve injured GPR84 KO mice to WT littermate controls. As before, injured WT mice showed 
an average reduction of 68.8% in mechanical thresholds from baseline (D0, 0.8 ± 0.1 g) and 
thresholds remained reduced from day 4 (0.3 ± 0.1 g) up to day 21 (0.1 ± 0.1 g). On days 18 
(0.2 ± 0.1 g) and 21 there was a significant difference compared to WT sham controls (D18, 




0.6 ± 0.1 g; D21, 0.5 ± 0.1 g; Fig. 2.5A). Similarly, WT PNL mice exhibited an average 
reduction of 25.4% in thermal thresholds from baseline (D0, 10.1 ± 1.0 s) over the 21 testing 
days, which was significant from baseline on days 4 and 21 and WT sham controls on days 4, 
7 and 21 (D4, 6.1 ± 0.8 s; D7, 7.6 ± 1.4 s; D21, 6.5 ± 0.6 s vs WTS: D4, 11.7 ± 1.1 s; D7, 11.1 ± 
1.7 s; D21, 11.5 ± 1.3 s; Fig. 2.5B). Strikingly, nerve injured GPR84 KO mice did not develop 
mechanical (Fig. 2.5C) or thermal (Fig. 2.5D) hypersensitivity over the 21 testing days and 
thresholds did not drop from baseline or differ from KO sham controls; (KOPNL mechanical: 
D0, 0.7 ± 0.1 g to D21, 0.6 ± 0.1 g vs KOS: D0, 0.8 ± 0.1 g to D21, 0.5 ± 0.1 g; KOPNL thermal: 
D0, 11.3 ± 1.1 s to D21, 11.1 ± 1.4 s vs KOS: D0, 12.1 ± 0.8 s to D21, 11.9 ± 1.1 s). 
 
Data are presented separately for each genotype and only the ipsilateral paw withdrawal 
responses of each experimental group are shown for clarity. However, statistical analysis 
was performed across all four experimental groups. These data suggest that deletion of the 
GPR84 gene impairs the development of neuropathic pain behaviours in nerve injured mice. 
This result was obtained across three independent experiments; in every one of them, 
experimental procedures were carried out exactly the same and the experimenter was blind 
to treatment and genotype. One animal was excluded as a result of death during surgery. 
  











Figure 2.4: GPR84 KO mice display normal responses to acute painful stimuli and normal 
locomotor ability 
 
To assess acute nociception in naïve GPR84 WT and KO mice, responses to a range of thermal and 
mechanical acute pain tests were compared. There were no significant differences in the responses of 
WT and KO mice in the temperature threshold tests (Hargreaves, (A); tail immersion withdrawal at 
49°C, (B), or 52°C, (C); hot plate at 49°C, (D); cold plate at 10°C, (E)) or mechanical threshold tests 
(von Frey, (F); paw pressure, (G)). GPR84 KO mice also displayed normal locomotor function using 
the RotaRod apparatus, (H). Data are presented as the mean ± SEM. p > 0.05, independent Student’s t-
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Figure 2.5: Reduced neuropathic pain in GPR84 knockout mice 
 
Mechanical (A, C) and thermal (B, D) withdrawal responses of GPR84 WT (A, B) and KO (C, D) mice 
were measured before (day 0) and up to 21 days post PNL or sham surgery. WT mice developed 
significant mechanical hypersensitivity and showed reduced thermal thresholds compared to sham 
(WTS) controls. Mechanical allodynia and thermal hyperalgesia were absent in KO mice and did not 
differ from sham values at any time (KOS). Data are presented as the mean ± SEM. *p < 0.05, **p < 
0.01, ***p < 0.001 vs baseline (day 0). #p < 0.05, ##p < 0.01, ###p < 0.001 vs sham control, two-way 
repeated measure (RM) ANOVA with SNK post hoc, n = 9-12. 
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2.3.3 GPR84 KO mice exhibit a normal microglial response 7 days post PNL 
 
Having established a behavioural phenotype, we then sought to correlate these findings 
with histological analysis. Microglia are known to play a key role in the initiation of pain-
associated behaviours and GPR84 is exclusively expressed on these cells in the CNS 
(Bouchard et al., 2007); we therefore investigated the microglial phenotype after nerve 
injury in WT and KO mice to elucidate if GPR84 deletion alters the microglial response. To 
achieve this we examined immunohistochemical changes of microglia in lumbar spinal cord 
sections at 7 days post PNL; a time point where anatomical changes in response to nerve 
injury such as microgliosis are robust.  
 
To investigate whether deletion of GPR84 specifically alters microglial numbers, we stained 
for Iba1, which is a marker of microglial cells. Quantification of immunoreactivity revealed 
that there was no significant difference between GPR84 WT and KO microglial cell numbers 
in the ipsilateral or contralateral dorsal horns of sham controls (Fig. 2.6). Therefore, under 
normal conditions GPR84 deletion has no effect on microglial numbers. Furthermore, we 
also observed that under these conditions, microglia morphology in the KO was no different 
to that of the WT and microglial cells exhibited characteristic long, thin processes and a 
ramified appearance. Subsequent to peripheral nerve injury both GPR84 WT and KO mice 
showed a significant 3.2 fold increase in Iba1 positive cells in the ipsilateral dorsal horn 
(WTPNL, 21.1 ± 1.7/4x104 μm2; KOPNL, 21.6 ± 2.4/4x104 μm2) compared to sham controls 
(WTS, 6.6 ± 2.0/4x104 μm2; KOS, 6.7 ± 0.7/4x104 μm2; Fig. 2.6). There was no significant 
difference between the genotypes. Microglia morphology in response to nerve injury was 
typically de-ramified and amoeboid in shape, which was again exhibited by both genotypes. 
This indicates that GPR84 KO mice are capable of launching a normal microgliosis response 
subsequent to peripheral nerve injury and thus this receptor does not play a role in 
regulating microglial numbers under neuropathic conditions.  
 
Although there were no differences in microglial numbers, we also investigated whether 
GPR84 deletion may effect phosphorylation of p38 MAPK, which is a key kinase in 
nociceptive pathways and a marker of microglial activation (Ji and Suter, 2007; Ji et al., 
2009). In sham animals, we found no significant difference in the number of p-p38 positive 
cell numbers in ipsilateral or contralateral dorsal horn between GPR84 WT and KO (Fig. 
2.6). Therefore, under normal circumstances GPR84 deletion has no effect on microglial 
activation. Subsequent to peripheral nerve injury both GPR84 WT and KO mice showed a 
significant 3.4 and 4.1 fold increase in p-p38 positive cells, respectively, in the ipsilateral 




dorsal horn (WTPNL, 20.4 ± 2.1/4x104 μm2; KOPNL, 18.6 ± 3.7/4x104 μm2) compared to 
sham controls (WTS, 6.0 ± 2.3/4x104 μm2; KOS, 4.5 ± 1.3/4x104 μm2; Fig. 2.6) and there was 
no significant difference between genotypes. These results suggest that GPR84 is not 
important for the regulation of p-p38 expression in microglial cells under neuropathic pain 
states. 
  







Figure 2.6: Nerve injured GPR84 KO mice exhibit a normal microglial response in the spinal 
cord 7 days post PNL 
 
Subsequent to peripheral nerve injury there was a significant increase in Iba1 and p-p38 positive 
cells in the ipsilateral dorsal horn of the spinal cord of GPR84 WT (WTPNL) and KO (KOPNL) mice, 
compared to control sham groups (WTS and KOS, respectively) (A), quantified in (B). There was no 
significant difference between genotypes. Data are presented as the mean ± SEM. ***p < 0.001 vs 
contralateral; ###p < 0.001 vs sham, one-way RM ANOVA with SNK post hoc, n = 4-6. Scale bar = 200 
μm.  
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2.3.4 GPR84 KO mice exhibit a normal microglial response 21 days post PNL 
 
So far we have seen no evidence of a role of GPR84 in the microgliosis response at 7 days 
post PNL, therefore we investigated whether deletion of this receptor affects the microglial 
phenotype at a later time point of 21 days. Although there may be an element of resolution 
at this later time point, there is still a significant difference in the mechanical and thermal 
paw withdrawal thresholds of the WT PNL group compared to the WT sham group. 
Importantly, this difference is absent in the KO at this later time point. Furthermore, 
behavioural hypersensitivity correlating with increased microglial cell numbers in the 
ipsilateral dorsal horn has been reported up to 50 days post PNL in rats (Clark et al., 2006).  
 
To investigate if deletion of GPR84 specifically alters microglial numbers, we stained for 
Iba1 in L4 and L5 spinal sections. Similar to our findings at day 7 post PNL, there was no 
significant difference between GPR84 WT and KO microglial cell numbers in the ipsilateral 
or contralateral dorsal horns of sham controls at 21 days post surgery (Fig. 2.7). Microglial 
morphology was also observed to be no different between genotypes. Subsequent to 
peripheral nerve injury both GPR84 WT and KO mice showed a significant 1.8 fold increase 
in Iba1 positive cells in the ipsilateral dorsal horn compared to sham controls (WTPNL, 9.3 ± 
0.7/4x104 μm2; KOPNL, 11.1 ± 0.8/4x104 μm2 vs WTS, 5.3 ± 0.6/4x104 μm2; KOS, 6.1 ± 
0.9/4x104 μm2; Fig. 2.7). The increased number of microglial cells in response to injury 21 
days post PNL was similar to that seen at the earlier time point, and there was no significant 
difference between the genotypes. Again, morphological changes of microglial cells in 
response to nerve injury were similar and no different between the genotypes. However, it 
is worth noting that the increase in microglial numbers at 21 days post PNL was 
approximately 50% of that at 7 days post injury, confirming a degree of resolution at this 
later time point. These data illustrate that GPR84 KO mice are capable of an extensive 
microgliosis response over the course of traumatic neuropathy and that GPR84 deletion 















Figure 2.7: Nerve injured GPR84 KO mice exhibit a normal microglial response in the spinal 
cord 21 days post PNL 
 
Subsequent to peripheral nerve injury there was a significant increase in Iba1 positive cells in the 
ipsilateral dorsal horn of the spinal cord in WTPNL and KOPNL mice compared to control sham 
groups (WTS and KOS, respectively) (A), quantified in (B). There was no significant difference 
between the genotypes. Data are presented as the mean ± SEM. **p < 0.01, ***p < 0.001 vs 
contralateral; ###p < 0.001 vs sham, one-way RM ANOVA with SNK post hoc, n = 4. Scale bar = 200 μm.  




































2.3.5 GPR84 KO mice exhibit a normal macrophage response 7 days post PNL 
 
So far we have seen no evidence of a CNS change in the microglial profile of GPR84 KO mice 
that correlates with the behavioural phenotype after injury. As GPR84 expression is 
restricted to immune cells, we decided to examine the response of macrophages in the 
sciatic nerves. These are the key phagocytic immune cells of the PNS and have been well 
documented to play a role in nerve injury-induced behavioural hypersensitivity (Myers et 
al., 1996; Liu et al., 2000; Barclay et al., 2007). 
  
To elucidate whether deletion of GPR84 may alter the peripheral inflammatory response to 
nerve damage mediated by infiltrating macrophage cells, we carried out immunostaining of 
Iba1 in longitudinal sciatic nerve sections, distal and proximal to the site of injury. We 
examined this marker of macrophage cells at 7 days post PNL, as the immune response at 
this time point is robust and correlates with the behavioural hypersensitivity seen in WT 
mice. We found that there was no significant difference between GPR84 WT and KO 
macrophage cell numbers in the ipsilateral sciatic nerves of sham controls (Fig. 2.8.). 
Therefore GPR84 deletion has no effect on macrophage cell numbers per se. Following 
peripheral nerve injury both WT and KO mice showed a 95.1% and 91.3% increase in Iba1 
positive cells, respectively, in the ipsilateral sciatic nerve, distal to the lesion site compared 
to sham controls (WTPNL, 10.0 ± 1.2/4x104 μm2; KOPNL, 9.4 ± 0.3/4x104 μm2 vs WTS, 0.5 ± 
0.2/4x104 μm2; KOS 0.8 ± 0.1/4x104 μm2; Fig. 2.8). Due to a degree of macrophage 
infiltration into intact axons of the nerve injury site, proximal counts of the injured nerve 
were also greater than sham controls, which were significant in WT mice (WTPNL, 3.0 ± 
1.0/4x104 μm2; KOPNL, 2.0 ± 0.5/4x104 μm2). There was no significant difference between 
the genotypes. These data demonstrate that GPR84 has no effect on macrophage infiltration 
in response to nerve injury and therefore these cells are not essential for the behavioural 
phenotype observed in GPR84 KO mice. However, we must acknowledge that following 
nerve injury macrophage cells can also infiltrate the CNS and contribute to the Iba1 cell 
population in the dorsal horn, and thus a CNS macrophage involvement cannot be excluded 
(Zhang et al., 2007). The contribution of macrophage infiltration into the DRG in GPR84 WT 












Figure 2.8: GPR84 KO mice exhibit a normal macrophage response in the sciatic nerve 7 days 
post PNL 
 
There was a significant increase in Iba1 positive cells in the injured ipsilateral sciatic nerve in GPR84 
WTPNL and KOPNL mice compared to their corresponding control sham groups (WTS and KOS, 
respectively) (A), quantified in (B). There was no significant difference between genotypes. Data are 
presented as the mean ± SEM. *** p < 0.001 vs corresponding proximal (PROX); #p < 0.05, ###p < 0.001 













































2.3.6 Raw PCR array data: Comparing nerve injury induced mediator transcript 
changes in GPR84 WT and KO mice 
 
We have shown that deletion of GPR84 results in the prevention of behavioural 
hypersensitivity after nerve injury (Fig. 2.5). To investigate whether this correlates to 
changes in mediator expression induced by peripheral nerve injury we utilised high 
through-put custom-made Taqman array cards, to compare the expression of a range of 
putative mediators of interest (a majority of which were chemokines and cytokines) in 
sciatic nerve and spinal cord tissue of GPR84 WT and KO at two time points. An explanation 
of analysis is provided in the methods section (2.2.8) and in more detail in (Perkins et al., 
2012). 
 
Appendix Tables 1-8 display the raw CT values of 92 different chemokine/cytokines, growth 
factors and cell markers as well as raw CT values of control HK genes in the sciatic nerve at 
7 and 21 days post sham or PNL surgery (1, 2), (5, 6) respectively; and in the spinal cord at 7 
and 21 days post PNL or sham surgery (3, 4), (7, 8) respectively, in GPR84 WT and KO mice.  
Transcripts which had amplification curves that failed to pass a set threshold within the 
exponential phase were denoted as non-detectable (ND). Note that ARG1, Mannose receptor 
c-type 1 (MRC1), Colony stimulating factor 3 (granulocyte) receptor (CSF3R), neuregulin 1 
(NRG1) were only examined at 7 days post PNL; CCL26, CCL28, Colony stimulating  factor 1 
(macrophage) receptor (CSF1R), Histocompatibility 2, class II antigen E beta (H2.EB1) were 
only examined at 21 days post PNL.  
 
Gene expression was measured via the amplification of a target cDNA sequence that 
corresponds to a particular gene of interest. The samples were subjected to 40 cycles of 
temperature controlled PCR amplification, which entails three key phases of denaturation, 
primer annealing and elongation. During amplification the level of fluorescence was 
measured and once it reached above background to a set threshold within the exponential 
phase, the number of cycles required to reach this threshold were used to estimate the 
amount of cDNA sequence present and hence the amount of transcript in the original sample 
(Perkins et al., 2012). A CT value of 1 corresponds to doubling of a transcript and so the 
lower the CT value the greater the expression of the gene. 
 
Incomplete reverse transcription of RNA or error in sample loading can result in faulty 
reactions and incorrectly calculated CT values. However, the raw CT values of individual 
genes were generally consistent within experimental groups (Appendix Tables 1-8), 




implicating biological differences rather than experimentally-driven variability. At the end 
of each table within an experimental group are the raw CT values for the four HK genes, 
which are used to normalise the data. We observed that the CT values of the HK genes 
within experimental groups varied no more than 1 cycle, particularly in the spinal cord 
tissue, which is indicative of consistency. In the sciatic nerve tissue the CTs were slightly 
more variable at both time points, perhaps reflecting differences in tissue compositions. 
Overall consistency was also exhibited between experimental groups of both genotypes, 
where the average CT values for HK genes varied no more that 1 cycle in the spinal cord 
tissue at both time points and in the sciatic nerve tissue at D7. Likewise, in the D21 sciatic 
nerve tissue, all HK genes except 18s exhibited an average increase of 1 CT in the WT PNL 
group and 2 CTs in the KO PNL group, compared to corresponding sham groups. Despite 
this, an up-regulation in the HK genes in fact reduces the FC values of up-regulated 
transcripts rather than enhances them and hence limits significance. Therefore, we can 
assume that the data is consistent enough to limit the incidence of false positives. 
 
It was observed that a majority of fluorescent readings for each gene transcript crossed the 
arbitrary threshold within the exponential phase generally between 15 and 35 cycles. 
Transcripts that were below detection level, and did not cross the threshold or had CT 
values close to 38 were denoted as ND (Appendix Tables 1-8). As stated in the methods 
section, transcripts that attained a ND CT value in more than 50% of the samples within an 
experimental group were given a default value of 38, and if this occurred in both 
experimental groups (i.e. PNL and sham) then the transcript did not obtain a FC value. In all 
cases the amplification plots of individual transcripts for each card were checked for faulty 
reactions caused by bubbles or evaporation of the reaction mixture due to unsealed wells. 
Hence we can be confident that lack of gene detection was due to a biological factor rather 
than a technical error. 
 
2.3.7 Top dysregulated mediators in nerve injured GPR84 WT and KO mice  
 
Tables 2.1-2.4 display the top differentially regulated genes in GPR84 KO mice. Data are 
displayed as the mean FC relative to control levels (see Appendix Tables 11 and 12 for FC 
values of all genes profiled). The standard deviation (SD) values are only those of the case 
samples where variability is considered to be the greatest, rather than the control samples. 
A FC threshold of ≥ 2 in one or both genotypes for a particular gene was set to reduce noise 
by eliminating those genes that showed marginal expression changes. A FC ratio (KO FC/WT 
FC) threshold of ≥ 1.5 was also set and genes were ranked according to this ratio. The FC 




ratio was employed in the screening criteria so that unless a particular transcript changed 
by ≥ 1.5 fold between genotypes, it would not be considered to be transcriptionally 
regulated by GPR84. This enabled us to efficiently filter irrelevant genes that are un-related 
to the behavioural pain phenotype despite a correlated expression and thus focus on 
transcripts that were considerably dysregulated between genotypes. With such a large data 
set it is important to implement careful criteria to dissociate genes of interest from those 
not showing substantial transcriptional changes (Antunes-Martins et al., 2013). However, 
setting up a very stringent threshold also creates the possibility that some genes of 
relevance may be disregarded.  
 
The concept that the development of behavioural hypersensitivity is driven by an increased 
expression of mediators has led many genomic studies to focus on those genes that are up-
regulated after nerve injury. However, nociception is also driven by a down-regulation in 
the expression of some genes, hence why we have examined both up- and down-regulated 
transcripts. Table 2.1A displays the top ranking down-regulated genes in the sciatic nerve of 
GPR84 KO mice 7 days post PNL. These genes are of particular interest because they were 
either up-regulated or more greatly expressed in WT than KO mice after nerve injury by a 
FC ratio of ≥ 1.7, correlating with an absence of behavioural hypersensitivity in the KO. As 
expected GPR84 was not detectable in the KO, but was strikingly up-regulated in WT sciatic 
nerve tissue after nerve injury (FC: 51.3). Intriguingly, of the top 10 down-regulated 
transcripts half, were epidermal growth factors (EGFs): amphiregulin (AREG) (WT FC: 12.2, 
KO FC: ND); betacellulin (BTC) (WT FC: 4.1, KO FC: 2.0); artemin (ARTN) (WT FC: 4.5, KO FC: 
2.4); epiregulin (EREG) (WT FC: 55.3, KO FC: 30.5); heparin-binding EGF-line growth factor 
(HBEGF) (WT FC: -3.3, KO FC: -5.7). Unlike the other EGFs, which exhibited similar patterns 
of up- or down-regulation between the genotypes, amphiregulin was particularly interesting 
despite a lack of significance as it was not detectable in the KO and was considerably up-
regulated in the WT. The other top five down-regulated transcripts were cytokines, 
including the pro-inflammatory IL-23a and IL-5. However, since these were down-regulated 
in both genotypes (although considerably more in the KO) they are unlikely to be related to 
the KO behavioural phenotype.  
 
Table 2.1B ranks the top up-regulated genes in KO sciatic nerve 7 days post PNL compared 
to WT. Intriguingly, the pro-inflammatory mediators IL-1β, IL-6, TNF-α, CCL2 and CCL3, 
which are well documented to play a role in nociception (Thacker et al., 2007; Austin and 
Moalem-Taylor, 2010) were up-regulated in both genotypes but to a greater extent in the 
KO. This finding was unexpected as KO mice did not display neuropathic pain-related 




behaviour at this time point. IL-1β, TNF-α and CCL3 were significantly expressed in both 
genotypes, where IL-6 and CCL2 were detected only in the KO: (IL-1β: WT FC: 24.9, KO FC: 
71.9; IL-6: WT FC: 1.8, KO FC: 14.3; TNF-α: WT FC: 6.8, KO FC: 18.3; CCL2: WT FC: 1.9, KO FC: 
4.9; CCL3 WT FC: 10.2, KO FC: 25.7. A majority of up-regulated transcripts in the KO were 
chemokines, reflecting their important role in neuropathology. Pro-inflammatory IL-12b, 
CCL4, CCL7, CCL8, CCL9, CXCL9, CXCL10 and chemotactic XCL1 were significantly induced in 
the KO and showed a greater FC increase than the WT (Table 2.1B) along with a few 
immune cell markers including ARG1, allograft inflammatory factors-1 (AIF1), and T-cell 
surface glycoprotein CD3 delta chain (CD3D). AIF1 (Iba1 gene) was up-regulated in both 
genotypes but was 2.1 times more greatly expressed in the KO (AIF1: WT FC: 4.3, KO FC: 
9.2). This complies with our previous observation that macrophage infiltration into the 
sciatic nerve after injury is normal in the KO (Fig. 2.8). Interestingly ARG1, a marker of a 
sub-population of anti-inflammatory macrophages was significantly up-regulated in the KO 
in contrast to the WT (WT FC: 5.7, KO FC: 20.7). 
 
In the spinal cord 7 days post PNL, very few transcripts met the threshold criteria. FC values 
of individual genes were also smaller than that seen in the sciatic nerve and did not reach 
significance (Table 2.2). CXCL3 and IL-24 were up-regulated in the WT and were 
undetectable or less expressed in the KO, respectively; however, these proteins are not 
documented to have a role in nociception (Table 2.2A). Top up-regulated transcripts in the 
KO included a mixture of chemokines and cytokines (Table 2.2B), three of which are 
implicated in pro-nociceptive transmission: CCL5, TNF-α and IL6 (DeLeo et al., 1996; 
Homma et al., 2002; Benamar et al., 2008). Notably, CXCR3 (the receptor for pro-
inflammatory CXCL10) was the top up-regulated transcript in the KO and was down-
regulated in the WT (WT FC: -1.5, KO FC: 7.0). CXCL10 mRNA was found to be significantly 
induced in both the sciatic nerve and spinal cords of KO mice 7 days post PNL (Table 2.1B). 
Therefore, elevated expression of CXCR3 could be a result of infiltrating T-cells via the 
chemotactic properties of CXCL10 (Taub et al., 1993), a hypothesis also supported by an 
increased expression of the T cell receptor, CD3D, in the spinal cord tissue of KO mice. 
 
We also examined transcriptional changes induced by the PNL model in the sciatic nerves 
and spinal cords of GPR84 WT and KO mice at a later time point as behavioural 
hypersensitivity was absent throughout the 21 testing days in the KOs (Fig. 2.5). Table 2.3 
illustrates a range of chemokines, cytokines and growth factors differentially regulated 
between the genotypes in the nerve. However, none of these changes were significant except 
for BTC which was up-regulated in the KO (unlike the earlier time point where it was up-




regulated in the WT) (Table 2.3B). The only other top regulated EGF at this later time point 
was EREG, which showed considerably less induction in the WT compared to day 7 and was 
not detectable in the KO (Table 2.3A). Despite a lack of significance, the pro-nociceptive 
mediators IL-1β, IL-6, COX-2 (PTGS2), inducible nitric oxide synthase 2 (NOS2)  and CCL3 
were amongst the top 17 ranking genes that showed a greater expression in the WT sciatic 
nerve than the KO, correlating with the observed behavioural hypersensitivity in 
neuropathic WT mice (Table 2.3A). At the earlier time point these mediators were in fact 
considerably up in the KO as opposed to the WT, which represents a striking transcriptional 
switch between the genotypes at the later time point. Consistent with the earlier time point, 
CXCL17, CCL8 and CXCL9 were up-regulated in the KO but down-regulated or undetectable 
in the WT and the pro-nociceptive mediators IL-12b, BDNF and CCL21a,b also had a higher 
expression in the KO. The immune cell marker, integrin alpha M (ITGAM; CD11b), was 
amongst the top hits and showed a greater induction in the KO, which again supports our 
observation that the macrophage response to nerve injury is indistinguishable from the WT 
(Fig. 2.8). 
 
In spinal cord tissue at 21 days post PNL fewer genes met the threshold criteria and 
transcript changes were smaller and lacked significance, similar to the D7 time point (Table 
2.4). None of the top up-regulated (A) or top down-regulated (B) transcripts in the KO were 
consistent with the earlier time point except for CCL8, which was consistently up-regulated 
in the KO spinal cord. Top regulated mediators included pro-inflammatory IL-12b, IL-23a, 
CCL7, and CXCL9; with only IL-12b and CXCL9 being previously implicated in nociceptive 
transmission. Contrary to the early time point, CXCR3 exhibited reduced expression in the 
KO, although there was an increase in the selective ligand CXCL9 (Table 2.4). CXCR3 is 
preferentially expressed by pro-inflammatory T helper type 1 (Th1) lymphocytes and so 
this could indicate resolution of T cell infiltration into the spinal cord at this later time point, 
consistent with the behavioural phenotype in the KO mice. On the other hand, the greater 
expression of CXCR3 in the WT is suggestive of increased T-cell infiltration into the spinal 
cord, which could mark the slower onset of the T-cell contribution to neuropathic pain (WT 
FC: 3.5, KO FC: 1.2). 
 
In summary, we have identified a number of genes which were dysregulated in the nerves 
and spinal cords of GPR84 KO mice at two time points after nerve injury. It is evident that 
the greatest transcriptional changes occurred in the sciatic nerve at both time points, an 
observation further highlighted in the profile distribution graphs (Fig. 2.9). This 
representation shows the distribution of average FC values relative to sham controls and the 




FC ratios of genes in the sciatic nerve and spinal cord of GPR84 WT and KO mice at 7 and 21 
days post PNL. The gene profiles are ranked in order of FC ratio from the greatest down-
regulated to the most up-regulated in the WT as opposed to the KO. The blue shaded region 
corresponds to the cut off threshold of a FC of 2. 
 
The profile distribution graphs illustrate the important temporal relationships in gene 
expression as well as the differences in gene regulation between distinct tissue types. 
Considering that a majority of the transcripts screened are driven by intrinsic 
immunological activity, gene expression changes may be somewhat diluted in the spinal 
cord compared to the sciatic nerve due to different cellular compositions. As previously 
discussed, both tissues exhibited greater transcriptional changes at the early time point. The 
spatial temporal relationship with transcriptional regulation is an interesting aspect of 
these data sets and would require additional studies examining different time points to gain 
further understanding. Interestingly, at the earlier time point in both tissue types a subset of 
genes were more strongly induced in the KO than the WT (Fig. 2.9A & B).  However, the vast 
majority of FC ratio values resided below threshold and only a minority of genes were 
differentially regulated between the genotypes. These results indicate that transcriptional 
changes in response to peripheral nerve injury are generally similar between the two 
genotypes, as illustrated by the tight correlation profiles of the FC values. In contrast to the 
earlier time point, more genes are differentially regulated between the genotypes in the 
sciatic nerve at D21 as indicated by the FC ratio profile (despite lower FC values). In the 
spinal cord, the FC profiles are tighter at the later time point but there is a similar number of 
dysregulated genes as in the D7 data set.  
 
In each genotype FC data points that clearly resided outside the threshold are differentially 
regulated from control tissue and those genes that also have FC ratios ≥ 1.5 are differentially 
regulated between the genotypes. These genes are of particular interest as they could 
potentially play a role in behavioural hypersensitivity modulated by GPR84 and are 










Table 2.1: Top down- (A) and up- (B) regulated genes in GPR84 KO sciatic nerve 7 










Rank ID WT KO
KOFC / WTFC 
RATIO
1 GPR84 51.3 (22.43-117.2)** ND -51.3
2 AREG 12.2 (2.5-59.1) ND -12.2
3 IL5 -1.5 (0.1-3.6) -16.2 (0.05-0.08)*** -10.8
4 IL23A -3.0 (0.3-0.4)* -7.3 (0.02-1.2) -2.4
5 BTC 4.1 (2.2-7.4)* 2.0 (0.5-7.6) -2.0
6 IL34 -4.5 (0.1-0.4)* -8.7 (0.03-0.4) -1.9
7 ARTN 4.5 (2.4-8.3)* 2.4 (1.3-4.6) -1.9
8 EREG 55.3 (18.6-163.9)* 30.5 (11.8-78.6)* -1.8
9 HBEGF -3.3 (0.2-0.4)** -5.7 (0.09-0.4)* -1.7
10 CXCL13 -11.7 (0.05-0.1)*** -20.1 (0.02-0.2)* -1.7
Top down-regulated genes in GPR84 KO sciatic nerve tissue 7 days post  PNL
2.1 (B)
Rank ID WT KO
KOFC / WTFC 
RATIO
1 IL6 1.8 (0.3-9.5) 14.3 (4.8-42.6)* 8.0
2 CCL1 -1.3 (0.2-3.1) 8.0 (2.5-25.8) 6.4
3 CCL7 1.6 (0.7-4.0) 7.6 (3.5-16.6)* 4.7
4 XCL1 4.7 (0.9-24.3) 19.8 (9.5-41.0)* 4.2
5 CCL4 8.3 (6-11.4)** 32.0 (17.7-57.7)** 3.9
6 IL12B 7.1 (1.4-36.2) 26.2 (16-43.1)* 3.7
7 ARG1 5.7 (4.7-7.0) 20.7 (9.8-43.8)** 3.6
8 CXCL17 -6.2 (0.02-1.3) -1.9 (0.2-1.2) 3.2
9 CXCL10 1.8 (1.0-3.1) 5.5 (2.4-12.3)* 3.1
10 IL1B 24.9 (13.7-45.2)* 71.9 (42.1-123.0)*** 2.9
11 CXCL9 3.5 (2.4-5.0)* 9.8 (4.4-21.8)* 2.8
12 CXCL2 20.0 (13.3-30.0)** 55.9 (41.9-74.7)** 2.8
13 CCL8 7.6 (7.0-8.2) 21.0 (9.0-49.3)* 2.8
14 TNF 6.8 (5.3-8.6)** 18.3 (13.3-25.2)** 2.7
15 CCL2 1.9 (1.1-3.3) 4.9 (2.8-8.5)* 2.5
16 CCL3 10.2 (8.3-12.5)** 25.7 (17.0-38.9)*** 2.5
17 CSF2 -1.4 (0.1-3.8) 3.5 (0.9-13.9) 2.4
18 CD3D 2.5 (0.4-14.2) 5.9 (3.1-11.0)* 2.4
19 CCL9 1.8 (1.6-2.1) 4.2 (2.6-6.6)* 2.3
20 AIF1 4.3 (3.2-5.8)** 9.2 (5.8-14.6)** 2.1
Top up-regulated genes in GPR84 KO sciatic nerve tissue 7 days post  PNL






























Rank ID WT KO
KOFC / WTFC 
RATIO
1 GPR84 2.6 (1.5-4.4) ND -2.6
2 IL19 -1.4 (0.6-0.9) -3.1 (0.1-1.5) -2.3
3 CXCL3 2.0 (0.8-5.2) ND -2.0
4 IL24 9.0 (2.3-35.1) 5.7 (2.1-15.8) -1.6
Top down-regulated genes in GPR84 KO spinal cord tissue 7 days post  PNL
2.2 (B)
Rank ID WT KO
KOFC / WTFC 
RATIO
1 CXCR3 -1.5 (0.4-1.1) 7.0 (3.5-13.9) 4.7
2 CCL8 1.2 (0.7-2.3) 3.8 (2.4-6.0) 3.0
3 CCL5 1.0 (0.6-1.6) 2.3 (1.0-5.8) 2.3
4 TNF 2.2 (1.5-3.1) 4.1 (3.1-5.3) 1.9
5 CD3D -2.3 (0.1-1.9) 3.9 (2.1-7.1) 1.7
6 IL6 1.5 (0.6-3.3) 2.4 (1.5-3.8) 1.6
Top up-regulated genes in GPR84 KO spinal cord tissue 7 days post  PNL




Table 2.3: Top down- (A) and up- (B) regulated genes in GPR84 KO sciatic nerve 21 







Rank Gene WT FC KO FC
KOFC/WTFC 
RATIO
1 IL1B 42.8 (17.7-103.6) 3.2 (0.6-17.8) -13.3
2 IL27 16.4 (9.8-27.6) 2.2 (0.8-6.2) -7.4
3 XCL1 17.2 (0.3-1140.4) 2.5 (1.1-5.6) -7.0
4 CCL3 17.8 (6.9-46.2) 4.0 (1.7-9.7) -4.4
5 GPR84 3.6 (1.1-11.5) ND -3.6
6 IL6 -1.4 (0.2-2.8) -4.4 (0.1-0.5) -3.1
7 CXCL11 -3.7 (0.3-0.6) -11.1 (0.02-0.4) -3.0
8 EREG 2.9 (0.8-11.1) ND -2.9
9 PPBP -2.6 (0.2-0.8) -7.1 (0.1-0.3) -2.8
10 PTGS2 -1.5 (0.2-2.1) -3.7 (0.1-1.0) -2.5
11 CCL4 8.0 (4.6-14.0) 3.3 (0.8-13.9) -2.4
12 IL23A -6.0 (0.04-0.6) -14.3 (0.01-0.4) -2.4
13 CXCL1 2.2 (0.9-5.7) 1.0 (0.1-7.5) -2.1
14 CCL28 -3.2 (0.2-0.5) -6.4 (0.1-0.4) -2.0
15 NOS2 4.3 (3.5-5.4) 2.2 (1.7-2.9) -2.0
16 CCL22 3.1 (0.8-12.3) 1.8 (0.4-8.7) -1.7
17 CXCL3 18.1 (3.0-107.5) 12.4 (1.5-100.8) -1.5
Top down-regulated genes in GPR84 KO sciatic nerve tissue 21 days post  PNL
2.3 (B)
Rank Gene WT FC KO FC
KOFC/WTFC 
RATIO
1 CXCL17 -2.1 (0.1-0.9) 12.1 (4.1-35.7) 5.7
2 IL12B ND 4.7 (1.3-16.7) 4.7
3 CCL8 3.3 (2.3-4.6) 13.4 (7.1-25.3) 4.1
4 IL34 -3.6 (0.2-0.5) -1.1 (0.1-11.5) 3.2
5 STAT4 -9.4 (0.03-0.4) -3.4 (0.1-0.6) 2.8
6 BDNF 8.3 1.1-62.2) 23.0 (3.1-310.0) 2.8
7 CXCL14 1.2 (0.6-2.2) 3.2 (1.3-7.7) 2.7
8 CCL24 -4.2 (0.1-0.4) -1.7 (0.3-1.2) 2.4
9 CCL21A,B -4.5 (0.2-0.4) -1.9 (0.2-1.9) 2.4
10 CXCL9 1.3 (0.7-2.2) 2.9 (1.9-4.6) 2.3
11 CCL25 -3.5 (0.2-0.5) -1.6 (0.4-0.9) 2.2
12 FGF7 -4.5 (0.1-0.4) -2.4 (0.1-1.7) 1.9
13 CXCL13 -9.9 (0.03-0.4) -5.5 (0.1-0.2) 1.8
14 BTC 2.8 (1.3-6.3) 5.0 (3.3-7.4)* 1.8
15 ITGAM 2.0 (0.9-4.3) 3.2 (1.2-8.0) 1.6
16 CCL19 -2.3 (0.2-1.1) -1.5 (0.2-2.3) 1.6
17 IL18 -3.2 (0.2-0.6) -2.1 (0.3-0.9) 1.5
18 IL1A 11.5 (1.7-79.0) 17.3 (6.3-47.1) 1.5
Top up-regulated genes in GPR84 KO sciatic nerve tissue 21 days post  PNL




Table 2.4: Top down- (A) and up- (B) regulated genes in GPR84 KO spinal cord 21 










Tables  2.1-2.4:  Top down- (A) and up- (B) regulated gene transcripts in the sciatic nerve and 
spinal cord of nerve injured GPR84 KO mice  
 
Tables displaying the top down-regulated (A) and the top up-regulated (B) genes in the ipsilateral 
sciatic nerve at 7 and 21 days post PNL (2.1 and 2.3, respectively) and ipsilateral spinal cord at 7 and 
21 days post PNL (2.2 and 2.4, respectively). The genes are ranked in descending order of FC ratio. FC 
ratio = KO FC/WT FC, where FC = PNL/sham within each genotype. Only genes with a FC of ≥ 2 within 
one or both of the genotypes and a FC ratio of ≥ 1.5 have been ranked. This enables the identification 
of transcripts that exhibit the greatest FC from control and are considerably dysregulated between 
genotypes. Genes with a FC ratio of less than 1.5 are considered to be similarly expressed between 
genotypes. Data are presented as the mean FC (± 1 SD range of the case samples (PNL tissue)). P < 





Rank ID WT FC KO FC
KOFC/ WTFC 
RATIO
1 CXCR3 3.5 (2.7-4.6) 1.2 (0.6-2.5) -2.9
2 CXCL17 4.2 (3.2-5.5) 2.2 (1.3-3.8) -1.9
3 IL23A 1.3 (1.0-1.6) -2.3 (0.04-4.5) -1.8
4 IL12B 2.0 (0.5-8.5) -3.1 (0.1-1.3) -1.6
Top down-regulated genes in GPR84 KO spinal cord tissue 21 days post  PNL
2.4 (B)
Rank ID WT FC KO FC
KOFC/ WTFC 
RATIO
1 CCL7 1.6 (0.6-4.6) 7.5 (3.7-15.2) 4.6
2 AREG -1.1 (0.3-3.5) 2.6 (0.7-9.7) 2.4
3 IL11 -1.2 (0.6-1.2) -2.1 (0.2-1.0) 1.7
4 CXCL9 1.5 (0.4-6.4) 2.5 (0.9-6.9) 1.7
5 CXCL13 2.9 (0.6-13.4) 4.7 (0.7-31.3) 1.7
6 IL19 1.4 (0.8-2.5) 2.2 (0.5-10.0) 1.5
7 CCL8 2.4 (0.9-6.3) 3.7 (2.5-5.6) 1.5
Top up-regulated genes in GPR84 KO spinal cord tissue 21 days post  PNL
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Figure 2.9: Distribution of PNL induced gene transcript changes in the sciatic nerve and spinal 
cord of GPR84 WT and KO mice 
 
Transcript expression profiles of a range of cytokines, growth factors and cell markers 7 and 21 days 
post PNL in ipsilateral sciatic nerve (A & C, respectively) and ipsilateral spinal cord (B & D, 
respectively) of GPR84 WT and KO mice relative to appropriate sham control tissue. Transcripts are 
ranked in order of increasing FC ratio. Where FC ratio = WT FC/KO FC; FC = PNL/sham. The 
distribution profiles for most genes are similar between the genotypes, however a subset are 
considerably dysregulated. The greatest transcript FCs occur in the sciatic nerve 7 days post PNL (A), 
where a greater subset of transcripts appear to be up- or down-regulated in KO mice as opposed to 
day 21 (C), where transcript FCs are smaller but exhibit greater dysregulation between the 
genotypes. In the spinal cord, transcript changes post PNL are much smaller compared to the nerve, 
particularly at day 21 and show tighter FC profiles and hence greater similarity between the 
genotypes. The data points show the average FC or FC ratio for each gene transcript ranked from the 
most down-regulated to the most up-regulated. The blue shaded box represents an area of > 2 and 
each data point shows the mean FC for each individual transcript. Adjacent FC data points represent 




































D.     Spinal cord tissue day 21 post PNL
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2.3.8 Correlation of PNL induced gene expression between GPR84 WT and KO mice 
 
To directly compare nerve injury induced transcriptional changes between genotypes, 
average FC values for each gene in GPR84 WT and KO mice are plotted against each other 
(Fig. 2.10). As indicated by the Pearson’s correlation coefficient, there is a positive 
correlation between the WT and KO data sets in each tissue and at each time point, which is 
significant (p < 0.001). This relationship is stronger in the sciatic nerve (0.868 (A), 0.734 
(C)) than the spinal cord (0.643 (B), 0.360 (D)) and at 7 days (0.868 (A), 0.643 (B)) than 21 
days post PNL (0.734 (C), 0.360 (D)). These data indicate that mediator changes induced by 
PNL required for the development of behavioural hypersensitivity is generally similar 
between genotypes. Although, the R values for the D21 data sets are notably lower than the 
D7 data sets, particularly in the spinal cord, the correlations are significant. However, this 
leaves us some room to speculate that transcriptional regulation in the nerve and spinal 
cord at D21 is different between the genotypes. Therefore, our focus is on the few outlying 
transcripts, which are identified as data points that deviate markedly from the correlation of 
the data sets. These data points skew the Pearson’s correlation coefficient as they are 
differentially regulated between genotypes and have been highlighted in red on the graphs. 
GPR84 is denoted as a red triangle.  
 
Presenting the transcript changes in this format enables the assessment of data scatter and 
the identification of genes that do not conform to the rest of the data.  In the sciatic nerve 7 
days post PNL amphiregulin showed a strong induction in the WT but was not detectable in 
the KO (A). At 21 days post PNL, IL-1b showed a marked up-regulation in the WT sciatic 
nerve tissue compared to the KO, whereas contrariwise CXCL17 showed a considerable 
induction in the KO and down-regulation in the WT tissue (C). In the spinal cord at 7 days 
post PNL, CXCR3 and CD3D were more abundant in the KO tissue than the WT and at 21 
days IL-12b went up in the WT and down in the KO tissue, whereas CCL7 was induced more 
substantially in the KO (D). All these outliers are top hits in the gene ranking tables above.  
 
2.3.9 A direct comparison between nerve injured GPR84 WT and KO tissues 
 
Figure 2.11 compares transcriptional changes between GPR84 WT and KO nerve injured 
tissues directly where the FC is expressed as KOPNL/WTPNL. In this case, FC values of gene 
transcripts in nerve injured KO mice are expressed relative to those in nerve injured WT 
mice, where the WT serves as a control. Figure 2.11A presents the FC profiles of transcripts 
across the tissue types and time points examined, which are ranked from the lowest to the 




highest FC. Adjacent data points do not necessarily correspond to the same gene across the 
experimental groups.  We found that processing the data in this format yields similar key 
findings to the alternative method of analysis presented previously. The greatest 
transcriptional changes in response to nerve injury occurred in the sciatic nerve, with more 
genes up-regulated at 7 days post PNL and down-regulated at 21 days post PNL in the KO 
relative to the WT. Not surprisingly, the three most down-regulated data points correspond 
to GPR84 as it is non-detectable in the KO (7 day sciatic nerve, 7 and 21 day spinal cord). 
The overall trend indicates that most genes are not differentially regulated between 
genotypes and lie below the threshold, implicating a similar transcriptional response to 
nerve injury in WT and KO mice. 
 
 To compare gene changes between the two time points (7 and 21 days post PNL) the 
average FC values for each transcript are plotted against each other. As indicated by the 
Pearson’s correlation coefficient there is no relationship between the sciatic nerve time 
point data sets (-0.0622), which implies no consistency in transcriptional regulation 
between 7 and 21 days post PNL and that overall changes in gene expression vary 
considerably over time in the sciatic nerve (Fig. 2.11B).  The few genes that were 
consistently up- or down-regulated in the sciatic nerve at both time points are highlighted in 
red: CXCL17 (D7 FC: 2.9 (1.3-6.6), D21 FC: 2.1 (0.7-6.2)) or IL23a (D7 FC: -2.3 (0.1-3.7), D21 
FC -2.5 (0.1-2.2)), respectively. GPR84 is denoted as a red triangle. Intriguingly, the anti-
inflammatory chemokine, CXCL17, has continuously been a top ranking gene in the data 
analysis and thus may be a plausible target for further validation.  
 
Despite a significant positive correlation (0.740), which is clearly driven by a single data 
point rather than a relationship in the scatter between the two data sets, most of the gene 
changes in the spinal cord have a FC < 2 (Fig. 2.11C). The only consistent transcript changes 
between the two time points above the threshold criteria was IL-19 (D7 FC: -2.4 (0.1-1.9), 
D21 FC -3.5 (0.1-1.3)) and GPR84, which are highlighted in red. None of the average FC 
values for individual genes were significant via this method of analysis (except for GPR84 in 













Figure 2.10: Correlation of injury-induced transcriptional changes in the sciatic nerve and 
spinal cord of GPR84 WT and KO mice 
 
Transcript expression changes of a range of cytokines, chemokines, growth factors and cell markers 
in the ipsilateral sciatic nerve and spinal cord of nerve injured GPR84 WT and KO mice relative to 
sham tissues are plotted against each other on a log 2 scale.  The Pearson’s correlation coefficient for 
the sciatic nerve (0.868 (A), 0.734 (C)) and spinal cord (0.643 (B), 0.360 (D)) at 7 and 21 days post 
PNL, respectively, indicate a significant relationship between genotypes (p < 0.001). Expression of the 
data in this format enables the identification of gene transcripts that have a FC induction or reduction 
≥ 2, where FC = PNL/sham. Visual analysis of the FC scatter identifies gene transcripts that show 
differential regulation between genotypes (highlighted in red, see text). Red triangle denotes GPR84 
FC. Data is presented as the mean FC. Pearson’s correlation coefficient, n = 92.  
D.  Spinal cord tissue day 21 post PNL
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Figure 2.11: Analysis of the distribution and correlation of gene transcripts induced by PNL in 
the sciatic nerve and spinal cord of nerve injured GPR84 KO mice relative to nerve injured WT 
mice 
 
Direct comparison of nerve injury-induced gene expression changes in GPR84 WT and KO mice 
showing expression profiles of a range of cytokines, chemokines, growth factors and cell markers at 7 
and 21 days post PNL in ipsilateral sciatic nerve and spinal cord (A). Transcripts are ranked in order 
of increasing FC; FC = (KOPNL/WTPNL). Generally, the gene distribution profiles between the two 
genotypes are similar. The greatest transcript FCs occur in the sciatic nerve tissue where at 7 days 
post PNL where a subset of transcripts appear to be more strongly up- or down-regulated in the KO. 
In both tissues at 21 days post PNL, a greater proportion of transcripts appear to be down-regulated 
in the KO relative to the WT in contrast to transcriptional changes at the earlier time point. In the 
spinal cord transcriptional changes are much smaller compared to the nerve, at both time points. The 
data points show the average FC for each gene transcript ranked from most down- to most up-
regulated. The blue shaded box represents an area of < 2 and each data point shows the mean FC for 
FC ratio rank
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each individual transcript. Adjacent data points do not necessarily represent the same gene 
transcript, n = 88. The x-axis is on a log 2 scale. Transcript expression changes in the sciatic nerve and 
spinal cord at the two examined time points are plotted against each other to investigate the factor of 
time, on a log 2 scale. The Pearson’s correlation coefficients for the sciatic nerve (-0.0622) (B) and 
spinal cord (0.740) (C) at 7 and 21 days post PNL indicate that there is no correlation between both 
time points in sciatic nerve and a significant positive relationship between both time points in spinal 
cord tissue (p < 0.001). Expression of the data in this format enables the identification of gene 
transcripts that have a consistent FC induction or reduction of ≥ 2 between the two time point data 
sets. Red triangle denotes GPR84 FC. Data is presented as the mean FC. Pearson’s correlation 
coefficient, n = 88.  
 
These analyses exclude the following genes as they were not examined at both time points: ARG1, 
MRC1, CSF3R, NRG1, CCL26, CCL28, CSF1R and H2EB1.  
  




Table 2.5: The top five down- and up-regulated super ranked genes in the sciatic 







Tables displaying the top five down-regulated (A) and top 5 up-regulated (B) genes super ranked by 
FC ratio in GPR84 KO mice from left to right, where FC ratio = (KOPNL/KO sham)/(WTPNL/WT 
sham). Genes are super ranked via the FC ratio’s of genes from either two data sets: sciatic nerve 
7/21 days; spinal cord 7/21 days; time point 7, sciatic nerve/cord; time point 21, sciatic nerve/cord; 
or all four data sets: sciatic nerve/spinal at 7/21 days excluding those genes that were only examined 
at one time point: ARG1, MRC1, CSF3R, NRG1 (only examined at 7 days post PNL); CCL26, CCL28, 




Nerve 7 + 21 
days 
Spinal cord 7 
+ 21 days
7 days nerve + 
spinal cord 
21 days nerve 
+ spinal cord All tissues
1 GPR84 IL23A GPR84 IL23A GPR84
2 EREG CXCL2 AREG CCL22 IL23A
3 IL23A CCL11 IL23A CXCL1 CCL11
4 CXCL11 CCL22 CCL11 CCL3 CCL22
5 AREG IL25 CXCL3 GPR84 TXLNA
Top down-regulated genes in GPR84 KO mice
2.5 (B)
Super rank
Nerve 7 + 21 
days
Spinal cord 7 
+ 21 days
7 days nerve + 
spinal cord 
21 days nerve 
+ spinal cord All tissues
1 CXCL9 CCL8 CD3D CXCL9 TNF
2 CCL8 CCL21A,B CCL8 CCL21A ARG1
3 ARG1 CCL5 CXCL17 CCL8 CCL21A,B
4 CXCL17 STAT4 IL6 STAT4 STAT4
5 IL12B CD3D CCL17 IL5 CCL8
Top up-regulated genes in GPR84 KO mice




The extensive analysis of transcriptional profiles in WT and KO tissues before and after 
injury highlighted some interesting outliers that are differentially regulated between 
genotypes. Super ranking the data permits the identification of transcripts that are 
consistently down- or up-regulated in the KO across time points or tissues (Table 2.5) and 
hence strengthens the hypothesis that these genes warrant further investigation. Genes are 
super-ranked by cross-comparing top up- and down-regulated transcripts ranked by FC 
ratio in each of the four data sets. For each data set, those genes with the largest FC obtained 
the lowest value, whilst undetected genes were given a rank of 84. The average rank values 
across different data sets, as specified in the table 2.5A and B, was used to give a super-rank 
value for each gene so that those transcripts with lower values were the most consistently 
up- or down-regulated. 
 
Many of the top super ranking hits are common denominators within the top hit tables (2.1-
2.4). In the sciatic nerve these include; top down-regulated: IL23a, EREG, GPR84 (Table 
2.5A); top up-regulated: IL-12b, CCL8, CXCL9, CXCL17 (Table 2.5B). In the spinal cord none 
of the super-ranked down-regulated genes were previous hits (Table 2.5A) and only CCL8 
was a top up-regulated hit (Table 2.5B). At D7, GPR84 was a top down-regulated gene and 
IL-6, CCL8 and CD3D were top up-regulated genes (Table 2.5A,B). At D21, IL-23a was a top 
down-regulated gene and CCL8 was a top up-regulated gene in this data set and across all 
four data sets (Table 2.5A,B).  IL-23a and CCL8, are in fact consistently regulated across 3-4 
data sets, but these pro-inflammatory mediators are unlikely to play a role in the 
behavioural phenotype as IL-23a is down-regulated in both genotypes but more 
substantially in the KO and CCL8 is consistently up-regulated in the KO. By super-ranking 
the data many top regulated genes in particular tissues and time points are substituted by 
lower ranking genes that are more commonly regulated across data sets. These genes tend 
to show little relevance to the behavioural phenotype such as IL-23a and CCL8.  Therefore, it 
may be more appropriate to analyse individual data sets to identify genes of interest rather 
than conducting cross analysis over multiple data sets.  
 
In agreement with our hypothesis that GPR84 is a target in chronic pain mechanisms, its 
expression in the WT was up-regulated in both sciatic nerve and spinal cord after PNL in 
comparison to sham at both time points; however this trend was only significant in the 
nerve 7 at days post PNL (Fig.2.12A & B). Hence, in conjunction with the stiking behavioural 
phenotype observed in nerve injured GPR84 KO mice this receptor is clearly a potential 
pain-mediating target. ARG1 was also amongst the top up-regulated genes in the sciatic 
nerves of KO mice 7 days post PNL. This anti-inflammatory macrophage marker increased 




significantly after nerve injury compared to the WT, along with a marginal increase in Mrc1. 
Mrc1 is an alternative anti-inflammatory macrophage marker that also showed a greater 
induction in the sciatic nerves of KO mice compared to WT mice, although not significant 
(Fig. 2.13).  ARG1 is a potentially interesting target as there is a substantial degree of 
dysregulation between the genotypes after nerve injury and its anti-inflammatory role 
corresponds with the absence of behavioural hypersensitivity in nerve injured KO mice.  It 
would therefore be interesting to further validate this transcript and examine the M1 and 
M2 macrophage populations in the sciatic nerves of neuropathic WT and KO mice. 
  









Figure 2.12: Nerve injury induces an increase in GPR84 expression in the sciatic nerve and 
spinal cord of WT mice 
 
Subsequent to nerve injury there is an induction of GPR84 expression in the sciatic nerve (A) and 
spinal cord (B) at 7 and 21 days post PNL compared to sham tissue. This was only significant in the 
sciatic nerve at 7 days post PNL. Changes in mRNA expression are normalised to the mean ΔCT of 
sham groups, where ΔCT = (mean GPR84 CT) – (mean CT of the HK genes). Data are presented as the 























































































Figure 2.13: Nerve injured GPR84 KO mice show a greater induction of the anti-inflammatory 
macrophage markers, Arginase 1 (Arg1) and Mannose receptor c-type 1 (Mrc1) 
 
(A) Nerve injury induces a significant increase in the expression of Arginase 1 and a greater induction 
in the expression of Mannose receptor c-type 1 in sciatic nerve of GPR84 KO mice 7 days post PNL, in 
comparison to their WT littermate controls. Changes in mRNA expression are relative to the four HK 
genes and expressed as a FC (PNL/sham). Data are presented on a log 2 scale as the mean ± SEM. p < 
0.01** vs WT, T-test with FDR for multiple testing correction, n = 4.   
 
  






























Neuropathic pain is a debilitating disease affiliated with a spectrum of pathologies. 
Neuronal-immune and glial interactions as well as the vast signalling networks of immune 
mediators play a principal role in neuropathic pain. In this chapter we utilised transgenic 
mice, exploiting the PNL model (Seltzer et al., 1990) to examine the role and function of 
GPR84 in neuropathic pain states. Peripheral nerve injury elicits profound adaptive and 
maladaptive transcriptional changes in metabolism, cell survival, excitability and 
transmitter synthesis, ultimately leading to the generation of neuropathic pain (Costigan et 
al., 2002). Amongst the many receptor classes that show substantial up- or down-regulation 
in response to nerve injury, GPCRs are one of the foremost classes. We have demonstrated 
that following PNL, the relative expression of GPR84 increased in the sciatic nerves and 
spinal cords of WT mice and that deletion of this GPCR abolished mechanical and thermal 
hypersensitivity; consistent with a critical role in neuropathic pain modulation. GPR84 
appears to be exclusively expressed on immune cells and is therefore a new alternative non-
neuronal target in therapeutic treatment of chronic pain. 
 
2.4.1 GPR84 plays a role in neuropathic pain mechanisms independent of microglia 
and macrophage recruitment 
 
The PNL paradigm (Seltzer et al., 1990) is a well established model of peripheral nerve 
injury that results in considerable damage to both myelinated and unmyelinated axons. As a 
partial nerve injury model, the preservation of some input enables behavioural 
responsiveness to mechanical and thermal stimuli to be tested. This model shows highly 
consistent pain-related changes in rodents (Malmberg and Basbaum, 1998). Although many 
groups initially employed rats to determine the molecular basis of pain pathology, there is 
an increasing shift towards the use of transgenic mice. The use of transgenic mice enables 
researchers to study specific proteins in complex pain mechanisms, which is an approach 
we have also adopted in our own studies to investigate the role of GPR84. 
 
We showed that after nerve injury there was a significant reduction in mechanical and 
thermal thresholds of neuropathic mice in contrast to sham controls, recapitulating the 
literature. An accumulating body of literature has reported that these pain-related 
behaviours correlate with a rapid spinal cord glial response (Garrison et al., 1991). 
Alongside neuronal changes in the dorsal horn, microglial cells undergo extensive 
proliferative and morphological changes (Kreutzberg, 1996) by increasing the expression of 




an array of cell surface receptors (e.g. CD11b, MHCII, CD4+) and by releasing algesic 
mediators (Watkins et al., 2001; Coull et al., 2005; Clark et al., 2007a). This rapid phenotypic 
switch, which can be visualised by Iba1 and OX-42 antibody markers, normally correlates 
with the presence of hyperalgesic and allodynic behaviours. Pharmacological blockade of 
glial metabolism via inhibitors such as minocycline, fluorocitrate and propentofylline has 
demonstrated anti-allodynic properties and the attenuation of microglial activation, as 
revealed by reduced OX-42 immunofluorescence (Sweitzer et al., 2001; Ledeboer et al., 
2005; Clark et al., 2007a). Targeting of specific microglial pathways or receptors in the CNS 
also alleviates pain associated behaviours; TLR4 and CX3CR1 null mice exhibit decreased 
microglial proliferation and activation, as shown by reduced OX-42/Iba1 immunoreactivity 
and p-p38 expression (Tanga et al., 2005; Staniland et al., 2010). Moreover, neuropathic 
pain was inhibited with intrathecal administration of CCL2 neutralising antibody and 
abolished in the CCR2 null mouse (Abbadie et al., 2003; Thacker et al., 2009). In both cases 
this correlated with decreased microglial activation. However, there is some controversy 
with regards to the cell types that express CCR2, which has been reported to be exclusively 
neuronal in contrast to evidence of predominant microglial expression (Abbadie et al., 2003; 
Gosselin et al., 2005; Gao et al., 2009). Furthermore, the role of the purigenic microglial 
expressed receptors, P2X4 and P2X7 has been underscored by studies using null mice or 
selective antagonists, which also report diminished neuropathic pain (Tsuda et al., 2003; 
Chessell et al., 2005; Clark et al., 2010b).  Thus, an overwhelming amount of data deriving 
from the manipulation of microglial signalling in the CNS, supports a role of these immune 
cells in the pathology of neuropathic pain (Watkins and Maier, 2003; McMahon and 
Malcangio, 2009).  
 
On the other hand, in the periphery macrophages are the key immune cell players. Here, 
they infiltrate damaged axons, mediate WD via the phagocytosis of cell debris (Perry et al., 
1987) and release a repertoire of pro-inflammatory mediators that sensitise primary 
afferent axons. This temporal relationship has been shown to strongly correlate with 
behavioural hypersensitivity (Myers et al., 1996). Importantly, pharmacological 
manipulation of macrophage expressed receptors, systemic depletion or attenuation of 
macrophage cell recruitment and infiltration is linked to reduced neuropathic pain 
behaviours (Myers et al., 1996; Perrin et al., 2005; Barclay et al., 2007; Boivin et al., 2007). 
Furthermore, a recent study showed that administration of the anti-inflammatory 
transforming growth factor-β1 (TGF-β1) directly into partially ligated sciatic nerves of mice 
reduced pro-inflammatory MAC+ (CD11b/CD18) macrophages at the site of injury with a 
corresponding decrease in IL-6 and CCL3 and reduced neuropathic pain behaviours 




(Echeverry et al., 2013). Treatment with this cytokine had no effect on the ED1+ (CD68) 
population of phagocytic macrophages and the WD process was normal. Based on these 
findings the authors proposed the notion of targeting specific macrophage populations to 
alleviate neuropathic pain without compromising nerve regeneration (Echeverry et al., 
2013). 
 
In light of this evidence and the fact that GPR84 is selectively expressed by immune cells, we 
focused on characterising the microglia and macrophage response to nerve injury in GPR84 
WT and KO mice. To quantify these populations, reliable and sensitive methods are 
required. We used Iba1 and p-p38, which are well established immunohistochemical 
markers used to quantify the abundance and activation status, respectively, of microglia in 
the dorsal horn. We also stained for Iba1 in the sciatic nerve to quantify the presence of 
macrophages. It is well documented that nerve injury results in increases in both the 
activation and population size of microglia in the dorsal horn and macrophages in the 
injured sciatic nerve (Thacker et al., 2007; Austin and Moalem-Taylor, 2010; Gaudet et al., 
2011; Calvo and Bennett, 2012; Calvo et al., 2012). Moreover, attenuation of behavioural 
hypersensitivity by pharmacological manipulation of membrane receptors or metabolic 
activity of these cells results in a reduction in these markers (Liu et al., 2000; Sweitzer et al., 
2001; Ma and Eisenach, 2003b; Ledeboer et al., 2005; Tanga et al., 2005; Clark et al., 2007a). 
 
We report that neuropathic pain is abolished in nerve injured GPR84 KO mice in contrast to 
WT littermates. As expected, WT mice demonstrated a significant reduction in mechanical 
and thermal withdrawal thresholds. This induction in behavioural hypersensitivity 
correlated well with a significant increase in microglial numbers and activation in the 
ispilateral dorsal horn, as revealed by enhanced Iba1 and p-p38 immunoreactivity, 
respectively. A significant degree of macrophage infiltration into the injured sciatic nerve 
was also shown by an increase in Iba1 positive cells. Interestingly, although behavioural 
hypersensitivity was absent, nerve injured GPR84 KO mice exhibited microgliosis and 
macrophage infiltration similar to that of the WT mice. Put together, these data suggest that 
GPR84 is a novel and promising target as gene deletion diminished neuropathic pain but did 
not alter acute pain thresholds. Although the recruitment of microglia and macrophage cells 
appears to play a limited role in neuropathic pain mechanisms mediated by GPR84, perhaps 
other features of these cells may be important or other immune cell types. We set out to test 
the former possibility with PCR array cards as discussed below. 
 




2.4.2 GPR84 regulates the expression of a subset of pro-inflammatory mediators 
 
In order to correlate the observed KO behavioural phenotype to altered genomic regulation, 
we next investigated whether GPR84 deletion affects transcriptional changes of mediators 
induced by nerve injury. Using custom designed mouse PCR array cards we examined 
changes in the sciatic nerve and spinal cord tissue of GPR84 WT and KO mice in the PNL 
model at two different time points. This produced four sets of gene expression data. Despite 
the immense potential of large data sets, the amount of information gathered can be difficult 
to interpret and manage. In addition, there are concerns about the representation, 
sensitivity and reproducibility of such data (Costigan et al., 2002). Therefore the 
implementation of a standard criteria, as well as the validation of gene changes at both 
mRNA and protein level are crucial steps for the conclusive determination of novel pain 
mediators. 
 
We analysed the data sets via implementing a strict threshold criteria of a FC ≥ 2 and a FC 
ratio ≥ 1.5 and conducted multiple comparisons. Based on this approach, we examined the 
top ranking genes for consistency within and across data sets in addition to analysing 
transcriptional profiles and correlations between genotypes. Despite extensive analysis of 
the data it is unclear as to which mediators are contributing to the KO behavioural 
phenotype. It is evident that the largest transcriptional changes occurred in the sciatic 
nerve, some of which were only significant at 7 days post PNL. Greater changes in gene 
expression were observed at 7 days than at 21 days in both tissues and more genes were 
dysregulated in the sciatic nerve than in the spinal cord (at both 7 and 21 days). Therefore, 
as the more robust regulatory response was observed in the sciatic nerve at 7 days, we 
chose to subject this data set to further analysis. Here, nerve injury induced an up-regulation 
of 33 genes in the WT and 44 genes in the KO, and a down-regulation of 18 genes in the WT 
and 16 genes in the KO. It is well recognised that rodent models of peripheral nerve injury 
possess an inflammatory component (some to a greater extent than others) (Bennett, 1999; 
Bridges et al., 2001), which is accounted for in our data by an induction of pro-inflammatory 
genes. However, unexpectedly the induction of gene expression was similar between 
genotypes and KO mice exhibited as great, if not greater, increases in some pro-
inflammatory mediators, particularly algogenic factors such as IL-1β, IL-6, TNF-α, PTGS2, 
NOS2 and CXCL5 (Follenfant et al., 1989; DeLeo et al., 1996; Aley et al., 1998; Homma et al., 
2002; Ma and Eisenach, 2002; Dawes et al., 2011). There was also an increase in the cell 
surface markers AIF and ITGAM, which corresponded with our previous 




immunohistochemical findings of a normal macrophage response in the KO as discussed in 
2.3.5.  
 
2.4.3 GPR84 is involved in the regulation of a subset of growth factors in the sciatic 
nerve 7 days post PNL 
 
Strikingly, many of the top down-regulated transcripts in the injured sciatic nerves of 
GPR84 KO mice (compared to WT) were EGFs. AREG, was not detected in the KO but was 
induced by nerve injury in the WT. BTC and EREG were induced in both genotypes but to a 
greater extent in the WT. HBEGF was down-regulated in both genotypes but more so in the 
KO. EGFs mediate multiple and versatile cellular functions including cell proliferation, 
survival, development and homeostasis via binding to their tyrosine-kinase epidermal 
growth factor receptors (EGFR/ERBBI) to initiate receptor dimerisation, 
autophosphorylation and the activation of vast signalling cascades (Schneider and Wolf, 
2009). In the last decade, experimental evidence has revealed that GPCRs are able to 
augment potent mitogenic signals via a signalling partnership with EGFRs in a 
metalloprotease-dependent process. This pathway has been linked to many crucial 
physiological events such as cell proliferation, apoptosis, migration and disease (Schneider 
and Wolf, 2009). Little is known about EGFs in association with pain transmission, although 
one study reported that intradermal administration of EGF did not generate mechanical 
hyperalgesia and blocked PGE2-mediated sensitisation, indicating a role in the attenuation of 
nociception (Andres et al., 2010). Then again, ERBB mediated signalling has been implicated 
in pain pathways (Calvo et al., 2010; Calvo et al., 2011). 
 
ARTN, a member of the GDNF family, was induced in both genotypes after nerve injury but 
more substantially in the sciatic nerves of WT mice. Neurotrophins derived from immune 
cells such as mast cells and T lymphocytes exert multiple actions on sensory neurons and 
after nerve injury some neurotrophins and their receptors including NGF, BDNF and GDNF 
are markedly increased, particularly in Schwann cells (Woolf and Salter, 2000). We 
observed that NGF and BDNF were similarly induced by nerve injury in both genotypes, 
indicating that GPR84 is not involved in the regulation of these growth factors. Unlike NGF 
and BDNF, which are well documented in literature to play a role in pain transmission via 
sensitising nociceptors and increasing the excitability of dorsal horn neurons (Woolf, 1996; 
Latremoliere and Woolf, 2009), the story around GDNF is contradictory. GDNF has been 
postulated to have a neuroprotective role (Bennett et al., 2000; Ramer et al., 2003), and 
intrathecal administration was shown to reverse nerve injury induced behavioural 




hypersensitivity; an effect attributable to normalised expression of sodium channels in the 
DRG (Boucher, 2000; Wang et al., 2003). Systemic administration of ARTN was also shown 
to reverse neuropathic pain behaviours in a dose and time-dependent manner and 
morphological/neurochemical manifestations generated by nerve injury were normalised 
by treatment (Gardell et al., 2003; Bennett et al., 2006). On the other hand, GDNF has also 
been shown to contribute to inflammatory induced pain in a model of CFA (Fang et al., 
2003) and acute administration of GDNF induced mechanical hyperalgesia in the rat by 
sensitising nociceptors (Bogen et al., 2008). 
 
2.4.4 GPR84 is involved in the regulation of cytokine/chemokine expression in the 
sciatic nerve 7 days post PNL 
 
We report that nerve injury induces an increase in expression of many chemokines and 
cytokines that have been well documented for their pro-nociceptive properties. 
Interestingly, many of the pro-nociceptive cytokines, such as TNF-α, IL-1β, and IL-6, were 
amongst the top up-regulated hits in the sciatic nerve of KO mice. Subsequent to peripheral 
nerve injury Schwann cells, resident macrophages and mast cells release TNF-α, whose 
expression peaks concurrently with the maximal decrease in pain thresholds (Shubayev and 
Myers, 2000). Subcutaneous administration of TNF-α elicits mechanical allodynia and 
thermal hyperalgesia, which is rapidly reversed via the application of neutralising 
antibodies (Homma et al., 2002).  IL-1β is up-regulated within hours of peripheral nerve 
injury and intraplantar or intraneural administration of the rat sciatic nerve produces a 
rapid onset of hypersensitivity (Follenfant et al., 1989; Zelenka et al., 2005). The role of IL-6 
in pain is less clear due to its multifunctional role that has caused conflicting experimental 
reports. After nerve injury the expression of IL-6 and its receptor, IL-6R, increase proximal 
to the site of damage, in the DRG and in the spinal cord (Murphy et al., 1995; DeLeo et al., 
1996). Whilst some have demonstrated that spinal administration of IL-6 produces dose-
dependent anti-allodynic effects in SNL rats (Flatters et al., 2003, 2004), others have shown 
that intrathecal administration of IL-6 generates pain behaviours, which can be markedly 
attenuated in several models of neuropathy via anti-IL-6 neutralising antibodies (DeLeo et 
al., 1996; Lee et al., 2010). Amongst the top down-regulated transcripts in the sciatic nerves 
of KO mice were IL-5, IL-11, IL-23a, IL-34 and CXCL13. Little is known about these 
mediators in the context of pain but given that they were down-regulated in both genotypes 
(albeit to a greater extent in the KO) they are unlikely to play a role in the attenuated 
behavioural pain phenotype of KO mice.  
 




A majority of the top ranking up-regulated genes in the KO vs WT were chemokines 
including CCL1, 2, 3, 4, 7, 8, 9; CXCL9, 10, 17 and XCL1. Chemokines have also been reported 
in pain transmission, acting on their neuronal, immune and glial cell expressed receptors, 
which are coupled to Gαi/o signalling pathways (see Chapter 1). These pathways play a 
pivotal role in inflammation and orchestrate numerous cellular functions such as leukocyte 
trafficking, angiogenesis and haematopoiesis (White et al., 2013).  As previously discussed, 
neuropathic pain is abolished in CCR2 null mice and hypersensitive behaviours are 
attenuated with the administration of CCL2 neutralising antibodies. These observations 
correlate not only with an attenuated microglial response, but also with a reduction in 
macrophage recruitment (Abbadie et al., 2003). CCL3 is similarly postulated to contribute to 
neuropathic pain; peripheral or central administration of this ligand elicits pain behaviours 
that are reversed via antibody neutralisation (Kiguchi et al., 2010b). After nerve injury 
increased expression of CCL3 facilitates WD and nociceptor sensitisation via direct action on 
its CCR1+ and CCR5+ Schwann and macrophage cells (Kiguchi et al., 2012). The receptor for 
the chemokine IL-8 (CXCL8), CXCR2, was interestingly up-regulated 2.8 times more in the 
KO than in the WT.  IL-8 is thought to facilitate inflammation and studies using CXCR2 null 
mice report defective neutrophil recruitment (Chapman et al., 2009). Chemotactic 
chemokines CCL4, CCL7 and CCL8 are involved in the recruitment of macrophages, acting 
through the same receptors that confer the pro-nociceptive properties of CCL2, CCL3 and 
CCL5 and thus could potentially play a role in nociceptive pathways (Wells et al., 2006). In 
addition, these chemokines also act through CCR1, 2 and 5, which have been well 
documented to increase in expression in a range of PNS inflammatory disorders in humans.  
For instance, sural nerve biopsies from patients with Guillain-Barré syndrome exhibited an 
increase in CCR1 and CCR5 due to infiltrating endoneurial macrophages (Kieseier et al., 
2002).  
 
Pro-inflammatory CXCL9 and CXCL10 interact independently and synergistically at their 
receptor, CXCR3, which is primarily expressed by T lymphocytes. In chronic inflammatory 
conditions such as RA and experimental models of MS, CXCL9 and CXCL10 are considerably 
up-regulated in synchrony with their receptors, where they critically orchestrate leucocyte 
entry into the nervous system (Iwamoto et al., 2008; Kohler et al., 2008). Increased 
expression of these chemokines may be indicative of enhanced nerve injury-induced T-cell 
recruitment in the KO. Despite a lack of significance, intriguingly, CCL1 was up-regulated in 
the KO but down-regulated in the WT sciatic nerve. The relevance of CCL1 signalling via its 
receptor, CCR8, in pain or inflammation is yet to be determined. Nevertheless, CCL1 has 




been shown to possess chemotactic properties and induce the expression of pro-
inflammatory cytokines (Reimer et al., 2011).  
 
The anti-inflammatory chemokines, CXCL17 and XCL1, were up-regulated in the sciatic 
nerves of KO mice 7 days post PNL. CXCL17 is thought to be involved in tissue repair in 
response to injury and XCL1, also known as lymphotactin, harbours its chemotactic effects 
via its receptor, XCR1. Both chemokines are involved in the regulation of T cell function and 
the suppression of the immune response, but little is known with regards to their 
contribution to nociceptive pathways (Nguyen et al., 2008; Lee et al., 2013). Based on these 
data, we can conclude that the deletion of GPR84 causes an up-regulation of a subset of 
chemokines and cytokines in the injured sciatic nerve; unexpectedly a majority of which are 
pro-inflammatory or implicated in nociception. However, it is possible that GPR84 mediated 
signalling may usually exert a suppressive role over these particular mediators. It is a 
common concept that heterotrimeric Gαi/o protein signalling in macrophage cells favours a 
pro-inflammatory cytokine response, although intriguingly inhibition of Gαi subunits in 
murine macrophages has been documented to augment LPS induced cytokines (Fan et al., 
2007). This striking observation parallels our own studies as we to report increased 
expression of many pro-inflammatory mediators as a result of the deletion of a Gαi/o coupled 
receptor. In relation to the behavioural phenotype this finding is unexpected and does not 
coincide with our original hypothesis that GPR84 deletion would in fact attenuate the 
expression of some key pro-nociceptive mediators, hence emphasising the differential 
regulation of chemokines via Gαi/o proteins and the possibility of compensatory systems. 
 
2.4.5 GPR84 signalling 
 
Under basal conditions GPR84 has a low level of expression in macrophage and microglial 
cells but is markedly induced by factors that activate the NFκB pathway such as LPS, TNF-α, 
IL-1β and MCFFAs (Wang et al., 2006a; Bouchard et al., 2007). IL-1β and TNF-α null mice 
exhibit reduced expression of GPR84 mRNA in the cerebral cortex, while the addition of IL-
1β and TNF-α blocking antibodies also reduces GPR84 transcripts in microglial cell cultures 
(Bouchard et al., 2007). Interestingly, we did not see differential regulation between the 
genotypes of these mediators in our studies, suggesting that these cytokines are not 
positively regulated by GPR84 activation after nerve injury. Wang et al. (2012) were the first 
to report that MCFFAs with carbon chain lengths of 9-12 residues may serve as endogenous 
ligands of GPR84. During a screen of more than 20 cytokines, MCFFA stimulation was shown 
to dose-dependently amplify LPS-stimulated production of pro-inflammatory IL-12p40 (IL-




12b) (Wang et al., 2006a).  This indicated that activation of GPR84 promotes Th1 
differentiation and the production of Th1-associated cytokines such as INF-γ and IL-2. 
Therefore, we may have expected to see IL-12p40 expression decrease or remain 
unchanged in the injured sciatic nerve tissue of GPR84 KO mice along with 
decreased/unchanged expression of Th1-associated cytokines and an increase in Th2-
associated cytokines such as IL-4, 5, 6, 10 and 13. Interestingly, another study examining 
GPR84 KO T-cells showed an increased IL-4 production in response to in vitro stimulation 
with anti-CD3 (Venkataraman and Kuo, 2005). Thus, GPR84 is implicated in the regulation 
of T cells and the production of a subset of cytokines. However, in contrast to what we 
would anticipate from the Wang (2012) study, we found an increase in IL-12p40 expression 
in the injured sciatic nerves of KO mice compared to WT. Moreover, there was no change or 
detection of IL-2, 4 and 13 and a decrease in IL-5 expression, although we did observe an 
increase in IL-6 and IL-10. Although our data does not entirely coincide with previous 
findings, we must consider the fact that functional in vitro assays do not necessarily reflect 
the in vivo situation. Furthermore, IL-12p40 may either form a functional pro-nociceptive 
IL-12p70 subunit (via heterodimersation with the IL-12p35 (a)), or a biological blocker of 
IL-12p70 (via homodimerisation with other IL-12p40 subunits), which has been 
documented to produce analgesic effects when administered to nerve injured mice (Chen et 
al., 2013).  Therefore, we can postulate that the observed decrease in IL-12p35 mRNA in the 
injured sciatic nerves of KO mice indicates a consequential increase in IL-12p40 
homodimerisation; this would inhibit IL-12 and attenuate the pro-inflammatory Th1 
phenotype, consistent with the behavioural phenotype of GPR84 null mice. 
 
More recent studies using modified MCFFAs with added hydroxyl groups revealed that 
GPR84 mediates granulocyte and macrophage chemotaxis and the production of pro-
inflammatory IL-8 and TNF-α, respectively, under LPS stimulated conditions (Suzuki et al., 
2013). Systemic administration of the surrogate agonist, 6-OAU, was also shown to raise 
CXCL1 levels in rats (Suzuki et al., 2013). We did not see corresponding changes in the 
expression of these cytokines in GPR84 KO mice, but as previously discussed, these 
experimental conditions may diverge from cytokine/chemokine changes induced by the 
PNL model. 
 
2.4.6 Future work 
 
The expression of GPR84 was significantly up-regulated in the sciatic nerve at 7 days after 
peripheral nerve surgery. This finding, in conjunction with the striking behavioural 




phenotype of null mice, suggests that GPR84 is critical for neuropathic pain. In light of this 
evidence we hypothesised that GPR84 deletion might affect transcriptional changes of pro-
nociceptive mediators that are normally induced by nerve injury; these mediators may be 
involved in the activation of GPR84 and/or downstream signalling effects of this receptor in 
neuropathic states. We also characterised the microglia and macrophage response as key 
immune cell players in neuropathic pain mechanisms. However, we unexpectedly found that 
key allogenic mediators were up-regulated in the KO and that the microglia and macrophage 
phenotype did not differ between the genotypes. Thus the mechanisms behind GPR84 
nociceptive signalling are unclear. 
 
It is apparent that GPR84 is not necessary for global changes in inflammatory mediators but 
may be important in regulating specific factors produced by microglia and/or macrophage 
cells. Our screening study indicated that the gene for the anti-inflammatory macrophage cell 
marker, ARG1, may be of particular importance. We observed a striking up-regulation of 
ARG1 in the injured sciatic nerve of KO mice in contrast to WT mice. Macrophages can be 
broadly categorised into two basic subsets: the pro-inflammatory classically-activated M1 
class and the anti-inflammatory alternatively-activated M2 class, as discussed in Chapter 1. 
In a study investigating the role of TNF-α in a model of EAN, clinical severity scores were 
attenuated in TNF-α null mice, correlating with a pro-M2 macrophage phenotype (Zhang et 
al., 2012b). In another study, IL-12p40 null mice exhibited enhanced polarity for the M2 
phenotype as well as increased secretion of the anti-inflammatory TGF-β (Bastos et al., 
2002). Therefore, it would be instrumental to further validate the pro-M2 phenotype we 
observed in the PNL model and examine the expression of M1 and M2 macrophages in the 
injured sciatic nerves of GPR84 WT and KO mice. 
 
Importantly, we must note that our examination was limited to a set array of 92 genes of 
interest to our group, and thus further studies profiling alternative mediators may prove 
more informative. We utilised the PNL model not only because it is mechanistically simple 
but also due to the remaining innervation of un-ligated nerve fibres, which allowed us to 
measure reproducible behavioural outcomes between the genotypes. However, we found 
that transcript changes were only significant in the sciatic nerve at 7 days and so a more 
robust nerve injury model may be more appropriate. For example, the SNI model  
(Decosterd and Woolf, 2000) would induce greater transcriptional changes as more neurons 
are damaged, hence providing a larger scope to observe differential regulation of transcripts 
between the genotypes. We did not observe positive evidence for the involvement of 
microglia or macrophage cell recruitment in GPR84 mediated nociceptive signalling. 




Therefore, it would be interesting to further investigate other immune cell types known to 
play a role in neuropathic pain behaviours, such as neutrophils and T-cells. 
 
In light of the behavioural phenotype in null mice and up-regulation of GPR84 mRNA in 
response to nerve injury, GPR84 appears to be a promising new target in pain research. 
Unfortunately, we were unable to visualise staining of this receptor in the PNL model as 
protein expression was not high enough for detection via this method (data not shown). It 
would be interesting to determine whether intrathecal or subcutaneous administration of a 
GPR84 blocking antibody to nerve injured mice would alleviate behavioural 
hypersensitivity. Conversely, the putative role of this receptor could be thoroughly tested by 
administration of a selective agonist to determine whether direct GPR84 activation can 






















The Role of GPR84 in Chronic Inflammatory Pain 
 
Chapter 3 The Role of GPR84 in Inflammatory Pain 
  





3.1.1 Inflammatory pain 
 
Inflammation is a protective response that is usually a result of tissue damage, infection or 
irritation and is classically associated with symptoms of redness (rubor), heat (calor), pain 
(dolor), swelling (tumor) and loss of function (function laesa). Vasodilation of blood vessels 
during inflammation decreases vascular resistance and thus enables increased blood flow to 
the area of damage, resulting in redness and heat. Increased vascular permeability facilitates 
the exudation of plasma proteins and fluid into the tissue, producing swelling (oedema). 
Concurrently, the process of inflammation activates free nerve endings, ultimately leading to 
the sensation of pain (Chiu et al., 2012). In doing so, the inflammatory response facilitates 
tissue healing by removing damaged tissue and limiting the use of the affected area. The 
final stage of a successful acute inflammatory response is resolution, which is a passive but 
highly co-ordinated sequence of events that restores homeostasis (Lee and Surh, 2012). 
However, in some cases where the pro-inflammatory signals persist and the immune 
response is uncontrolled, inflammatory pain outlasts the healing process of the underlying 
tissue damage and so no longer serves as a protective mechanism, leading to the 
development of chronic pain (Lee and Surh, 2012). Chronic inflammatory pain is a major 
clinical problem in many human diseases such as RA, OA, cancer, diabetes, fibromyalgia, 
inflammatory back pain and IBS and not only compromises the quality of lives of patients 
but also amounts to huge socioeconomic costs in patient care. Furthermore, increasing 
evidence has highlighted the role of neuroinflammatory processes in the etiology of many 
neurological diseases such as Alzheimer’s, Parkinson’s disease and multiple sclerosis 
(DeLeo and Yezierski, 2001). Therefore, the convergent involvement of the immune system 
and its multiple signalling molecules in the genesis of many inflammatory diseases is an 
important avenue for the development of successful therapeutic treatments. 
 
3.1.2 Models of inflammatory pain 
 
Hyperalgesia is a symptom that follows various forms of tissue injury and is typically 
characterised by a reduction in nociceptive thresholds. Such abnormal sensations may also 
be accompanied by allodynia and spontaneous pain, which are measurable behavioural 
outcomes in animal models of pain, although interpretation of the latter is subjective. To 
study chronic inflammatory pain, a number of experimental models in rodents have been 
developed that entail the cutaneous or subcutaneous application of an inflammogen or 
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chemical irritant to the hind paw, joint or muscle tissue followed by behavioural tests to 
examine changes in thermal and mechanical pain thresholds (Zhang and Ren, 2010). Some 
of the classical models routinely used include CFA (inactivated mycobacteria tuberculosis 
emulsified in mineral oil), zymosan (extract of yeast cell wall), carrageenan (seaweed 
extract) and formalin (Pillemer and Eaker, 1941; Freund, 1947; Dubuisson and Dennis, 
1977; Svensson et al., 2003b). CFA, zymosan and carrageenan produce a rapid local 
inflammatory response, paw oedema and persistent pain. The hyperalgesia and allodynia 
last for approximately 1-2 weeks in the CFA model and 24 hours in the carrageenan and 
zymosan models. On the other hand, formalin consists of two phases; an initial 5 minute 
period of guarding, licking and biting behaviour, which is attributed to direct activation of 
nociceptor afferent terminals followed by a second phase of shaking and licking that lasts 
approximately 40 minutes and is thought to be mediated by central sensitisation of dorsal 
horn neurons within the spinal cord (Dubuisson and Dennis, 1977; Dickenson and Sullivan, 
1987). Formalin treated rodents may also exhibit behavioural hypersensitivity lasting up to 
4 weeks as a result of central sensitisation caused by ongoing peripheral signals from 
inflamed tissues and nerve damage (Fu et al., 1999). Several clinically relevant models of 
inflammatory pain have also been developed including the application of CFA into the knee 
joint or base of the tail to induce models of monoarthritis or polyarthritis, respectively (De 
Castro Costa et al., 1981). Type II collagen emulsified in Freund’s incomplete adjuvant may 
also be injected into the base of the tail to induce polyarthritis (Baek et al., 2005). 
 
CNS inflammation is a common feature of many neurological pathologies associated with 
pain (Felts et al., 2005). A number of inflammogens have been injected into the CNS to 
experimentally induce central inflammation. These include the cytokines IL-1β, TNF-α and 
INF-γ as well as LPS (Andersson et al., 1992a, b; Minghetti et al., 1999). LPS is a cell wall 
component of Gram-negative bacteria and is an amphiphillic compound consisting of a lipid 
A, a core oligosaccharide and an O side-chain. LPS is one of the most potent inflammatory 
inducing agents of the immune system and may be administered in several ways; for 
instance, systemic administration is used as a model of endotoxemia, while intrathecal 
treatment generates an inflammatory response that is isolated from immune-mediated 
disease processes (Andersson et al., 1992b; Felts et al., 2005). 
 
3.1.3 LPS/TLR4 signalling pathway 
 
LPS stimulation of mammalian cells occurs via the interaction with several binding proteins 
including CD14, MD2 and TLR4 followed by a cascade of signalling pathways. TLR4 is 
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believed to be unable to directly bind to LPS and so LPS/TLR4 signalling is permitted by the 
physical association of the MD2 protein on the cell surface, which may also be facilitated by 
the TLR4 co-receptor, CD14 (Lu et al., 2008). The Toll protein was first discovered in 
Drosophila and research carried out on the C3H/HeJ mouse, which possesses a defective LPS 
response, warranted the notion that TLR4 signalling is an essential component of the LPS 
response (Poltorak, 1998). Briefly, upon LPS recognition, TLR4 undergoes oligomerization 
and interacts with one of the five Toll-interleukin-1 receptor (TIR) domain-containing 
adaptor proteins, most commonly, the myeloid differentiation primary response gene 88 
(MyD88) (Poltorak, 1998). Once associated with the TIR domain of the TLR, MyD88 recruits 
the serine/threonine kinase, IL-1 receptor-associated kinase 4 (IRAK4), to the TLR complex 
via an interaction between the death domains of both molecules and undergoes rapid 
phosphorylation and re-association with tumor necrosis factor receptor-associated factor 6 
(TRAF6) (Cao et al., 1996a; Cao et al., 1996b). TRAF6 and phosphorylated TRAK1 
subsequently dissociate from the receptor complex and go on to interact with TGF-β 
activated kinase (TAK1) and TAK-1 binding proteins (TAB) where a cascade of 
ubiquitination reactions occur on TRAF6 (Doyle and O'Neill, 2006). Eventual 
phosphorylation of TAK1 and TAB2 triggers the dissociation of the membrane bound 
TRAF6/TAK1/TAB1,2 complex to the cytosol where IRAK-1 is subsequently degraded. As a 
result, TAK1 is activated and phosphorylates the inhibitory κB (IκB) kinase complex (IKK) 
(Cao et al., 1996a; Cao et al., 1996b). The activated IKK complex in turn mediates 
phosphorylation and degradation of the IκB protein and subsequent liberation of NF-κB. NF-
κB may then translocate to the nucleus to initiate the transcriptional regulation of many 
pro-inflammatory cytokines and immune-related genes (Lu et al., 2008). In parallel TAK1 
also activates the MAPK kinases (MKKs), resulting in the eventual phosphorylation and 
activation of MAPKs such as p38 and JNK. Initiation of MAPK pathways leads to the 
activation of transcription factors, which drive the synthesis of many pro-inflammatory 













Figure 3.1: Diagram of LPS/TLR4 signalling pathway 
 
Molecular components involved in TLR4 signalling pathway. Activated TLR4 interacts with MyD88, 
leading to the recruitment of IRAK, which undergoes rapid phosphorylation and re-association with 
TRAF6. After a series of phosphorylation-dependent events, the IKK complex is activated and 
mediates the phosphorylation and degradation of the IκB protein. Liberated NF-κB may then 
translocate to the nucleus to initiate the transcriptional regulation of many target genes. TRAF6 




In this chapter, we utilised a peripheral (CFA) and a central (LPS) model of inflammation. 
Injection of CFA to the hind paw produces a dose-dependent inflammation and behavioural 
hyperalgesia in rodents via the activation of the innate immune system and subsequent 
activation of the adaptive immune system in a TLR dependent manner (Freund, 1947; Marta 
et al., 2009). As GPR84 is normally only expressed by immune cells, the CFA model is 
appropriate for investigating the role of this receptor in persistent inflammatory induced 
pain. Intrathecal administration of LPS into the lumbar spinal cord is also associated with 
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such as IL-1β, TNF-α and IL-6 that contribute to the initiation and maintenance of 
behavioural hypersensitivity (DeLeo and Yezierski, 2001; Wieseler-Frank et al., 2005). Since 
TLR4 serves as a specific sensor of LPS and is exclusively expressed by microglial cells in the 
CNS (Lehnardt et al., 2002) we employed the LPS-induced CNS inflammatory model to 
selectively evaluate the response of microglial cells to a robust inflammatory stimulus in the 
absence of GPR84. Notably, GPR84 expression is up-regulated in microglia and macrophage 
cells by LPS or cytokines which are capable of stimulating the NF-κB pathway, such as TNF-
α and to a lesser extent IL-1β (Wang et al., 2006a; Bouchard et al., 2007). Therefore, we also 
measured GPR84 expression in cultured microglia and macrophage cells subsequent to LPS 
stimulation and examined LPS-induced mediator profiles in WT and KO macrophages. 
 
3.1.4 Mechanisms of chronic inflammatory pain 
 
Subsequent to an inflammatory insult, multiple factors are released from damaged cells, 
producing an ‘inflammatory soup’ rich in protons (K+, H+), histamine, 5HT, PGs, growth 
factors, bradykinin, ATP and cytokines (Scholz and Woolf, 2002; Marchand et al., 2005; 
Linley et al., 2010). These nociceptor sensitizers act via their cognate receptors expressed 
on C-fibre terminals and generate an axonal reflex response by inducing the release of the 
neuropeptides, SP and CGRP (Chiu et al., 2012). SP and CGRP are considered to be the main 
initiators of neurogenic inflammation and upon C-fibre stimulation are released into the 
periphery where they act directly on vascular endothelial smooth muscle cells to elicit 
vasodilation and plasma extravasation, respectively. This results in the aforementioned 
characteristic redness and swelling (Chiu et al., 2012). Other mediators released in response 
to tissue damage such as PGE2 and bradykinin, contribute to peripheral sensitisation of 
nociceptors by driving the activation of multiple intracellular transduction signalling 
pathways such as PKA, PKC and PI3K, as well as the MAPKs, p38, ERK and JNK (Fig. 3.2) 
(Woolf and Ma, 2007). There are two main downstream effects of these cascades, one being 
rapid phosphorylation-dependent modifications in ionotropic and metabotropic receptors, 
receptor subunits and subsets of ion channels, which alter activation thresholds and kinetic 
properties of nociceptor terminals. The other encompasses changes in transcriptional 
programmes that generate long-term effects (Linley et al., 2010). For example, sensitising 
agents such as PGE2, adenosine and 5HT may enhance Na+ conductance of TTX resistant 
channels by shifting the voltage-dependence and accelerating channel activation (Gold et al., 
1996). Products of the COX pathway may also induce a transcriptional increase in the 
expression of Nav1.7 and Nav1.8 in large and small DRG neurons (Gould et al., 2004). In 
addition to increased excitability of primary afferent neurons, thermal hypersensitivity is a 
cardinal sign of an inflammatory response, and appears to be largely driven by enhanced 
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TRPV1 currents. NGF mediated activation of PI3K via TrkA activation leads to the down-
stream phosphorylation of TRPV1 by src kinase and hence an increase in membrane current 
(Zhang et al., 2005d). Increased membrane currents of ion channels is mainly attributed to 
sensitisation or greater trafficking out of the DRG cell bodies to the surface membrane of 
peripheral processes (Coggeshall et al., 2004; Zhang et al., 2005d). In addition to post-
translational effects, NGF may also mediate transcriptional regulation over multiple 
ionotropic (TRPV1, P2X3, ASIC3) and metabotropic (B2 receptor, μ-opiod receptor) 
receptors and voltage-gated ion channels (Na+, Ca2+, K+) (Pezet and McMahon, 2006). NGF is 
a major contributor to inflammatory hyperalgesia and has been shown to be up-regulated in 
various experimental models of inflammation as well as in a number of human diseases with 
some correlation to the extent of reported pain. Correspondingly, anti-NGF treatment has 
successfully demonstrated alleviation of behavioural hyperalgesia in experimental models 
of inflammation using rodents (Pezet and McMahon, 2006). 
 
Mobilisation of the resident immune cell response occurs in conjunction with the activation 
of sensory neurons. Here, activated mast cells and dendritic cells release a range of 
chemokines and cytokines that contribute to the localised pool of accumulating signalling 
molecules, many of which possess chemotactic properties for neutrophils, eosinophils, 
macrophages and T-cells (Chiu et al., 2012). The synthesis and release of chemotactic and 
cellular adhesion molecules establishes a concentration gradient, which is essential for the 
re-orientation, homing and migration of target leucocytes to active sites of inflammation 
(DeLeo and Yezierski, 2001). Immune cell infiltration and migration to the injury site is a 
hallmark of the stereotypical inflammatory response, where the initial activation of the 
innate immune system results in further production of cytokines and the expression of cell 
surface antigens, leading to the recruitment of the adaptive immune system (DeLeo and 
Yezierski, 2001).  
 
In effect, activation of the immune system generates a second series of signals, which 
unanimously contribute to changes in the chemical milieu and transduction properties of 
nociceptive neurons. Cytokines are well documented to play an important role in the 
pathogenesis of many inflammatory diseases via their direct or, more commonly, indirect 
actions (Arai et al., 1990; Woolf et al., 1997). Characteristically, cytokines exhibit functional 
redundancy and overlap as they tend to share multiple receptors to carry out various 
autocrine, paracrine and hormonal effects. The complex signalling pathways of these 
molecules encompass a combination of pro- and anti-inflammatory actions on a broad range 
of cell types. This may involve transcription-dependent or independent effects that 
contribute to peripheral sensitisation and hence inflammatory pain hypersensitivity (Woolf 
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et al., 1997; Verri et al., 2006). The first cytokines described to play a role in inflammatory 
and/or neuropathic pain mechanisms were IL-1β, TNF-α, IL-6 and IL-8/CXCL8 followed by 
the more recently discovered contribution of IL-12 and IL-18. IL-1β and TNF-α are 
expressed by a range of cells and are prototypically involved in the establishment of 
peripheral sensitisation via recruiting and activating immune cells (Verri et al., 2006). These 
cytokines may also induce the expression of NGF and PGE2 and exert direct effects on 
nociceptive neurons, which exacerbates neuronal excitability and evokes spontaneous firing 
(Woolf et al., 1997; Binshtok et al., 2008). Intraplantar administration of IL-1β was shown to 
elicit mechanical hypersensitivity in rodents that was dependent on the release of 
prostanoids, whereas local injection of the anti-inflammatory IL-1 receptor antagonist (IL-
1ra) inhibited carrageenan and LPS induced hyperalgesia by means of competitive action at 
the IL-1R (Ferreira et al., 1988; Cunha et al., 2000). Consistent with this, mechanical and 
thermal hypersensitivity in the CFA model, were reported to be alleviated with pre-
treatment of IL-1ra or an NGF neutralising antibody (Safieh-Garabedian et al., 1995).  
 
TNF-α is a potent pro-inflammatory cytokine predominantly produced by macrophage cells 
in response to aberrant stimuli and mediates its effects through its high affinity receptors, 
TNFR1 and TNFR2. Similar to IL-1β, TNF-α has been experimentally demonstrated to evoke 
mechanical hypersensitivity subsequent to intraplantar administration and pre-treatment 
with anti-TNF-α antiserum attenuated CFA induced mechanical and thermal hyperalgesia 
(Woolf et al., 1997). In models of overt pain, subcutaneous injection of formalin or 
intraperitoneal zymosan/acetic acid evoked the release of IL-1β, TNF-α and IL-8/CXCL8, 
which are concomitantly involved in the writhing response, whereas administration of their 
corresponding anti-serums inhibited nociceptive behaviours  (Ribeiro et al., 2000). Patients 
with chronic inflammation of the connective tissue exhibit raised levels of TNF-α in the 
temporomandibular joint synovium, which correlates with reported symptoms of local 
allodynia at the joint (Nordahl et al., 2000). Encouragingly, anti-TNF-α therapy is beneficial 
in some inflammatory diseases such as OA and psoriatic arthritis and has exemplified 
clinical success in RA treatment (Rankin et al., 1995; Haraoui, 2005). 
 
 IL-6 elicits a range of bio-activities that encompass both anti- and pro-inflammatory effects. 
Like the previously discussed cytokines, IL-6 administration to the hind paw induces a 
bilateral dose- and time-dependent mechanical hypersensitivity, which is indicative of 
systemic distribution (Cunha et al., 1992; Verri et al., 2006). This concept is supported by 
the fact that smaller doses of IL-6 produce correspondingly smaller effects in the 
contralateral paw and that intraplantar administration of IL-6 antagonists and neutralising 
antibodies inhibit hypersensitivity of the ipsilateral paw, with no effect on the contralateral 
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paw (Cunha et al., 1992). Furthermore, pre-treatment with indomethacin (COX inhibitor) 
specifically attenuated IL-1β or IL-6 evoked behavioural hyperalgesia whilst bearing no 
effect on IL-8 evoked hyperalgesia. Likewise, pre-treatment with atenolol (B1 blocker) 
attenuated IL-8 but not IL-1β or IL-6 evoked hyperalgesia (Cunha et al., 1991; Cunha et al., 
1992). This suggests that these cytokines elicit their effects via different mechanisms, 
involving either the COX pathway (IL-1β/IL-6) or the sympathetic nervous system (IL-8) 
(Cunha et al., 1991; Cunha et al., 1992).  In a model of carrageenan evoked hyperalgesia, it 
was further demonstrated that co-administration of atenolol and anti-IL-8 serum were not 
additive in contrast to co-administration of indomethacin and anti-IL-8 serum, which 
exhibited additive effects and abolished behavioural hypersensitivity in the rat (Cunha et al., 
1991). In addition, TNF-α induced mechanical hypersensitivity is partially attenuated with 
pre-treatment of indomethacin or atenolol and is abolished by co-treatment of these drugs 
(Verri et al., 2006). Correspondingly, anti-IL-1β, anti-IL-8 or anti-IL-6 treatment partially 
attenuated TNF-α induced hypersensitivity, whereas the combination of anti-IL-1β and anti-
IL-8 or anti-IL-6 and anti-IL-8 neutralising antibodies abolished pain behaviours (Cunha et 
al., 1992; Verri et al., 2006). This evidence therefore suggests that TNF-α possess a pivotal 
role in inflammatory mechanisms and its effects are mediated by two distinguishable 
pathways: TNF-α/IL-1β/IL-6/prostaglandin and TNF-α/IL-8/sympathetic (Cunha et al., 
1992; Verri et al., 2006).   
 
Subsequent to inflammatory stimuli, IL-12 and IL-18 are also released from a range of 
immune cells including monocytes, macrophages, B cells and dendritic cells (Nakanishi et 
al., 2001; Verri et al., 2006) and synergistically promote Th1 differentiation and the 
production of IFN-γ (Nakanishi et al., 2001). Like IL-6, IL-12 exhibits dual roles; while it 
exacerbates collagen-induced arthritis when administered during the early stages of the 
disease, it exerts anti-inflammatory effects when administered at later stages (Joosten et al., 
1997). IL-12 has also been shown to consistently produce pain in humans. For example, a 
cohort of renal cancer patients receiving intravenous recombinant IL-12 therapy presented 
cases of arthralgias in the finger joints and shoulder region (Gollob et al., 2000). Intraplantar 
administration of IL-12 also elicits hypernociceptive behaviours in rodents (Verri, 2005). IL-
18 is a member of the IL-1 family and shares caspase 1 with IL-1β, which is the enzyme that 
catalyses the cleavage of its pro-IL-18 precursor molecule to yield the active glycoprotein 
(Bazan et al., 1996). Normally IL-18 is constitutively expressed in many cell types, unlike 
many other cytokines that are induced upon appropriate stimulation. In various 
inflammatory diseases including Crohn’s disease, type 1 diabetes and RA, IL-18 expression 
increases in specific tissues associated with the particular disease (Nakanishi et al., 2001). 
In a collagen-induced arthritis model, IL-18 null mice were reported to show attenuated 
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disease severity, which correlated with reduced levels of TNF-α. The authors postulated that 
this was a neutrophil mediated mechanism as IL-18 promotes neutrophil migration via 
inducing TNF-α, which in turn up-regulates the neutrophil chemoattractant molecule LTB4 
(Canetti et al., 2001; Wei et al., 2001). 
 
Incoming signals from the periphery and subsequent release of neurotransmitters into the 
dorsal horn generates changes in the chemical milieu of the CNS. Microglia and astrocytes 
respond via gliosis and a concomitant release of mediators (see Chapter 1) that contribute to 
the development of central sensitisation and behavioural hypersensitivity (Watkins et al., 
2001; Watkins and Maier, 2003). Centrally released glutamate and SP directly activate 
NMDA and NK1 receptors expressed by microglial cells, which induces the activation of NF-
κB and the sequential synthesis of pro-inflammatory mediators (Rasley et al., 2002). Upon 
neuronal activation the chemokine, fractalkine, is diffusely released from neuronal cell 
membranes and binds to its exclusively expressed microglial receptor, CX3CR1. This forms a 
direct neuronal to glial cell signalling pathway, which essentially drives p38 activation and 
down-stream events that maintain hyperalgesia (Chapman et al., 2000). Once activated p38 
is translocated to the nucleus where it phosphorylates transcriptional factors including 
activating transcription factor 2 (ATF-2), which mediates the biosynthesis of many 
mediators such as IL-1β, TNF-α, COX-2 and iNOS (Kumar et al., 2003; Svensson et al., 2003b; 
Ji and Suter, 2007; Ji et al., 2009). In addition to orchestrating transcriptional events, p38 is 
also thought to exert its effects via direct interaction with enzymes, receptors and ion 
channels (Svensson et al., 2003a). For example, during inflammation spinal p38 activates 
phospholipase A2 (PLA2) leading to the generation of arachidonic acid and the production of 
PG. Conversely, it was shown that pre-treatment with intrathecally administered p38 
inhibitors (SB20358 or SD-282) prevented COX-2 up-regulation with a concomitant 
attenuation of intraplantar formalin/carrageenan- and intrathecal SP-induced hyperalgesia 
(Svensson et al., 2003a; Svensson et al., 2003b). Similarly, Clark et al. (2006) showed that 
the release of IL-1β from LPS stimulated spinal cord slices was mediated by p-38 activation 
in spinal microglia, which could be prevented by the administration of a p-38 inhibitor. This 
was later shown to be dependent on the activation of the P2X7 receptor as a result of LPS 
evoked ATP release (Clark et al., 2010b). Neuronally released ATP activates microglial cells 
via a selection of purigenic metabotropic (P2Y) and ionotropic (P2X4 and P2X7) receptors, 
which in turn initiate the release of several cytokines (Franke et al., 2007). As previously 
discussed (Chapter 2) the central release of proinflammatory cytokines (IL-1β, TNF-α, IL-6) 
enhances EPSCs and potentiates AMPA and NMDA currents in lamina II dorsal horn neurons 
via a combination of direct and indirect effects on neuronal properties (Kawasaki et al., 
2008). Here chemokines are critical players in neuroinflammatory responses to a peripheral  





Figure 3.2: Inflammation-induced pain mechanisms 
 
Subsequent to tissue damage, resident mast cells and macrophages are activated and blood-borne 
immune cells (neutrophils and monocytes) infiltrate the site of inflammation. Various mediators are 
released from damaged tissue cells and immune cells, which act via their cognate receptors expressed 
on primary afferent neurons. For example, TNF-α/TNFR, histamine/H1, bradykinin/B2, NGF/TrkA, 
PGE2/EP2, CCL2/CCR2, CCL3/CCR1,5 signalling leads to the activation of intracellular kinases (PKA, 
PKC, PI3K, MAPK), which initiate post-translational modifications such as phosphorylation and 
increased trafficking of ion channels and receptors. Chemokines and cytokines may exert their pro-
nociceptive effects directly by binding to their receptors expressed on nociceptors. They may also act 
indirectly via recruiting immune cells and initiating the release of other mediators such as PGs, which 
can activate and sensitise nociceptors. Modified from Marchand et al. (2005). 
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insult and in addition to neuronal modulation they may also induce further release of COX2, 
NOS and SP. Ultimately, microglial activation and the subsequent release of cytokines, 
glutamate, ATP, prostanoids, NO and proteases drives multiple signalling pathways that 
contribute to increased excitability, the up-regulation of neuronal receptors and enhanced 
neurotransmission leading to centrally maintained hypersensitivity (DeLeo and Yezierski, 
2001; Watkins et al., 2001; Watkins and Maier, 2003). 
 
3.1.5  Aims 
 
In this chapter we utilised a peripheral (CFA) and a central (LPS) model of inflammation in 
transgenic mice to evaluate the role of GPR84 in persistent inflammatory pain mechanisms. 
In both models we characterised pain behaviours of GPR84 WT and KO mice and examined 
the spinal microglial phenotype. Lastly, we investigated changes in mRNA transcript 
expression of 92 different chemokines, cytokines, growth factors and cell markers in LPS 
stimulated WT and KO macrophage cells. This approach enabled us to identify putative 
mediators that are modulated by GPR84 and hence may contribute to inflammatory-pain 
behaviour via down-stream signalling of this receptor. 
  
Chapter 3 - The Role of GPR84 in Chronic Inflammatory Pain 
 
146 




Breeding and genotyping of GPR84 WT and KO animals was carried out as described in the 
methods section in Chapter 2. Experiments were conducted on randomly selected mixed sex 
and age-matched mice weighing 20-25 g (7-14 weeks old). Mice were housed individually or 
in groups (no more than 4 per cage) in standard environmental conditions (12 hour 
light/dark cycle) with ad libitum access to food and water. Animal husbandry and 
experiments were carried out in a non-sterile housing environment in accordance with the 
United Kingdom Animals (Scientific Procedures) Act 1986.  
 
To calculate the number of animals required for behavioural studies a priori power analysis 
was carried out using G*Power (v-3.1.7) software. Based on an estimated 60% reduction 
effect (deduced from previous experimental studies in our lab), the software estimated that 
a total sample size of 36 (n = 9 per group) would be required to detect statistical differences 
(α = 0.05, 1-β = 0.95, d = 3 or 6). For the CFA study two groups of animals were tested and 
the contralateral paw was used as a control for both genotypes. For the CNS inflammatory 
model four groups of animals were tested including a saline-treated control group and an 
LPS-treated group for each genotype. For all studies the experimenter was blinded to 
genotype and treatment. Allocation concealment was carried out by assigning each animal 
with an individual identification number (see Chapter 2) and by employing an independent 
investigator to prepare treatments. Blinding codes were broken after completion of 
behavioural experiments to determine if further anatomical assessment was necessary. 
According to pre-determined exclusion criteria, animals were excluded from experimental 
analysis as specified by the project license e.g. excessive self-mutilation. 
 
3.2.2 Inflammatory pain models 
 
Complete Freund’s Adjuvant (CFA) 
 
A single 15 μl dose of CFA (1 mg/mL, Mycobacterium tuberculosis in mineral oil; Sigma, UK) 
was injected into the plantar surface of the left hind paw. The contralateral paw served as a 
control. Mechanical (von Frey, paw pressure) and thermal/cold (Hargreaves, cold plate) 
withdrawal thresholds were examined pre- and post-CFA on days 1, 3, 7, 10 and 14. To 
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quantify the degree of paw oedema the dorsal-ventral thickness was measured using a 
pocket thickness gauge (Mitutoyo, UK) pre and post CFA treatment. 
 
Lipopolysaccharide (LPS) – induced mechanical hyperalgesia 
 
Animals were anesthetised with 2-3% isoflurane (Abbott Animal Health, UK) inhalation 
anaesthesia. Two intrathecal injections of LPS were administered into the lumbar region of 
the spinal cord, an initial ‘priming’ dose and a second dose 24 hrs later. Intrathecal 
injections were carried out using a 25 G needle on a Hamilton syringe, which was inserted at 
a 20° angle between the L5/L6 vertebrae as previously described (Hylden and Wilcox, 
1980). LPS-treated mice received two 5 μl doses of 2 μg of LPS (Sigma, UK; dissolved in 0.9% 
saline) while control mice received two 5 μl doses of 0.9% saline. Mechanical (von Frey, paw 
pressure) and cold (cold plate) withdrawal thresholds were examined pre- and at 1 and 3 
hrs post-LPS (Clark et al., 2006; Clark et al., 2010b).  
 




Tactile mechanical thresholds of alert and unrestrained mice were examined via von Frey 
hair application (0.008-1 g, Touch Test, Stoelting, USA) to the plantar surface of the hindpaw 
via the ‘up-down’ method (Chaplan et al., 1994). Before testing, mice were acclimatised for a 
period of 1 hr in individual acrylic testing cubicles (8 x 5 x 10 cm) on an elevated wire mesh 
floor. Placement in testing cubicles was selected at random for each testing day. This 
enabled access to the lateral paw surface. Calibrated von Frey hairs were applied starting 
with the 0.6 g filament, in an alternate fashion to the left and right hind paw. The flexible 
nylon hair was applied so that the fibre bent for a duration of 3 s or until a paw withdrawal 
reflex occurred that was not coupled with movement or grooming. A positive withdrawal 
response is followed by a lower force hair and vice versa for a negative response until a 
change in behaviour occurs. Via this ‘up-down’ sequence four subsequent hairs were 
assessed and the 50% PWT was calculated according to the method described by (Dixon, 
1980).  
 





Noxious mechanical thresholds were examined in the hindpaws of restrained alert mice via 
an Analgesymeter (7200; Ugo Basile, Italy) (Randall and Selitto, 1957). Each hindpaw was 
tested separately; briefly, the plantar surface was placed on a pedestal with a probe resting 
on the dorsal surface. Increasing pressure was applied via the probe, up to a maximum of 
120 g to prevent tissue damage. The nociceptive threshold was taken as the force at which 
the mouse responded. 
 




Thermal thresholds in unrestrained and alert mice were determined with the Hargreaves 
method using the Plantar Test (7370; Ugo Basile, Italy) (Hargreaves et al., 1988). Prior to 
testing, mice were acclimatised for 1 hr in individual acrylic testing cubicles (8 x 5 x 10 cm) 
on a glass plate. Placement in testing cubicles was selected at random for each testing day. 
An infrared light source of an arbitrary intensity of 30 (calibrated to elicit a PWL of 10-15 s 
in naïve mice) was directed onto the plantar surface of the hind paw through the glass plate. 
The PWL was automatically recorded in secs upon a withdrawal reflex. The left and right 
paws were tested alternately and responses were recorded for each paw on three separate 
occasions with at least 2 mins between assays. Each test had a maximum latency of 23 s to 




Noxious cold thresholds of the hind paws of lightly restrained mice were examined using the 
cold plate (IITC Life Sciences, USA) set at a temperature of 10°C ± 0.1°C. Each paw was 
tested separately by being placed with the plantar surface touching the plate. The latency to 
withdraw was taken as the threshold and recorded to the nearest 0.01 s. A 20 s cut-off was 
implemented to prevent tissue damage. 
 
3.2.5 Tissue preparation and immunohistochemistry 
 
On completion of behavioural testing, mice were anaesthetised with sodium pentobarbital 
(0.2 g/mL i.p.; Euthatal, Merial Animal Health Ltd) and perfused transcardially with a 0.9% 
saline and 0.1% heparin solution (Leo Laboratories Ltd, UK) followed by fixation with 4% 
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paraformaldehyde (PFA; VWR, UK) in 0.1 M PB. Lumbar spinal cords were dissected and 
post-fixed for 2 hrs in PFA and cryoprotected in a 20% sucrose/0.1 M PB solution (VWR, 
UK) for a minimum of 3 days at 4°C. Subsequently, tissue was embedded in OCT medium 
(VWR, UK), snap frozen with liquid nitrogen and stored at -80°C. Transverse spinal cord 
sections of the L4 and L5 lumbar region were cut on the cryostat in sets of 8 series at 20 μm 
thickness and subsequently thaw-mounted onto Superfrost plus microscope slides (VWR, 
UK). After drying, spinal cord sections were incubated overnight with primary antibody 
solution for p-p38 (rabbit anti-p-p38, 1:100; Sigma, UK) or GPR84 (goat anti-GPR84, 1:100; 
Santa Cruz, UK), and visualised with extra avidin-FITC following two stages of signal 
amplification with Avidin Biotin Complex (ABC; Vector Laboratories, USA) and biotinyl 
tyramide (PerkinElmer Life Sciences, UK) as previously shown (Clark et al., 2006). The 
sections were then incubated overnight with the second primary antibody, raised against 
Iba1 (rabbit anti-Iba1, 1:1000; Wako Chemicals, Germany), neuronal nuclei (mouse anti-
NeuN clone A60, 1:500; UK) or GFAP (rabbit anti-GFAP, 1:1000; DakoCytomation, 
Denmark), and subsequently incubated with the appropriate secondary antibody solution 
for 2 hrs (1:1000; IgG conjugated Alexa Fluor 350, 488 or 546; Invitrogen, USA). All 
antibodies were prepared in PBS supplemented with 0.1% Triton X-100 (VWR, UK) and 
0.2% sodium azide (Sigma, UK). Slides were carefully cover slipped with Vectashield 
Mounting Medium with or without DAPI (Vector Laboratories, UK), nail-varnished and 
dried.  
 
Quantification of immunoreactivity 
 
Images were visualised and captured using a Zeiss Axioplan microscope (Zeiss, UK) and for 
blinding purposes were labelled according to the identification code of the animal. Blinding 
codes were broken after study completion. Analysis of p-p38 and Iba1 immunoreactivity 
was performed by counting the number of positive profiles in the whole dorsal horn (7.3 x 
105 μm2) or within three fixed 4 x 104 μm2  boxes in the lateral, central and medial areas of 
the dorsal horn, using the nuclear marker DAPI to assist in determining positive cells, as 
previously described (Clark et al., 2007a). A mean value was obtained for both the 
ipsilateral and contralateral dorsal horns of a minimum of three sections per animal. The 
experimenter was blinded to both the genotype and treatment throughout the analysis. 
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3.2.6 In vitro assays 
 
Bio-gel elicited peritoneal macrophage (B-GEPM) cell culture and stimulation 
 
Adult GPR84 WT and KO mice were given an i.p. injection (1 mL) of Bio-Gel P-100 2% 
polyacrylamide beads (Bio-Rad, UK). Four days later mice were culled via neck dislocation, 
and the layer of skin covering the peritoneum was wiped with 70% ethanol. A total volume 
of 20 mL of sterile cold phosphate-buffered saline (phosphate buffered saline (PBS); 
Invitrogen, UK) containing ethylenediaminetetraacetic acid (EDTA; 3 mM; Invitrogen, UK) 
was injected into the peritoneal cavity using a 25 G needle. After gentle massaging the buffer 
was retrieved in 14 mL Falcon tubes, filtered to remove the polyacrylamide beads and spun 
to obtain a pellet. Cells were then re-suspended and plated at a density of 2 x 106 cells/well 
in Dulbecco’s Modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS) 
(Invitrogen, UK) and incubated at 37°C. The cells were washed 2 hrs after plating and the 
medium was replaced. Twenty four hrs later the media was replaced with FBS-free medium 
for 2 hrs, followed by 3 hrs of LPS stimulation (1 μg/mL; Sigma, UK). The culture medium of 
control wells was replaced with fresh FBS-free medium without subsequent stimulation. 
 
Microglial cell culture and stimulation 
 
Mixed primary cell cultures of glial cells were isolated from the cortical tissue of P7 rat pups 
(Staniland et al., 2010). Cultures were maintained for two weeks at 37°C (5% CO2/95% O2) 
in medium containing 1% penicillin-streptomycin (Sigma, UK) and 15% FBS (Invitrogen, 
UK), which was changed every 2-3 days. Two weeks later the microglial cells were 
harvested via forceful shaking of the flask and plated in 6 well plates at a density of 5 x 105 
cells/well. Forty eight hrs later the medium was replaced with FBS-free medium, for a 
duration of 2 hrs followed by 3 hrs of LPS stimulation (1 μg/mL; Sigma). For control 
experiments, culture medium was replaced with FBS-free media and the stimulation step 
was omitted. 
 
3.2.7 RNA extraction and cDNA synthesis 
 
Following LPS stimulation of cultured microglia and B-GEPMs, cells were homogenised by 
removing the media and adding Trizol (Invitrogen, UK) directly to the well and pipetting up 
and down. RNA was extracted and cDNA was synthesised as described in Chapter 2.   
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3.2.8 Taqman array set-up and quantitative real-time PCR 
 
Taqman® PCR mouse mediator arrays cards were custom designed using the Applied 
Biosystem website (http://www.appliedbiosystems.com). Each card contained 92 different 
transcripts and 4 HK genes and was run and subsequently analysed as described in Chapter 
2. For each transcript the ΔΔCT values are presented as FC (FC = LPS/control). Transcripts 
with undetermined values in more than 50% of the samples were assigned an average 
default CT value of 38. If this occurred in both LPS and control sample groups, no FC value 
was calculated. Transcripts that were undetermined in less than 50% of samples obtained 
an average CT value based on the remaining data values.   
 
To validate GPR84 and CCL19 expression in microglia and macrophage cells, respectively, 
individual quantitative real-time PCR (qRT-PCR) was performed using the Corbett Rotor-
Gene 6000. Samples were added to Roche LightCycler master mix containing SYBR Green 
(Roche, UK) to produce a final [cDNA] of 5 ng/μl in a total volume of 20 μl. Four samples per 
experimental group were run in duplicate and subjected to 40 cycles of amplification. 
Primer sequences were designed using the Primer Blast software 
(http://www.ncbi.nlm.nih.gov/tools/primer-blst/) and tested to ensure an amplification 
efficiency within the range of 0.8-1.2 (see table below). Transcript levels were calculated 
using the ΔΔCT method, normalised against GAPDH (for GPR84 quantification) or HPRT (for 
CCL19 quantification). For each transcript the ΔΔCT values are presented as FC (FC = 
LPS/control). Control reactions with RNAse-free water produced no amplification signal. 
 
Gene Primer sequence Product size (bp) 
GAPDH 
Forward  5’ - TGTGTCCGTCGTGGATCTGA - 3’ 
Reverse  5’ - TTGCTGTTGAAGTCGCAGGAG - 3’ 
150 
HPRT 
Forward  5’ - GTCCTGTGGCCATCTGCCTAG - 3’ 




Forward  5’ - TCAGGTGAGTCTCCATCATGTGGAA - 3’ 




Forward  5’ - CTTCTGCCAAGAACAAAGGCAA - 3’ 
Reverse  5’ - ACAGACTTGGCTGGGTTAGG - 3’ 
150 
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3.2.9 Data and statistical analysis 
 
All behavioural and immunohistochemical data were analysed using SigmaPlot 12.3 and 
SigmaStat software.  For single comparisons between two groups, a paired Student’s t-test 
was applied (behavioural data). For multiple comparisons, one-way (immunohistochemical 
data) or two-way (behavioural data) ANOVA was used, followed by SNK post hoc test to 
determine individual group differences. For the Taqman mouse PCR array card data, two-
sided Welch’s t-tests were run in the R programme on the ΔCT values. The p values were 
adjusted using the FDR method to correct for multiple hypothesis testing, as previously 
described (Benjamini et al., 2001). Non-parametric tests were applied where the data was 
not normally distributed. In all cases the data is presented as the mean ± SEM and p < 0.05 
was set as the statistical significance level. 
  





3.3.1 GPR84 KO mice show attenuation of pain-associated behaviours after CFA 
 
Having established that GPR84 plays a role in neuropathic pain mechanisms (see Chapter 2) 
we investigated whether this receptor may also contribute to chronic inflammatory pain 
pathways, especially in light of its documented role in clinically-relevant pathologies 
associated with inflammatory pain such as endotoxemia, EAE (model of MS), obesity and 
diabetes (Bouchard et al., 2007; Nagasaki et al., 2012). It is well established that 
experimental administration of inflammogens to the hind paw of rodents produces 
nociceptive hypersensitivity (Raghavendra et al., 2004; Clark et al., 2007a). Therefore, we 
utilised the CFA model as a relatively ‘pure’ model of persistent peripheral inflammation.  
 
To investigate whether GPR84 deletion alters inflammatory pain-associated behaviours, 
CFA was administered to the hind paw of GPR84 WT and KO mice and mechanical and 
thermal thresholds were examined. As expected, WT mice showed a significant reduction in 
ipsilateral paw pressure thresholds by day 3 (D3, 64.3 ± 2.7 g) which remained down up 
until day 14 (D14 76.3 ± 6.0 g) compared to baseline (D0, 118.1 ± 4.2 g) or the contralateral 
paw (D3, 104.4 ± 3.1 g; D14, 110.6 ± 5.6 g) which served as an additional control (Fig. 3.3A). 
In contrast, KO mice showed an initial reduction at day 1 (88.1 ± 3.5 g) in ipsilateral 
thresholds compared to baseline (117.5 ± 4.1 g) and the contralateral paw (D1, 110.0 ± 3.1 
g), which recovered by day 3 (93.1 ± 3.1g) and reached contralateral values by day 7 (106.2 
± 3.5 g) and remained unchanged (Fig. 3.3A). There was an average reduction of 35.2% in 
WT mice and 14.8% in KO mice from baseline over the 14 testing days. In both genotypes 
contralateral values did not significantly differ from baseline at any point. Area under the 
curve (AUC) quantification revealed that, in contrast to WT, KO mice did not develop 
mechanical hyperalgesia in the CFA treated paw and that there was a significant difference 
in ipsilateral thresholds between genotypes (Fig. 3.3B). Mechanical thresholds were also 
assessed using von Frey filaments. Interestingly, both genotypes showed a non-significant 
reduction in mechanical paw withdrawal thresholds expressed as calculated AUC of the 
ipsilateral hind paw compared to the contralateral side (Fig. 3.3D). These data suggest that 
GPR84 is involved in the maintenance of nociceptor driven mechanical hyperalgesia induced 
by inflammation but not mechanical allodynia.  
 
Following peripheral inflammation, WT mice also showed a significant reduction in thermal 
thresholds of the ipsilateral hind paw from day 1 to 7 (D1, 3.9 ± 0.4 s; D3, 3.0 ± 0.4 s; D7, 4.8 
± 1.3 s; Fig. 3.3C) compared to baseline (D0, 8.9 ± 0.5 s) or the contralateral paw (D1, 11.2 ± 
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0.9 s; D3, 10.7 ± 0.6 s; D7, 13.9 ± 1.1 s). On day 7 thresholds started to recover to baseline 
and by this time point there was an average reduction of 55.8%. By day 10 thresholds were 
no longer significantly different from baseline (D10, 8.9 ± 1.6 s). Contralateral values did not 
significantly differ from baseline at any point. Similarly, KO mice showed an average 
reduction of 35.1% in thermal thresholds of the ipsilateral paw by day 7, which recovered to 
baseline thereafter. However, this was attenuated on days 1 and 3 (D1, 8.9 ± 3.7 s; D3, 4.7 ± 
0.5 s) compared to WT mice. At no point was the change in thermal thresholds significantly 
different to baseline (10.1 ± 0.7 s) and only on days 3, 7 and 10 (D10, 7.1 ± 1.3 s) was there a 
significant difference from the control contralateral paw (D3, 11.0 ± 1.4 s; D7, 13.2 ± 1.3 s; 
D10, 15.7 ± 1.2 s).  
 
Changes in sensitivity to cold stimuli was assessed, and as expected, WT mice developed 
significant cold hyperalgesia of the ipsilateral hind paw post CFA by day 3, which lasted up 
to day 14 (D3, 7.5 ± 0.6 s; D7, 9.9 ± 0.9 s; D10, 10.4 ± 0.8 s; D14, 8.7 ± 0.9 s) compared to 
baseline (D0, 17.5 ± 0.7 s) and the contralateral paw  (D3, 10.7 ± 0.7 s; D7, 16.1 ± 1.0 s; D10, 
16.5 ± 0.9 s; D14, 15.3 ± 1.6 s; Fig. 3.3F). Although, perhaps surprisingly, induction of cold 
hypersensitivity did not occur before day 3. There was an average reduction of 38.0% from 
baseline. Strikingly, KO mice showed an initial reduction of 32.1% in ipsilateral cold 
thresholds compared to baseline (16.4 ± 1.6 s) on day 1 (11.1 ± 1.0 s), which rapidly 
recovered to contralateral thresholds by day 3 (ipsi: 11.7 ± 0.6 s vs contra: 12.7 ± 0.5 s) and 
baseline thresholds by day 7 (15.5 ± 1.8 s) and remained unchanged throughout the rest of 
the testing days. In both genotypes contralateral values did not significantly differ from 
baseline at any point. AUC analysis showed that WT but not KO mice developed significant 
cold hyperalgesia in the CFA treated paw and that there was a significant difference 
between ipsi values of the two genotypes (Fig. 3.3G). Together these data show that GPR84 
KO mice developed a transient thermal and cold hypersensitivity after peripheral 
inflammation that quickly recovered back to baseline. In contrast, the development of 
thermal and cold hypersensitivity in WT littermate controls was maintained. This finding 
suggests that GPR84 may be important for the maintenance rather than the initiation of 
inflammatory thermal and cold hyperalgesia.  
 
GPR84 is expressed by immune cells involved in peripheral inflammation. To compare 
levels of peripheral inflammation between genotypes, the extent of oedema in the ipsilateral 
hind paw was assessed by measuring dorso-ventral paw thickness (Fig. 3.3E). We observed 
paw oedema in both genotypes from 24 hrs post CFA, which became significant on days 3 
(both genotypes) and 7 (only KO mice) in comparison to baseline. However, there was no 
significant difference between genotypes. This result suggests that GPR84 deletion has no 
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effect on the degree of hind paw inflammation (WT: D0, 1.6 ± 0.1 mm; D1, 3.4 ± 0.5 mm; D3, 
3.2 ± 0.2 mm; D7, 2.8 ± 0.1 mm vs KO: D0, 1.7 ± 0.03 mm; D1, 3.12 ± 0.4 mm; D3, 3.1 ± 0.2 
mm; D7, 3.2 ± 0.1 mm). 
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Figure 3.3: CFA treated GPR84 KO mice show attenuated inflammatory pain hypersensitivity 
 
(A) Starting at 24 hrs post intra-plantar CFA administration (15 μl; 1 mg/mL), GPR84 WT mice 
showed a significant reduction in ipsilateral mechanical PWTs compared to baseline (day 0) and the 
control contralateral hind paw, which persisted throughout the 14 testing days. In contrast, GPR84 
KO mice showed an initial reduction that recovered to baseline by day 7 and remained unchanged up 
until day 14. There was a significant difference between genotypes. ***p < 0.001 vs baseline; †††p < 
0.001 vs contralateral paw; ###p < 0.001 vs KO, two-way RM ANOVA; post-hoc SNK. (B) AUC analysis 
for WT and KO ipsilateral and contralateral PWTs from baseline to 14 days post CFA were calculated 
(arbitrary units). In contrast to WT littermates, KO mice did not develop mechanical hyperalgesia in 
the ipsilateral hind paw. There was a significant difference between genotypes. ***p < 0.001 vs 
contralateral paw; ###p < 0.001 vs KO, one-way ANOVA; post-hoc SNK. (C) WT mice showed a 
significant reduction in thermal PWLs of the ipsilateral paw from baseline on days 1 to 7, which 
recovered to baseline by day 14. In contrast, KO mice showed an attenuated level of reduction in 
thermal thresholds of the ipsilateral paw on days 1 and 3, which was significant on day 1. The 
thresholds of KO mice were not significantly different from baseline at any point. *p < 0.05, **p < 0.01 
vs baseline; ††p < 0.01, †††p < 0.001 vs contralateral paw; #p < 0.05 vs KO; two-way RM ANOVA, post-
hoc SNK. (D) WT and KO mice showed equivalent levels of mechanical allodynia in the ipsilateral hind 
paw, expressed as calculated AUC over the 14 day testing period. (E) Dorso-ventral paw thickness 
was measured as an indicator of paw oedema following CFA injection. WT and KO mice showed an 
equivalent increase in dorso-ventral paw thickness post CFA at all time points tested and there was 
no significant difference between genotypes at any point. *p < 0.05 vs baseline, Friedman RM ANOVA 
on Ranks, post-hoc Bonferroni–Dunn. (F) WT mice showed a long-lasting reduction in cold sensitivity 
thresholds post CFA injection in contrast to KO mice, which after an initial reduction recovered to 
baseline by day 3 and remained unchanged thereafter. There was a significant difference between 
genotypes on all testing days from 1 to 14. **p < 0.01, ***p < 0.001 vs baseline; #p < 0.05, ##p < 0.01, 
###p < 0.001 vs KO; ††p < 0.01, †††p < 0.001 vs contralateral paw, two way RM ANOVA with SNK. (G) 
Calculation of AUC for cold PWLs of both genotypes from baseline to 14 days post CFA. WT, but not 
KO, mice developed significant cold hyperalgesia in the ipsilateral paw. There was a significant 
difference between genotypes. **p < 0.01 vs contralateral paw; #p < 0.05 vs KO, one-way ANOVA; 
post-hoc SNK. In all cases data are presented as the mean ± SEM, n = 8, except von Frey data where n 
= 16 up to day 7 and n = 8 thereafter. 
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3.3.2 CFA induced microgliosis is attenuated in GPR84 KO mice  
 
Having established a behavioural phenotype, we then sought to correlate this with 
anatomical findings. In virtually all animal models of inflammation-induced pain, a 
microglial response has been immunohistochemically detected in the spinal cord (Sweitzer 
et al., 1999; Svensson et al., 2003b; Raghavendra et al., 2004; Hua et al., 2005; Guo et al., 
2007; Sun et al., 2007). Therefore, to examine microglial cells in GPR84 mediated 
inflammatory pain we examined immunophenotypic changes of these cells in lumbar spinal 
cord sections of WT and KO mice at 14 days post CFA.  
 
Quantification of Iba1 immunoreactivity revealed that at 14 days post CFA there was a 
significant 1.8-fold increase in microglia cell numbers in the ipsilateral dorsal horn of WT 
mice (8.7 ± 1.1/4x104 μm2) compared to saline control (4.9 ± 0.5/4x104 μm2; Fig 3.4A, B). 
This is in accordance with previous work where microglial activation was observed 4-14 
days after CFA treatment (Raghavendra et al., 2004). In CFA treated KO mice there was a 
non-significant 1.8 fold increase (8.6 ± 1.6/4x104 μm2) in microglial cells numbers in the 
ipsilateral dorsal horn compared to saline controls (4.9 ± 0.5/4x104 μm2). Therefore both 
genotypes exhibited an equivalent increase in Iba1 positive cells and there was no 
significant difference between them. These data suggest that GPR84 does not play a role in 
regulating microglial numbers subsequent to a peripheral inflammatory insult. In CFA-
treated mice both genotypes also exhibited similar microglial morphology, which varied 
from the typical ramified ‘quiescent’ state through to various stages of ‘activation’, in which 
cells appeared deramified and more amoeboid in shape with thicker and shorter processes. 
 
We also investigated whether GPR84 deletion may alter the ability of microglial cells to 
respond to an inflammatory insult by examining staining for the microglia activation marker 
p-p38 MAPK (Ji and Suter, 2007; Ji et al., 2009). Quantification of immunoreactivity revealed 
a significant 1.8-fold increase in p-p38 positive cells in the ipsilateral dorsal horn of WT 
mice (8.6 ± 1.1/4x104 μm2) compared to saline controls (4.9 ± 0.4/4x104 μm2; Fig 3.4A, B). 
CFA treated KO mice showed a 1.7-fold increase (8.3 ± 1.8/4x104 μm2) in p-p38 positive 
cells in the ipsilateral dorsal horn, which was not statistically significant compared to saline 
control (4.9 ± 0.3/4x104 μm2). Again, there was no significant difference between the 
genotypes, suggesting that GPR84 signalling may not be important in the activation of 
microglial cells in inflammatory pain states. 






Figure 3.4: CFA induced microgliosis is attenuated in GPR84 KO mice  
 
Subsequent to intraplantar CFA, there was a significant increase in Iba1 and p-p38 positive cells in 
the ipsilateral dorsal horn of the spinal cord in WT mice (WT CFA) compared to saline control (WTC). 
CFA-injected KO mice (KO CFA) also showed an increase in Iba1 and p-p38 positive cells compared to 
saline control (KOC), however, this was not significant (A); quantified in (B). There were no 
significant differences between genotypes. Data are presented as the mean ± SEM; *p < 0.05, vs 
control; one-way ANOVA on ranks; post-hoc Tukey, n = 4-6. Scale bar = 200 μm. 
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3.3.3 LPS treated GPR84 KO mice show attenuated behavioural hyperalgesia 
 
Although a number of experimental models of neuropathic and inflammatory pain 
demonstrate that microglia activation plays a role in the development of chronic pain 
(DeLeo and Yezierski, 2001; Watkins and Maier, 2003; McMahon et al., 2005; Clark et al., 
2007a), we have been unable to correlate the behavioural phenotype of GPR84 KO mice 
after PNL or CFA to an altered microglial response. Therefore, to conclusively exclude the 
contribution of microglial cells in GPR84 mediated signalling we examined the role of these 
cells in the CNS by utilising the LPS-induced inflammatory model. Since intrathecal LPS 
specifically activates microglial cells via the TLR4 and is associated with heat and 
mechanical hyperalgesia (Lehnardt et al., 2002; Cahill et al., 2003), we investigated whether 
GPR84 deletion alters microglia mediated nociceptive behaviour. 
  
Mice were primed with intrathecal LPS (2 μg/mouse) on day 1, which has been previously 
reported not to alter PWT to noxious or innocuous mechanical stimuli (Clark et al., 2006). As 
expected, the second dose of LPS 24 hrs later induced transient mechanical allodynia in 
GPR84 WT mice at 1 hr post treatment (0.4 ± 0.1 g), which rapidly recovered by 3 hrs (0.7 ± 
0.1 g) and was no longer significantly different from baseline (0 hr, 0.9 ± 0.1 g) or control 
animals (0hr, 0.9 ± 0.1 g; 1hr, 0.9 ± 0.2 g; 3hr, 0.7 ± 0.1 g; Fig 3.5A). KO mice also showed a 
reduction in mechanical thresholds in response to intrathecal LPS however, this was not 
significant (LPS: 0hr, 0.8 ± 0.1 g; 1hr, 0.4 ± 0.1 g; 3hr, 0.6 ± 0.1 g vs control: 0hr, 0.8 ± 0.03 g; 
1hr, 0.7 ± 0.2 g; 3hr, 0.7 ± 0.1 g; Fig 3.5B). One hr post LPS, WT and KO mice showed 
reductions of 57.5% and 52.2%, respectively, and there was no significant differences 
between genotypes. 
 
Subsequent to priming and the second dose of intrathecal LPS, WT mice also developed 
significant mechanical hyperalgesia at 3 hrs post treatment (88.9 ± 1.6 g) in comparison to 
saline controls (100.8 ± 1.1 g; Fig. 3.5C). According to the literature, intrathecal LPS has 
been shown to induce significant mechanical hyperalgesia from as early as 1 hr post 
treatment that persists up to 6 hrs and returns to baseline thresholds by 24 hrs (Clark et al., 
2006). Interestingly, we observed an increase in thresholds at 1 hr post treatment (112.5 ± 
1.9 g) that dropped 15% below baseline (104.6 ± 1.7 g) by 3 hrs. Similarly KO mice also 
exhibited an increase in thresholds at 1 hr post treatment (112.5 ± 3.1 g) compared to 
baseline (101.9 ± 1.9 g) or saline controls (102.5 ± 0.6 g). However, at 3 hrs post LPS, KO 
mice showed a marginal 5.6% drop in mechanical thresholds (96.3 ± 4.0 g) from baseline 
and did not significantly differ from saline controls (101.3 ± 1.5 g) in contrast to WT mice 
(Fig. 3.5C).  
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In both genotypes cold sensitivity was unaltered 1 hr (WT: 13.1 ± 0.2 s; KO: 13.2 ± 0.5 s) 
after the second LPS dose but significantly dropped 3 hrs post treatment (WT: 10.7 ± 0.7 s; 
KO: 10.7 ± 0.4 s) in comparison to baseline (WT: 12.2 ± 0.4 s; KO: 12.4 ± 0.3 s; Fig 3.5D). 
There were no significant differences between genotypes. Together, the above data suggests 
that GPR84 may be involved in mediating mechanical hyperalgesia via the modulation of 
microglial cells but not mechanical allodynia or cold hyperalgesia. This modality-specific 
inhibition could be a result of phenotypic differences in populations of afferent fibres such 
as the expression of TRP channels and mechanosensors, which may be regulated down-
stream of GPR84 activation under inflammatory conditions.  
  





Figure 3.5: LPS treated GPR84 KO mice show attenuated behavioural hyperalgesia  
 
GPR84 WT (A) and KO (B) mice showed a reduction in PWTs 1 hr after a second dose of intrathecal 
LPS, in comparison to vehicle treated mice (WTC, KOC, respectively). There was no significant 
difference between genotypes. (C) GPR84 WT, but not KO mice, mice showed a significant reduction 
in paw pressure thresholds 3 hrs post LPS in comparison to baseline and WTC. There was a 
significant difference between the LPS treated genotype groups. (D) Both GPR84 WT and KO mice 
showed significant increases in cold sensitivity at 3 hrs post LPS. There was no significant difference 
between genotypes. Data are presented as the mean ± SEM. *p < 0.05, ***p<0.001 vs baseline; †p < 
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3.3.4 LPS treated GPR84 KO mice exhibit a normal microglia response  
 
Despite a weak behavioural phenotype, we sought to immunohistochemically characterise 
the microglial response to LPS in order to determine whether direct activation of these cells 
is altered in the absence of GPR84. Therefore, we immunostained lumbar spinal cord 
sections for Iba1 and p-p38 to examine microglia numbers and activation, respectively, at 3 
hrs after the second dose of LPS. 
 
In accordance with literature (Clark et al., 2006), we observed a significant 1.5-fold bilateral 
increase in Iba1 and p-p38 positive cells (61.7 ± 3.9/7.3 x 105 μm2 and 61.7 ± 3.9/7.3 x 105 
μm2, respectively) in the dorsal horns of LPS treated WT animals in comparison to saline 
controls (41.7 ± 3.4/7.3 x 105 μm2; 41.6 ± 3.4/7.3 x 105 μm2, respectively; Fig 3.6A, B). 
Interestingly, GPR84 KO mice exhibited a similar 1.5-fold bilateral increase in Iba1 and p-
p38 positive cells (61.8 ± 3.7/7.3 x 105 μm2 and 61.5 ± 3.7/7.3 x 105 μm2, respectively) in 
LPS treated animals in comparison to saline controls (41.5 ± 5.1/7.3 x 105 μm2; 41.4 ± 
5.2/7.3 x 105 μm2, respectively) (Fig 3.6A, B). These data indicate that deletion of GPR84 
does not impair the ability of microglial cells to respond to a potent inflammatory stimulus 
and thus it is unlikely that the KO behavioural phenotype is mediated by microglial cells in a 
GPR84 dependent manner. 
  







Figure 3.6: LPS treated GPR84 KO mice exhibit normal microgliosis  
 
There was a significant bilateral increase in Iba1 and p-p38 positive cells in the dorsal horn of the 
spinal cord subsequent to intrathecal LPS in both GPR84 WT and KO mice (WT LPS, KO LPS, 
respectively) compared to vehicle control (saline) groups (WTC, KOC respectively) (A), quantified in 
(B). There was no difference between genotypes. Data are presented as the mean ± SEM. *p < 0.05, **p 
< 0.01 vs control, one-way ANOVA; post-hoc SNK, n = 4. Scale bar = 200 μm.  
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3.3.5 Immunohistochemical assessment of GPR84 protein expression  
 
Under physiological conditions GPR84 expression is low and virtually undetectable even 
with a sensitive method like qPCR. However, subsequent to an appropriate immunological 
stimulus such as LPS, GPR84 expression increases in both monocytes/macrophages and 
microglial cells (Wang et al., 2006a; Bouchard et al., 2007). To characterise the protein 
expression of GPR84 we used a commercially available antibody against lumbar spinal cord 
sections from saline or LPS treated WT and KO mice. 
 
In accordance with the literature (Bouchard et al., 2007), GPR84 immunostaining was 
absent in saline treated spinal cords of either WT or KO mice (Fig. 3.7A). However, 
characteristic bilateral GPR84 immunoreactivity was detected in LPS stimulated WT mice, 
which exhibited a punctate pattern that resembled microglial morphology (Fig. 3.7A). In 
contrast, GPR84 staining was completely absent in LPS treated KO mice, validating GPR84 
silencing in this transgenic. To determine the identity of cells expressing GPR84 we carried 
out triple staining against GPR84, Iba1 (microglial marker), NeuN (neuronal marker) and 
GFAP (astrocytic marker; Fig. 3.7B). GPR84 immunoreactivity co-localised with a majority of 
Iba1 positive cells but did not co-label with NeuN or GFAP. This confirms that GPR84 is 
exclusively expressed by microglial cells and raises the possibility that only a subpopulation 
of microglia express this receptor.  
  







Figure 3.7:  Protein verification of GPR84 deletion and co-localisation with microglia cells 
 
GPR84 deletion was confirmed via the absence of staining in KO mice in both saline (KOC) and LPS 
stimulated conditions (KO LPS) (A). GPR84 immunoreactivity was not present in saline treated WT 
animals (WTC) but under LPS conditions (WT LPS) bilateral punctuate staining was evident (A). 
GPR84 immunoreactivity exclusively co-labelled with Iba1 positive cells under LPS stimulated 
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3.3.6 GPR84 mRNA is induced in cultured microglia and macrophage cells 
subsequent to LPS stimulation 
 
GPR84 gene transcription is strongly induced by diverse endogenous and exogenous 
inflammatory stimuli in a time dependent manner in subsets of central microglial cells and 
peripheral macrophages, as demonstrated by both in vitro and in vivo studies (Wang et al., 
2006a; Bouchard et al., 2007). To verify our observation of GPR84 expression in central 
microglia in addition to peripheral macrophages, we cultured cortical microglial cells and 
peritoneal macrophage cells and measured GPR84 expression subsequent to 3 hrs of LPS (1 
μg/ml) stimulation.  
 
Since the moderate number of macrophage cells normally harvested from the peritoneum 
cavity are insufficient for extensive studies, eliciting agents such as Bio-Gel, thioglycollate 
and proteose-peptone are used to increase monocyte migration into the peritoneum and 
thus enhance yields (Zhang et al., 2008). Elicited macrophage populations consist of a 
mixture of resident and infiltrating cells of haematogenous origin similar to what we see in 
the in vivo situation. Both populations play an equal role in the response to a peripheral 
insult; the faster-acting resident cells initiate the response, followed by the later recruitment 
of infiltrating cells (Ton et al., 2013). We therefore utilised B-GEPMs not only for their 
practical advantages (ready availability, easy access and high yields), but also because this 
approach allowed us to study a heterogenous population of cells. In addition, these cells 
have been extensively studied in literature, where most of our understanding of tissue 
resident macrophages originates (Gordon, 2007; Zhang et al., 2008). B-GEPMs are also free 
of intracellular debris as they are unable to phagocytose the Bio-Gel beads. Nevertheless, B-
GEPMs differ from resident cells in numbers and function and exhibit increased membrane 
turnover, respiratory and phagocytic capacity as well as alternative responses to various 
chemokines (Zhang et al., 2008). In comparison to other relevant sources of cells such as 
bone-marrow derived macrophages (BMM), elicited macrophages are similarly F4/80high, 
CD11bhigh, and CD68+. However, GPR84 expression is restricted to BMMs and microglia in 
non-stimulated conditions and robustly increases in both BMMs and elicited peritoneal 
populations subsequent to LPS exposure (Lattin et al., 2008). Likewise, although we have 
focused on spinal microglia in this thesis, we have utilised cortical microglia in this study 
due to the requirement of greater cell yields. 
 
 Using qPCR, we observed a significant increase in GPR84 expression subsequent to LPS 
stimulation by 2.6-fold (1.7-3.6) in cortical microglial cells (A) and 30.8-fold (23.0-41.2) in 
B-GEPMs (B, Fig. 3.8). Therefore, GPR84 is highly inducible under inflammatory conditions 
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and is likely to act down-stream of pro-inflammatory mediators. Interestingly, there was a 
greater induction in macrophages than in microglia, which may indicate a more prominent 
role in regulating peripheral macrophages with regards to our previous findings (Fig 3.4 
and 3.6). Furthermore, the exclusive expression of GPR84 in cells of the myelomonocytic 
lineage and the fact that its expression is only up-regulated in response to peripheral or 
central insult makes it an attractive therapeutic target. 
 
3.3.7 Raw PCR array data: Comparing LPS induced mediator transcripts in GPR84 
WT and KO Bio-Gel elicited macrophages 
 
Using two models of inflammation (CFA and LPS) we have shown that GPR84 KO mice 
exhibit attenuated behavioural hypersensitivity that is restricted to particular modalities. 
We have verified that the microglial response does not correlate with GPR84 mediated 
nociceptive signalling in these models. The role of macrophages in chronic pain is well 
documented in models of inflammation and traumatic nerve injury. These cells promote the 
inflammatory response by releasing a range of mediators such as TNF-α, IL-1β, NGF, NO and 
PGE2 (Marchand et al., 2005). TLR4 is an important player in the activation of macrophages 
and application of a potent exogenous TLR4 agonist (LPS) to cultured B-GEPMs provides a 
simple in vitro paradigm where the macrophage response can be evaluated. Therefore, to 
investigate whether there is any impairment in the ability of macrophage cells to launch an 
inflammatory response in the absence of GPR84, we have utilised high through-put custom-
made Taqman array cards to analyse the relative expression of putative mediators in WT 
and KO B-GEPMs following LPS exposure. An explanation of analysis is provided in the 
methods section (2.2.8) and in more detail in (Perkins et al., 2012). 
 
Appendix Tables 9 and 10 display the raw CT values of 92 different chemokines, cytokines, 
growth factors and cell markers as well as the HK genes of control and LPS stimulated 
GPR84 WT and KO macrophages. Generally, CT values exhibited consistency within 
experimental groups and the HKs varied no more than 1 cycle, except HPRT, which 
decreased by an average CT of 1.6 in LPS stimulated KO macrophages. Therefore, the data is 
consistent enough to assume a limited incidence of false positives and negatives. In the case 
of transcripts below detection level, the relevant amplification plots were checked for faulty 
reactions to confirm that the lack of gene detection was due to a biological factor rather than 
a technical error. 
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3.3.8 A subset of gene transcripts induced by LPS are differentially regulated by 
GPR84 WT and KO macrophages  
 
Tables 3.1A and B display the top differentially regulated genes in GPR84 KO mice. Data are 
displayed as the mean FC relative to control (see Appendix Tables 11 and 12 for FC values of 
all genes profiled). The SD values are only those of the case samples where variability is 
considered to be the greatest, rather than the control samples. For each gene, a FC threshold 
of ≥ 2 in one or both genotypes was set to reduce noise by eliminating those genes that 
showed marginal expression changes. A FC ratio (KO FC/WT FC) threshold of ≥ 1.5 was also 
set and genes were ranked according to FC ratio. The FC ratio was employed in the 
screening criteria so that unless the FC value of a particular transcript differed by ≥ 1.5 – 
fold between genotypes, it would not be considered to be transcriptionally regulated by 
GPR84. This enabled us to efficiently filter irrelevant genes and focus on those transcripts 
that were considerably dysregulated between genotypes. 
 
As expected, GPR84 was undetectable in KO macrophages but strongly up-regulated in LPS 
stimulated WT cells (FC: 30.8). Strikingly, both pro-inflammatory CCL19 and anti-
inflammatory IL-13 were up-regulated in WT cells but remained un-detectable in the KO 
(FC: 71.0; FC: 7.7, respectively). Other pro-inflammatory mediators including IL-18, CCL2, 
CCL3, CCL7, CXCL5 and CXCL9 were significantly induced in both genotypes but to a greater 
extent in the WT (IL-18, WT FC: 4.0, KO FC: 2.6; CCL2, WT FC: 27.2, KO FC: 15.6; CCL3, WT 
FC: 249.5, KO FC: 165.1; CCL7, WT FC: 41.4, KO FC: 21.3; CXCL5, WT FC: 33.7, KO FC: 18.5; 
CXCL9, WT FC: 25.4, KO FC: 11.8), of which IL-18, CCL2, CCL3 and CXCL5 are documented to 
be pro-nociceptive (Wei et al., 2001; Abbadie et al., 2003; Kiguchi et al., 2010b; Dawes et al., 
2011). These data suggest that in the absence of GPR84 mediated signalling macrophage 
cells exhibit an attenuated release of some pro-inflammatory cytokines/chemokines. 
However, key pro-inflammatory factors that are well documented to contribute directly or 
indirectly to pro-nociceptive behaviours were equivalently or more greatly induced in the 
KO subsequent to LPS stimulation compared to the WT, including IL-1β: (WT FC: 749.5 
(548.0-1030.0), KO FC: 823.0 (555.0-1220.0)); IL-6: (WT FC: 1785.4 (1430.0-2220.0), KO 
FC: 1440.0 (878.0-2360.0)); TNF-α: (WT FC: 134.6 (119.0-152.0), KO FC: 267.0 (236.0-
301.0));  PTGS2: (WT FC: 1120.5 (906.0-1390.0), KO FC: 1290.0 (902.0-1850.0));  PTGES: 
(WT FC: 30.1 (18.9-47.9), KO FC: 41.1 (24.5-69.0))  and NOS2: (WT FC: 130.0 (92.2-183.0), 
KO FC: 204.0 (81.8-510.0); (p < 0.05)). This suggests that under inflammatory conditions, 
GPR84 may suppress the expression of particular mediators whilst promoting the 
expression of others, thus reflecting the differential regulation of mediators by Gαi/o coupled 
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receptors. These data also indicate that on the whole, KO macrophages are equally capable 
of a robust inflammatory response as their WT controls. 
 
Interestingly, IL-10, which is a potent anti-inflammatory interleukin, was one of the top five 
dysregulated factors and exhibited a greater induction in the WT. AIF1 (Iba1 gene) 
remained unchanged in the WT and was down-regulated in the KO, which is an unexpected 
finding with regards to our previous observations that LPS treated mice exhibited increased 
Iba1 immunoreactivity in the spinal cord (Fig 3.6). Notably, upon LPS stimulation all 
classical immune cell markers either remained unchanged or were down-regulated in both 
genotypes, including H2-EB1 (MHC class II), TLR4 and ITGAM (CD11b). Genes for IL-19, IL-
20, CCL22, CCL24, CXCL3 and CXCL13 were also more greatly induced in the WT, some of 
which are implicated in inflammation but not documented to have a role in nociceptive 
pathways. Nevertheless, they may contribute via the exacerbation of inflammation or 
through binding to receptors that are known to mediate the effects of algogenic chemokines. 
For example, CXCL3 binds to CXCR2, which is the same receptor that pro-nociceptive CXCL5 
binds to (Dawes et al., 2011). 
 
Amongst the top up-regulated transcripts in the KO were the growth factors EREG and 
BDNF. EREG was significantly induced in both genotypes but by 1.8-fold more in the KO, 
whereas BDNF was down-regulated in the WT and remained unchanged in the KO. BDNF 
has a well established role in pain transmission (Latremoliere and Woolf, 2009), as opposed 
to EREG for which little is known. A selection of cytokines and chemokines were also more 
significantly induced in the KO, including IL-23A, IL-33, CCL20, CXCL11 and CSF2 (Table 
3.1(B)). Of those, IL-33 and CXCL11 have been recently implicated in inflammatory pain 
pathways (Strong et al., 2012; Han et al., 2013; Zarpelon et al., 2013). In contrast, there is no 
established link between IL-23A, CCL20 and CSF2 and pain signalling and thus, although 
possible, a specific relevance to the KO behavioural phenotype is unlikely. 
 
3.3.9 Distribution and correlation of LPS induced genes in GPR84 WT and KO 
macrophages  
 
We have identified a number of genes which were dysregulated in GPR84 KO macrophages 
after a robust inflammatory stimulus. However, upon closer inspection it is evident that the 
majority of the 92 profiled transcripts exhibit similar changes in expression between 
genotypes. The distribution graph (Fig. 3.9A) illustrates the profiles of average FC values of 
individual genes relative to control (non-stimulated cells) for each genotype as well as the 
FC ratios of each gene. Gene profiles are ranked in order of FC ratio from the most down-
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regulated to the most up-regulated in the WT vs the KO. The blue shaded region 
corresponds to the cut-off threshold of a FC ≥ 2. Within each genotype FC data points that 
clearly reside above or below this threshold are differentially regulated from control tissue 
and those genes that also have FC ratios ≥ 1.5 are differentially regulated between 
genotypes. 
 
In both genotypes, it is evident that LPS exposure elicits a substantial induction of many of 
the 92 different transcripts examined, with very few genes down-regulated. In the WT 49 
genes were up-regulated, 36 genes were unchanged and 7 genes were down-regulated. 
Similarly, in the KO 46 genes were up-regulated, 40 genes were unchanged and 6 genes 
were down-regulated. The FC profiles of the genotypes are tightly correlated, which 
indicates that the transcriptional response to LPS was similar (Fig 3.9A). This is further 
supported by the fact that a majority of FC ratio values are < 1.5 and only a small subset of 
genes are differentially regulated between the genotypes. These genes are of particular 
interest as they could potentially play a role in behavioural hypersensitivity mediated by 
GPR84 signalling and are presented and evaluated in the tables 3.1A and B. 
 
To directly compare LPS induced transcriptional changes between genotypes, WT and KO 
average FC values are plotted against each other (Fig. 3.9B). Presenting the transcript 
changes in this format enables the assessment of data scatter and the identification of genes 
that do not conform to the rest of the data. As indicated by the Pearson’s correlation 
coefficient, there is a positive correlation between the WT and KO data sets (p < 0.001). This 
indicates that the transcriptional changes in macrophage cells required to launch an 
inflammatory response are similar between genotypes and is not hindered in the absence of 
GPR84. Therefore, a majority of the 92 different pro-inflammatory genes profiled are not 
regulated by GPR84 except for those outliers highlighted in red (CCL19 and IL-13), which 
are also top hits in the ranking table 3.1A. These outliers are data points that skew the 
Pearson’s correlation coefficient as they markedly deviate from the positive correlation of 
the two data sets, which is due to considerable differences in expression between the 
genotypes.  
 
3.3.10 Validation of CCL19 expression 
 
The extensive analysis of the Taqman PCR array data has led to the identification of two LPS 
induced mediators that are differentially regulated between WT and KO macrophages. Both 
CCL19 and IL-13 were undetectable in baseline conditions in both genotypes, however 
subsequent to LPS stimulation both mediators were up-regulated in WT cells in contrast to 
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KO cells.  CCL19 is a pro-inflammatory chemokine with some implications in nociceptive 
transmission (Biber et al., 2011; Schmitz et al., 2013) and exhibited a significant up-
regulation (p < 0.001), whereas IL-13 exhibited a non-significant up-regulation and 
possesses anti-inflammatory properties that are less fitting to the behavioural phenotype in 
question. Thus based on this evidence we decided to further validate the expression of 
CCL19 in WT and KO macrophage cells using conventional qRT-PCR. We found that the 
results were highly consistent with the original findings of the Taqman PCR array method; 
we observed a significant induction of CCL19 expression post LPS stimulation in WT but not 
in KO macrophages (WTC: 1.0 ± 0.3, WT LPS: 12.4 ± 7.3 vs KOC: 1.1 ± 0.1, KO LPS: 3.2 ± 1.1; 
Fig. 3.10A). However, when we repeated the experiment in an independent group of animals 
(Fig. 3.10B) CCL19 induction in the WT LPS group was considerably less and both genotypes 
showed an equivalent level of CCL19 up-regulation (WTC: 1.0 ± 0.6, WT LPS: 4.8 ± 0.4 vs 
KOC: 0.7 ± 0.2, KO LPS: 4.3 ± 1.0; p < 0.05 Fig. 3.10B). Due to time constraints, it was not 
possible to repeat the experiment; however, it would be worthwhile re-validating CCL19 













Figure 3.8: LPS stimulation induces an abundant increase in GPR84 expression in microglia 
and macrophage cells 
 
The relative expression of GPR84 in WT cortical microglia (A) and Bio-gel elicited peritoneal 
macrophage cells (B), significantly increased subsequent to 3 hrs LPS (1 μg/ml) stimulation.  Change 
in mRNA expression is normalised to the mean ΔCT of control cells where ΔCT = (mean GPR84 CT) – 
(mean HK CT). Data are presented as mean ± SEM. A, HK: GAPDH; t-test, *p < 0.05 vs control, n = 4. B, 
HKs: GAPDH, HPRT, X18S, ACTB, p < 0.001*** vs control, t-test with FDR for multiple testing 
correction, n = 4. 
 



















































































Table 3.1: Top down- and up-regulated gene transcripts in GPR84 KO macrophages 
subsequent to LPS stimulation 
 
Tables displaying the top down- (A) and top up- (B) regulated gene transcripts 3 hrs post LPS 
stimulation (1 μg/ml) in GPR84 KO B-GEPMs ranked in order of FC ratio, where FC = LPS/control; FC 
ratio = KOFC/WTFC. Only genes with a FC  ≥ 2 and a FC ratio of ≥ 1.5 have been ranked. Genes with a 
FC ratio < 1.5 are considered equally expressed between genotypes. Data are presented as the mean ± 
SD range of the case samples (LPS stimulated cells); p < 0.05*, p < 0.01**, p < 0.001*** vs control; t-
test with FDR correction for multiple comparisons, n = 4.  
3.1 (A)
Rank Gene WT FC KO FC 
KOFC/WTFC  
RATIO
1 CCL19 71.0 (49.8-101.0)*** ND -71.0
2 GPR84 30.8 (23.0-41.2)*** ND -30.8
3 IL13 7.7 (1.9-31.8) ND -7.7
4 FGF7 -2.2 (0.3-0.8) -12.1 (0.04-0.2)** -5.0
5 IL10 153.2 (100.0-234.0)** 42.2 (34.0-524.0)** -3.6
6 CXCL13 4.2 (2.4-7.3) 1.3 (0.6-2.8) -3.2
7 CCL22 2360.1 (1080.0-5150.0)*** 798.4 (142.0-450.0)** -3.0
8 IL19 219.6 (17.4-27.7)* 100.0 (68.3-147.0)** -2.2
9 CXCL9 25.4 (23.1-27.9)** 11.8 (7.1-19.6)** -2.2
10 AIF1 1.0 (0.9-1.2) -2.2 (0.2-2.2)* -2.0
11 CCL7 41.4 (23.4-73.3)*** 21.3 (10.4-43.6)** -1.9
12 CXCL5 33.7 (23.7-47.8)*** 18.5 (11.1-30.8)* -1.8
13 CCL2 27.2 (17.0-43.6)*** 15.6 (12.4-19.7)*** -1.7
14 IL20 13.1 (6.1-28.0)* 7.6 (2.9-20.1)* -1.7
15 CXCL3 959.8 (796.0-1160.0)*** 597.2 (394.0-905.0)*** -1.6
16 IL18 4.0 (3.2-4.9)** 2.6 (1.5-4.4) -1.5
17 CCL3 249.5 (197.0-317.0)*** 165.1 (129.0-211.0)*** -1.5
18 CCL24 3.0 (1.8-5.1)* 2.1 (1.5-2.9) -1.5
Top down-regulated genes in LPS stimulated GPR84 KO macrophages
3.1 (B)
Rank Gene WT FC KO FC 
KOFC/WTFC  
RATIO
1 CXCL11 35.1 (26.8-46.1)*** 268.9 (112.0-647.0)*** 7.7
2 CCL11 4.3 (1.1-17.4) 11.3 (2.1-61.6) 2.6
3 CCL20 28.7 (19.5-44.4) 66.6 (25.3-176)* 2.3
4 BDNF -2.5 (0.1-1.9) 1.2 (0.3-5.9) 2.1
5 TNF 134.6 (119-152)*** 266.6 (236-301)*** 2.0
6 IL23A 1227.4 (812.0-1860)*** 2374.0 (1300-4350)** 1.9
7 CCL28 -2.2 (0.2-1.0) 1.2 (0.5-2.5) 1.9
8 EREG 19.7 (14.9-26.2)** 35.6 (23.0-55.1)*** 1.8
9 CSF2 6884.0 (3450.0-13800)*** 11030.0 (2980.0-40800.0)** 1.6
10 NOS2 130.0 (92.2-183.0)*** 204.2 (81.8-510.0)** 1.6
11 IL33 7.5 (4.3-13.1)** 11.5 (7.7-17.2)** 1.5
Top up-regulated genes in LPS stimulated GPR84 KO macrophages






Figure 3.9: Distribution and correlation of LPS induced genes in GPR84 WT and KO 
macrophages 
 
(A) Transcript expression profiles of a range of cytokines, growth factors and cell markers 
subsequent to 3 hrs LPS (1 μg/ml) stimulation of GPR84 WT and KO B-GEPMs. Transcripts are 
ranked in order of increasing FC ratio, where FC = LPS/control; FC ratio = WT FC/KO FC.  Both 
genotypes demonstrate similar distribution profiles and only a few transcripts are differentially 
regulated as indicated by the FC ratio. The data points show the average FC or FC ratio for each gene 
transcript ranked from the most down-regulated to the most up-regulated in the WT. The blue 
shaded box represents an area of 2 ≤ FC and each data point shows the mean FC for each individual 
transcript. Adjacent FC data points represent the same gene transcript, n = 92. The x-axis is on a log 2 
scale. (B) Transcript expression changes in WT and KO macrophages are plotted against each other 
on a log 2 scale. The Pearson’s correlation coefficient (r = 0.960) indicates that there is a positive 
relationship between the two data sets (p < 0.001). Outliers are highlighted in red, see text. GPR84 is 
denoted as a red triangle. Data is presented as the mean FC. Pearson’s correlation coefficient, n = 92.  
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Figure 3.10: qRT-PCR validation of CCL19 expression in LPS stimulated GPR84 WT and KO 
macrophages  
 
Following LPS stimulation (1 μg/ml), CCL19 mRNA expression increased in GPR84 WT but not KO 
macrophages (A). There was no significant difference between the LPS stimulated genotype groups. 
In an independent second experiment the expression of CCL19 significantly increased in both LPS 
stimulated GPR84 WT and KO macrophages compared to their appropriate control groups (B). There 
was no significant difference between the LPS stimulated genotype groups. Changes in mRNA 
expression is relative to the mean ΔCT of control cells where ΔCT = (mean CCL19 CT) – (mean HPRT 
CT). Data are presented as the mean ± SEM; *p < 0.05, **p < 0.01; (A): Kruskal one-way ANOVA on 
ranks, post hoc Dunn’s method; (B): one-way ANOVA, post hoc Tukey; n = 4.  
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Chronic inflammatory pain is associated with a range of pathologies from autoimmune and 
neurological diseases to OA and cancer. Patients often have to contend with additional 
associated co-morbidities and thus quality of life is greatly compromised with current 
therapeutic treatment largely inadequate. The immune system with its array of signalling 
molecules plays a principle role in inflammation and thus the identification of key immune 
targets is a viable approach in the development of new therapeutic treatments. In this 
chapter we utilised two well documented experimental models of inflammatory pain to 
investigate the role of the immune cell expressed GPR84 in nociceptive transmission. We 
have demonstrated that following intraplantar CFA or intrathecal LPS, GPR84 KO mice 
exhibit attenuated behavioural hyperalgesia restricted to particular modalities; this 
however did not correlate with an altered microglia phenotype. We also verified deletion of 
GPR84 in the KO at the protein level and showed exclusive co-localisation with microglia in 
the CNS. Finally, we showed that subsequent to LPS stimulation, GPR84 mRNA expression is 
induced in cultured microglia and macrophages and that a subset of transcripts are 
differentially regulated in LPS stimulated KO macrophages. Therefore, GPR84 is a pro-
inflammatory receptor mediating inflammation-induced pain and is specifically up-
regulated upon exposure to appropriate inflammatory stimuli, which makes it an appealing 
target in chronic pain treatment. 
 
3.4.1 GPR84 plays a role in inflammatory pain pathways that is independent of 
microglial activation 
 
Intraplantar administration of CFA to the hind paw is one of the most common models of 
persistent inflammation that possesses both a peripheral and a central component, where 
the development of central sensitisation is manifested as thermal and mechanical 
hyperalgesia. Microglia are active participants in the initiation of chronic pain states by 
releasing a plethora of algesic factors, which is well documented in experimental models of 
nerve injury-induced neuropathic pain. However, the involvement of these cells in 
experimental models of inflammatory pain is somewhat more questionable (DeLeo and 
Yezierski, 2001; Watkins et al., 2001; Watkins and Maier, 2003; McMahon et al., 2005; 
McMahon and Malcangio, 2009). In a study utilising the CFA model, sustained spinal 
microglia activation was observed up to 14 days post CFA, indicated by an up-regulation of 
TLR4, CD14 and Mac-1 mRNAs  as well as elevated OX-42 immunoreactivity, which 
correlated with behavioural allodynia and hyperalgesia (Raghavendra et al., 2004). In an 
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earlier study using two models of peripheral inflammation, animals treated with 
intraplantar formalin and zymosan exhibited spontaneous pain and persistent mechanical 
allodynia at later time points (Sweitzer et al., 1999). Immunohistochemical analysis 
revealed that glial activation correlated with the development and maintenance of 
mechanical allodynia, however, this was only evident as a moderate bilateral increase in OX-
42 and GFAP staining (Sweitzer et al., 1999). Administration of formalin to the hind paw 
produces two phases of spontaneous nociceptive behaviour followed by a later onset of 
prolonged allodynia for up to three weeks. Using this model many groups have reported an 
ipsilateral increase in microglia numbers as revealed by OX-42 staining in the superficial 
dorsal horn that correlates with the onset of allodynia (Fu et al., 1999; Aumeerally et al., 
2004). However, discrepancies in the literature with regards to microglial markers and their 
temporal regulation suggests caution should be applied to the interpretation of these 
results. For example, Fu et al. (1999) reported an ipsilateral increase in OX-42 in the medial 
portion of the dorsal horn and gracile nucleus of the brainstem post formalin administration 
but failed to observe any change in OX-6 (marker for MHC class II). Likewise, Sweitzer et al. 
(2001) reported an absence of MHC class II as well as CD4 in the spinal cord following 
intraplantar zymosan and observed a mild glial activation that paralleled with behavioural 
allodynia. In contrast, Yeo and colleagues (2001) demonstrated an increase in microglial cell 
markers in the caudal spinal trigeminal nucleus, including OX-18 (marker for MHC class I), 
OX-42 and OX-6, 21 days post subcutaneous formalin injection into the lateral facial surface 
of rats. Notably, the most striking observations using the formalin model ultimately indicate 
that the microglia response tends to peak 3 to 7 days post treatment despite the fact that 
nociceptive behaviours are most prominent within the first 2 hours of treatment. This 
microglia response also parallels with the development of allodynia, which has been 
documented to persist for up to three weeks post formalin. Together, these data argue 
against a contribution of microglial cells in the early formalin-induced nociceptive 
behaviour phase; in contrast there appears to be an association with long-lasting 
inflammation and tissue damage, implying a relationship between microglial activation and 
the extent of nerve damage rather than nociception (Fu et al., 1999; Wu et al., 2004).  
  
 Evidence against a central microglial role has also been documented in other inflammatory 
as well as neuropathic pain models, where authors reported unaltered OX-42 staining in 
response to CFA, topical application of mustard oil and CCI surgery (Colburn et al., 1997; 
Molander et al., 1997; Honore et al., 2000; Zhang et al., 2003; Clark et al., 2007a). On the 
contrary, many recent studies have demonstrated that microglia do in fact show an early 
response to peripherally injected inflammogens with increases in OX-42 staining within 
hours of treatment (Svensson et al., 2003a; Hua et al., 2005; Clark et al., 2007a; Guo et al., 
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2007; Sun et al., 2007). Notably, whilst early studies have relied on observing morphological 
changes or increases in the density of microglia markers as a criterion, more recent work 
reflects the importance of using markers that reflect alterations in intracellular function, 
such as p-p38, rather than markers like OX-42 that require de novo protein synthesis (DeLeo 
and Yezierski, 2001; Hua et al., 2005). Phosphorylated p-38 is a prerequisite for NF-κB 
mediated cytokine synthesis and release from microglial cells and since phosphorylation is a 
very rapid process, p-p38 is regarded as a sensitive marker of spinal microglia activation (Ji 
and Suter, 2007; Ji et al., 2009). Indeed, this marker has been reported to correspond closely 
with the development of behavioural hyperalgesia in a variety of experimental models of 
inflammation (Kim et al., 2002; Svensson et al., 2003b). While intrathecal or systemic 
infusion of p38 inhibitors alleviate pain symptoms (Kumar et al., 2003; Svensson et al., 
2003a; Svensson et al., 2003b). Interestingly, contradictory temporal and expression 
findings are also present in studies using this marker of microglia activation. For example, Ji 
et al. (2002) failed to see p38 phosphorylation in the dorsal horn but observed an increase 
in p-p38 expression in small DRG neurons 6 hours to 7 days post CFA treatment. Svensson 
et al. (2003) and Kim et al. (2002) observed an increase in spinal microglia p-p38 
immunoreactivity following intraplantar formalin, with the former reporting a transient 
peak at 5 minutes whilst the later observed an increase in immunostaining 12 hours-2 days 
post treatment (Kim et al., 2002; Svensson et al., 2003b). Despite some discrepancies in the 
literature, on the whole these data support a clear role of spinal microglial cells in numerous 
models of inflammation that correlates with the development of pain behaviours. (Yeo et al., 
2001) 
In light of this evidence and the fact that GPR84 is a pro-inflammatory receptor exclusively 
expressed by microglial cells in the CNS (Bouchard et al., 2007; Suzuki et al., 2013) we 
utilised the CFA model to investigate whether GPR84 contributes to inflammatory pain via 
the modulation of microglial cells. We report that GPR84 KO mice exhibited attenuated 
mechanical, thermal and cold hyperalgesia in contrast to WT littermate controls and that 
both genotypes exhibited non-significant mechanical allodynia. As expected WT mice 
developed significant mechanical, thermal and cold hyperalgesia subsequent to intraplantar 
CFA that correlated with a significant increase in microglial numbers and activation in the 
ipsilateral dorsal horn, as revealed by enhanced Iba1 and p-p38 immunoreactivity, 
respectively. Similarly, CFA treated KO mice exhibited increased ipsilateral Iba1 and p-p38 
immunoreactivity in the dorsal horn, but this did not reach significance. Furthermore, we 
did not find a statistical difference between the CFA treated genotype groups and so these 
findings indicate that GPR84 may not be involved in the modulation of microglial cells in 
persistent inflammatory pain mechanisms. Together our data suggest that GPR84 mediated 
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nociceptive signalling encompasses specific modalities and is unlikely to involve the 
modulation of microglial cells.  
 
Studies examining the role of microglial expressed Gαi/o coupled GPCRs in transgenic mice 
have demonstrated a strong correlation between the observed behavioural phenotype and 
an altered microglial response. For example, zymosan treated CX3CR1 null mice developed 
mechanical allodynia but showed an absence of thermal hyperalgesia which, unlike our 
findings, correlated with reduced microglial numbers in the dorsal horn as revealed by Iba1 
immunoreactivity (Staniland et al., 2010). Likewise, CFA treated CCR2 null mice exhibited 
attenuated mechanical allodynia compared to WT controls from 6 hours to 2 days post 
treatment, in addition to markedly reduced pain compared to WT controls in the 2nd 
formalin phase (Abbadie et al., 2003). Administration of a CCL2 neutralising antibody 
reversed both mechanical allodynia and microglial activation. However, the reversal effect 
of an anti-CCL2 antibody has only been documented in a model of nerve injury (Thacker et 
al., 2009). These studies showed that paw oedema occurred in both genotypes, indicating an 
equivalent level of peripheral inflammation, which was a finding we also documented 
(Abbadie et al., 2003; Staniland et al., 2010). The central role of microglial cells in the 
initiation and maintenance of pain states is further supported by studies using microglial 
inhibitors. For example, administration of fluorocitrate attenuated the 2nd phase of formalin 
evoked flinching behaviours and zymosan-induced hyperalgesia (Meller et al., 1994; 
Watkins et al., 1997). Intrathecal minocycline also alleviated formalin and carrageenan 
evoked hyperalgesia, which corresponded with reduced spinal p-p38 immunoreactivity 
(Hua et al., 2005). However, in the CFA model the role of microglial cells is not that well 
established. Clark et al. (2007) reported an absence of microgliosis 24 hours post CFA 
despite the presence of behavioural hyperalgesia and intrathecal fluorocitrate failed to 
reduce pain behaviours. Furthermore, Raghavendra et al. (2004) reported low levels of 
microgliosis 1 day post CFA and in a study using CFA treated CCR2 null mice, animals 
showed a non-significant reduction of mechanical allodynia (Abbadie et al., 2003). The 
expression of P2X4, which has been shown to up-regulate in reactive microglia, also 
remained unaltered 7 days post CFA (Tsuda et al., 2003). However, these studies have 
examined earlier time points than the one we report, and in accordance with a study 
examining the microglia response 14 days post CFA we observed significant microgliosis in 
the dorsal horn (Raghavendra et al., 2004). Put together, these data suggest that microglia 
may not be involved in the early stages of acute pain but may play a more important role in 
the later chronic phase of this model. 
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Previously we were unable to correlate the behavioural phenotype of GPR84 KO mice to an 
altered microglial phenotype in a peripheral nerve injury model of neuropathic pain (see 
Chapter 2) and have found no evidence of microglial involvement in a peripheral 
inflammation model. Therefore, to directly evaluate the contribution of microglial cells to 
GPR84 mediated nociceptive signalling we examined the role of these cells in an LPS-
induced CNS inflammatory model. Intrathecal LPS specifically activates microglial cells via 
the TLR4 and induces thermal hyperalgesia and tactile allodynia, which is dependent on a 
prior priming dose (Lehnardt et al., 2002; Cahill et al., 2003). Such acute activation of spinal 
microglia has relevance to both inflammatory and neuropathic pain mechanisms as nerve 
injured TLR4 null mice display attenuated behavioural hypersensitivity and decreased 
expression of proinflammatory cytokines (Tanga et al., 2005). LPS stimulation initiates 
dimerization of the TLR4 cytoplasmic domains and subsequent activation of p38 MAPK and 
NF-κB mediated transcription, which induces the release of pro-inflammatory cytokines 
such as IL-1β and TNF-α, leading to an increase in excitability of dorsal horn neurons (Reeve 
et al., 2000; Clark et al., 2006; Clark et al., 2010b). Phosphorylation of p38 MAPK in 
microglia is a key intracellular signal that orchestrates their pain-related actions and 
correlates with the development of behavioural hypersensitivity. This has been 
demonstrated by spinal cord administration of LPS in ex vivo and in vivo models of CNS 
inflammation and a number of nociceptive models (Svensson et al., 2003b; Clark et al., 
2006). The effects of LPS are very much dependent on the induction of pro-inflammatory 
cytokines and systemic administration of LPS has been shown to induce an increase in IL-
1β, TNF-α, IL-6, CCL2 and CCL5 in the DRG and spinal cord. Correspondingly, systemic or 
perineural administration of these individual cytokines elicits mechanical hypersensitivity 
and thermal hyperalgesia (Cunha et al., 1992; Safieh-Garabedian et al., 1995; Woolf et al., 
1997; Cunha et al., 2000; Strong et al., 2012; Yoon et al., 2012). Conversely, administration 
of minocycline suppresses systemic LPS induced hyperalgesia by reducing 
microglial/macrophage cell numbers and cytokine expression (Yoon et al., 2012) and pre-
treatment of BV-2 cells with a p38 inhibitor reduces LPS stimulated cytokine production 
(Horvath et al., 2008).  
 
In a model of neonatal priming, which reflects the long-term neuro-developmental changes 
in adults associated with neonatal surgery and intensive care, adult rats exhibited a similar 
predisposition to enhanced sensory sensitivity and stress to that seen in humans (Beggs et 
al., 2012). It was shown that rodents which received a hind paw incision at 3 days of age had 
increased hyperalgesic responses in comparison to animals that did not experience an early 
life pain experience, and this change was correlated to increased microglial reactivity in the 
adult dorsal horn. Selective targeting of microglial cells via intrathecal administration of 
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minocycline prevented hypersensitivity and the early microglia response seen in animals 
that had a prior neonatal injury (Beggs et al., 2012).  Together these studies underscore the 
key role of microglia in nociception and importantly the notion of a required priming 
stimulus for the development of behavioural hypersensitivity, which is a crucial factor in the 
LPS model presented in this chapter.  
 
We report that GPR84 KO mice exhibited attenuated mechanical hyperalgesia subsequent to 
intrathecal LPS administration but showed an equivalent development of mechanical 
allodynia and cold hyperalgesia to WT mice. In accordance with literature, the development 
of behavioural hyperalgesia in WT mice correlated with a significant increase in dorsal horn 
Iba1 and p-p38 immunoreactivity; however, a similar microglial response was also 
observed in the KO despite the behavioural differences. It has been previously reported that 
LPS induced mechanical hypersensitivity is absent in P2X7 null mice, which corresponds 
with reduced p38 MAPK phosphorylation of spinal microglia (Clark et al., 2010b). Therefore 
our findings are somewhat puzzling as one would expect the KO behavioural phenotype to 
correlate with an altered microglial response, considering that these cells have been 
selectively activated and solely express GPR84, which is itself robustly induced by LPS 
exposure. In conclusion, these data suggest that GPR84 exerts its effects through complex 
signalling pathways that may involve a specific subset of afferent fibres or 
mechanoreceptors but does not regulate microgliosis in response to CNS inflammation. 
Interestingly, a previous study showed that administration of P2X4 antisense 
oligodeoxynucleotides does not prevent activation of microglial cells despite suppressing 
both allodynia and an increase in P2X4 expression in nerve injured rats (Tsuda et al., 2003). 
In light of this evidence, the up-regulation of GPR84 expression alone in response to nerve 
injury or inflammation could perhaps be the important factor contributing to nociceptive 
transmission. However, we have been unable to investigate this due to a lack of 
pharmacological tools. 
 
3.4.2  GPR84 expression is exclusive to spinal microglial cells and is up-regulated in 
response to inflammatory stimuli  
 
GPR84 is a pro-inflammatory receptor that is highly inducible upon endogenous or 
exogenous inflammatory insult. In experimental models of endotoxemia, EAE and diabesity 
GPR84 is markedly up-regulated due to the release of soluble mediators (Bouchard et al., 
2007; Nagasaki et al., 2012). Molecules able to stimulate the NF-κB pathway such as LPS, IL-
1β and TNF-α enhance the expression of GPR84 in monocytes/macrophages and microglial 
cells, which can be blocked via the administration of NF-κB inhibitors (Wang et al., 2006a; 
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Bouchard et al., 2007; Lattin et al., 2008; Nagasaki et al., 2012). Furthermore heterologous 
expression systems have demonstrated that GPR84 is involved in the regulation of subsets 
of cytokines/chemokines (Venkataraman and Kuo, 2005; Wang et al., 2006a; Suzuki et al., 
2013). Therefore, it is likely that the expression of this receptor is regulated by multiple 
pathways involving the activation of TLR4, TNFR or IL-1R, which eventually culminate in 
NF-κB mediated GPR84 transcription. In accordance with literature, we showed that under 
normal conditions GPR84 immunoreactivity was absent in the spinal cord of saline treated 
WT mice, in contrast to LPS treated mice which exhibited bilateral punctate staining that 
resembled microglial morphology. We also showed that GPR84 immunoreactivity 
exclusively co-localised with a majority of Iba1 positive cells and failed to co-label with 
NeuN and GFAP. This confirms that GPR84 expression is restricted to microglial cells and 
raises the possibility that only certain microglial subpopulations express this receptor. As 
expected, GPR84 staining was absent in the spinal cords of both saline and LPS treated KO 
mice. Lastly, in conjunction with these findings we demonstrated that GPR84 expression is 
robustly up-regulated in cortical microglia and B-GEPMs subsequent to LPS exposure.  
 
3.4.3 A subset of LPS induced gene transcripts are differentially regulated in GPR84 
WT and KO macrophages  
 
As GPR84 is a highly inducible pro-inflammatory receptor we expected to observe a more 
robust behavioural phenotype in the two inflammatory models examined, similar to our 
previous findings in the neuropathic pain model. However, we saw a mild behavioural 
phenotype that was restricted to particular modalities, suggesting that the signalling 
pathway of GPR84 is complex and may encompass different mechanisms in animal models 
of persistent inflammatory and neuropathic pain. Due to the restricted expression of this 
GPCR to spinal microglial cells and marked up-regulation by an appropriate immunological 
stimulus, we expected to see an altered microglial phenotype in KO mice. However, the 
microglial response was equivalent between the genotypes in both the CFA and LPS-induced 
CNS inflammation models. We also demonstrated a dissociation of microglial and 
macrophage involvement in GPR84 mediated pain pathways in a nerve injury-induced 
model of neuropathic pain (Chapter 2). These findings are puzzling in light of the 
behavioural phenotype in KO mice as microglia and macrophage cells are well documented 
to contribute to pain behaviours.  Based on this evidence and the fact that we observed a 
partial reduction in inflammation-induced hyperalgesia in the KO that was not associated 
with an altered microglia response, we sought to examine the possible contribution of 
peripheral macrophages by assessing the ability of B-GEPMs to launch an inflammatory 
response in the absence of GPR84. Here, we used a simple in vitro system to measure 
Chapter 3 - The Role of GPR84 in Chronic Inflammatory Pain 
 
184 
transcriptional changes of a selection of putative mediators subsequent to LPS stimulation. 
Macrophage cells are central players in the innate immune response to a peripheral insult 
and promote inflammation by releasing a range of mediators such as TNF-α, IL-1β, NGF, NO 
and PGE2 (Nathan, 1987; Tannenbaum and Hamilton, 1989; Marchand et al., 2005). LPS 
stimulation of cultured macrophage cells increases cytokine synthesis in a TLR4 dependent 
manner (Feng et al., 2002; Schmid et al., 2009) and application of LPS to the injured sciatic 
nerve enhances the recruitment of macrophage cells to the site of injury and the process of 
WD (Boivin et al., 2007). Therefore, our in vitro paradigm using a potent exogenous TLR4 
agonist is a relevant representation of the in vivo situation. 
 
Using custom designed mouse PCR array cards we examined LPS induced transcriptional 
changes in GPR84 WT and KO mice relative to appropriate control cells of each genotype. 
We analysed the data sets via implementing strict threshold criteria and examined top 
ranking up- or down-regulated genes in addition to transcriptional profiles and correlations 
between the two genotypes. We found that GPR84 KO macrophages were as equally capable 
as WT cells at launching a pro-inflammatory response upon LPS exposure and that there 
was an equivalent, if not greater induction of pro-nociceptive IL-1β, TNF-α, IL-6, PTGS2, 
PTGES and NOS2 in the KO than the WT. However, a subset of pro-nociceptive mediators 
(IL-18, CCL2, CCL3 and CXCL5) showed an attenuated induction in the KO in contrast to the 
WT. This reflects the differential regulation of mediators by Gαi/o proteins and suggests that 
GPR84 may concurrently down-regulate the expression of some mediators whilst up-
regulating the expression of others. Together, these data indicate that GPR84 may be 
involved in the regulation of a small subset of cytokines that are known to contribute to 
nociceptive transmission.  
 
IL-18 possesses a variety of functions particularly concerned with the regulation of T-cells, 
including the promotion of Th1 cell development and the activation/facilitation of IFN-γ and 
TNF-α secretion (Nakanishi et al., 2001). Intrathecal or intraplantar administration of this 
cytokine generates behavioural hypersensitivity (Verri, 2005; Verri et al., 2006; Miyoshi et 
al., 2008) and SNL-injured rodents exhibit increased expression of IL-18 and its receptor, IL-
18R, in microglia and astrocytes, respectively (Miyoshi et al., 2008). It has also been 
reported that LPS stimulation potentiates IL-18 expression in microglial cells, indicating 
that IL-18 induction is downstream of TLR4-dependant activation of microglial cells 
(Miyoshi et al., 2008).  
 
CCL2 is a chemotactic factor that contributes to the recruitment and activation of 
macrophages and microglial cells to the site of inflammation or injury (Charo and Ransohoff, 
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2006). Intraspinal administration of CCL2 in naïve rats results in microglial activation and 
pain behaviours, which are reversed via CCL2 neutralising antibodies (Thacker et al., 2009). 
Furthermore, CCR2 null mice show a reduction in pain behaviours in models of 
inflammatory and neuropathic pain (Abbadie et al., 2003). CCL3 is predominantly expressed 
in hematopoietic immune cells and exerts similar chemotactic properties to CCL2, 
regulating migration, proliferation and cytokine synthesis of immune cells via its cognate 
CCR1 and CCR5 receptors (Charo and Ransohoff, 2006). Intrathecal administration of CCL3 
in naïve mice produced dose-dependent pain behaviours that were reversed via antibody 
neutralisation (Kiguchi et al., 2010b). CXCL5 is also involved in immune cell recruitment and 
activation and in an ultraviolet B model of inflammation high levels of expression of this 
chemokine correlated with peak behavioural hypersensitivity (Charo and Ransohoff, 2006; 
Dawes et al., 2011). In addition, intraplantar injection of CXCL5 evoked mechanical allodynia 
but not thermal hyperalgesia, attributed to the infiltration of macrophage and neutrophil 
cells (Dawes et al., 2011). 
 
Among the top up-regulated genes in the KO were the growth factors BDNF and EREG. BDNF 
was down-regulated in the WT and remained unchanged in the KO after LPS, whereas EREG 
was up-regulated in both but to a greater extent in the KO. Little is known about EREG in 
nociceptive pathways and the expression pattern of pro-nociceptive BDNF (Latremoliere 
and Woolf, 2009) does not correspond to the behavioural phenotype in the KO. A subset of 
cytokines/chemokines were also induced in both genotypes but to a greater extent in the 
KO including IL-23a, IL-33, CCL20, CXCL11 and CSF2. Whilst a majority of these are 
currently unrelated to pain with only recent implications for IL-33 and CXCL11 (Strong et 
al., 2012; Han et al., 2013; Zarpelon et al., 2013), these expression patterns are unlikely to be 
relevant to the KO behavioural phenotype. This is because an increase in the expression of 
pro-nociceptive mediators does not coincide with our previous observations of an absence 
of mechanical hyperalgesia in CFA or LPS treated KO mice. 
 
Pro-inflammatory CCL7, CCL19 and CXCL9 as well as IL-13, IL-19, IL-20, CCL22, CCL24, 
CXCL3 and CXCL13 showed attenuated induction in LPS stimulated KO cells. Whilst CCL7, 
CCL19 and CXCL9 have been linked to nociception (Biber et al., 2011; Dawes et al., 2011; 
Strong et al., 2012; Schmitz et al., 2013), the latter group have very little documentation in 
the context of pain. The transcriptional regulation of CCL19 was striking and under basal 
conditions this chemokine was undetectable, whereas subsequent to LPS stimulation CCL19 
was markedly induced in WT but not KO cells. In response to inflammatory insult, CCL19 is 
co-released with CCL21a from a variety of stromal cells within the lymphoid organs where 
they act with similar affinities on CCR7+ T-cells, B-cells and dendritic cells to promote 
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migration into lymphatic vessels and mediate the adaptive immune response (Comerford et 
al., 2013). Subsets of macrophage populations are also CCR7+ and migrate in response to 
CCL19 and CCL21a to the marginal zone of the spleen where blood-borne pathogens are 
cleared (Ato et al., 2004). In a study utilising the paucity of lymph node T-cells (PLT) mice, 
which have a naturally occurring defect in the expression of both CCL19 and CCL21a, pain 
associated behaviours were absent subsequent to SNI and microglia failed to up-regulate 
P2X4 mRNA expression (Biber et al., 2011). Intrathecal administration of CCL21a in these 
mice produced long lasting mechanical allodynia to a similar extent to that seen in the WT 
mice, which was dependent on P2X4 receptor function. Although CCL19 was undetected in 
neuronal tissue and plays a minimal role in the behavioural phenotype of PLT mice, the 
contribution of this chemokine was not entirely excluded (Biber et al., 2011). A similar study 
also reported the anti-nociceptive effects of CCL19/21a deficient mice in the SNI model and 
again showed that this was not related to a reduced microglial response but rather due to an 
altered feature of microglial cells (Schmitz et al., 2013). 
 
In light of this evidence and the intriguing transcriptional regulation of this chemokine we 
further validated the differential regulation of CCL19 between genotypes and were 
successfully able to re-produce the original Taqman PCR array data via individual qRT-PCR. 
However, we were unable to repeat these data in an independent group of animals. This 
could be due to the fact that the WT cells were not as stimulated as before and hence did not 
induce CCL19 to the same extent as seen previously or perhaps because the original findings 
were a false positive. It would therefore be interesting to re-validate our findings to clarify 
this discrepancy.  
 
3.4.4 GPR84 signalling 
 
The intriguing finding that GPR84 expression is restricted to immune cells sparked recent 
studies into the functional characterisation of this receptor under in vitro and in vivo 
conditions. In one study it was shown that T-cells from GPR84 null mice exhibited a hyper 
Th2 cytokine production of IL-4, IL-5 and IL-13 in contrast to WT controls, indicating that 
GPR84 may suppress anti-inflammatory cytokines. However, this hyper Th2 cytokine 
phenotype was not present in immunised KO mice in vivo, perhaps due to a degree of 
compensation driven by the effects of an active immune response or due to differences 
between in vitro and in vivo systems (Venkataraman and Kuo, 2005). As the expression of 
GPR84 is robustly induced by an inflammatory stimulus, many studies have examined the 
functional responses of immune cells subsequent to LPS stimulation, particularly since 
GPR84 has a very low level of expression under basal conditions. Exposure of RAW 264.7 
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cells to GPR84 ligands such as capric acid and lauric acid subsequent to LPS stimulation 
produced a dose-dependent increase in IL-12p40 transcription and secretion (Wang et al., 
2006a). This was consistent with findings from Venkataraman and Kuo (2005) who 
reported increased Th2 cytokine production in KO T-cells. Suzuki et al. (2013) also showed 
that under LPS conditions, granulocyte and macrophage cells exhibited amplified 
production of IL-8 and TNF-α subsequent to stimulation with the GPR84 ligand 6-OAU. In 
addition, intravenous dosing with 6-OAU increased levels of CXCL1 in rodents (Suzuki et al., 
2013). Based on this literature, we anticipated that LPS-stimulated GPR84 KO cells would 
exhibit enhanced production of Th2-associated cytokines: IL-4, IL-5, IL-6, IL-10 and IL-13 
and decreased/unchanged production of Th1-associated cytokines: IFN-γ and IL-2 as well as 
decreased/unchanged levels of IL-12p40. We report non-detectable levels of IL-2 and IL-4 
in LPS stimulated WT and KO macrophages; IL-13 increased in WT cells and was non-
detectable in KO cells. There was also a robust up-regulation of IL-6, IL-10 and IL-12p40 in 
both genotypes. Although our findings do not entirely align with previous reports, we 
hypothesise that this is due to the use of different cell types where GPR84 may exert 
different functions. 
 
As a Gαi/o coupled receptor, GPR84 is likely to be involved in the differential regulation of 
subsets of cytokines and chemokines exerting both positive or negative modulatory effects, 
which is also supported by our findings in this chapter. In a study examining the differential 
regulation of LPS-induced cytokines and chemokines in peritoneal macrophages from mice 
lacking particular isoforms of Gαi proteins, it was found that the KO mice generally exhibited 
attenuated induction of cytokines/chemokines except for some notable cases (Fan et al., 
2007).  TNF-α, IL-6 and IL-10 were all decreased in Gαi2 and Gαi1/3 KO mice in contrast to 
WT littermates, whereas CCL3 and CSF2 were more greatly expressed in Gαi1/3 null mice and 
IL-1β remained unchanged in both Gαi2 and Gαi1/3 null mice (Fan et al., 2007). Therefore, it is 
apparent that Gαi proteins are capable of exerting both positive and negative regulatory 
effects on the expression of some pro-inflammatory cytokines and chemokines. Likewise, 
we observed equivalent or greater induction of pro-nociceptive mediators IL-1β, TNF-α, IL-
6, PTGS2, PTGES and NOS2 in the KO than in the WT and attenuated expression of IL-18, 
CCL2, CCL3 and CXCL5, suggesting that GPR84 exerts both positive and negative effects.  
 
3.4.5 Future work 
 
In this chapter we examined the role of GPR84 in two experimental models of inflammatory 
pain and established a modality specific behavioural phenotype in KO mice, but found no 
evidence for the contribution of microglial cells. Resident or recruited macrophages have 
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been reported to contribute to inflammatory pain by the release of mediators such as TNF-α, 
IL-1β, NGF, NO and PGE2 (Marchand et al., 2005). Experimental depletion or recruitment of 
these cells has been shown to significantly reduce or enhance zymosan and acetic acid 
induced pain (Ribeiro et al., 2000) while intraperitoneal administration of supernatants 
from LPS stimulated macrophages is hyperalgesic (Thomazzi et al., 1997). Furthermore, 
during an inflammatory response macrophage cells also contribute to the recruitment and 
activation of other immune cell types such as neutrophils (Souza et al., 1988). Therefore, it 
would be interesting to characterise the peripheral macrophage response in WT and KO 
mice via examining immunohistochemical markers of macrophage cells (Iba1 and F4/80) in 
the hind paws of CFA treated mice as well as profile transcriptional changes between 
genotypes in spinal cord and hind paw tissue. In addition, we characterised the peripheral 
response by measuring paw oedema and found no differences between the genotypes. 
However, the extent of peripheral inflammation could be further investigated by measuring 
myeloperoxidase activity and carrying out an assessment of leucocyte infiltration into the 
hind paw. Since we have only achieved successful GPR84 staining after LPS treatment it may 
also be interesting to behaviourally assess WT and KO mice subsequent to intraplantar 
administration of LPS, in conjunction with examining GPR84 immunoreactivity and 
immunophenotypic changes of peripheral macrophages that have infiltrated the hind paw. 
 
As a pro-inflammatory receptor, it is likely that GPR84 may be involved in regulating the 
expression of subsets of mediators in response to an inflammatory insult. Therefore, the 
validation of CCL19 will need to be repeated alongside other top dysregulated genes (IL-18, 
CCL2, CCL3, CXCL5) in an independent group of animals, as this would prove instrumental 
in warranting further in vivo studies. Unfortunately, our examination was limited to a set 
selection of 92 genes and thus further studies profiling alternative mediators may prove to 
be more informative. The development of a selective agonist or antagonist would also 
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Signal transduction is performed via membrane proteins and vitally determines cellular 
homeostasis and activity. Under normal conditions, GPCRs exist in an equilibrium of 
conformations, which are altered upon ligand binding. Activating ligands (agonists) stabilise 
receptor conformation and promote signalling via the coupled heterotrimeric G-protein 
subunit, whereas inhibitory ligands (antagonists) stabilise conformations that decrease 
signalling. Such pharmacological tools have been widely exploited in experimental studies 
investigating the physiological role and signalling pathways of receptors in vitro and in vivo. 
Throughout this thesis, we have utilised transgenic mice to examine GPR84 in chronic pain 
mechanisms, and have been able to show that this receptor indeed contributes to the 
development and maintenance of pain-associated behaviours. However, a lack of 
commercially available agonists or antagonists selective for GPR84 has hindered further 
progression in the characterisation of this receptor. Therefore, in this chapter we assessed 
three putative ligands using two different functional assays to identify a selective agonist 
that could be used in further characterisation studies.  
 
GPR84 is an orphan receptor and its signalling pathway is currently unknown, with only a 
single study postulating that the free fatty acid, capric acid (CA), is the natural ligand that 
activates GPR84 in a Gαi/o -dependent pathway (Wang et al., 2006a). Based on this limited 
evidence we tested CA and two other ligands kindly provided by GSK/Convergence 
Pharmaceuticals (Embelin and CNV) for efficacy and selectivity in microglia and 
macrophage cells via Ca2+ and cAMP signalling assays. 
 
4.1.1 Calcium signalling in microglia and macrophages 
 
Calcium is a second messenger that regulates a range of cellular functions, including 
metabolism, secretion, proliferation, exocytosis and transcription (Kettenmann et al., 2011). 
Like any other eukaryotic cell, microglia and macrophages tightly control their intracellular 
Ca2+ concentration ([Ca2+]i), which is determined by a delicate balance between processes 
that introduce Ca2+ into the cell (channels, receptors, intracellular stores) and those that 
remove Ca2+ (buffers, pumps, exchangers) as summarised in Fig. 4.1. The influx and 
intracellular release of Ca2+ is a passive but gated function, whereas extrusion of Ca2+ from 
the cell or sequestration into intracellular stores is constitutive but energy-dependent 
(Moller, 2002).  
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In neurons, changes in [Ca2+]i  participates in electrical excitability (∼ -70 mV to ∼ +150 mV), 
neurotransmitter release and synaptic efficacy. In contrast, microglia and macrophages are 
non-excitable cells, meaning that they are unable to generate propagating electrical 
responses (action potentials). However, like neurons they express VGCCs and so are able to 
depolarise their membranes (∼ -70 mV to ∼ -10 mV) in response to external stimuli and 
thus can be considered as ‘internally Ca2+ excitable’. Generally, extracellular Ca2+ levels are 
20,000 fold higher than intracellular levels. In neurons Ca2+ signalling is at the fast end of the 
scale ranging from microseconds to milliseconds, with a resting [Ca2+]i of ∼100 nM that can 
rise to several μM (Clapham, 1995; Verkhratsky et al., 1998; Kettenmann et al., 2011). In 
non-excitable cells Ca2+ signalling is also a transient event, ranging from milliseconds to 
minutes, with a resting [Ca2+]i of ∼50 nM that can rise to several μM. This enables the cell to 
respond appropriately to extracellular signals, depending on the magnitude, duration and 
location of the Ca2+ signal. (Clapham, 1995; Moller, 2002). 
 
The tight regulation of Ca2+ influx during numerous physiological mechanisms underlying 
cell activation is mediated via VGCCs (L-type), or receptor-operated channels (ROCs) 
(ionotropic glutamate and purinergic receptors), which are triggered by membrane 
depolarisation or ligand binding, respectively (Moller, 2002; Kettenmann et al., 2011). 
Essentially, ion channels control the flow of ions across the cell membrane and hence 
influence intracellular voltage-gated channels, membrane potential and cell volume. 
Correspondingly, the modulation of these features affects many processes such as 
respiration, proliferation, migration, secretion and cell morphology (Eder, 2005). Evidence 
for the existence of microglial expressed VGCCs is limited to a single study, in which the 
authors demonstrated the presence of a current with properties similar to that of L-type 
Ca2+ channels in rat microglial cells (Colton et al., 1994). It was shown that administration of 
the L-type Ca2+ channel opener, BAY K8644, enhanced the inward Ca2+ current, whereas the 
L-type antagonist, nifedipine, reduced the current and the production of superoxide anions 
(Colton et al., 1994). It was thus proposed that this small VGCC current contributed to 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase synthesis of superoxide 
anions, which are cytoactive molecules released in response to infection or injury (Colton et 
al., 1994). The presence of L-type VGCCs has also been documented in macrophages where 
increases in [Ca2+]i during membrane depolarisation was dependent on external Ca2+ and 
blocked by nifedipine and verapamil whilst enhanced by BAY K8644 (Hijioka et al., 1992; 
Kong et al., 1992). Moreover, it has also been documented that non Ca2+ permeable voltage-
gated channels may participate in Ca2+ signalling. For example, K+ channels negatively 
regulate membrane potential, which enhances Ca2+ influx through non-selective cation 
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channels and intracellular stores, and in effect modulates functions such as proliferation and 
cell volume (Rouzaire-Dubois et al., 2000).  
 
ROCs, such as the ionotropic ATP receptors (P2X4 and P2X7), were first identified in rodent 
and human microglial cultures (McLarnon et al., 1999; Kettenmann et al., 2011). Activation 
of P2X receptors results in Na+ and Ca2+ influx and K+ efflux through non-selective cationic 
channels and subsequent membrane depolarisation (McLarnon, 2005). Low levels of ATP 
(micromolar range) activate P2X4 receptors while higher levels (millimolar range) also 
recruit P2X7 receptors. P2X7 receptors possess a large pore that is permeable to hydrophilic 
molecules of high molecular weights (> 600 Da) (Farber and Kettenmann, 2006b). 
Activation of these receptors produces a strong cellular depolarisation, a substantial 
increase in [Ca2+]i and p38/ERK mediated release of signalling molecules such as TNF-α 
(Suzuki et al., 2004; McLarnon, 2005; Farber and Kettenmann, 2006a). ATP-induced Ca2+ 
signalling may also be facilitated via inward rectifying K+ channels, as blocking these using 
barium attenuates Ca2+ levels (Franchini et al., 2004).  
 
 In non-excitable cells, Ca2+ signals are predominantly produced via metabotropic receptors 
and subsequent mobilisation of the second messenger IP3, which activates Ca2+ channels 
(IP3Rs) expressed by the endoplasmic reticulum (ER) (Verkhratsky and Parpura, 2013).  
The ER is a major Ca2+ store and consists of a membranous network that extends from the 
cell membrane through the cytoplasm to the nuclear envelope. Here, Ca2+ release is executed 
by several different types of endomembrane-resident Ca2+ channels, including the well-
characterised ryanodine receptors (RyRs) and IP3Rs. Microglial cells possess both types of 
Ca2+ channels, but while RyRs are currently considered less important, IP3R signalling 
pathways are the primary route for generating an increase in microglial [Ca2+]i (Kettenmann 
et al., 2011). IP3Rs are initiated via transduction pathways involving the activation of 
specific isoforms of PLC coupled to metabotropic GPCRs or receptor tyrosine kinases. For 
example, microglia express a number Bordetella pertussis toxin-sensitive heterotrimeric 
GPCRs for the chemokines CCL2 (CCR2), CCL3 and CCL4 (CCR1, 5, 9), CCL5 (CCR3) and 
fractalkine (CX3CR1) (Murdoch and Finn, 2000; Flynn et al., 2003). Activation of PLC results 
in the biosynthesis of DAG and IP3 from the membrane-bound lipid precursor, PIP2. While 
DAG goes on to activate PKC, soluble IP3 diffuses across the cytosol and binds to ER IP3Rs. 
This results in increased IP3Rs sensitivity to Ca2+ and the initiation of a biphasic Ca2+ signal; 
thus at low [Ca2+]i the receptor is activated but subsequent to calcium release, high [Ca2+]i 
inhibits the receptor (Murdoch and Finn, 2000; Kettenmann et al., 2011). In neurons, newly 
released Ca2+ binds to calmodulin (CaM), which possesses four high affinity Ca2+ binding 
sites. Upon formation of the Ca2+/CaM complex, CaM increases its affinity for target enzymes 
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such as Ca2+/calmodulin-dependent kinase kinase (CaMKK) and its substrates, 
Ca2+/calmodulin-dependent kinase (CaMK) I and IV, which are phosphorylated and 
activated by CaMKK (Soderling, 1999; Racioppi and Means, 2008). The CaMK cascade 
orchestrates the activity of transcription factors such as CREB and may cross-talk with other 
intracellular pathways. For example, CaMKIV can inactivate AC and thus reduce levels of 
cAMP and may also interact with the MAPK signalling pathways (Soderling, 1999). There 
are reports of the CAMK pathway in microglia and macrophage cells but a majority of 
evidence coincides with neurons (Sola et al., 1999; Suh et al., 2005; Racioppi and Means, 
2008, 2012; Racioppi et al., 2012). In immune cells the initiation of PKC and other Ca2+-
dependent kinases results in protein phosphorylation and a co-ordinated cascade of 
signalling events, which may also entail the activation of Ras and Rho proteins as well as 
PLCA2, PI3k and MAPK pathways (Murdoch and Finn, 2000). 
 
Following depletion of intracellular ER Ca2+ stores, which is sensed by stromal interaction 
molecules, Ca2+-permeable store-operated channels (SOCs) such as the calcium release-
activated Ca2+ channel (CRAC) and transient receptor potential channels (TRPM2,7; TRPC1-
7) are opened to aid the replenishment of Ca2+ levels (Hoth and Penner, 1992; Zhang et al., 
2005c; Feske et al., 2006; Worley et al., 2007). This mechanism is referred to as ‘capacitative 
Ca2+ influx’ and is employed by many non-excitable cells as the main route of Ca2+ entry 
(Putney, 1986, 1990; Semenova et al., 1999; Vig and Kinet, 2009; Gao et al., 2010; 
Verkhratsky and Parpura, 2013). Ca2+ entry in this manner tends to outlast the initial 
stimulus and thus provides a long-lasting influx that is crucial for regulating many aspects of 
microglial cell function such as morphology, proliferation, NO and cytokine production, 
antigen presentation, migration and phagocytosis (Farber and Kettenmann, 2006a; 
Kettenmann et al., 2011). This striking phenomenon was initially demonstrated in cultured 
microglia, where the activation of the P2Y2/4 receptors via supramaximal doses of ATP or 
UTP resulted in complete depletion of the ER Ca2+ store and the prolonged opening of SOCs 
that lasted for tens of minutes (Toescu et al., 1998). Similarly, BDNF and LPS exposure 
acting via TrkB and TLR4, respectively, also induced long-lasting SOC activation in microglia 
(Hoffmann et al., 2003; Mizoguchi et al., 2009). This persistent SOC mediated increase in 
[Ca2+]i is thought to perhaps account for the sustained elevation of basal [Ca2+]i and 
associated attenuation of evoked Ca2+ signals upon further stimulation (Moller et al., 2000; 
Hoffmann et al., 2003). A corresponding elevated [Ca2+]i profile has also been reported in 
cultured microglial cells incubated with toxic β-amyloid fragment (25-35) (Korotzer et al., 
1995) as well as microglial cells isolated from post-mortem brains of Alzheimer patients, 
which exhibited reduced ATP or platelet aggregating factor induced Ca2+ signals (McLarnon 
et al., 2005). Furthermore, LPS stimulation induces the release of many cytokines including 
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TNF-α, IL-1β, IL-6, IFN-γ and IL-12. Accordingly, application of TNF-α, IL-1β or IFN-γ to 
human microglial cells has been demonstrated to evoke sustained Ca2+ signals via TNFR1/2, 
IL-1R and IL-6R, respectively (Goghari et al., 2000; McLarnon et al., 2001; Franciosi et al., 
2002).  
 
Abnormal Ca2+ signalling as a result of aberrant SOC activity has been implicated in several 
human inflammatory diseases such as IBS and allergy (Parekh, 2010). Interestingly, a recent 
study demonstrated that YM-58483, which inhibits SOCs in immune cells, alleviated CFA 
and SNI behavioural hypersensitivity as well as formalin-induced nociceptive behaviour, in 
addition to suppressing the release of pro-inflammatory mediators (Gao et al., 2013). Thus, 
the development of SOC channel inhibitors as a means to control aberrant Ca2+ activity could 
provide considerable clinical benefits for patients suffering from chronic inflammatory 
diseases and/or pain.  
 
Ca2+ signalling in microglia/macrophages varies in magnitude as well as temporally and 
spatially (Moller, 2002; Kettenmann et al., 2011). Rapid Ca2+ signals are usually generated by 
Ca2+ released from internal stores and the fast opening of membrane channels is followed by 
a rapid decay. Other transient [Ca2+] signals are characterized by an extended plateau phase 
and are attributed to an initial Ca2+ release and a subsequent Ca2+ influx through ROCs or 
SOCs, which play an important role in down-stream cellular events such as mediator release, 
transcriptional regulation and cell motility (Moller, 2002). More complex oscillatory Ca2+ 
signals are generated by Ca2+ release from internal stores and subsequent opening of SOCs, 
whereas slow rising Ca2+ signals are a result of modulatory effects on Ca2+ extrusion 
mechanisms (Moller, 2002). Subsequent to a cellular response and an elevation in [Ca2+]i, 
extrusion of Ca2+ is accomplished by plasma membrane Ca2+-ATPase (PMCA) pumps, which 
are facilitated by Na+/Ca2+ exchangers (NCX) (Carafoli, 1994; Nagano et al., 2004; Lytton, 
2007; Staiano et al., 2013). These exchange proteins utilise the Na+ gradient produced by 
Na+ pumps to rapidly expel Ca2+ into the extracellular environment. In addition, Ca2+ may 
also be sequestered into the ER or mitochondria (Moller, 2002). Ca2+ -ATPase located on the 
ER membrane actively transports Ca2+ into the ER, whereas mitochondria act as potent Ca2+ 
buffers and uptake cytosolic Ca2+ via uniporters, which are highly selective integral 
membrane proteins (Carafoli, 1994; Gilabert and Parekh, 2000; Moller, 2002; Nagano et al., 









Figure 4.1: Intracellular calcium signalling 
 
Simplified schematic of Ca2+ signalling in microglia and macrophage cells. Ca2+ may enter via ROCs 
(P2X4/7, AMPAR), VGCCs (L-type) and SOCs (TRPM2,7, TRPC1-7, CRAC). Activation of GPCRs (H1, B1/2, 
P2y2/4, chemokine receptors) or tyrosine kinase receptors (TrkB) leads to the mobilisation of Ca2+ via 
IP3Rs. Cytokine receptors and TLR4 also initiate Ca2+ release but the mechanisms are unclear. Ca2+ is 
extruded from the cell via Ca2+-ATPase pumps and Na+/Ca2+ exchangers (NCX) and may also be 
sequestered into the ER or mitochondria. 
 
 
4.1.2 Cyclic AMP signalling in microglia and macrophages 
 
Cyclic AMP was the first ubiquitous second messenger to be discovered and plays a crucial 
role in many cellular functions in response to hormones and neurotransmitters (Sutherland 
and Rall, 1958). Intracellular levels of cAMP are tightly regulated by two key enzymes, ACs 
and cyclic nucleotide phosphodiesterases (PDEs), which are involved in the biosynthesis or 
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AC is down-stream of the activation of GPCRs coupled to stimulatory Gαs by ligands such as 
epinephrine (β2), adenosine (A2a), histamine (H2) and PGE2 (EP2) (Peters-Golden, 2009; 
Kettenmann et al., 2011). Subsequent to ligand binding, GPCRs undergo a conformational 
change and initiate the activation of a G-protein. This leads to the release of αs from the αβγ 
heterotrimeric complex, which binds to AC and catalyses the formation of cAMP from ATP. 
Newly synthesised cAMP then binds to PKA, which consists of a symmetrical complex of two 
regulatory and two catalytic subunits. Binding of cAMP to the two regulatory subunits 
initiates subunit dissociation and passive diffusion into the nucleus (Taylor et al., 1992). In 
turn, activated PKA phosphorylates numerous target proteins such as CREB, which binds to 
the conserved cAMP response element expressed within the promoter regions of many 
cAMP-responsive genes. CREB may then form a complex with its transcription co-activator, 
CBP (Mayr and Montminy, 2001). Alternatively, cAMP may also bind to guanine-nucleotide-
exchange proteins, Epac-1 and 2, which are involved in the activation of the monomeric 
GTPase, Rap-1, which binds to B-Raf (Bos, 2006). The formation of the B-Raf-Rap-1 complex 
has been implicated in the activation of MAPKs such as ERK as well as the regulation of 
CREB-mediated gene transcription in various cell types including microglia and 
macrophages (Wang et al., 2006b). The cAMP/CREB pathway is summarised in Fig. 4.2. 
 
Elevation in intracellular cAMP generally suppresses innate immune function such as 
phagocytosis, microbe killing and the production of pro-inflammatory mediators, whilst 
promoting the release of anti-inflammatory mediators (Bourne et al., 1974; Serezani et al., 
2008; Peters-Golden, 2009). Upon activation, cells of the innate immune system 
(microglia/macrophages) produce an array of pro-inflammatory mediators. Many immune 
system molecules such as chemokines and cytokines act through inhibitory GPCRs and 
reduce the production of cAMP via preventing AC activity. However, the extent to which the 
immunostimulatory effects of these molecules depend on a reduction in intracellular cAMP 
is not clear (Serezani et al., 2008). Elevation of cAMP by mediators such as PGE2 alters the 
release of many cytokines/chemokines and lipid mediators from ‘activated’ microglia or 
macrophage cells. For instance, the expression of pro-inflammatory TNF-α, IL-6, IL-12, 
CCL3, CCL4 and LTB4 is reduced, while levels of anti-inflammatory IL-10 and IL-6 are 
enhanced (Martin and Dorf, 1991; Aloisi et al., 1997; Caggiano and Kraig, 1999; Prinz et al., 
2001; Feng et al., 2002; Iwasaki et al., 2003; Uchiya et al., 2004; Aronoff et al., 2005; Aronoff 
et al., 2006). Notably, Aronoff and colleagues (2005) showed that this mechanism was PKA-
dependent and Epac-1-independent and it was later found that PKA can directly regulate 
NF-κB (Wall et al., 2009). Aronoff et al. (2005) also demonstrated that pre-treatment with 
PGE2 or an Epac-1 agonist prevented phagocytosis, whereas prior exposure of alveolar 
macrophages to a PKA inhibitor had no effect. Phagocytosis is a highly co-ordinated process 
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that entails the re-arrangement of the cytoskeleton and membrane upon complement 
receptor (CR) and FCγ receptor recognition of microbial particials (Gordon, 2007). An 
increase in cAMP levels suppresses CR and FCγ receptor mediated phagocytosis in an Epac-
1-dependent manner and to a lesser extent PKA (Aronoff et al., 2005). However, this can 
very much depend on the cell type; both PKA and Epac-1 have been reported to inhibit 
phagocytic activity in microglia and peritoneal macrophages, but in monocytes this was 
found to be solely dependent on PKA (Bryn et al., 2006; Makranz et al., 2006). Elevated 
levels of intracellular cAMP also suppress microbicidal activity by down-regulating NADPH 
oxidase activity and hence the production of reactive oxygen intermediates such as 
hydrogen peroxide (Aronoff et al., 2005). Accordingly, pre-treatment with PGE2, Epac-1 or 
PKA agonists inhibited the ability of alveolar macrophages to successfully kill ingested 
microbes (Aronoff et al., 2005). The role of cAMP in the regulation of inducible NO synthase 
and NO production is contradictory; while some groups have reported a facilitatory role of 
cAMP others have reported an inhibitory effect (Mustafa, 1998; Chen et al., 1999). Likewise, 
conflicting evidence also applies to phagolysosome maturation. For example, Muschel et al. 
(1977) showed that PKA was necessary for phagosomal acidification, whereas Kalamidas et 
al. (2006) demonstrated that elevated cAMP levels reduced phagolysosome formation and 
























Figure 4.2: Cyclic AMP signalling in microglia and macrophages 
 
Schematic illustrating the regulation of intracellular cAMP in microglia and macrophage cells. 
Activation of GPCRs leads to either the stimulation (Gαs) or inhibition (Gαi) of AC mediated synthesis 
of cAMP. Downstream effectors of cAMP (PKA and EPAC1/2) initiate the phosphorylation and 
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4.1.3 Putative GPR84 ligands 
 
This chapter investigates the efficacy and selectivity of three GPR84 ligands in microglia and 
macrophage cells. The signalling pathway of GPR84 is unknown so we utilised Ca2+ and 
cAMP signalling assays to examine changes in the intracellular concentrations of two well-
characterised second messengers that are down-stream of most classes of heterotrimeric 
GPCRs. There is very little data available on selective GPR84 agonists and antagonists. 
Embelin and CNV were identified as potentially interesting agonists in a series of screening 
assays performed by GSK/Convergence Pharmaceuticals (proprietary GSK/Convergence 





Embelin (2,5-dihydroxy-3-undecyl-1,4-benzoquinone) is a naturally occurring alkyl-
substituted hydroxybenzoquinone derived from the Embelia ribes BURM plant (Myrsinaceae 
family). Strikingly, embelin has demonstrated anti-inflammatory properties in several 
models of acute and chronic inflammation as well as analgesic, anti-tumor, anti-convulsant 
and neuroprotective effects in animals (Nikolovska-Coleska et al., 2004; Kalyan Kumar et al., 
2011; Kumar et al., 2011; Mahendran et al., 2011b; Mahendran et al., 2011a; Thippeswamy 
et al., 2011b; Thippeswamy et al., 2011a). Despite its numerous well-documented 
pharmacological effects in vivo, little is understood about its molecular targets. However, it 
has been postulated that embelin mediates its effects via the inhibition of IκBα kinase and 
subsequent modulation of NF-κB, which is in agreement with its role in the regulation of 
genes associated with inflammation, tumorgenesis, proliferation and apoptosis (Ahn et al., 
2007). In addition, embelin exerts inhibitory effects on X chromosome-linked inhibitor-of-
apoptosis protein, which is thought to contribute to its anti-tumor properties (Nikolovska-




CA is a MCFFA of a carbon chain length of 10 and is derived from animal fats and oils. 
Dietary fatty acids are the precursors for eicosanoids and other lipid mediators and were 
solely regarded as a source of calories. However, it is now well recognised that FFAs can 
behave as direct signalling molecules via cell surface GPCRs and exert many regulatory 
effects on metabolism and the immune system (Hwang, 2000). FFAs can be broadly 
classified into three groups depending on the length of their carbon backbone: short-chain 
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fatty acids (SCFFAs; 1-6 carbon atoms), MCFFAs (7-12 carbon atoms) and long-chain fatty 
acids (LCFFAs; 12 + carbon atoms) (Ulven, 2012). FFAs have obtained a lot of interest due to 
their association with diseases such as obesity and diabetes (Evans et al., 2004), which led 
to the identification of several GPCR receptors activated via lipids of various chain lengths 
(Ichimura et al., 2009). These include GPR40 (FFAR1), which is activated via LCFFAs 
(Briscoe et al., 2003), GPR41 (FFAR3) and GPR43 (FFAR2), which are activated by SCFFAs 
(Brown et al., 2003; Ulven, 2012) and GPR120, which is activated via LCFFAs (Hirasawa et 
al., 2005). GPR84 is thought to be activated by MCFFAs such as CA, which was shown to 
inhibit forskolin-induced cAMP production in transfected CHO cells (Wang et al., 2006a). 
MCFFAs have also been shown to activate leucocytes via the modulation of Ca2+ and PKC 
signalling as well as induce NF-κB transcription and the expression of pro-inflammatory 
markers such as COX-2 in RAW 264.7 cells, suggesting a contributory role in inflammation 
(Hwang, 2000; Lee et al., 2001; Wanten et al., 2004; Wanten and Naber, 2004; Wanten, 




CNV (MW 268) is a novel GPR84 ligand identified by GlaxoSmithKline, which has exhibited 
characteristics of a full agonist in heterologous in vitro systems (proprietary GSK/ 














Chapter 4 - GPR84 Cell Signalling 
 
201 
4.1.4 Fatty acid metabolism 
 
Fatty acids are an important source of metabolic energy and can be stored as triglycerides 
until needed for oxidation. They are also substrates for membrane biogenesis and form the 
necessary building blocks for structurally complex glycolipid and phospholipid cell 
membrane components. Furthermore, their down-stream metabolites such as eicosanoids 
and resolvins serve as key intracellular signalling molecules that execute a number of 
physiological roles.  
 
Fatty acids are hydrophobic molecules composed of long saturated, monounsaturated 
(MUFA) or polyunsaturated (PUFA) hydrocarbon chains and a terminal carboxylate group. 
Whilst saturated fatty acids have no double bonds between any of the carbon atoms, 
unsaturated fatty acids have double bonds between adjacent carbon atoms; MUFAs contain 
a single double bond and PUFAs have multiple. Both saturated and unsaturated fatty acids 
can be further sub-categorised according to their carbon chain lengths (Yaqoob, 2004; 
Kalish et al., 2012). 
 
There are three main families of PUFAs: omega (ω) -3, derived from α-linolenic acid (18 : 
3n-3); ω-6, derived from linoleic acid (18 : 2n-6); and ω-9, derived from oleic acid (18 : 1n-
9) (Kalish et al., 2012). As linoleic acid and α-linolenic acid cannot be synthesised de novo 
(unlike oleic acid) and can be metabolised to form all downstream fatty acids, they are 
classified as essential dietary fatty acids. These two main families of PUFAs are uptaken by 
virtually every cell, possibly via diffusion or protein mediated translocation across the 
plasma membrane. Once inside a cell they bind to fatty acid binding proteins and undergo a 
series of desaturation and elongation steps. In humans, the three desaturase enzymes, Δ5, Δ6 
and Δ9, insert double bonds at the corresponding 5th, 6th and 9th carbon atom in a fatty acid 
chain. The metabolism of α-linolenic acid, linoleic acid and oleic acid is a competitive 
process as all three fatty acids compete for the same Δ5 and Δ6 desaturases and elongases 
(Kalish et al., 2012). Linoleic acid is metabolised by Δ6 to γ-linoleic acid, which is elongated 
to form dihomo-γ-linoleic acid and subsequently converted by the Δ5 desaturase enzyme to 
arachidonic acid. Similarly, α-linolenic acid is converted to eicosapentaenoic acid via Δ6 
desaturation, elongation and Δ5 desaturation. Eicosapentaenoic acid may undergo further 
elongation, desaturation and β-oxidation to form docosahexaenoic acid, however, very little 
α-linolenic acid proceeds along the entire metabolic pathway. As linoleic acid is abundantly 
found in vegetable oils, whilst α-linolenic acid is present in green leafy vegetables, vegetable 
and seed oils, the former pathway is more quantitatively important than the latter pathway. 
Finally, oleic acid may be metabolised into mead acid (Yaqoob, 2004; Kalish et al., 2012). 
Chapter 4 - GPR84 Cell Signalling 
 
202 
As previously mentioned, membrane-bound PUFAs serve as precursors to multiple second 
messengers, which may be pro- or anti-inflammatory. Eicosanoids are a dynamic class of 
signalling molecules that regulate a number of crucial biological functions such as host 
defence, vasoactivity and reproduction and are classically divided into PGs, prostacyclins 
(PGI2s), thromboxanes (TXA2s) and leukotrienes (Funk, 2001). These second messengers 
are not stored in cells but are synthesised upon demand by three key enzymes: COX, 
lipoxygenase and cytochrome P450. COX metabolises arachidonic acid, eicosapentaenoic 
acid and dihomo-γ-linoleic acid into pro-inflammatory PGs and TXA2, whereas lipoxygenase 
mediates the synthesis of leukotrienes and anti-inflammatory lipoxins (see Fig. 4.4). Lastly, 
cytochrome P450 converts arachidonic acid into pro-inflammatory hydroxyeicosatetraenoic 
acid or anti-inflammatory epoxyeicosatrienoic acid. In addition, docosahexaenoic acid may 
be further metabolised to form the D-series of resolvins and protectins, which play immuno-
protective roles during inflammation (Kalish et al., 2012).  
 
Subsequent to nerve injury or inflammatory insult, COX is up-regulated in damaged nerve 
axons or tissues as well as in resident/infiltrating immune cells (Ma and Eisenach, 2002; 
Muja and DeVries, 2004; Durrenberger et al., 2006; Ma et al., 2012). This induces the 
production of pro-nociceptive PGs in nerve terminals and non-neuronal cells and the 
consequential development of behavioural hypersensitivity. PG acts via its four EP receptors 
expressed in DRG neurons to directly excite nociceptors and indirectly stimulate the release 
of SP and CGRP from nociceptors and their peripheral and central terminals (Vasko, 1995; 
Vanegas and Schaible, 2001). As previously described (Chapter 3), SP and CGRP are key 
mediators of neurogenic inflammation and nociception in the periphery, whilst centrally 
they may directly excite nociceptive specific dorsal horn neurons and thus contribute to 
central sensitisation and hyperalgesia. Accordingly, systemic or local administration of 
selective or non-selective COX inhibitors or EP1/EP4 antagonists alleviates neuropathic and 
inflammatory pain-associated behaviours in rodents and reduces the production of SP and 
CGRP in DRG neurons and the spinal cord (Kawahara et al., 2001; Ma and Eisenach, 2002, 
2003a, b; Suyama et al., 2004; Staton et al., 2007; St-Jacques and Ma, 2011). Interestingly, in 
immune cells PG production exhibits immunosuppressive or anti-inflammatory effects as 
discussed in section 4.1.2. In addition, DHA-derived mediators such as D-series resolvins, 
docosatrienes and neuroprotectins, which are produced by COX-2, also exert anti-
inflammatory actions and have been shown to be protective in various models of 
inflammation (Kalish et al., 2012). It is possible that the effects of these mediators are 
dampened in the presence of pathology and are thus potential therapeutic targets. 
 
 






Figure 4.4: The biosynthesis of eicosanoids 
 
Schematic presenting the pathways involved in the formation of eicosanoids from arachidonic acid. 
COX metabolises arachidonic acid, eicosapentaenoic acid and dihomo-γ-linoleic acid into PGs and 






The use of pharmacological tools provides a valuable method in investigating the direct role 
of a particular receptor in a physiological system. Therefore, the aim of this chapter was to 
identify a GPR84 agonist that could be utilised in further studies to aid our understanding of 
the role of this receptor in chronic pain mechanisms. We explored the efficacy and 
selectivity of three potential GPR84 ligands, embelin, CA and CNV, in microglia and WT and 
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Breeding and genotyping of GPR84 WT and KO animals was carried out as described in the 
methods section in Chapter 2. Randomly selected mixed sex and age-matched mice weighing 
20-25g (7-14 weeks old) were used for cell culture. Mice were housed individually or in 
groups (no more than 4 per cage) in standard environmental conditions (12 hour light/dark 
cycle) with ad libitum access to food and water. Animal husbandry and experiments were 
carried out in a non-sterile housing environment in accordance with the United Kingdom 
Animals (Scientific Procedures) Act 1986.  
 
4.2.2 Microglial cell culture and stimulation 
 
Mixed primary cultures of glial cells were isolated from spinal cord tissue of P7 rat pups. 
Cultures were maintained for two weeks at 37°C (5% CO2/95% O2) in medium containing 
1% penicillin-streptomycin (Sigma, UK) and 15% FBS (Invitrogen, UK), which was changed 
every 2-3 days. Two weeks later microglial cells were harvested via the forceful shaking of 
the flask and plated in 24 well plates at a density of 5 x 104 cells/well. Forty eight hrs later 
the microglial cells were stimulated for 3 hrs with LPS (1 μg/mL; Sigma, UK) (Clark et al., 
2010a) to up-regulate the expression of GPR84. For control wells, culture medium was 
replaced with fresh medium and the stimulation step was omitted. 
 
4.2.3 Resident and B-GEPM culture and stimulation 
 
For the calcium-imaging assay resident peritoneal macrophages were cultured. For the 
cAMP assay B-GEPMs were cultured as previously described in Chapter 3 as a higher yield of 
macrophages were required for this assay. Briefly, mice were culled via neck dislocation, 
and the layer of skin covering the peritoneum was wiped with 70% ethanol. A total volume 
of 20 mL of sterile cold PBS (Invitrogen, UK) containing 3 mM EDTA (Invitrogen, UK) was 
injected into the peritoneal cavity using a 25 G needle. After gentle massaging the buffer was 
retrieved in 14 mL Falcon tubes and spun to obtain a pellet. Cells were then re-suspended 
and plated in DMEM (Invitrogen, UK) with 10% FBS (Invitrogen, UK) and incubated at 37°C. 
The cells were washed 2 hrs after plating and the medium was replaced. Forty-eight hrs 
later, macrophage cells were stimulated for 3 hrs with LPS (1 μg/mL; Sigma, UK) to up-
regulate the expression of GPR84. The culture medium of control wells was replaced with 
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fresh medium without subsequent stimulation. For B-GEPMs the LPS stimulation protocol 
was carried out 24 hrs after washing.  
 
4.2.4 Cell preparation and immunocytochemistry 
 
Microglia and macrophage cells were fixed with 4% PFA (VWR, UK) in 0.1 M PB for 30 mins 
followed by incubation with ice-cold methanol (VWR, UK) for 23 mins. Subsequently cells 
were washed three times with PBS and incubated for 2 hrs with primary antibody solution 
for Iba-1 (rabbit anti-Iba1, 1:1000; Wako Chemicals, Germany), followed by a 45 min 
incubation period with the secondary antibody solution donkey anti-rabbit Cy3 (1:1000; 
Stratech, UK). All antibodies were prepared in PBS supplemented with 0.1% Triton X-100 
(VWR, UK) and 0.2% sodium azide (Sigma, UK). Slides were carefully cover slipped with 
Vectashield Mounting Medium with DAPI (Vector Laboratories, UK), nail-varnished and 
dried. Images were visualised and captured using a Zeiss Axioplan microscope (Zeiss, UK).  
 
Cell cultures from the naïve peritoneal cavity contain ∼ 40% macrophages, whilst elicited 
cultures contain 40-45% macrophages; purity increases to almost 80-90% by adherence in 
both types of culture. Eosinophils and neutrophils are the main cell types that contaminate 
peritoneal macrophage cultures and can affect the results of in vitro assays, leading to data 
misinterpretation (Fauve et al., 1983; Misharin et al., 2012). Mixed primary cultures of glial 
cells consist of heterogenous populations of astrocytes, oligodendrocytes and microglial 
cells and may become contaminated with fibroblasts. Upon adherence microglial cultures 
have a high purity in the range of ∼ 95-99% (Ni and Aschner, 2010). In our studies, we 
visually verified the purity of microglia and macrophage cell cultures by examining Iba1 
staining relative to DAPI expression as shown in Fig. 4.5. We found that almost all nuclear 
staining (DAPI) was co-localised with Iba1, indicating > 95% purity. 
 





Figure 4.5: Verification of macrophage and microglia culture purity 
 
The purity of microglia and macrophage cell cultures was verified via observing colocalisation of 
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4.2.5 Calcium imaging 
 
Control or LPS stimulated microglia and macrophage cells were incubated for 60-90 mins at 
37°C with the Ca2+ indicator Fura-2AM (2 μM; Invitrogen, UK) in HBSS (Invitrogen, UK) 
containing probenecid (0.5 M; Sigma, UK). Cells were subsequently transferred to a 
perfusion chamber attached to an inverted microscope (Nikon, UK) equipped with a 
monochromator (Photon Technology, UK). Cells were washed and fluorescence was 
measured at 340 nm and 380 nm excitation and 510 nm emission. The baseline level was 
defined as the average [Ca2+] -based ratio taken over the first 2-5 mins of each run under 
continuous perfusion (4 mL/min) with HEPES buffer solution (hydroxyethyl 
piperazineethanesulfonic acid; 10 mM; 7 mM glucose; pH 7.4; Invitrogen, UK) prior to drug 
challenge. Calcium responses to embelin (Sigma, UK) or CA (Sigma, UK) were subsequently 
tested. Each dose was tested on a separate run and continuously perfused for a duration of 1 
min followed by a 5 min wash out period using HEPES buffer.  Ionomycin (Sigma, UK) or 
ATP (Sigma, UK) were used as positive controls to define viable microglia or macrophage 
cells, respectively. All experiments were conducted at room temperature. Results are 
expressed as a change (Δ) in the F340/380 emission ratio, which is proportional to the 
change in [Ca2+]i, where ΔF340/380 = max drug F340/380 – average baseline F340/380 
(Fig. 4.6). In order to be defined as a responder, a cell’s ratio change had to be 10% greater 
than the average baseline value of the cells examined per run, and respond positively to the 




Figure 4.6: Diagram illustrating how ΔF340/380 is calculated 
 
Drug or positive control response = maximum drug or positive control response – average baseline 
Vehicle response (HEPES buffer) = maximum baseline value – average baseline   
Baseline, BL; Maximum response, MaxR 
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4.2.6 cAMP-screen direct chemiluminescent ELISA 
 
Bio-gel elicited GPR84 WT and KO macrophage cells were harvested as previously described 
in Chapter 3 and plated in cAMP-Screen Direct® pre-coated 96-well assay plates (Invitrogen, 
UK) at a density of 150,000 cells/well. Two hrs later the cells were washed, replenished 
with fresh DMEM (Invitrogen, UK) and left overnight to settle. All cell stimulation protocols 
were carried out 24 hrs later and done in FBS-free DMEM (Sigma, UK) at 37°C.  In order to 
increase GPR84 expression, WT cells were stimulated with LPS (1 μg/ml; Sigma, UK) for 3 
hrs prior to incubation with a GPR84 ligand. WT and KO cells were then incubated for 20 
min with embelin (Sigma, UK), CA (Sigma, UK) or CNV0022600A (CNV; GSK/Convergence 
Pharmaceuticals, UK), followed by 20 mins incubation with forskolin (R&D Systems, UK). 
Each GPR84 ligand was tested on a separate plate. Control wells were incubated with ligand 
solvents DMSO (0.005-0.1%), methanol (0.002%) and ethanol (0.002%). 
 
To terminate the assay the media was aspirated and cells were incubated for 30 mins with 
60 μl of lysis buffer at 37°C. During this time cAMP standards ranging from 0.006 to 6000 
pM were prepared in lysis buffer. After lysis, 60 μl of each standard concentration was 
added to designated wells followed by the addition of 30 μl of cAMP-alkaline phosphatase 
solution and 60 μl of anti-cAMP antibody to every well. Following 1 hr incubation, the plate 
was washed 6 times with wash buffer and 100 μl of disodium 2-chloro-5-(4-methoxyspiro 
[1,2-dioxetane-3,2'-tricyclo [3.3.1.13,7] decan]-4-yl) phenyl phosphate (CSPD)®/Sapphire-
II™ RTU substrate/enhancer solution was added for 30 min. Finally, the luminescence signal 
for each well was measured using a standard luminometer (1 sec/well) and the cAMP 
concentration was calculated via extrapolation from the standard curve (see Fig 4.7). All 
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4.2.7 Data and statistical analysis 
 
All data were analysed using SigmaPlot 12.3 and SigmaStat software. For single 
comparisons between two groups, a paired Student t-test was applied. For multiple 
comparisons, a one-way ANOVA was used with SNK post hoc test to determine individual 
group differences. For non-parametric data, Kruskal-Wallis one-way ANOVA on ranks was 
carried out, with Dunn’s method. In all cases the data is presented as the mean ± SEM and p 
< 0.05 was set as the statistical significance level. 
  





4.3.1 Calcium fluorometry  
 
Although the use of transgenic animals has been instrumental in our studies, there is the 
possibility of compensatory mechanisms operating to mask phenotypes. For this and other 
practical factors, the development of pharmacological tools could complement experiments 
and further advance our understanding of the role of GPR84 in chronic pain mechanisms. 
Currently, there are no commercially available compounds for GPR84 modulation and there 
is little evidence of a definitive signalling pathway for this receptor. Only a single study 
suggests that GPR84 is sensitive to MCFFAs with carbon chain lengths of 9-14, particularly 
CA. In this study Wang and colleagues showed that CA-mediated activation was dependent 
on a Pertussis toxin-sensitive Gαi/o coupled pathway, which produced a corresponding 
decrease in cAMP levels in transfected CHO cells (Wang et al., 2006a). MCCFAs have also 
been shown to modulate Ca2+ responses in leucocytes (Wanten et al., 2004; Wanten and 
Naber, 2004; Wanten, 2006) and so based on this evidence, we tested the efficacy and 
selectivity of CA in addition to two other agonists provided by GSK/Convergence 
Pharmaceuticals (embelin and CNV) via Ca2+ and cAMP signalling assays.  
 
Intracellular Ca2+ is central to a multitude of cellular processes and may be studied using 
sensitive fluorescent Ca2+ indicators. These indicators can only bind to freely diffusible Ca2+ 
ions, however, a majority of intracellular Ca2+ is bound to various buffers, depending on cell 
type and compartment. In addition, because chemical Ca2+ indicators may themselves act as 
buffers and hence affect Ca2+ signalling kinetics, the type of Ca2+ indicator must be chosen 
with regards to spectral characteristics and binding properties (Paredes et al., 2008). In our 
studies, we utilised Fura-2 engineered with acetoxymethyl (AM) esters, which is one of the 
most popular ratiometric dyes. Addition of the ester permits sufficient hydrophobicity for 
membrane permeability so that the dye can passively diffuse into the cell when added 
extracellularly. Subsequent to loading esterases cleave the ester group, trapping the dye 
intracellularly and thus only alive cells are labelled (Paredes et al., 2008). Upon Ca2+ binding 
the Fura-2 peak absorbance shifts from 380 nm (unbound state) to 340 nm (Ca2+ bound 
state) while fluorescence is emitted at a peak wavelength of 510 nm. Ratiometric indicators 
enable accurate quantification of [Ca2+]i and also control for uneven dye loading and changes 
in cell size (Paredes et al., 2008). As Fura-2 is resistant to photobleaching and has a high 
affinity for Ca2+, less dye can be used thus reducing buffering and cytotoxicity (Di Virgilio et 
al., 1988). However, similar to other types of chemical indicators Fura-2 can become 
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compartmentalized, which is prevented via the addition of probenecid; an organic anion 
transport inhibitor (Di Virgilio et al., 1988). 
 
4.3.2 ATP induces robust Ca2+ responses in microglial cells, whereas embelin 
exhibits poor efficacy  
 
We initially tested the system setup and the ability to obtain calcium responses in microglial 
cells using ATP, which is a well-documented second messenger that generates Ca2+ 
responses via its ionotropic and metabotropic receptors (Farber and Kettenmann, 2006b). 
An intracellular Ca2+ response is represented as ΔF340/380 emission ratio. The ΔF340/380 
ratio for individual cells was calculated by subtracting the average baseline F340/380 ratio 
of the cells examined per run, from the maximum F340/380 ratio upon stimulation. To 
accurately quantify Ca2+ responses we employed two criteria in the analysis of the data; a 
cell was regarded as a responder only if it a) had an average ΔF340/380 value greater than 
10% of the average baseline F340/380 ratio of cells examined in a run and b) produced a 
Ca2+ response to the positive control, ionomycin. Quantification of responders was 
performed by calculating the number of cells that responded to a challenge as a percentage 
of the total number of cells that responded to ionomycin for each run. Ionomycin is an 
ionophore produced by the bacterium Streptomyces conglobatus and acts directly on 
intracellular Ca2+ stores to raise [Ca2+]i, and thus provides an excellent tool for our studies 
(Morgan and Jacob, 1994).  
 
We found that perfusion (4 mL/min) of 100 μM ATP elicited a strong Ca2+ response (Fig. 
4.8A, B). Quantification of the number of responders revealed that almost all viable cells 
examined responded to ATP (93.4 ± 3.5%) and showed a significant ΔF340/380 (0.4 ± 0.08) 
compared to vehicle (0.04 ± 0.01; Fig. 4.8C, D). Following validation of our assay by 
demonstrating ATP-induced Ca2+ transients in microglial cells in accordance with literature 
(Walz et al., 1993; McLarnon et al., 1999; Moller et al., 2000; Hoffmann et al., 2003; 
McLarnon, 2005), we investigated responses to embelin, a compound previously shown to 
possess a high affinity for GPR84 in transfected CHO cells (proprietary GSK data). We report 
that embelin produced small Ca2+ responses in microglial cells as illustrated by image (B) 
and the example trace (E) from a single cell response (Fig. 4.9). Quantification of the 
percentage of responders showed that there was a non-significant number of cells 
responding to embelin at 1 μM (10.7 ± 4.7%), 50 μM (12.5 ± 5.6%) and 100 μM (7.8 ± 3.8%; 
Fig. 4.9F) and only at the 1 μM dose (0.2 ± 0.05) was there a significant increase in the Fura-
2AM based Ca2+ signal compared to vehicle (0.02 ± 5x10-6; Fig. 4.9G). The lack of consistency 
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and concentration dependence suggests that embelin does not effectively evoke receptor-
mediated Ca2+ transients in microglial cells.  
 
4.3.3 ATP induces robust Ca2+ responses in GPR84 WT and KO macrophages  
 
Alongside our studies in microglial cells we also investigated embelin and capric acid 
selectivity for GPR84 by examining Ca2+ responses in WT and KO peritoneal macrophages. 
To confirm we could detect Ca2+ signals from this cell type we examined the responses of 
WT and KO macrophage cells to the positive control ATP, under non-stimulated or LPS 
simulated conditions (1 μg/mL; Fig. 4.10A, B). We observed that both WT and KO 
macrophages produced robust Ca2+ responses represented by the ΔF340/380 ratio (WT: 
ATP, 0.15 ± 0.01 vs vehicle, 0.02 ± 0.001; KO: ATP, 0.17 ± 0.02 vs vehicle, 0.02 ± 0.002), 
which was significantly enhanced by LPS (WT: ATP, 0.23 ± 0.02; KO: ATP, 0.24 ± 0.02; Fig. 
4.10B). Virtually all cells examined in each run responded to ATP under non-stimulated 
(WT: 93.7 ± 5.2%; KO: 99.1 ± 0.4%) and LPS stimulated conditions (WT: 96.3 ± 1.4%; KO: 
99.3 ± 0.4%; Fig. 4.10A). These observations are interesting, considering that previous 
groups have reported attenuated Ca2+ responses to ligands (including ATP) subsequent to 
LPS stimulation (Moller et al., 2000; Hoffmann et al., 2003). However, our protocol entailed 
a much shorter incubation period compared to these studies, which could pose as a reason 
for this discrepancy. Notably, there were no significant differences between genotypes or 
non- and LPS stimulated groups, suggesting that KO macrophages are just as capable as 
their WT controls in generating successful ATP induced Ca2+ responses. Therefore, ATP is an 
excellent positive control for exploring ligand selectivity in WT and KO macrophages.  
 
4.3.4 Embelin-induced Ca2+ transients are attenuated in GPR84 KO macrophages 
 
Having verified the ability to obtain Ca2+ responses from macrophages of both genotypes, we 
examined the selectivity of embelin by comparing the responses of WT and KO cells to 
different doses of this ligand (Fig 4.10). Although we previously observed modest responses 
in microglial cells to embelin, we hypothesised that embelin may be more effective at 
inducing Ca2+ signals in macrophage cells based on our previous findings that peripheral 
macrophages express greater levels of GPR84 mRNA than microglia upon stimulation (see 
Chapter 3). We found that GPR84 WT cells (D) exhibited greater embelin induced Ca2+ 
responses in contrast to KO (G) as illustrated in the example images and traces from single 
WT (I) and KO (J) cells responding to 10 μM embelin. Quantification of the number of 
responders shows that a greater percentage of WT cells responded to embelin than KO cells 
at doses 1, 10 and 50 μM, which was significant compared to vehicle at 10 μM (WT: 41.6 ± 
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10.8%; KO: 13.0 ± 7.6%) (Fig 4.10K). Quantification of the changes in the Fura-2AM signal 
showed that WT macrophages exhibited a greater increase in [Ca2+]i than the KO, which was 
significant at 0.1, 1 and 10 μM (WT: 0.08 ± 0.01, 0.07 ± 0.01, 0.11 ± 0.02; KO: 0.05 ± 0.01, 
0.07 ± 0.004, 0.05 ± 0.02, respectively) compared to vehicle (WT: 0.02 ± 9x10-4; KO: 0.02 ± 
5x10-4). Notably, embelin recruited a greater number of responding WT macrophages than 
microglia (Fig 4.9F), however, interestingly the ΔF340/380 ratios were generally smaller 
but more consistent (Fig 4.10L). As the Ca2+ responses to embelin were generally greater in 
the WT than the KO, this suggests that embelin may exert selective actions at GPR84, 
particularly at a dose of 10 μM where both the percentage of responders and ΔF340/380 
were significant compared to vehicle.  













Figure 4.8: ATP induces an increase in [Ca2+]i in microglial cells  
 
Subsequent to application of ATP (100 μM) there is a change in [Ca2+]i in comparison to baseline as 
indicated (arrows in A). Representative trace of a single microglial cell showing changes in the 
F340/380 emission ratio in response to ATP (B). Quantification of the number of responders shows 
that the percentage of microglial cells responding to ATP was significantly greater than vehicle 
treatment (HEPES; C). Quantification of the Ca2+ response is represented as a ΔF340/380 emission 
ratio (D). Microglial cells exhibit a robust increase in [Ca2+]i in response to ATP. Data are presented as 
the mean ± SEM. **p < 0.01 vs vehicle, Mann-Whitney Rank Sum Test (C); Student’s t-test (D), n = 5 
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Figure 4.9: Embelin produces weak Ca2+ responses in microglial cells  
 
(A-D) Embelin elicits a weak Ca2+ response in microglial cells. Representative trace of a single 
microglial cell showing the change in F340/380 in response to 1 μM embelin (E). Quantification of the 
number of cells responding to different doses of embelin was not significantly different from vehicle 
(F). Quantification of the Ca2+ response is represented as a ΔF340/380 emission ratio (G). There was 
a significant increase in [Ca2+]i in microglial cells treated with 1 μM embelin compared to vehicle. Data 
are presented as the mean ± SEM. *p < 0.05 vs vehicle, one-way ANOVA (F); Kruskal-Wallis one-way 
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Figure 4.10: Embelin induced Ca2+ transients are attenuated in GPR84 KO macrophages 
 
Quantification of percentage responders (A) and the Ca2+ response (B) to ATP (100 μM) in GPR84 WT 
and KO macrophages under non-stimulated and LPS stimulated conditions. There were a significant 
number of responders to ATP under non- and LPS stimulated conditions in both genotypes compared 
to vehicle. This correlated with an increase in [Ca2+]i, which was significant under LPS stimulated 
conditions compared to vehicle in both genotypes (WTV, KOV). (C-H) Embelin (10 μM) induced Ca2+ 
responses are greater in WT macrophages (D) than KO (G), as illustrated by the example traces from 
single WT (I) and KO (J) cells. Quantification of the number of responders (K) and the Ca2+ response 
(L) to 0.1, 1, 10 and 100 μM doses of embelin. The number of responders (at doses of 1, 10 and 50 
μM) and changes in [Ca2+]i (at doses of 0.1, 1 and 10 μM) was greater in WT than KO cells compared 
to vehicle. Increases in [Ca2+]i are expressed as a Δ340/380 emission ratio. Data are presented as the 
mean ± SEM. **p < 0.01, ***p < 0.001 vs vehicle, Kruskal-Wallis one-way ANOVA on ranks, post-hoc 
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4.3.5 Capric acid elicits Ca2+ transients in microglial cells 
 
To determine whether CA could produce Ca2+ responses in microglia and macrophage cells 
we utilised a similar approach to as previously presented. CA is a FFA with a carbon chain 
length of 10 and is postulated to be a natural ligand of GPR84 (Wang et al., 2006a). We found 
that CA was a successful inducer of Ca2+ transients in microglial cells as represented by the 
ΔF340/380 ratio, which was significant at doses of  1 and 10 μM (0.10 ± 0.02; 0.10 ± 0.03, 
respectively) compared to vehicle (0.02 ± 8x10-4; Fig. 4.11L). CA also recruited a greater 
number of responders compared to embelin, which was significant at doses of 1 and 100 μM 
(33.9 ± 14.0%; 31.6 ± 14.0%, respectively) vs vehicle (Fig. 4.11K). To extend these findings, 
we also investigated two additional parameters: desensitisation upon a second challenge 
and the effect of LPS stimulation. We previously showed that LPS up-regulates the 
expression of GPR84 (Chapter 3), which may enhance Ca2+ responses to CA. In addition, we 
also reported that 3 hrs of LPS stimulation does not attenuate Ca2+ responses (Fig. 4.10A, B) 
and so would not hinder the ability of cells to respond to succeeding challenges.  
 
As illustrated in images (A-H) and the representative traces of single cells responding to 1 
μM CA under non- (I) and LPS (J) stimulated conditions, LPS substantially enhanced CA 
induced Ca2+ transients and the responses of cells to a second challenge of CA were generally 
smaller (Fig. 4.11). Under LPS stimulated conditions, all doses tested (0.1 μM: 23.1 ± 4.9%; 1 
μM: 26.8 ± 7.8%; 10 μM: 27.1 ± 11.9% and 100 μM: 47.6 ± 23.4%) produced a significant 
number of responders compared to vehicle (Fig. 4.11K). Correspondingly, LPS stimulation 
significantly enhanced Fura-2AM based Ca2+ signals compared to vehicle (0.02 ± 6x10-4) at 
every dose tested (0.1 μM: 0.09 ± 0.01; 1 μM: 0.22 ± 0.06; 10 μM: 0.17 ± 0.06 and 100 μM: 
0.13 ± 0.01; Fig. 4.11L). Under non- or LPS stimulated conditions the percentage of 
responders or the ΔF340/380 ratio emissions to the second challenge were either reduced 
or remained unchanged compared to the first dose. Responses to a second challenge were 
significant compared to vehicle in LPS stimulated cells at 1 μM (0.12 ± 0.01), 10 μM (0.07 ± 
0.01) and 100 μM (0.12 ± 0.02). These data suggest that CA induces Ca2+ responses in 
microglial cells, which can be enhanced via prior LPS exposure and that GPR84 may undergo 
receptor desensitisation upon further stimulation. 
 
4.3.6 Capric acid shows weak selectivity for GPR84 in macrophages  
 
In conjunction with our studies where we showed that different doses of CA elicit Ca2+ 
responses in microglia, we also investigated the selectivity of this ligand by comparing Ca2+ 
responses in WT and KO macrophages. As illustrated in the example images (Fig. 4.12A-L) 
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and traces (Fig. 4.12M-P), CA (1 μM) induces Ca2+ responses in both WT and KO 
macrophages that are enhanced by LPS stimulation (3hrs, 1 μg/ml). However it is apparent 
that at this particular dose (under both non- and LPS-stimulated conditions) a greater 
number of WT than KO cells are responsive (Fig. 4.12A-L) and under non-stimulated 
conditions WT cells also exhibited a greater change in [Ca2+]i than KO cells (Fig. 4.12M-P). 
 
Quantification of the percentage of responders revealed that there was a significant number 
of CA responding cells at 1 μM in WT (54.1 ± 10.7%) and 10 μM in both genotypes (WT: 46.3 
± 11.2%; KO: 48.8 ± 13.9%) following LPS exposure compared to vehicle (Fig. 4.12Q). Doses 
of 0.1 μM and 100 μM of CA failed to stimulate a significant number of cells compared to 
vehicle under non- and LPS-stimulated conditions. However, despite a greater percentage of 
WT than KO responders at 1 μM CA, there was an equivalent induction in [Ca2+]i in both 
genotypes (WT: 0.10 ± 0.01; KO: 0.09 ± 0.01) compared to vehicle (WT: 0.02 ± 0.002; KO: 
0.02 ± 0.001; Fig. 4.12R). There was also a significant increase in [Ca2+]i in LPS stimulated 
WT and non-stimulated KO cells at 10 μM and 100 μM doses of CA compared to vehicle (WT: 
10 μM, 0.08 ± 0.001; 100 μM; 0.08 ± 0.003;  KO: vehicle, 0.02 ± 0.002; 10 μM 0.07 ± 0.003; 
100 μM, 0.08 ± 0.004; Fig. 4.12R). In general, the data shows that the effects of CA on 
macrophage Ca2+ responses lack a concentration dependent effect (although the dose-
response curve could be bell-shaped) and that the relationship between the percentage of 
responders and the ΔF340/380 ratio was variable. CA failed to show consistent selectivity 
for GPR84 except at a dose of 1 μM in terms of the percentage of responders (under both 
conditions) and the ΔF340/380 ratio under non-stimulated conditions. Together, these data 
suggest that CA and embelin only show selectivity for GPR84 at particular doses (1 μM and 
10 μM, respectively). Therefore the data must be interpreted with caution and further 
experiments are required to validate these findings.  
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Figure 4.11: Capric acid produces a Ca2+ response in microglia, which is enhanced by LPS 
 
Under non-stimulated conditions capric acid (CA, 1 μM) produces weak Ca2+ responses in microglial 
cells as illustrated in the top row (panels A-D) and the example trace (I). However, subsequent to 3 
hrs LPS stimulation (1 μg/mL) Ca2+ signals generated by the 1st and 2nd challenges of CA are much 
greater (E-H, J). Under non-stimulated conditions, 1 μM and 100 μM doses recruited a significant 
number of responders to the 1st CA challenge, whereas under LPS stimulated conditions all doses 
recruited a significant number of responders compared to vehicle (K). The number of responders to 
2nd challenges of CA were smaller or unchanged compared to the 1st challenge. Increases in [Ca2+]i in 
response to the 1st and 2nd CA challenge at different doses are quantified in (L). Again, the 1st CA 
challenge produced a significant increase in [Ca2+]i at all doses tested under LPS stimulated 
conditions, whereas only 1 μM and 10 μM CA produced a significant increase in [Ca2+]i under non-
stimulated conditions compared to vehicle. Responses to 2nd CA challenges were smaller or 
unchanged compared to the 1st challenge. Increases in [Ca2+]i are expressed as a Δ340/380 emission 
ratio. Data are presented as the mean ± SEM. *p < 0.05, ***p < 0.001 vs vehicle, Kruskal-Wallis one-
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Figure 4.12: Capric acid shows weak selectivity for GPR84 in macrophages 
 
Capric acid (CA, 1μM) generates Ca2+ transients in WT (E and F) and KO (G and H) macrophages 
under control (E and G) and LPS stimulated (F and H) conditions. Panels M-P illustrate images and 
example traces of WT (M and N) and KO (O and P) macrophage cells under non-stimulated (M and O) 
and LPS stimulated (N and P) conditions. The number of responders to different doses of CA are 
quantified in (Q). LPS stimulation enhanced the percentage of responding WT cells at 1 μM and in 
both genotypes at 10 μM compared to non-stimulated cells, which was significant in comparison to 
vehicle. LPS stimulation also significantly enhanced [Ca2+]i responses in WT cells to doses of 1, 10 and 
100 μM of CA and in the KO to a dose of 1 μM (R) compared to vehicle. Under non- and LPS stimulated 
conditions there were no significant differences between genotypes. Increases in [Ca2+]i are expressed 
as a Δ340/380 emission ratio. Data are presented as the mean ± SEM. ***p < 0.001 vs vehicle, 
Kruskal-Wallis one-way ANOVA on ranks, post-hoc Dunn’s method, n = 3-8 experiments; average of ≥ 
30 cells. 
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4.3.7 cAMP assay 
 
Although embelin and CA generated Ca2+ transients in microglia and macrophage cells this 
response was considerably variable, resembled an unlikely bell-shaped dose-response curve 
and the relationship between the number of responders and ΔF340/380 ratio was 
inconsistent. This suggests that examining Ca2+ responses to test ligand selectivity might not 
be the most appropriate assay for this receptor and that GPR84 mediated Ca2+ mobilisation 
may be complex and further down-stream in the signalling pathway rather than directly 
coupled to receptor activation. As we were unable to gain definitive answers from these 
studies we sought to investigate selectivity of embelin, CA and CNV by examining changes in 
cAMP levels, based on evidence that GPR84 is directly coupled to the Gi/o G-protein family 
(Wang et al., 2006a). Here, CA was shown to reduce forskolin-stimulated cAMP production 
in a dose-dependent fashion in GPR84 transfected CHO cells (Wang et al., 2006a). We 
therefore hypothesised that a selective ligand would inhibit forskolin-induced cAMP in WT 
macrophages, but have no effect on KO macrophages. Forskolin is a valuable and widely 
used compound due to its ability to directly interact with the catalytic subunit of AC and 
increase the synthesis of cAMP (Insel and Ostrom, 2003) and thus provides an excellent 
positive control for the study of cAMP in our studies.  
 
The cAMP-screen direct chemiluminescent ELISA system provides a rapid and sensitive 
quantification of cellular cAMP for functional assays examining receptor activation and can 
be used for receptor characterisation and ligand identification. In principle, the system is a 
competitive immunoassay where the addition of an AP-labelled cAMP conjugate competes 
with cAMP from sample extracts for a highly specific anti-cAMP antibody. AP is an enzyme 
that removes phosphate groups from a substrate via hydrolysis in a process termed 
dephosphorylation and is most effective in alkaline environments. Subsequent to the 
competitive antibody reaction the addition of the chemiluminescent substrate, CSPD, results 
in enzymatic dephosphorylation by AP, which leads to the formation of a metastable 
phenolate anion that decomposes to emit light at a maximum wavelength of 477 nm. CSPD 
requires an alkaline hydrophobic environment for rapid decomposition and emission of 
bright chemiluminescent signals, which is provided by an enhancer such as sapphire-II. In 
practise, the less cAMP present in the sample, the more cAMP-AP is bound to the antibody 
and the greater the amount of light emitted. Thus the light signal intensity, measured by a 
luminometer, is inversely proportional to the concentration of cAMP in the sample.  
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4.3.8 The effects of embelin, capric acid and CNV on forskolin-induced cAMP levels 
in WT and KO B-GEPMs  
 
We examined inhibition of cAMP in non- and LPS stimulated conditions in WT B-GEPMs to 
determine if increased expression of GPR84 enhances ligand efficacy, which would be 
apparent by augmented inhibition of cAMP levels. GPR84 KO B-GEPMs were only examined 
under non-stimulated conditions. Three doses of each ligand, CA (A), embelin (B) or CNV (C) 
were comparatively examined in both WT and KO macrophages (Fig. 4.13). Despite testing 
two doses of forskolin which are documented to elicit marked increases in intracellular 
cAMP levels (Chang et al., 1984; Kreckler et al., 2009), we were unable to induce cAMP in 
WT macrophages. In general, under LPS stimulated conditions there was a greater induction 
of cAMP and each of the ligands exhibited a slight inhibitory trend, however due to the small 
difference between basal levels and forskolin-induced cAMP levels there was a limited 
window to observe a clear inhibitory effect (Fig. 4.13A, B, C). In contrast, KO cells showed a 
striking induction of cAMP (64.7 ± 6.5 fmol/mL (A); 216 ± 17.0 fmol/mL (B); 469.0 ± 53.9 
fmol/mL (C)) which was significant compared to control (26.2 ± 0.3 fmol/mL (A); 54.2 ± 1.9 
fmol/mL (A); 122.7 ± 3.2 fmol/mL (C)) and forskolin stimulated WT cells (23.4 ± 0.5 
fmol/mL (A); 79.6 ± 0.6 fmol/mL (C)). In KO cells, CA elicited a significant inhibition of 
cAMP levels at the 1 μM dose (38.3 ± 2.3 fmol/mL) compared to the positive forskolin 
control (Fig. 4.13B). The inhibitory effect of CA in KO cells appeared to have a dose-
dependent trend, suggesting that CA could indeed be exerting non-GPR84 selective effects. 
However, this assumption is difficult to ascertain without a comparative effect in the WT. 
Despite this we were able to show that subsequent to appropriate stimulation, KO cells are 
capable of inducing greater cAMP responses than WT cells (KO + FSK: 342.5 ± 37.9 fmol/mL 
vs WT + FSK: 121.2 ± 6.4 fmol/mL), compared to control (WT: 68.5 ± 2.8 fmol/mL vs KO: 
88.4 ± 7.8 fmol/mL; Fig 4.13D). This elevated cAMP phenotype in the KO is particularly 
interesting with regards to the immunosuppressive role of this second messenger (Bourne 
et al., 1974; Serezani et al., 2008; Peters-Golden, 2009) and may be associated with the KO 
behavioural phenotype in experimental models of persistent pain (Chapters 2 and 3). 
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Figure 4.13: The effects of putative GPR84 ligands on forskolin-induced cAMP levels in WT and 
KO B-GEPMs  
 
Examining the production of cAMP in GPR84 WT and KO B-GEPMs to test the selectivity of capric acid 
(CA; A), embelin (EMB; B) and CNV (C). None of the three ligands inhibited forskolin (FSK)-induced 
cAMP in WT cells under non- and LPS stimulated conditions (3hrs; 1μg/ml). Mean ± SEM; ***p<0.001, 
*p<0.05 vs appropriate control (-); ###p<0.001 KO+FSK vs WT+FSK; †p<0.05 CA+FSK vs FSK. One-way 
ANOVA with Tukey’s post-hoc. n = 4-6 wells/condition. (D) GPR84 KO cells show greater FSK induced 
cAMP production (KO FSK) than WT cells (WT FSK) in comparison to control cells (KOC, WTC, 
respectively). Mean ± SEM; ***p<0.001 vs appropriate control. Kruskal-Wallis one-way ANOVA on 
ranks with Tukey’s. n = 12 wells/condition. 
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Pharmacological tools have been widely exploited in experimental studies investigating the 
physiological role and signalling pathways of receptors in vitro and in vivo systems. 
Throughout this thesis, we have utilised transgenic mice to investigate GPR84 in chronic 
pain mechanisms, and have shown that this receptor contributes to pain-associated 
behaviours in a model of nerve injury (PNL) and inflammation (CFA) (Chapter 2 and 3). 
However, a lack of commercially available agonists or antagonists selective for GPR84 has 
prevented further characterisation of this receptor. GPR84 is an orphan receptor and its 
signalling pathway is currently unknown, with only a single study postulating that CA is the 
natural ligand (Wang et al., 2006a). Based on this limited evidence we explored the efficacy 
and selectivity of three potential GPR84 ligands (embelin, CA and CNV) in microglia and WT 
and KO macrophages via Ca2+ and cAMP signalling assays to identify a selective agonist that 
could be utilised in further functional studies. We report that embelin and CA generate Ca2+ 
transients in microglia and WT macrophage cells and exhibited selectivity for GPR84 at 
doses of 10 μM and 1 μM, respectively. We were unable to conclusively show CA, embelin or 
CNV -induced inhibition of cAMP formation and so could not validate ligand efficacy and 
selectivity in this assay. However, interestingly we observed that KO macrophages showed a 
greater increase in forskolin induced cAMP than control WT cells. 
 
4.4.1 GPR84 and Ca2+ signalling 
 
Spinal microglia and peripheral macrophages express a number of chemokine receptors 
such as CCR2, CCR4, CCR5 and CX3CR1, which are altered under chronic pain conditions; 
conversely pain-associated behaviours are attenuated in null mice or via the administration 
of chemokine receptor neutralising antibodies (Kieseier et al., 2002; Abbadie et al., 2003; 
Thacker et al., 2009; Kiguchi et al., 2010b; Staniland et al., 2010). Activation of chemokine 
receptors initiates rapid mobilisation of PLC, the subsequent generation of IP3 and a 
resultant increase in cytosolic [Ca2+]i. This pathway is characteristic of chemokine signalling 
and can be utilised to investigate the responsiveness of these receptors to different ligands. 
PI3K is also a key player in chemokine signalling and initiates the subsequent activation of 
the MAPK cascade, particularly involving ERK (Bajetto et al., 2002).  Elevated levels of [Ca2+]i 
have been experimentally demonstrated in microglia, monocytes and macrophages 
following exposure to CCL2, CCL3, CCL5, CXCL5 and CX3CL1, whereas pharmacological 
antagonism correspondingly blocks Ca2+ signalling (Harrison et al., 1998; Boddeke et al., 
1999; Cardaba and Mueller, 2009; Serrano et al., 2010; Dawes et al., 2011; Clark and 
Malcangio, 2012). The GPR84 signalling pathway is currently unknown, but is postulated to 
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be coupled to the Gαi/o family (Wang et al., 2006a) where its activation may lead to the 
mobilisation of intracellular Ca2+ in a similar pathway to that of a chemokine receptor. 
However, there is some evidence that GPR84 signalling may be independent of a Pertussis 
toxin sensitive pathway (Versleijen et al., 2009). Chemokine receptors may also activate  
several other intracellular effectors including PLA2, PI3K and MAPK (Murdoch and Finn, 
2000), leading to the mobilisation of [Ca2+]i and the activation of the p38 MAPK pathway 
(Kreideweiss et al., 1999; Elzi et al., 2001). Upon phosphorylation, p38 MAPK enters the 
nucleus where it phosphorylates transcription factors such as NF-κB, which mediate the 
biosynthesis of many pro-inflammatory factors documented to contribute to nociceptive 
transmission (Jana et al., 2003; Kumar et al., 2003; Ji and Suter, 2007).  
 
Circumstantial evidence has suggested that GPR84 is activated by MCFFAs and cytokines 
(IL-1β, TNF-α) capable of stimulating the NF-κB pathway and that the activation of this 
receptor elicits the release of CXCL1, IL-8 and IL-12p40 (Hwang, 2000; Wang et al., 2006a; 
Bouchard et al., 2007; Suzuki et al., 2013). It has been reported that MCFFAs demonstrate 
efficacy in GPR84 transfected CHO cells and are able to activate leucocytes by increasing 
[Ca2+]i (Wanten et al., 2004; Wanten and Naber, 2004; Wanten, 2006). Therefore, we 
postulated that as a pro-inflammatory receptor, GPR84 activation may be coupled to the 
mobilisation of Ca2+ and thus a functional assay examining Ca2+ responses in microglia and 
macrophages would be a relevant approach to examine the selectivity of embelin and CA.  
 
In accordance with literature we verified the ability to obtain Ca2+ responses in rat spinal 
microglia and GPR84 WT and KO mouse peritoneal macrophages to challenges of ATP (Walz 
et al., 1993; McLarnon et al., 1999; Moller et al., 2000; Hoffmann et al., 2003; McLarnon, 
2005; Farber and Kettenmann, 2006b). Purinergic signalling in these cells is mediated by 
the ionotropic P2X4 and P2X7 receptors and metabotropic P2Y receptors (McLarnon, 2005). 
Activation of P2X4/7 receptors results in the influx of Na+ and Ca2+ and efflux of K+ and 
subsequent depolarisation, whereas activation of the P2Y receptor leads to an increase in 
[Ca2+]i as a result of intracellular store depletion and subsequent SOC activation (McLarnon, 
2005). Having successfully shown that ATP elicits Ca2+ responses we then investigated 
whether we could show the same with embelin and CA in microglia and WT macrophage 
cells, where ligand selectivity would be evidential by an attenuated/abolished Ca2+ response 
in KO cells. We found that both ligands produced Ca2+ transients in microglia and 
macrophage cells, but these responses tended to be inconsistent and the number of 
responders did not correlate with changes in [Ca2+]i. Usually dose-response relationships of 
a GPCR ligand are sigmoidal; at low concentrations the biological effect is small but when a 
certain threshold is met the effect increases until it reaches a plateau. However, some drugs 
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may exhibit a bell-shaped relationship, which is characterised by low dose responses but 
loss of the effect at higher doses. Both embelin and CA exhibited bell-shaped dose response 
curves, with a trend towards GPR84 selectively particularly at doses of 10 μM for embelin 
and 1 μM for CA. 
 
Based on the fact that CA is a suggested natural ligand for GPR84 and the fact that CA 
recruited a greater number of microglial cells than embelin, we explored two additional 
parameters using CA to further complement our studies. We examined the concept of 
desensitisation by challenging the cells twice and also looked at the effect of LPS 
stimulation, which increases the expression of GPR84 in immune cells (Wang et al., 2006a; 
Bouchard et al., 2007). Desensitisation is a phenomenon that occurs subsequent to receptor 
activation via a number of mechanisms. These include phosphorylation of the receptor via 
second messenger kinases such as PKA and PKC, leading to the uncoupling of the receptor 
from its respective G-protein, or GRK-mediated phosphorylation and consequential sterical 
inhibition as a result of arrestin binding. Internalisation and sequestration of GPCRs via 
clathrin coated vesicles may also occur (Pierce et al., 2002). Accordingly, we showed that 
under normal and LPS stimulated conditions microglia exhibited reduced or unchanged CA 
responses to a second challenge at every dose tested. We also demonstrated that LPS 
substantially enhanced CA-induced Ca2+ transients in microglia and WT macrophages. 
However, as LPS stimulated KO cells also exhibited increased Ca2+ transients, whether this 
LPS-enhancing effect was due to increased expression of GPR84 is unknown. In conclusion, 
although embelin and CA clearly showed a degree of efficacy and selectivity at particular 
doses, the lack of consistency and residual responses in KO cells adds caution to the 
interpretation of a specific interaction with GPR84. Furthermore, selectivity at the 1 μM CA 
dose was lost in LPS stimulated cells as both WT and KO macrophages showed equivalent 
Ca2+ transients. This indicates a lack of selectivity or the possibility that other FFA-sensitive 
cell membrane receptors (as well as GPR84) may be up-regulated by LPS exposure, and may 
account for the greater Ca2+ responses observed in both genotypes compared to 
unstimulated conditions. 
 
4.4.2 GPR84 and cAMP signalling 
 
Our findings indicate that our initial approach using Ca2+ fluorometry to validate ligand 
selectivity for GPR84 may not have been the most appropriate assay for this receptor. 
GPR84 mediated Ca2+ mobilisation could be further down-stream of receptor activation 
rather than being directly coupled. We therefore supplemented our investigations on the 
selectivity of embelin, CA and CNV by assessing cAMP levels, based on evidence that GPR84 
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is coupled to the inhibitory Gαi/o family (Wang et al., 2006a). Here, Wang et al. (2006) 
employed a GPR84 heterologous expression system and showed that CA reduced forskolin-
induced cAMP production in a dose-dependent fashion and that this effect could be 
abolished by Pertussis toxin pre-treatment (Wang et al., 2006a). We therefore hypothesised 
that a selective ligand would inhibit forskolin-induced cAMP in WT macrophages but have 
little or no effect on KO macrophages. 
 
As we were unable to induce a sufficient level of cAMP in WT macrophages it is difficult to 
determine whether CA, embelin or CNV exerted inhibitory actions on cAMP formation and 
thus a comparison between WT and KO cells cannot be made. The induction of cAMP in 
macrophages is usually very small and within the picomolar range. However, forskolin 
induced formation of cAMP in macrophage cells is well documented, and many groups have 
shown the ability to increase cAMP levels using similar concentrations and incubation 
periods to the ones we employed (Chang et al., 1984; Osawa et al., 2006; Kreckler et al., 
2009; Ballinger et al., 2010). Therefore, the poor cAMP responses we obtained should be 
improved by altering experimental conditions such as using higher doses of forskolin and 
extending the incubation period. In contrast, GPR84 KO macrophages exhibited striking 
increases in forskolin-induced intracellular cAMP levels compared to vehicle, which we 
postulate is due to the absence of inhibitory GPR84 signalling. Surprisingly, 1 μM of CA 
significantly inhibited forskolin-induced cAMP in KO cells, which was a dose that appeared 
to be particularly selective in the Ca2+ fluorometry assays. Therefore we did not attempt to 
repeat a second cAMP assay study to test CA with a higher dose of forskolin due to this non-
selective action. However, we used a higher dose of forskolin (50 μM) in subsequent studies 
(embelin, CNV) in attempt to elicit greater cAMP responses in WT macrophages, which was 
disappointingly unsuccessful. 
 
The role of cAMP in macrophage function has historically been the centre of debate owning 
to conflicting data; while some thought that this second messenger enhanced phagocytosis 
and collagen production (Muschel et al., 1977; McCarthy et al., 1980) others believed that 
cAMP in fact did the opposite. However, it is now well established that elevated cAMP levels 
exert a broad range of immunosuppressive actions, including down- or up- regulation of 
pro- or anti-inflammatory mediators, respectively, and a reduction in phagocytic activity 
(Bourne et al., 1974; Aronoff et al., 2005; Serezani et al., 2008; Peters-Golden, 2009; Wall et 
al., 2009) as previously discussed (section 4.1.2). These effects are primarily coordinated by 
two effector molecules, PKA and the exchange proteins, Epac 1 and 2, which are directly 
activated by cAMP and play distinct, redundant or opposing roles in immune cell function 
(Wall et al., 2009; Ballinger et al., 2010). In light of this evidence, the KO macrophage 
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phenotype is very intriguing as upon forskolin stimulation these cells exhibited a robust 
cAMP up-regulation in contrast to WT macrophages, moreover despite a lack of significance, 
KO macrophages also possess slightly greater basal levels of cAMP. This may suggest that 
macrophage cells have a greater polarity towards an anti-inflammatory M2 state in the 
absence of GPR84. Accordingly, we observed increased expression of the M2 macrophage 
marker, ARG1, in the injured sciatic nerves of KO mice (Chapter 2) and have shown that KO 
macrophages exhibit attenuated production of some pro-inflammatory mediators in 
response to LPS (Chapter 3). Therefore, it is feasible that nerve injury and/or inflammation 
leads to an increase in cAMP levels in GPR84 KO microglia/macrophages, which inhibits the 
release of some pro-inflammatory mediators and hence alleviates pain-associated 
behaviours. Furthermore, it has been reported that forskolin increases cellular proliferation 
and differentiation via cAMP-dependent activation of PKA and Epac (Misra and Pizzo, 2005). 
This is consistent with our previous findings of an ipsilateral increase in Iba1 positive cells 
in the spinal cords of KO PNL and CFA treated mice and in the sciatic nerves of KO PNL mice 
(see Chapters 2 and 3). However, we must note that elevated cAMP has also been reported 
to suppress macrophage proliferation (Vairo et al., 1990).  
 
In contrast to its immunosuppressive role in immune cells, cAMP was one of the first second 
messengers to be implicated in nociceptive transmission (Hucho and Levine, 2007). At the 
site of inflammation nociceptor sensitisors such as PGE2 and adenosine activate AC via their 
Gαs coupled GPCRs, which initiates cAMP synthesis. Increased levels of cAMP enhances 
neuronal excitability via the phosphorylation dependent actions of its binding partner, PKA, 
which has been demonstrated to modulate voltage-gated channels (Nav1.8) and ligand-
gated channels (TRPV1) as well as augment neurotransmitter release (Hingtgen et al., 1995; 
Fitzgerald et al., 1999; Bhave et al., 2002). Elevated levels of cAMP is also associated with 
increased neuronal excitability in experimental models of chronic pain and the 
administration of cAMP inducing agents such as forskolin produces dose-dependent 
hyperalgesia in rats that can be prolonged via PDE inhibitors or blocked by the cAMP analog, 
RP-cAMP (Taiwo and Levine, 1991). Conversely, pre-treatment with AC inhibitors decreases 
PGE2 induced behavioural hyperalgesia and administration of PKA inhibitors pre or post 
PGE2 treatment produced a similar inhibitory effect on pain behaviours. Thus indicating that 
PKA plays a key role in the maintenance of hypersensitivity (Aley and Levine, 1999). Knock-
out mice have also been utilised in a number of studies exploring the roles of specific 
isoforms of AC in nociceptive transmission. Behavioural responses to PNL or subcutaneous 
administration of formalin or CFA was attenuated or abolished in AC type 1 and 8 double KO 
mice (Wei et al., 2002). Similarly, AC type 5 null mice demonstrated attenuated formalin or 
SNL evoked pain responses (Kim et al., 2007b). In light of this evidence and with regards to 
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our findings, the development of immune cell specific AC agonists or drugs exploiting cAMP 
function could be therapeutically beneficial in combating chronic inflammatory diseases 
associated with pain. Fascinatingly, several pathogenic microorganisms (Bordetella 
pertussis, Vibrio cholerae and Escherichia coli) have evolved cAMP enhancing mechanisms to 
disable host innate immune defences (Serezani et al., 2008). However, the selectivity of such 
drugs would be crucial, as non-selective effects at other cell types may result in pain. 
 
4.4.3 Future work 
 
In this chapter we tested the efficacy and selectivity of three putative GPR84 ligands 
(embelin, CA and CNV) using Ca2+ and cAMP assays. In the Ca2+ assays, we found that CA and 
embelin exhibited some selectivity for GPR84 at doses of 1 μM and 10 μM, respectively, and 
that LPS increased Ca2+ responses to CA but selectivity was lost. Notably, CA and embelin 
recruited a modest number of responding cells. Thus in light of previous findings, which 
suggested that GPR84 is only expressed by a subset of microglial cells (Chapter 3), it may be 
interesting to characterise which populations of microglia and macrophages express GPR84. 
 
Data from the cAMP assays were inconclusive as we were unable to generate sufficient 
forskolin-induced cAMP responses in WT macrophages. It would therefore be necessary to 
repeat the cAMP studies using an optimised stimulation protocol to achieve a greater cAMP 
induction window where the inhibitory effects of GPR84 ligands can be fully assessed. It 
would also be interesting to further investigate the elevated cAMP/M2 phenotype of KO 
macrophages via immunocytological assessment of cAMP and other relevant markers (p38 
MAPK, ARG1, iNOS) in ligand stimulated WT and KO macrophage cells. Here the 
development of selective agonists or antagonists would permit an extensive 
immunocytological evaluation of the cAMP phenotype. Previously we presented a selective 
antibody for GPR84 (Chapter 3), however as it possesses an intracellular epitope it is not 
appropriate for blocking GPR84 in live cells. Therefore, the development of a selective 
antibody possessing an extracellular epitope may enable further functional analysis of 
GPR84 in vitro and in vivo. Cyclic AMP signalling is also synonymous with the activity of its 
binding partner, PKA, thus it would be interesting to immunohistochemically examine 
immune cell-expressed phosphorylated PKA in the sciatic nerves and spinal cords of PNL 
and CFA treated WT and KO mice.  
 
In the Ca2+ and cAMP signalling assays, we utilised resident and B-GEPMs, respectively, due 
to different protocol demands in cell yields. B-GEPMs consist of a mixture of resident and 
infiltrating cells, and so are representative of the in vivo situation in addition to providing 
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greater yields. This population of macrophages differ in their respiratory and phagocytic 
capacity and chemokine responsiveness compared to resident cells (Zhang et al., 2008). It is 
worth noting that different types of cell cultures or the use of different populations of 
macrophages in primary cell cultures accounts for many of the discrepancies throughout the 
literature. Although B-GEPMs are perhaps the most relevant source of macrophages to use 
in our studies in comparison to other sources such as BMMs, under normal conditions the 
expression of GPR84 is the lowest in this population (Lattin et al., 2008), which could 
possibly account for a lack of potency of the ligands tested. Attempts to increase GPR84 
expression using LPS enhanced Ca2+ responses to ligands in some cases but not always 
specifically in WT cells and only markedly improved inhibition of forskolin-induced cAMP. 
Therefore the consideration of alternative populations of macrophages for future studies 
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5.1 Summary of experimental findings  
 
Owning to the compelling body of evidence on the interaction between neurons, immune 
and glial cells in nociceptive transmission (Marchand et al., 2005; Scholz and Woolf, 2007; 
Thacker et al., 2007; Austin and Moalem-Taylor, 2010; Calvo et al., 2012), experimental 
research on immune cell expressed targets is well underway in the chronic pain field. The 
exclusive expression of GPR84 in immune cells and its pro-inflammatory profile warrants 
this receptor as an exciting new candidate in pain pathways. Therefore the aim of this thesis 
was to explore GPR84 signalling in animal models of persistent pain. The main findings are: 
 
1. GPR84 mRNA is up-regulated in microglia and macrophage cells upon LPS 
stimulation as well as in the sciatic nerve and spinal cord tissue of neuropathic mice. 
2. GPR84 KO mice do not develop neuropathic pain behaviours in a model of traumatic 
nerve injury. 
3. Subsets of mediators, particularly ARG1, are dysregulated between the ipsilateral 
sciatic nerve and spinal cord tissues of nerve injured WT and KO mice.  
4. GPR84 KO mice exhibit attenuated pain behaviours in a model of inflammatory pain. 
5. LPS-induced up-regulation of some cytokines/chemokines including CCL2, CCL3 and 
CXCL5 are attenuated in KO macrophages. 
6. KO macrophages exhibit elevated basal and forskolin-induced levels of cAMP 
compared to WT cells. 
 
Using transgenic mice we have shown, for the first time to the best of our knowledge, that 
GPR84 KO mice have attenuated neuropathic and inflammatory pain. This indicates that 
GPR84 is necessary for the development of persistent pain and thus pharmacological 
manipulation of GPR84 signalling in immune cells may alleviate pain behaviours. 
Accordingly, the immunomodulatory role of GPR84 is evident by our gene profiling studies, 
where subsets of immune-derived pro-inflammatory mediators were dysregulated between 
nerve injured WT and KO mice. Although not significant, nerve injury-induced expression 
of IL-1β, IL-12p40, CCL3 and NOS2 was attenuated in the sciatic nerves and spinal cords of 
KO mice 21 days post PNL. These mediators are known to contribute directly or via second 
messengers to peripheral and/or central sensitisation (Sommer and Kress, 2004; Abbadie, 
2005; Austin and Moalem-Taylor, 2010), as previously discussed (Chapter 1), and so 
collectively their diminished expression in the KO may account for the absence of pain 
behaviours subsequent to nerve injury. Using a similar approach, we also observed 
decreased LPS-induced expression of a selection of chemokines and cytokines in KO 
Chapter 5 - General Discussion 
 
237 
macrophages, including pro-nociceptive CCL2, CCL3 and CXCL5 (Abbadie et al., 2003; 
Kiguchi et al., 2010b; Dawes et al., 2011).  
 
In both neuropathic and inflammatory pain models, spinal microglia and peripheral 
macrophage responses were equivalent between genotypes, although our 
immunohistological assessment was restricted to Iba1 and p-p38 MAPK. Likewise, LPS 
stimulated KO macrophages appeared just as capable as WT macrophages in launching a 
pro-inflammatory response, except for the attenuated expression of some chemokines. 
Despite the unaltered microglia/macrophage response, an explanation for the behavioural 
phenotype in the KO could indeed lie with reduced chemokine signalling. It is apparent in 
the literature that the interruption of a single receptor or signalling molecule can completely 
abolish pain behaviours due to the integrated nature of the nociceptive transmission 
system. On the other hand, our data could in fact argue against a critical role of microglia 
and macrophages in the pathogenesis of chronic pain. In this thesis we have reported that 
GPR84 mediated signalling contributes to the initiation of nerve injury-induced neuropathic 
pain and the maintenance of CFA-induced inflammatory pain. However, we did not observe 
a corresponding immune cell response via immunohistochemical analysis. Dissociation 
between a microglial or macrophage cell contribution and behavioural hypersensitivity in 
animal models of neuropathic and inflammatory pain has also been previously documented 
(Colburn et al., 1997; Molander et al., 1997; Colburn et al., 1999; Hashizume et al., 2000; 
Honore et al., 2000; Rutkowski et al., 2000; Winkelstein and DeLeo, 2002; Raghavendra et 
al., 2003a; Zhang et al., 2003; Barclay et al., 2007; Clark et al., 2007a; Shi et al., 2011). 
Furthermore, in models that are more representative of disease-associated pain conditions 
such as chemotherapeutic, bone cancer, HIV or VZV -induced neuropathy microgliosis was 
absent (Honore et al., 2000; Zheng et al., 2011a; Blackbeard et al., 2012; Zhang et al., 2012a). 
It was also found that minocycline failed to alleviate mechanical allodynia in painful diabetic 
neuropathy (Liao et al., 2011). Likewise, the clinical evidence for a role of microglia and 
macrophages in chronic pain patients is limited and unclear. For example, propentofylline 
was ineffective for the treatment of post-herpetic neuralgia in a randomised controlled trial 
(Landry et al., 2012) and the CCR2 antagonist AZD2423, bore no efficacy in patients with 
post-traumatic neuralgia (Kalliomaki et al., 2013).  
 
Despite the fact that some pre-clinical and clinical evidence suggests a limited role of 
microglia and macrophages in chronic pain, differences in disease aetiologies, failure of 
translational research and caveats in clinical trial design argue against this. Undoubtedly, 
there is a significant body of basic research supporting microglia and macrophages as active 
participants in chronic pain (discussed in Chapter 1), which is supported by growing clinical 
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evidence. For example, reactive microglia have been detected in the ipsilateral thalamus of 
amputees with chronic phantom limb pain by positron emission tomography (PET) using a 
radiolabelled ligand for the peripheral benzodiazepine receptor (Banati et al., 2001). This 
technique has also been employed to investigate the neural bases of pain, including the 
involvement of microglia in other types of neuronal injury. PET as well as functional 
magnetic resonance imaging (fMRI) have already exemplified success in animal research 
and therefore provide excellent alternatives to study microglia in humans in a non-invasive 
manner (Imamoto et al., 2013). Besides an obvious change in morphological phenotype and 
numbers, mediators released by microglia are well documented to contribute to behavioural 
hypersensitivity in animal models of chronic pain. Heightened levels of pro-inflammatory 
cytokines were detected in the CSF fluid of two CRPS patients and this increase correlated 
with pain intensity (Alexander et al., 2005; Backonja et al., 2008). However, since a number 
of cell types are capable of producing cytokines, these findings do not conclusively indicate 
microglial activation. A pro-inflammatory monocyte phenotype has also been documented 
in CRPS patients (Ritz et al., 2011) and an increase in inflammatory cell recruitment has 
been reported in nerve biopsies from neuropathic pain patients, where the extent of 
infiltration correlated with the pain experienced (Lindenlaub and Sommer, 2003). Despite 
previous failures, clinical trials examining alternative microglial modulators are well 
underway (NCT01314482) (Grace et al., 2011) and the p38 MAPK inhibitor SB-681323, 
which may also effect macrophages, was efficacious for neuropathic pain in a small double-
blind crossover trial (Anand et al., 2011). 
 
It is possibile that the up-regulation of GPR84 expression alone is driving the pain 
behaviours. Tsuda et al. (2003) demonstrated that the up-regulation of P2X4 receptors in 
hyperactive microglia in the spinal cord is crucial for nerve injury-induced allodynia. 
Pharmacological blockade or intraspinal administration of P2X4 receptor antisense 
oligodeoxynucleotides suppressed pain behaviours, whereas intraspinal transfer of P2X4-
expressing microglia generated behavioural hypersensitivity in naïve rats (Tsuda et al., 
2003). Here we demonstrate that GPR84 mRNA is strikingly up-regulated in the sciatic 
nerve and more modestly in the spinal cord at 7 days post PNL, and this increase persisted 
up to day 21. We also demonstrated that GPR84 mRNA was considerably up-regulated in 
peritoneal macrophages and moderately in cortical microglia subsequent to LPS 
stimulation. Immunohistochemical assessment revealed GPR84 up-regulation in a majority 
of microglial cells in LPS-treated spinal cords, indicating that this receptor may represent a 
sub-population specific marker. Together, these data suggest a prominent role of GPR84 
signalling in peripheral macrophages.  
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Interestingly, we found that under normal conditions GRP84 expression was undetectable, 
however upon appropriate immunostimulation there was an increase in transcript and 
protein levels. Therefore, GPR84 may be a silent receptor that is recruited only under 
pathological circumstances. Accordingly, GPR84 up-regulation has been reported in 
clinically relevant animal models of diabesity and EAE, which feature pain-associated 
pathologies (Bouchard et al., 2007; Nagasaki et al., 2012). This response-specific up-
regulation is a particularly appealing property for the development of selective ligands as 
only erroneous immune activity would be targeted whilst normal nociceptive transmission 
would remain unaffected, limiting the possibility of detrimental side effects. Likewise, 
pharmacological blockade of P2X4 had no effect on acute pain behaviours of naïve rats but 
suppressed tactile allodynia in neuropathic animals (Tsuda et al., 2003). 
 
One of the most intriguing outcomes of the gene profiling studies was the considerable up-
regulation of the anti-inflammatory M2 macrophage marker, ARG1, in the sciatic nerve of 
KO mice 7 days post PNL, in contrast to WT controls. ARG1 is associated with the alternative 
pathway, which entails the metabolism of L-arginine to produce L-ornithine and urea. In 
mammals there are two isoforms of ARG, cytosolic ARGI and mitochondrial ARGII, both of 
which carry out the same reaction (Bogdan, 2001). Ornithine amino transferase may then 
synthesise proline from ornithine, which is crucial in collagen production, whereas 
ornithine decarboxylase generates polyamines that are involved in cellular proliferation. 
Together these pathways contribute to cell growth and differentiation as well as the 
formation of the ECM (Kreider et al., 2007). On the other hand, pro-inflammatory M1 
macrophages are associated with the expression of inducible nitric oxide synthase (iNOS), 
which catalyses the oxidation of the substrate L-arginine to form NO and L-citrulline. The 
transfer of electrons by iNOS subunits to the co-substrate O2 results in the formation of 
superoxide (O-2). Superoxide may then react with NO or L-citrulline to produce the reactive 
nitrogen oxide species, peroxynitrite, or may react with water to form hydrogen peroxide. 
Both of these highly reactive agents are able to cross the membrane and damage biological 
targets (Bronte and Zanovello, 2005). NO exerts multiple immunoregulatory functions in 
host protection such as antimicrobial activity, cytokine modulation and Th cell development. 
Hence the expression of NO in macrophages is tightly regulated by the competing enzymes, 
iNOS and ARG, for their common substrate, L-arginine, where the induction of one enzyme 
suppresses the expression of the other and vice versa (Modolell et al., 1995; Sonoki et al., 
1997; Chang et al., 1998). Notably, there are three isoforms of NOS, neuronal NOS (nNOS), 
endothelial NOS (eNOS, NOS3) and iNOS, with the former two collectively known as cNOS 
due to their constitutive expression. All three isoforms operate in the immune system and 
catalyse the same reaction. Importantly, iNOS expression in macrophages depends on 
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localised chemokine profiles. Thus, Th-1-derived IL-2, IL-12 and INF-γ increase iNOS 
expression and promote M1 polarity. Conversely, Th-2-derived IL-4, IL-10 and IL-13 induce 
ARG1 activity while IL-4, IL-13 also inhibit iNOS mRNA expression and so promote M2 
polarity (Modolell et al., 1995; Munder et al., 1998; Bogdan, 2001). 
 
In the context of neuropathic pain, iNOS+/ARG- M1 macrophages have been reported to 
rapidly infiltrate the injured nerve as soon as day 1, while iNOS-/ARG+ M2 macrophages 
infiltrate the DRG by day 2, suggesting distinct roles of macrophage populations in different 
tissues (Komori et al., 2011). In a similar study, M1 macrophage infiltration in the nerve was 
observed 1-2 days post PNL, while in IL-1R1/TNFR1 null mice, M1 macrophage infiltration 
was attenuated by 90% on day 1 post injury (Nadeau et al., 2011). M1 macrophage 
infiltration has also been observed in the inflamed paws of CFA treated mice, which 
correlated with mechanical hyperalgesia. Administration of the peroxisome proliferator-
activated receptor-γ agonist, rosiglitazone, alleviated pain behaviours by promoting M2 
infiltration at inflamed sites (Hasegawa-Moriyama et al., 2013). In addition to chronic pain, 
the pro-inflammatory M1 macrophage phenotype has been implicated in numerous diseases 
such as cancer and diabetes (Mosser and Edwards, 2008) whereas the M2 phenotype is 
generally perceived as M1 suppressive and pro-healing/repair. This is supported by studies 
demonstrating the beneficial effects of pro-M2 polarity. For example, clinical severity scores 
in a model of EAN were attenuated in TNF-α null mice, correlating with a pro-M2 
macrophage phenotype (Zhang et al., 2012b). In the same model, treatment with compound 
A (a plant-derived glucocorticoid receptor ligand) inhibited the progression of mechanical 
allodynia and increased numbers of M2 macrophages in the sciatic nerve by promoting M2 
polarity (Zhang et al., 2009). These studies are consistent with our own findings of a pro-M2 
state in GPR84 KO mice and diminished chronic pain behaviours and thus provides a 
credible explanation for the behavioural phenotype. 
 
Although the M1/M2 classification is useful in pertaining discrete macrophage populations 
to particular physiological functions, discrepancies in the literature suggest that such a 
broad segregation may not always be appropriate since it undermines the complexity of 
these cells. For instance, whilst ARG1 expression is considered a hallmark of alternative 
activation in murine macrophages, other studies have reported an increase in the 
expression of this marker following LPS stimulation (Sonoki et al., 1997; Menzies et al., 
2010). Therefore it is evident that ARG1 is induced by both innate (LPS) and alternative 
cues and so experimental classification of macrophages should ideally be carried out with 
more than one marker. For example, dectin-1 and MRC-1 can be used as early markers (6 
hours) of alternative activation involved in pathogen recognition and combating fungal 
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infections, whereas fizz1, ym1 and ARG1 can be used as late markers (24 hours) of 
alternative activation and are associated with tissue repair, wound healing and the control 
of parasitic infections. Evidentially, M2 classification encompasses different subtypes of 
macrophage cells, which exhibit a spectrum of overlapping functions and characteristics, as 
discussed in Chapter 1 (Menzies et al., 2010; David and Kroner, 2011). Hence caution should 
be applied when interpreting studies that have used broad markers such as ARG1, as this 
group of cells are not solely involved in passive healing and anti-inflammatory functions.  
 
Nevertheless, in conjunction with our findings of a pro-M2 macrophage polarity in nerve 
injured KO animals, we also observed greater intracellular cAMP production in KO 
macrophages than in WT. Elevated cAMP is associated with a broad range of 
immunosuppressive actions, including the down- or up- regulation of pro- or anti-
inflammatory mediators, respectively, as well as a reduction in phagocytic activity (Bourne 
et al., 1974; Aronoff et al., 2005; Serezani et al., 2008; Peters-Golden, 2009; Wall et al., 2009) 
as previously discussed (Chapter 4). In light of this evidence, we postulate that under 
pathological conditions the ability of GPR84 KO macrophages to launch an inflammatory 
response and release certain subsets of chemokines/cytokines is compromised. Therefore, 
we propose that GPR84 is a pro-inflammatory receptor that suppresses intracellular cAMP 
via Gαi/o coupled signalling mechanism and contributes to peripheral and central 
sensitisation via the release of pro-nociceptive CCL2, CCL3 and CXCL5. As GPR84 expression 
is regulated by LPS and other stimulators of the NF-κB pathway (IL-1β, TNF-α) (Bouchard et 
al., 2007), we suggest that GPR84 may signal in a similar way to chemokine receptors. Thus, 
GPR84 activation may initiate hydrolytic activity of PLA2, leading to the mobilisation of 
intracellular Ca2+ and possibly the activation of several other intracellular effectors 
including, PI3K and p38 MAPK (see Fig. 5.1) (Murdoch and Finn, 2000). According to our 
findings and the literature, GPR84 is also likely to be involved in the induction of NF-κB 
mediated transcription of pro-inflammatory mediators such as CXCL1, IL-8/CXCL8 and IL-
12p40 (Hwang, 2000; Wang et al., 2006a; Bouchard et al., 2007; Suzuki et al., 2013), as well 
as CCL2, CCL3 and CXCL5. We propose that under pathological conditions GPR84 is a FFA 
sensor trans-activated by TLR4 or activated via autocrine cytokine/chemokine signalling.  
 






Figure 5.1: GPR84 signalling pathway in a microglia/macrophage cell 
 
MCFFAs bind to GPR84, inhibiting the production of cAMP and initiating the hydrolytic activity of 
PLA2 via a Gαi/o coupled pathway. This leads to mobilisation of Ca2+ from intracellular stores (ER), the 
phosphorylation of p38 MAPK and the activation of NF-κB, which mediates the transcription of target 
genes. GPR84 expression is regulated via the activation of TLR4, TNFR1/2 and IL-1R. 
 
 
As GPR84 expression was more greatly induced by LPS in macrophages than microglia, as 
well as in nerve than spinal cord of neuropathic mice, GPR84 signalling may play a more 
prominent role in peripheral macrophages. Consistent with this, we ruled out microglial 
involvement as we did not observe an altered microglial response between genotypes in the 
PNL, CFA and LPS models of persistent/acute pain, despite an attenuation of pain 
behaviours in the KO. Although we did not see a difference in the injury-induced 
macrophage response in the sciatic nerve between genotypes, we only examined one 
marker (Iba1) at a single time point (7 days) and in a single model (PNL) and so there is 
scope for further investigation. It is also possible that the differences between WT and KO 
macrophages may not be detectable by staining for these traditional markers of activation. 
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some chemokines and cytokines rather than gross differences in their ability to become 
activated, proliferate or infiltrate sites of injury. The question is precisely how these subtle 
differences account for the absence of mechanical allodynia and thermal hyperalgesia in 
nerve injured KO mice.  
 
Macrophages are well-documented to contribute to mechanical and thermal hyperalgesia in 
models of neuropathic and inflammatory pain (Myers et al., 1996; Izikson et al., 2000; Liu et 
al., 2000; Abbadie et al., 2003; Barclay et al., 2007; Ulmann et al., 2010), but are reported to 
have a limited role in mechanical allodynia, since neither systemic or perineural 
administration of a macrophage inhibitor nor depletion or transfer of activated 
macrophages to the perineurium altered mechanical thresholds (Rutkowski et al., 2000; 
Barclay et al., 2007). This indicates that the absence of mechanical allodynia in nerve injured 
KO mice cannot be entirely attributed to a compromised macrophage response. However, in 
PNL injured mice engineered to express green fluorescent protein (GFP) in bone marrow, 
GFP+ monocytes infiltrated the spinal cord, proliferated and differentiated into activated 
microglia (Zhang et al., 2007). The authors concluded that both resident microglia and bone 
marrow-derived macrophages contribute to centrally driven mechanical allodynia and are 
equally important targets in therapeutic treatment. It has also been shown that intraneural 
injection of anti-inflammatory TGF-β1 alleviated mechanical allodynia and thermal 
hyperalgesia by reducing the numbers of pro-inflammatory macrophages in the injured 
sciatic nerve (Echeverry et al., 2013). Furthermore, a recent study using TLR2 null mice 
supported a prominent role of peripheral macrophages in behavioural hypersensitivity and 
found no evidence of microglial involvement (Shi et al., 2011). Here, it was reported that 
thermal hyperalgesia was abolished in nerve injured TLR2 KO mice whilst mechanical 
allodynia was partially attenuated, correlating with a reduction in macrophage infiltration 
(Shi et al., 2011). Therefore, although the contribution of reactive microglial cells to 
mechanisms underlying mechanical allodynia is well established, there is some evidence for 
the involvement of macrophages, however, these cells are unlikely to be the only drivers in 
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 Short procedure 
 Inexpensive 
 Maintains morphology of surrounding 
tissue 
 Cell numbers and IR can be quantified 
 Antibodies vary in specificity and sensitivity 
 No standard threshold for positivity 
 Non-specific staining 
 Staining can be variable based on tissue 
preparation 
 Overlapping of fluorophore signals can lead 
to false positives 
 A limited number of antibodies can be used 
simultaneously 




 Effectively detects and characterises 
proteins in small amounts 
 Sensitive  
 Antibodies vary in specificity and sensitivity 
 Non-specific staining 
 No morphological correlation 
 Inadequate protein transfer time can 
produce false negatives 




 Short procedure 
 Quantitative, accurate and reproducible 
 Distinct cell populations are defined by their 
size and granularity and can be sorted 
 Sensitive 
 5-6 antibodies can be assessed 
simultaneously 
 Cell number and IR can be quantified 
 Antibodies vary in specificity and sensitivity 
 No morphological correlation 
 Overlapping of fluorophore signals can lead 
to false positives if compensation is 
ineffective 




 Quantitative, accurate and reproducible 
 High through-put cards enables many genes 
to be examined simultaneously 
 Sensitive 
 Changes in the mRNA expression of cell 
markers and associated cytokines can be 
measured 
 Genomic contamination or faulty reactions 
can lead to inaccurate quantification 
 Time consuming 
 RNA degradation means there’s less/poor 
quality starting material 
 Protein verification is required 
 Non-specific amplification can lead to false-
positives 
 Expensive  
 
Table 5.1: Advantages and disadvantages of immune cell quantification techniques 
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The findings of this thesis support that pro-inflammatory GPR84 is a novel marker of 
chronic pain states primarily in macrophage cells. Hence an important extension of this 
work is to verify the differences in gene expression seen in the PNL model between 
genotypes, with a particular focus on the pro-M2 phenotype in the KO sciatic nerve. As 
previously mentioned quantification of the immune cell response in the PNL and CFA 
models was limited to the examination of two commonly used immunohistochemical 
markers.  Therefore a range of alternative immune cell markers associated with M1/M2 
polarity could be examined in WT and KO mice in models of chronic pain. However, since 
immunohistochemistry bears a number of technical limitations, alternative methods such as 
genetic profiling, western blotting and flow cytometry should be considered for quantifying 
the immune cell response. As presented in Table 5.1, each method possesses advantages and 
disadvantages and so the complementary use of more than one method is likely to be more 
informative and reliable. Finally, mediators that have shown reduced induction in LPS-
stimulated KO macrophages should be verified in vivo to examine their effects on acute pain 
thresholds and to determine which ones contribute to GPR84-mediated nociceptive 
transmission.  
 
The development of transgenic technology has enabled the robust study of single targets in 
a physiological context. This has led to great progression in pain research and an increase in 
published work featuring the mouse (Mogil, 2009). However, the KO mouse is not without 
its interpretational confounds. Genes tend to act in concert with one another and so gene 
targeting can result in compensatory up- (or even down-) regulation of other genes (Wilson 
and Mogil, 2001). Consequentially the observed behavioural phenotype we report could be 
the result of a number of developmental, physiological or behavioural processes that have 
altered to compensate for the null mutation. It is therefore possible that a number of 
phenotypical changes have occurred that are not necessarily related to the function of 
GPR84. Such compensatory effects may have masked any phenotypical differences between 
WT and KO microglia and macrophages, or may even be responsible for the absence of pain-
associated behaviours rather than GPR84 itself.  
 
Behavioural phenotypes can also be related to the genetic background of the mutant. 
Transgenic mice have been historically bred onto a C57BL/6 genetic background, which is 
not the most representative strain of pain sensitivity in a typical laboratory mouse (Mogil, 
2009). Nevertheless, most gene targeting is carried out on embryonic stem cells derived 
from the 129 strain and are placed on a C57BL/6 background strain. Both of which differ 
considerably in terms of pain-related traits (Wilson and Mogil, 2001). Therefore the gene 
alleles surrounding the locus of interest will be derived from the 129 strain in the null 
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mutants and B6 strain in the WT littermates. Consequentially, any phenotypical differences 
observed between the WT and KO mice could be due to the null mutation or a false positive 
generated by differences in genetic backgrounds. However, in this case an obvious solution 
would be to use a B6 cell line for gene targeting to prevent background genotype effects, 
which has exemplified previous success (Gerlai, 2001). 
 
To avoid the contingency of compensation compromising experimental results, more 
refined transgenic technology such as the inducible KO can be utilised. This allows genes to 
be switched on or off on demand, which facilitates the comparison of pre- and post- 
induction phenotypes (Gerlai, 2001). Therefore enabling the circumvention of 
compensatory mechanisms occuring during development that can lead to long-term 
changes in gene expression. However, due to the lack of pure bred backgrounds, 
experiments using these mice are also associated with interpretational complications 
(Gerlai, 2001). In our case a conventional pharmacological approach would provide a more 
feasible way to complement our studies and consolidate that the behavioural phenotype is a 
result of GPR84 deletion. Moreover, a selective agonist or antagonist would permit further 
in vitro and in vivo studies that directly examine the contribution of GPR84 to pain 
pathways.  
 
It is worth noting that no other developmental or behavioural abnormalities were observed 
in GPR84 KO mice, which exhibited normal acute pain thresholds and locomotor ability. 
However, this does not exclude the possibility of other undetected abnormalities, especially 
since WT littermates alone are not necessarily adequate controls due to the potential 
genetic background effects. Therefore, our experimental findings could possess greater 
credibility with additional non-littermate WT control groups. Furthermore, throughout this 
thesis sham-operated or saline-treated mice have served as experimental control groups. 
Although these groups serve as adequate controls for experimental variability introduced by 
surgery, general anaesthetic and handling, the potential effects of sham surgery or 
intrathecal saline administration on experimental results are not accounted for. Hence 
additional WT and KO naïve control groups should be considered in future experiments. 
Although this means that more animals are required, this is ethically justified with regards 
to the importance of good experimental design and the capability to adequately test an 
experimental hypothesis. 
 
Poorly designed studies and a failure to report methods and results appropriately is 
damaging to the efforts of researchers and the scientific community (Rice et al., 2013). The 
Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines, developed by the 
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National Centre for the Replacement, Refinement and Reduction of Animals in Research 
(NC3Rs), advocate that published research should provide all necessary information to 
enable other researchers to critically evaluate and utilise the work. These guidelines have 
steadily been adopted by an increasing number of journals and institutions and it has been 
shown that adherence to these reporting standards reduces bias and enforces better 
experimental design. This will not only improve confidence in pre-clinical research but will 
also increase the likelihood of developing effective therapies upon translation to humans 
(Rice et al., 2013).  
 
In light of these guidelines, a number of factors related to the work in this thesis should be 
considered. Firstly, as stated in the methods sections, age and sex-matched animals were 
allocated to experimental groups via the process of random selection. According to the 
ARRIVE guidelines this method does not provide adequate randomisation as manually 
selecting animals can introduce experimental bias; however, in our case this was necessary 
due to the limitations of an in-house transgenic colony. Even so, software-generated 
allocation would provide a preferable method of randomisation that we could adopt in 
future studies (Macleod et al., 2009). Another potentially impeding factor was the use of 
mixed sex animals, which introduces a number of variables such as hormonally driven 
differences in pain behaviours. Furthermore, the use of young and genetically identical mice 
is hardly a representation of the complex human chronic pain condition that is known to 
mainly affect women and the elderly. Likewise, the nerve injury and inflammatory models 
employed do not reflect the heterogeneity of clinical presentations of pain-related 
conditions or the associated comorbidities that many patients experience. In addition, 
although the outcome measures tested bear some similarity to symptoms of allodynia and  
hyperalgesia seen in the clinic, they do not account for spontaneous pain or the overall effect 
on quality of life in these patients (Andrews et al., 2012). Therefore, we could consider using 
elderly female mice and objective assays of innate behaviour such as spontaneous 
burrowing tests, alongside the conventional reflex based tests. We could also adopt 
alternative animal models that are more representative of the human condition in our 
studies.  
 
Allocation concealment was strictly carried out in every experiment reported in this thesis 
by assigning each mouse an individual identification number. However, it must be noted 
that although the genotype and treatment group of each mouse was blinded, in some cases 
the treatment group was visibly evident during testing due to hind paw swelling, limping or 
licking behaviours. Importantly, there were no visually obvious phenotypic differences 
between GPR84 WT and KO mice and so the genotype of the animals always remained 
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unknown until blinding was broken at the end of the experiment. In the same way as the 
behavioural studies, immunohistochemical assessment was carried out blind to treatment 
and genotype. However, the analysis could be improved by implementing more objective 
criteria to determine cell positivity such as a particular IR threshold, in addition to our prior 
requirement that a cell must be co-stained with a nuclear marker. 
 
Within the limited literature available, it is apparent that GPR84 is emerging as a 
functionally important receptor in fatty acid metabolism and immunoregulation, with some 
implications in metabolic diseases. Obesity and type 2 diabetes are associated with elevated 
levels of plasma FFAs, which can cause an accumulation of lipids and insulin resistance in 
pancreatic β-cells. Chronic exposure to FFAs may impair insulin secretion and contribute to 
hyper/hypoinsulinemia, which are characteristic of type 2 diabetes (Haber et al., 2003). 
Thus FFA-sensitive GPCRs are of particular interest in the development of therapeutic 
treatments against diabetes and other related disorders. In the past decade an increasing 
number of GPCRs have been deorphanised, leading to the identification of a number of FFA-
sensitive receptors such as GPR40/FFAR1, GPR41/FFAR3, GPR42 (functional polymorph of 
GPR41), GPR43/FFAR2, GPR84, GPR119 and GPR120 (Ichimura et al., 2009), which respond 
to FFAs of particular chain lengths, as previously discussed (Chapter 4). Obesity and type 2 
diabetes are usually accompanied by chronic low-grade metabolic inflammation that is 
related to immunological changes occurring in adipose tissue, liver, brain, islets and 
vasculature tissues in addition to changes in circulating leukocytes and their 
cytokine/chemokine profiles (Donath and Shoelson, 2011; Gregor and Hotamisligil, 2011).  
 
The contribution of macrophages to low-grade metabolic inflammation is of particular 
interest as they are the most abundant leukocyte population in the periphery and the key 
effector cells in inflammation-mediated insulin resistance. Macrophages have also been 
implicated in a number of other human diseases including RA, cancer, IBS, MS and psoriasis 
(Wynn et al., 2013). Macrophages express multiple GPCRs that contribute to immunological 
and inflammatory processes, including the newly identified GPR84, which has received 
substantial interest with regards to its immunoregulatory role in obesity and diabetes. 
Recruitment of inflammatory macrophages to adipose tissues and the consequential release 
of immune mediators is believed to promote inflammation and reduce insulin sensitivity in 
localised cells. Thus highlighting a link between the immune system and the incidence of 
adiposity and diabetes. In mice subjected to a high fat diet, GPR84 mRNA was up-regulated 
in fat pad tissues as a result of TNF-α release from invading macrophages, indicating that 
GPR84 may be directly involved in exacerbating the inflammatory changes occurring to 
adipocytes (Nagasaki et al., 2012). GPR40 has also been associated with impaired glucose 
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homeostasis and is highly expressed in pancreatic β-cells, where it plays a role in FFA 
mediated augmentation of insulin secretion (Talukdar et al., 2011). Interestingly, 
supraspinal GPR40 signalling has been implicated in pain; in the formalin model, 
intracerebroventricular injection of a selective GPR40 agonist (GW9508) attenuated pain 
behaviours, indicating an endogenous anti-nociceptive role of this receptor (Nakamoto et 
al., 2012). So far, GPR40 is the latest FFA-sensing GPCR that has been linked to nociceptive 
signalling. 
 
Painful diabetic neuropathy is one of the most prevalent complications in diabetes. Given 
the contribution of GPR84 signalling in chronic pain mechanisms and insulin resistance in 
inflamed adipocytes, it would be interesting to examine the involvement of GPR84 in 
diabetes. One of the most characterised models of painful diabetic neuropathy is the STZ-
induced neuropathy model in Psammomys obesus (Fat Sand rats), which show persistent 
mechanical, but not thermal, hyperalgesia starting at 2 weeks post STZ injection (Wuarin-
Bierman et al., 1987; Malcangio and Tomlinson, 1998). It would thus be informative to 
characterise pain responses and investigate the progression of obesity-induced adipocyte 
inflammation and insulin resistance in GPR84 transgenics. As previously discussed, the use 
of clinically relevant models such as the STZ-induced neuropathy model is an important step 
towards improving translational pain research. In addition, such approaches may reveal a 
critical role for GPR84 in low-grade metabolic diseases associated with chronic pain 
pathology. These metabolic diseases pose an increasing problem in the clinic, with the 
prevalence of obesity continuing to rise at alarming rates. However, encouragingly 
therapeutic interventions that inhibit inflammatory pathways in obesity by targeting the 
immune system are found to be effective and reduce the incidence of insulin sensitivity.  
 
In conclusion, the development of effective analgesics for chronic pain states remains a 
major challenge. However, our comprehension of the underlying mechanisms that 
contribute to pain pathophysiology has improved substantially. We now appreciate that the 
immune system is an important player in chronic pain and many related diseases. 
Therefore, the identification of novel immune cell targets like GPR84 holds a promising 
future for the development of superior therapies and enhanced patient care. 
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Appendix Table 1: Raw CT values of genes screened in the sciatic nerve of GPR84 WT 
sham and PNL operated mice 7 days post surgery 
  
Table 1
Gene 1 2 3 4 1 2 3 4
Allograft inflammatory factors -1 (Iba1; AIF) 29.5 29.8 29.7 28.5 27.7 28.7 27.6 27.4
Amphiregulin (AREG) ND ND 37.6 ND ND 34.6 32.9 33.8
Arginase 1 (ARG1) 26.9 27.2 28.9 30.1 25.9 26.7 26.1 26.5
Artemin (ARTN) 30.0 31.8 31.3 31.0 29.1 30.8 28.5 29.1
Brain-derived neurotrophic factor (BDNF) 33.8 31.8 33.1 31.2 30.5 31.2 29.0 29.5
Betacellulin (BTC) 28.6 28.9 29.8 28.6 27.0 28.4 26.5 28.1
Chemokine (C-C motif) ligand 1 (CCL1) ND 34.2 35.8 34.1 ND 35.7 ND 34.0
Chemokine (C-C motif) ligand 11 (CCL11) 22.2 22.2 22.2 22.0 23.7 25.1 23.7 24.5
Chemokine (C-C motif) ligand 17 (CCL17) 31.8 33.0 34.6 31.0 ND 33.8 34.0 33.2
Chemokine (C-C motif) ligand 19 (CCL19) 28.0 27.5 28.2 27.3 29.5 30.1 28.7 29.1
Chemokine (C-C motif) ligand 2 (CCL2) 27.5 27.3 27.7 26.6 26.8 27.8 25.8 27.2
Chemokine (C-C motif) ligand 20 (CCL20) ND ND ND ND ND ND ND ND
Chemokine (C-C motif) ligand 21a,b 
(CCL21a,b) 21.8 21.8 23.3 21.5 25.0 25.0 23.9 23.1
Chemokine (C-C motif) ligand 22 (CCL22) 30.8 31.0 30.5 29.2 28.7 29.7 28.9 28.6
Chemokine (C-C motif) ligand 24 (CCL24) 27.9 28.5 28.8 27.2 30.1 30.6 30.9 30.6
Chemokine (C-C motif) ligand 25 (CCL25) 28.5 27.7 27.9 27.8 28.5 29.8 29.7 29.4
Chemokine (C-C motif) ligand 27a,b 
(CCL27a,b) 25.3 24.8 25.1 25.0 26.9 27.4 27.3 27.2
Chemokine (C-C motif) ligand 3 (CCL3) 33.0 34.0 33.9 32.9 30.5 31.2 30.7 30.2
Chemokine (C-C motif) ligand 4 (CCL4) 31.8 31.6 31.5 31.4 28.6 29.9 29.0 28.6
Chemokine (C-C motif) ligand 5 (CCL5) 30.7 29.5 30.0 28.7 27.3 28.4 27.8 27.4
Chemokine (C-C motif) ligand 6 (CCL6) 21.9 22.7 22.6 20.3 20.8 21.3 21.5 21.0
Chemokine (C-C motif) ligand 7 (CCL7) 27.5 27.0 27.3 26.3 26.6 28.6 25.2 27.0
Chemokine (C-C motif) ligand 8 (CCL8) 28.5 26.3 27.8 22.6 23.9 24.0 24.0 23.9
Chemokine (C-C motif) ligand 9 (CCL9) 23.9 25.5 25.0 22.9 23.7 24.1 24.3 24.0
T-cell surface glycoprotein CD3 delta chain 
(CD3D) 36.8 36.0 33.9 33.9 33.1 ND 34.7 31.8
Colony stimulating  factor 1 (macrophage) 
(CSF1) 24.6 24.6 25.0 24.2 25.6 26.5 25.6 25.9
Colony stimulating  factor 2 (granulocyte-
macrophage) (CSF2) ND 33.5 35.2 32.4 ND ND 34.0 33.3
Colony stimulating  factor 3 (granulocyte) 
(CSF3) ND 31.3 35.0 31.8 32.7 33.3 30.2 33.6
Colony stimulating  factor 3 (granulocyte) 
receptor (CSF3R) 29.3 29.4 29.8 27.7 26.6 27.4 26.8 26.5
Chemokine (CX3-C motif) ligand 1 (CX3CL1) 27.1 26.7 26.9 26.2 26.3 27.6 26.6 26.7
Chemokine (C-X-C motif) ligand 1 (CXCL1) 29.9 28.0 30.5 27.7 30.0 32.6 29.4 29.5
Chemokine (C-X-C motif) ligand 10 (CXCL10) 28.7 28.5 29.2 27.5 27.3 29.0 28.9 27.5
Chemokine (C-X-C motif) ligand 11 (CXCL11) 28.1 28.0 27.9 27.8 30.9 30.5 32.7 31.4
Chemokine (C-X-C motif) ligand 12 (CXCL12) 28.6 28.7 29.6 28.8 27.5 29.2 28.4 27.5
Chemokine (C-X-C motif) ligand 13 (CXCL13) 24.6 25.1 25.6 23.5 28.3 28.2 29.2 29.3
Chemokine (C-X-C motif) ligand 14 (CXCL14) 23.7 24.7 24.3 23.9 23.9 24.2 24.3 24.8
Chemokine (C-X-C motif) ligand 16 (CXCL16) 26.9 26.5 27.0 25.7 24.6 25.3 24.5 23.9
Chemokine (C-X-C motif) ligand 17 (CXCL17) 32.5 32.6 32.6 31.7 ND 33.5 ND 32.5
Chemokine (C-X-C motif) ligand 2 (CXCL2) 32.6 32.2 33.6 30.9 28.0 29.3 28.0 28.9
Chemokine (C-X-C motif) ligand 3 (CXCL3) ND ND ND ND 29.8 32.3 29.8 31.0
Chemokine (C-X-C motif) ligand 5 (CXCL5) 34.5 32.4 ND 33.3 26.2 28.3 24.9 25.8
Chemokine (C-X-C motif) ligand 9 (CXCL9) 29.5 29.2 30.3 28.9 28.0 28.2 29.0 27.7
Chemokine (C-X-C motif) receptor 3 (CXCR3) 29.0 30.1 30.5 28.8 29.3 29.7 30.1 28.1
Epstein-Barr virus induced gene 3 (EBI3) 29.6 29.8 29.5 28.3 28.8 29.3 29.6 29.1
Epiregulin (EREG) ND 33.5 ND ND 33.1 31.9 29.5 32.0
Fibroblast growth factor 7 (keratinocyte 
growth factor; FGF7) 24.7 24.7 24.6 24.9 26.3 27.8 27.0 27.0
G-protein receptor 84 (GPR84) ND ND ND 34.6 31.2 31.7 31.4 33.7
Heparin-binding EGF-like growth factor 
(HBEGF) 25.0 24.2 24.4 24.5 26.5 27.0 26.5 27.1
Interleukin 10 (IL10) 34.1 35.9 34.3 31.3 32.9 33.5 32.8 32.3
Interleukin 11 (IL11) 32.0 31.1 31.5 31.3 32.1 32.5 31.1 32.0







Gene 1 2 3 4 1 2 3 4
Interleukin 12 alpha (IL12a) 31.7 30.8 30.5 31.4 33.9 32.2 33.5 33.3
Interleukin 12 beta (IL12b) ND 34.9 ND 35.5 33.5 ND 33.2 32.5
Interleukin 13 (IL13) 33.4 34.0 ND 36.6 ND ND ND 34.3
Interleukin 15 (IL15) 27.2 27.1 27.5 26.8 27.9 28.9 28.4 27.9
Interleukin 16 (IL16) 22.4 21.8 22.1 22.3 24.1 24.9 25.3 24.7
Interleukin 17 alpha (IL17a) ND 35.7 ND ND ND ND ND ND
Interleukin 18 (IL18) 28.1 27.9 28.6 27.0 28.1 29.5 29.3 28.3
Interleukin 19 (IL19) 34.1 ND 34.5 ND 34.5 ND ND ND
Interleukin 1 alpha (IL1a) ND ND ND 35.3 31.3 31.1 31.1 31.1
Interleukin 1 beta (IL1b) 31.8 30.2 32.9 29.2 26.5 28.3 26.1 26.9
Interleukin 2 (IL2) 37.6 ND ND ND ND ND ND ND
Interleukin 20 (IL20) ND ND ND ND ND ND ND ND
Interleukin 21 (IL21) 35.8 34.6 34.7 ND 33.9 ND ND ND
Interleukin 22 (IL22) ND ND ND ND ND ND ND ND
Interleukin 23 alpha (IL23a) 30.1 29.7 30.4 30.9 32.0 32.9 32.1 32.6
Interleukin 24 (IL24) ND ND ND ND ND ND ND ND
Interleukin 25 (IL25) 32.1 32.7 31.2 34.8 37.9 ND 33.6 33.6
Interleukin 27 (IL27) 32.7 ND 34.5 32.6 32.9 34.2 32.3 33.8
Interleukin 28 beta (IL28b) ND ND ND ND ND ND ND ND
Interleukin 3 (IL3) ND ND ND ND 34.6 ND ND ND
Interleukin 31 (IL31) ND ND ND ND ND ND ND ND
Interleukin 33 (IL33) 23.1 23.0 23.0 23.0 24.6 25.1 24.7 24.5
Interleukin 34 (IL34) 29.0 28.3 28.7 28.8 30.5 30.9 32.3 31.8
Interleukin 4 (IL4) ND ND ND ND ND ND ND ND
Interleukin 5 (IL5) 32.3 34.3 34.5 33.0 ND 33.2 34.5 32.9
Interleukin 6 (IL6) 32.6 30.0 32.5 30.5 31.1 34.2 28.2 30.8
Interleukin 7 (IL7) 30.5 30.1 31.3 29.6 31.2 33.0 30.7 31.0
Interleukin 9 (IL9) ND ND ND ND ND ND ND ND
Integrin alpha M (ITGAM); (CD11B) 25.3 25.8 26.0 24.0 23.3 24.1 23.6 23.4
Mannose receptor, C type 1 (MRC1) 23.9 24.0 24.1 22.4 23.4 23.9 23.4 23.5
Nerve growth factor (NGF) 26.9 26.4 27.5 26.2 26.8 28.4 26.5 27.1
Nitric oxide synthase, inducible (NOS2) 30.6 30.7 29.7 29.9 28.2 29.3 28.7 29.2
Neuregulin 1 (NRG1) 29.5 29.1 29.4 29.0 29.3 31.2 28.8 29.1
Platelet factor 4 (PF4; CXCL4) 24.4 24.7 24.6 23.1 22.6 24.3 23.1 23.2
Pro-platelet basic protein (chemokine (C-X-C 
motif) ligand 7 27.0 29.1 27.2 25.3 28.0 29.3 28.2 29.1
Prostaglandin E synthase (PTGES) 26.0 25.4 25.9 25.3 26.3 27.8 26.8 26.7
Prostaglandin-endoperoxide synthase 2     
(COX-2; PTGS2) 32.4 29.8 33.0 29.9 31.2 32.1 29.6 30.9
 Signal Transducer and Activator of 
Transcription protein 4 (STAT4) 29.6 29.7 29.7 30.1 30.1 30.5 29.6 29.9
Toll-like receptor 4 (TLR4) 25.5 25.7 25.7 24.9 25.7 26.7 25.8 25.8
Tumor necrosis factor (TNF) 30.8 30.6 31.6 30.2 28.2 29.2 28.7 28.1
Alpha-taxilin (TXLNA) 24.8 24.4 24.6 24.5 25.0 25.8 24.7 25.0
Chemokine (C motif) ligand 1 (XCL1) 35.8 ND 36.2 35.9 32.8 35.3 ND 32.9
Housekeeping genes
Beta-actin (ACTB) 18.7 18.4 18.7 18.3 18.6 19.4 18.7 18.8
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) 20.0 19.5 18.8 19.1 20.9 19.9 21.0 20.7
Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) 25.3 25.5 25.4 25.1 25.6 26.9 25.9 25.5
18s (X18S) 13.4 13.3 13.3 13.2 13.1 13.3 13.1 13.2




Appendix Table 2: Raw CT values of genes screened in the sciatic nerve of GPR84 KO 
sham and PNL operated mice 7 days post surgery 
 
Table 2
Gene 1 2 3 4 1 2 3 4
Allograft inflammatory factors -1 (Iba1; AIF) 29.2 29.4 30.1 30.0 28.0 25.5 27.2 27.2
Amphiregulin (AREG) ND ND ND ND ND ND ND ND
Arginase 1 (ARG1) 29.5 29.9 32.0 29.9 26.7 25.4 25.9 27.9
Artemin (ARTN) 30.5 32.4 30.6 31.7 29.9 29.5 31.6 31.0
Brain-derived neurotrophic factor (BDNF) 33.1 33.0 32.6 33.1 30.3 30.4 30.5 31.4
Betacellulin (BTC) 29.0 29.6 29.2 28.8 26.4 28.0 30.5 29.6
Chemokine (C-C motif) ligand 1 (CCL1) ND ND ND ND ND 35.3 33.7 34.9
Chemokine (C-C motif) ligand 11 (CCL11) 21.7 21.6 22.3 21.8 23.6 24.4 24.2 25.4
Chemokine (C-C motif) ligand 17 (CCL17) 34.5 32.9 32.7 33.9 35.4 33.5 32.4 31.4
Chemokine (C-C motif) ligand 19 (CCL19) 27.5 28.1 27.8 27.3 29.1 30.0 28.2 29.3
Chemokine (C-C motif) ligand 2 (CCL2) 28.1 28.0 28.3 28.5 27.1 24.9 26.6 27.1
Chemokine (C-C motif) ligand 20 (CCL20) ND ND ND ND ND ND ND 35.5
Chemokine (C-C motif) ligand 21a,b 
(CCL21a,b) 21.3 22.7 22.5 23.0 23.6 24.9 22.8 23.7
Chemokine (C-C motif) ligand 22 (CCL22) 29.8 30.1 30.4 30.8 31.1 27.6 28.4 28.3
Chemokine (C-C motif) ligand 24 (CCL24) 28.4 28.1 29.0 28.4 31.1 29.4 30.3 29.7
Chemokine (C-C motif) ligand 25 (CCL25) 27.4 28.0 28.1 27.6 28.7 28.7 29.7 29.1
Chemokine (C-C motif) ligand 27a,b 
(CCL27a,b) 24.8 24.9 25.1 24.9 27.2 27.1 27.4 26.8
Chemokine (C-C motif) ligand 3 (CCL3) 33.3 33.5 34.6 33.8 30.6 28.3 29.8 29.8
Chemokine (C-C motif) ligand 4 (CCL4) 31.7 32.5 33.0 32.2 29.1 26.4 27.6 28.2
Chemokine (C-C motif) ligand 5 (CCL5) 29.4 29.5 29.9 29.9 29.0 26.1 27.3 27.4
Chemokine (C-C motif) ligand 6 (CCL6) 21.9 22.2 22.2 22.5 21.9 19.6 20.6 21.1
Chemokine (C-C motif) ligand 7 (CCL7) 28.4 28.2 28.9 28.8 27.6 24.2 26.2 26.6
Chemokine (C-C motif) ligand 8 (CCL8) 27.3 27.6 28.1 27.3 25.2 21.5 23.7 24.2
Chemokine (C-C motif) ligand 9 (CCL9) 24.4 25.0 25.2 25.2 24.6 22.1 23.6 23.4
T-cell surface glycoprotein CD3 delta chain 
(CD3D) 34.4 33.8 34.6 33.7 33.6 30.5 32.4 31.9
Colony stimulating  factor 1 (macrophage) 
(CSF1) 24.3 24.7 24.8 24.6 26.4 25.3 26.1 26.3
Colony stimulating  factor 2 (granulocyte-
macrophage) (CSF2) 34.9 33.9 ND ND 34.9 33.0 ND 33.6
Colony stimulating  factor 3 (granulocyte) 
(CSF3) 34.6 ND 35.2 ND ND 34.2 32.7 32.9
Colony stimulating  factor 3 (granulocyte) 
receptor (CSF3R) 29.1 29.8 29.2 29.4 26.9 25.2 26.0 26.4
Chemokine (CX3-C motif) ligand 1 (CX3CL1) 26.5 26.9 27.1 27.1 28.0 27.1 26.9 28.2
Chemokine (C-X-C motif) ligand 1 (CXCL1) 30.3 29.3 30.4 30.0 29.9 27.9 29.6 30.7
Chemokine (C-X-C motif) ligand 10 (CXCL10) 28.1 29.1 29.4 29.0 28.3 24.9 26.9 27.5
Chemokine (C-X-C motif) ligand 11 (CXCL11) 27.3 27.3 27.7 27.4 29.9 31.0 30.7 33.1
Chemokine (C-X-C motif) ligand 12 (CXCL12) 28.3 28.6 29.0 28.9 29.7 27.8 28.8 28.2
Chemokine (C-X-C motif) ligand 13 (CXCL13) 24.3 25.2 24.6 24.3 27.5 30.1 29.3 30.7
Chemokine (C-X-C motif) ligand 14 (CXCL14) 24.0 25.4 24.6 25.5 24.2 24.5 23.9 25.4
Chemokine (C-X-C motif) ligand 16 (CXCL16) 26.1 26.7 26.7 26.8 25.1 23.4 24.1 24.3
Chemokine (C-X-C motif) ligand 17 (CXCL17) 31.2 33.4 33.3 31.9 32.9 33.9 33.8 35.2
Chemokine (C-X-C motif) ligand 2 (CXCL2) 34.3 32.1 32.8 32.9 28.6 26.8 27.8 27.8
Chemokine (C-X-C motif) ligand 3 (CXCL3) ND ND ND 34.4 31.9 29.3 29.4 29.8
Chemokine (C-X-C motif) ligand 5 (CXCL5) ND 34.0 34.5 33.8 28.2 24.1 24.9 25.9
Chemokine (C-X-C motif) ligand 9 (CXCL9) 29.7 30.8 30.2 30.5 29.5 25.9 27.1 27.5
Chemokine (C-X-C motif) receptor 3 (CXCR3) 29.7 30.1 30.0 29.8 30.1 27.5 28.5 28.9
Epstein-Barr virus induced gene 3 (EBI3) 29.2 29.2 29.2 29.1 31.1 28.3 29.3 29.5
Epiregulin (EREG) 33.9 ND ND 33.8 32.4 30.0 30.5 33.1
Fibroblast growth factor 7 (keratinocyte 
growth factor; FGF7) 24.3 24.2 24.7 24.5 26.2 26.4 27.0 28.0
G-protein receptor 84 (GPR84) ND ND ND ND ND ND ND ND
Heparin-binding EGF-like growth factor 
(HBEGF) 24.3 24.3 24.5 24.4 26.8 26.5 27.7 28.6
Interleukin 10 (IL10) 34.1 32.9 33.1 34.1 34.0 29.4 31.7 31.6
Interleukin 11 (IL11) 31.2 31.1 31.8 32.0 32.7 32.1 33.1 33.1










Gene 1 2 3 4 1 2 3 4
Interleukin 12 alpha (IL12a) 31.5 30.5 31.6 30.6 35.7 32.4 33.8 30.8
Interleukin 12 beta (IL12b) ND ND 34.8 35.0 33.0 31.6 33.2 31.1
Interleukin 13 (IL13) ND ND ND ND ND ND 34.9 ND
Interleukin 15 (IL15) 26.2 26.9 27.7 27.3 28.3 27.2 28.3 28.3
Interleukin 16 (IL16) 21.6 21.3 22.1 21.7 24.4 24.3 24.8 25.9
Interleukin 17 alpha (IL17a) 36.9 ND ND ND ND ND ND ND
Interleukin 18 (IL18) 27.8 28.2 28.7 28.3 28.5 26.8 28.5 28.8
Interleukin 19 (IL19) 36.6 ND ND 34.7 12.4 34.8 ND ND
Interleukin 1 alpha (IL1a) ND ND ND 35.1 30.7 30.2 32.0 32.0
Interleukin 1 beta (IL1b) 31.6 30.8 32.2 31.9 27.2 24.5 25.8 26.1
Interleukin 2 (IL2) 34.8 35.5 34.8 ND 35.0 33.9 ND ND
Interleukin 20 (IL20) 32.8 35.4 ND ND ND ND ND 35.6
Interleukin 21 (IL21) 37.0 34.6 ND ND ND ND ND 35.4
Interleukin 22 (IL22) ND ND ND ND ND ND ND ND
Interleukin 23 alpha (IL23a) 30.4 29.5 30.5 30.3 32.7 31.4 32.0 ND
Interleukin 24 (IL24) ND ND ND 35.0 ND ND ND ND
Interleukin 25 (IL25) 30.6 32.2 33.7 32.3 32.7 33.2 ND 34.4
Interleukin 27 (IL27) 32.8 34.5 ND 32.3 33.3 30.7 31.9 32.6
Interleukin 28 beta (IL28b) ND ND ND ND ND ND ND ND
Interleukin 3 (IL3) 38.0 ND ND ND ND ND ND ND
Interleukin 31 (IL31) ND ND ND ND ND ND ND ND
Interleukin 33 (IL33) 22.7 23.1 23.1 23.0 24.7 25.5 24.0 25.7
Interleukin 34 (IL34) 28.6 28.1 29.0 28.0 30.0 31.4 32.9 34.0
Interleukin 4 (IL4) ND ND ND ND ND ND ND ND
Interleukin 5 (IL5) 33.2 33.3 34.0 33.4 ND ND ND ND
Interleukin 6 (IL6) 33.4 34.6 34.4 34.3 32.4 28.4 30.4 32.0
Interleukin 7 (IL7) 29.5 30.3 30.9 30.3 31.8 30.5 32.2 31.4
Interleukin 9 (IL9) ND ND ND ND ND ND ND ND
Integrin alpha M (ITGAM); (CD11B) 25.4 25.5 25.5 25.8 24.4 22.3 23.3 23.5
Mannose receptor, C type 1 (MRC1) 23.8 24.0 24.2 24.0 24.5 21.9 23.5 23.8
Nerve growth factor (NGF) 27.3 27.3 27.7 27.9 28.2 27.5 28.0 28.2
Nitric oxide synthase, inducible (NOS2) 30.4 30.2 31.2 30.6 30.3 27.4 28.4 28.8
Neuregulin 1 (NRG1) 29.5 28.7 29.4 29.6 29.6 28.3 30.2 29.6
Platelet factor 4 (PF4; CXCL4) 24.0 24.4 24.7 24.3 24.4 21.4 22.7 23.3
Pro-platelet basic protein (chemokine (C-X-C 
motif) ligand 7 27.9 29.1 28.9 25.2 27.8 26.7 27.9 28.8
Prostaglandin E synthase (PTGES) 25.4 25.8 26.0 25.6 27.2 26.6 27.6 27.8
Prostaglandin-endoperoxide synthase 2               
(COX-2; PTGS2) 30.6 30.2 32.1 32.3 31.5 29.4 30.9 30.8
 Signal Transducer and Activator of 
Transcription protein 4 (STAT4) 29.5 29.3 30.1 29.7 30.4 27.8 29.2 29.5
Toll-like receptor 4 (TLR4) 25.4 25.8 25.6 25.4 25.7 24.3 25.8 26.1
Tumor necrosis factor (TNF) 30.2 31.3 31.5 32.2 28.7 26.7 27.8 27.2
Alpha-taxilin (TXLNA) 24.1 24.1 24.6 24.3 25.6 24.6 25.9 25.8
Chemokine (C motif) ligand 1 (XCL1) 35.8 34.7 35.4 ND 33.7 30.3 32.3 32.3
Housekeeping genes
Beta-actin (ACTB) 18.5 18.3 18.7 18.7 20.1 18.5 19.1 19.5
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) 19.4 19.5 19.9 19.8 21.3 20.0 20.9 18.9
Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) 25.0 25.2 25.4 25.1 25.5 24.8 26.0 26.1
18s (X18S) 13.2 13.1 13.3 13.1 13.3 13.3 13.5 13.3




Appendix Table 3: Raw CT values of genes screened in the spinal cord of GPR84 WT 




Gene 1 2 3 4 1 2 3 4
Allograft inflammatory factors -1 (Iba1; AIF) 28.5 26.9 27.2 26.9 26.8 27.6 27.6 28.0
Amphiregulin (AREG) ND ND 33.9 ND 34.0 34.9 ND ND
Arginase 1 (ARG1) 32.9 31.3 32.1 30.7 31.8 31.9 32.3 33.0
Artemin (ARTN) 30.9 29.9 30.9 29.6 30.1 30.4 30.8 30.5
Brain-derived neurotrophic factor (BDNF) 27.6 27.4 27.7 27.0 27.3 27.1 28.0 27.6
Betacellulin (BTC) 29.3 28.4 28.0 27.3 27.7 29.0 28.9 29.1
Chemokine (C-C motif) ligand 1 (CCL1) ND ND ND ND ND ND ND ND
Chemokine (C-C motif) ligand 11 (CCL11) 27.3 26.4 25.8 26.1 25.6 25.4 27.7 27.7
Chemokine (C-C motif) ligand 17 (CCL17) ND 32.6 35.3 ND 34.0 ND ND 36.7
Chemokine (C-C motif) ligand 19 (CCL19) 28.1 25.5 26.0 26.3 26.2 27.6 27.7 27.9
Chemokine (C-C motif) ligand 2 (CCL2) 31.3 30.6 31.6 30.0 27.5 29.0 29.5 30.3
Chemokine (C-C motif) ligand 20 (CCL20) ND ND ND ND ND ND ND ND
Chemokine (C-C motif) ligand 21a,b 
(CCL21a,b) 26.0 24.7 24.1 25.4 24.6 24.5 25.7 26.0
Chemokine (C-C motif) ligand 22 (CCL22) 30.6 30.2 29.3 29.2 29.4 30.7 30.6 30.5
Chemokine (C-C motif) ligand 24 (CCL24) 31.3 31.0 31.6 31.0 31.7 31.5 31.9 32.4
Chemokine (C-C motif) ligand 25 (CCL25) 26.0 25.7 25.5 25.1 25.3 25.8 26.0 26.0
Chemokine (C-C motif) ligand 27a,b 
(CCL27a,b) 23.2 22.8 22.9 22.3 22.7 23.1 23.5 23.3
Chemokine (C-C motif) ligand 3 (CCL3) 34.6 32.6 32.3 32.8 32.7 33.7 33.6 34.1
Chemokine (C-C motif) ligand 4 (CCL4) 32.8 31.0 30.5 29.9 30.8 31.4 31.4 32.8
Chemokine (C-C motif) ligand 5 (CCL5) 30.6 28.6 29.4 28.8 28.3 29.2 29.9 30.7
Chemokine (C-C motif) ligand 6 (CCL6) 25.8 24.0 24.7 24.7 24.5 23.9 25.9 26.0
Chemokine (C-C motif) ligand 7 (CCL7) 32.2 30.9 30.9 29.8 26.4 27.1 27.8 27.6
Chemokine (C-C motif) ligand 8 (CCL8) 32.6 29.8 32.8 30.7 30.2 31.2 31.3 33.0
Chemokine (C-C motif) ligand 9 (CCL9) 27.2 25.9 26.3 26.3 25.9 25.7 26.4 27.1
T-cell surface glycoprotein CD3 delta chain 
(CD3D) 33.7 31.7 33.3 33.2 32.4 33.3 ND 33.9
Colony stimulating  factor 1 (macrophage) 
(CSF1) 24.4 23.6 23.1 23.0 23.1 23.7 23.9 24.0
Colony stimulating  factor 2 (granulocyte-
macrophage) (CSF2) ND ND 35.1 35.1 ND ND ND ND
Colony stimulating  factor 3 (granulocyte) 
(CSF3) ND 35.1 ND ND 34.4 34.8 ND ND
Colony stimulating  factor 3 (granulocyte) 
receptor (CSF3R) 27.6 25.8 26.5 26.4 26.0 26.3 27.3 27.1
Chemokine (CX3-C motif) ligand 1 (CX3CL1) 21.2 20.8 20.9 20.0 20.5 21.1 21.6 21.2
Chemokine (C-X-C motif) ligand 1 (CXCL1) 33.2 30.4 31.8 31.4 31.2 32.1 33.7 34.6
Chemokine (C-X-C motif) ligand 10 (CXCL10) 31.3 30.4 28.3 29.0 28.8 29.2 29.0 29.7
Chemokine (C-X-C motif) ligand 11 (CXCL11) 31.7 30.2 29.4 29.1 29.4 29.9 31.0 32.0
Chemokine (C-X-C motif) ligand 12 (CXCL12) 31.3 30.5 30.7 30.5 30.8 30.8 31.4 31.4
Chemokine (C-X-C motif) ligand 13 (CXCL13) 33.7 29.2 31.9 33.7 30.5 29.3 32.6 31.3
Chemokine (C-X-C motif) ligand 14 (CXCL14) 22.1 21.2 21.4 21.1 21.3 21.9 22.4 22.0
Chemokine (C-X-C motif) ligand 16 (CXCL16) 27.4 25.2 26.0 25.5 25.9 26.5 26.5 27.5
Chemokine (C-X-C motif) ligand 17 (CXCL17) 35.0 32.4 32.9 32.2 32.9 33.8 33.5 35.0
Chemokine (C-X-C motif) ligand 2 (CXCL2) ND 35.2 35.4 35.9 33.5 ND ND ND
Chemokine (C-X-C motif) ligand 3 (CXCL3) ND 34.7 ND 34.5 34.6 34.7 ND 34.8
Chemokine (C-X-C motif) ligand 5 (CXCL5) 30.2 30.2 29.7 29.4 29.1 30.5 31.3 31.4
Chemokine (C-X-C motif) ligand 9 (CXCL9) 35.7 34.7 34.3 34.8 31.5 33.0 31.4 34.3
Chemokine (C-X-C motif) receptor 3 (CXCR3) 32.6 29.9 31.4 30.7 31.6 31.2 31.9 33.1
Epstein-Barr virus induced gene 3 (EBI3) 30.6 29.7 29.7 29.3 29.6 30.2 30.8 30.5
Epiregulin (EREG) ND ND ND 36.1 34.9 ND ND ND
Fibroblast growth factor 7 (keratinocyte 
growth factor; FGF7) 28.5 28.1 27.7 27.5 27.1 27.5 28.8 28.6
G-protein receptor 84 (GPR84) 31.7 29.4 29.4 29.8 27.8 28.5 29.3 30.2
Heparin-binding EGF-like growth factor 
(HBEGF) 26.0 25.5 25.3 24.2 24.9 25.5 26.0 26.1
Interleukin 10 (IL10) ND 36.4 ND ND ND 35.3 35.8 ND
Interleukin 11 (IL11) 31.8 32.0 31.5 31.0 31.7 32.5 33.0 33.3









Gene 1 2 3 4 1 2 3 4
Interleukin 12 alpha (IL12a) 30.9 29.7 29.6 30.1 30.4 30.4 31.0 30.8
Interleukin 12 beta (IL12b) ND 34.1 32.7 33.8 34.9 34.3 34.1 ND
Interleukin 13 (IL13) ND 35.3 ND 34.1 ND ND ND ND
Interleukin 15 (IL15) 28.9 28.4 28.5 27.6 28.1 29.0 28.9 29.9
Interleukin 16 (IL16) 25.9 24.5 24.1 24.6 24.0 24.4 26.0 26.0
Interleukin 17 alpha (IL17a) ND ND ND ND 34.3 ND ND ND
Interleukin 18 (IL18) 25.1 24.0 23.9 23.4 23.7 24.6 25.3 24.7
Interleukin 19 (IL19) 34.0 31.5 30.7 31.6 32.6 32.4 33.0 32.6
Interleukin 1 alpha (IL1a) 31.7 30.4 31.2 30.1 29.2 30.0 30.5 30.8
Interleukin 1 beta (IL1b) 30.4 31.7 31.3 30.4 28.2 28.9 31.2 32.6
Interleukin 2 (IL2) ND ND ND ND ND ND ND ND
Interleukin 20 (IL20) ND ND 34.7 36.0 ND ND ND ND
Interleukin 21 (IL21) 31.9 32.7 31.5 32.5 33.2 32.7 33.6 33.3
Interleukin 22 (IL22) ND ND ND ND ND ND ND ND
Interleukin 23 alpha (IL23a) 30.3 29.6 29.0 28.6 29.7 29.8 30.0 29.8
Interleukin 24 (IL24) ND ND ND ND 34.5 34.2 33.6 ND
Interleukin 25 (IL25) 31.8 30.9 31.4 30.8 30.0 30.2 31.7 31.7
Interleukin 27 (IL27) ND ND 33.7 33.1 32.9 34.7 34.4 ND
Interleukin 28 beta (IL28b) ND ND ND ND ND ND ND ND
Interleukin 3 (IL3) ND ND ND ND ND ND ND ND
Interleukin 31 (IL31) 35.5 ND ND ND ND ND ND ND
Interleukin 33 (IL33) 22.8 22.3 22.2 21.2 21.8 22.6 22.8 22.7
Interleukin 34 (IL34) 30.6 28.4 29.4 28.6 29.3 29.8 30.8 30.8
Interleukin 4 (IL4) ND ND ND ND ND ND ND ND
Interleukin 5 (IL5) 32.0 31.4 31.1 32.1 31.2 31.6 33.3 32.2
Interleukin 6 (IL6) 34.4 32.4 31.6 33.0 30.8 31.8 34.4 33.1
Interleukin 7 (IL7) 30.0 29.6 30.0 29.1 29.0 29.7 30.4 30.0
Interleukin 9 (IL9) ND ND ND ND ND ND ND ND
Integrin alpha M (ITGAM; CD11B) 25.2 23.6 24.3 23.9 23.4 23.2 24.2 24.3
Mannose receptor, C type 1 (MRC1) 27.4 25.1 25.9 25.3 25.9 25.8 26.6 27.3
Nerve growth factor (NGF) 29.1 27.4 27.6 26.9 27.4 27.8 28.4 28.5
Nitric oxide synthase, inducible (NOS2) 30.1 30.0 29.1 28.3 29.2 30.0 30.2 30.1
Neuregulin 1 (NRG1) 23.0 22.2 21.9 21.7 21.8 22.6 23.2 23.0
Platelet factor 4 (PF4; CXCL4) 25.5 25.6 26.0 25.4 24.0 25.1 26.4 27.6
Pro-platelet basic protein (chemokine (C-X-C 
motif) ligand 7 25.0 25.8 25.8 25.8 23.5 24.7 25.9 27.2
Prostaglandin E synthase (PTGES) 28.1 27.0 26.9 26.6 26.6 27.7 28.2 28.3
Prostaglandin-endoperoxide synthase 2      
(COX-2; PTGS2) 31.2 29.3 31.0 30.3 28.9 30.9 31.8 31.8
 Signal Transducer and Activator of 
Transcription protein 4 (STAT4) 31.7 30.5 31.9 30.2 31.2 31.2 32.1 31.5
Toll-like receptor 4 (TLR4) 28.9 26.9 27.4 27.2 27.2 27.3 28.2 28.6
Tumor necrosis factor (TNF) 31.3 30.8 31.8 32.5 29.8 30.1 31.5 31.4
Alpha-taxilin (TXLNA) 24.2 23.5 23.5 23.0 22.9 23.7 24.3 24.0
Chemokine (C motif) ligand 1 (XCL1) ND 34.0 35.4 33.6 34.6 35.3 34.3 36.0
Housekeeping genes
Beta-actin (ACTB) 18.4 17.7 17.6 17.2 17.3 17.9 18.4 18.3
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) 17.4 17.0 16.9 16.6 16.7 17.2 17.7 17.5
Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) 23.2 22.5 22.4 21.8 22.1 22.9 23.4 23.2
18s (X18S) 13.3 13.2 13.2 13.2 13.1 13.2 13.3 13.2




Appendix Table 4: Raw CT values of genes screened in the spinal cord tissue of GPR84 




Gene 1 2 3 4 1 2 3 4
Allograft inflammatory factors -1 (Iba1; AIF) 27.8 27.9 27.8 28.0 27.7 27.8 27.5 27.2
Amphiregulin (AREG) ND 34.9 34.4 ND ND ND 34.8 ND
Arginase 1 (ARG1) 33.3 31.9 32.6 32.2 33.2 32.6 32.5 32.0
Artemin (ARTN) 31.1 31.1 30.6 30.0 31.4 31.1 30.8 31.0
Brain-derived neurotrophic factor (BDNF) 27.3 28.0 27.8 27.2 28.2 28.2 27.7 28.0
Betacellulin (BTC) 29.1 28.5 28.6 29.2 29.1 28.6 28.2 28.7
Chemokine (C-C motif) ligand 1 (CCL1) ND ND ND ND ND ND 35.8 ND
Chemokine (C-C motif) ligand 11 (CCL11) 26.9 25.8 26.1 26.9 27.4 27.5 27.7 27.4
Chemokine (C-C motif) ligand 17 (CCL17) 35.2 35.6 35.6 ND 36.0 35.7 35.9 35.9
Chemokine (C-C motif) ligand 19 (CCL19) 26.7 27.7 26.3 27.0 28.0 27.7 27.9 27.5
Chemokine (C-C motif) ligand 2 (CCL2) 31.4 32.8 31.2 31.6 29.1 29.9 30.1 29.2
Chemokine (C-C motif) ligand 20 (CCL20) ND 35.2 ND ND ND ND ND ND
Chemokine (C-C motif) ligand 21a,b 
(CCL21a,b) 25.6 26.3 25.0 24.9 25.0 24.6 24.6 24.7
Chemokine (C-C motif) ligand 22 (CCL22) 29.8 30.7 30.2 29.8 30.9 31.7 30.4 30.4
Chemokine (C-C motif) ligand 24 (CCL24) 32.5 32.9 32.9 31.5 32.6 33.7 33.1 32.0
Chemokine (C-C motif) ligand 25 (CCL25) 25.4 25.8 25.7 25.6 26.5 26.2 25.8 25.9
Chemokine (C-C motif) ligand 27a,b 
(CCL27a,b) 22.8 23.2 22.9 22.8 23.5 23.4 23.0 23.0
Chemokine (C-C motif) ligand 3 (CCL3) 33.0 33.1 32.3 33.3 33.7 33.8 32.8 33.6
Chemokine (C-C motif) ligand 4 (CCL4) 32.0 31.3 31.0 31.7 31.9 31.7 30.7 31.8
Chemokine (C-C motif) ligand 5 (CCL5) 30.8 29.5 29.3 30.3 30.3 29.1 27.1 29.5
Chemokine (C-C motif) ligand 6 (CCL6) 25.3 25.1 25.2 25.6 25.9 25.3 24.6 25.5
Chemokine (C-C motif) ligand 7 (CCL7) 31.9 32.3 30.7 32.2 27.3 27.7 28.6 26.8
Chemokine (C-C motif) ligand 8 (CCL8) 34.7 32.7 31.9 32.2 32.2 31.4 30.5 30.7
Chemokine (C-C motif) ligand 9 (CCL9) 26.6 27.0 26.3 26.8 27.6 27.1 26.4 27.0
T-cell surface glycoprotein CD3 delta chain 
(CD3D) ND 33.7 34.5 34.8 34.4 33.5 32.3 34.0
Colony stimulating  factor 1 (macrophage) 
(CSF1) 23.7 24.0 23.7 24.0 24.2 24.0 23.7 23.8
Colony stimulating  factor 2 (granulocyte-
macrophage) (CSF2) ND ND ND ND ND ND ND ND
Colony stimulating  factor 3 (granulocyte) 
(CSF3) 33.9 34.1 ND ND ND 35.7 32.4 ND
Colony stimulating  factor 3 (granulocyte) 
receptor (CSF3R) 26.8 27.3 26.6 27.2 26.9 26.7 26.1 26.6
Chemokine (CX3-C motif) ligand 1 (CX3CL1) 20.7 21.2 21.0 20.6 21.5 21.3 21.0 21.1
Chemokine (C-X-C motif) ligand 1 (CXCL1) 33.9 32.4 31.6 32.4 ND 32.7 31.0 33.1
Chemokine (C-X-C motif) ligand 10 (CXCL10) 30.7 29.9 29.6 30.2 30.6 29.5 28.3 29.0
Chemokine (C-X-C motif) ligand 11 (CXCL11) 30.5 28.9 30.2 30.1 30.6 31.2 30.9 30.9
Chemokine (C-X-C motif) ligand 12 (CXCL12) 31.5 30.3 30.7 31.4 32.5 30.9 30.7 31.4
Chemokine (C-X-C motif) ligand 13 (CXCL13) 32.5 34.5 30.9 34.0 32.5 31.4 30.4 32.0
Chemokine (C-X-C motif) ligand 14 (CXCL14) 21.3 21.7 21.6 21.4 22.2 21.9 21.9 22.0
Chemokine (C-X-C motif) ligand 16 (CXCL16) 26.8 26.4 25.9 26.7 27.5 26.3 26.6 26.5
Chemokine (C-X-C motif) ligand 17 (CXCL17) 33.0 32.8 33.0 ND 34.2 34.4 32.1 34.1
Chemokine (C-X-C motif) ligand 2 (CXCL2) ND ND 32.6 35.6 ND ND 35.1 ND
Chemokine (C-X-C motif) ligand 3 (CXCL3) ND 35.2 ND ND ND ND ND ND
Chemokine (C-X-C motif) ligand 5 (CXCL5) 29.8 29.7 30.8 30.3 31.0 30.8 30.7 31.2
Chemokine (C-X-C motif) ligand 9 (CXCL9) 34.9 31.6 33.9 33.3 33.0 32.8 29.2 31.0
Chemokine (C-X-C motif) receptor 3 (CXCR3) 38.0 31.9 32.8 32.0 32.3 31.5 29.7 31.1
Epstein-Barr virus induced gene 3 (EBI3) 29.9 31.3 29.9 30.5 31.0 30.2 29.0 30.7
Epiregulin (EREG) ND ND ND ND ND ND 34.9 ND
Fibroblast growth factor 7 (keratinocyte 
growth factor; FGF7) 28.2 27.1 27.7 27.9 28.7 28.6 28.5 28.3
G-protein receptor 84 (GPR84) ND ND ND ND ND ND ND ND
Heparin-binding EGF-like growth factor 
(HBEGF) 25.6 25.5 25.7 25.6 26.2 25.8 25.5 25.6
Interleukin 10 (IL10) 35.9 ND ND 35.0 ND 34.8 34.9 35.5
Interleukin 11 (IL11) 32.2 32.7 32.2 32.0 33.2 33.2 32.4 32.1







Gene 1 2 3 4 1 2 3 4
Interleukin 12 alpha (IL12a) 29.7 30.1 30.2 30.4 30.9 30.7 31.2 30.8
Interleukin 12 beta (IL12b) 35.8 34.9 ND 34.9 ND 34.3 34.3 ND
Interleukin 13 (IL13) 34.8 ND ND ND ND ND ND 34.6
Interleukin 15 (IL15) 29.2 29.1 28.9 29.1 29.5 29.4 28.9 28.9
Interleukin 16 (IL16) 25.3 24.5 24.4 24.9 25.4 26.1 25.7 25.1
Interleukin 17 alpha (IL17a) ND ND ND ND ND ND ND ND
Interleukin 18 (IL18) 24.3 24.6 24.6 24.5 25.0 25.0 25.0 24.8
Interleukin 19 (IL19) 31.7 31.9 31.7 33.2 37.4 32.8 33.3 32.6
Interleukin 1 alpha (IL1a) 30.9 31.5 30.9 30.9 30.6 30.2 30.9 29.4
Interleukin 1 beta (IL1b) 31.9 31.3 31.5 32.4 32.9 31.7 28.3 31.9
Interleukin 2 (IL2) ND ND ND ND ND ND ND ND
Interleukin 20 (IL20) 34.9 ND ND ND ND ND ND ND
Interleukin 21 (IL21) 31.8 31.9 31.9 32.2 33.0 31.9 32.6 32.5
Interleukin 22 (IL22) ND ND 38.0 ND ND ND ND ND
Interleukin 23 alpha (IL23a) 29.4 29.2 29.4 29.4 30.7 30.4 29.7 29.9
Interleukin 24 (IL24) ND ND ND ND 35.2 ND 34.8 34.9
Interleukin 25 (IL25) 30.6 31.2 31.3 30.1 31.0 30.8 30.7 31.2
Interleukin 27 (IL27) 35.2 ND 34.3 31.9 ND ND 32.6 35.2
Interleukin 28 beta (IL28b) ND ND ND ND ND ND ND ND
Interleukin 3 (IL3) ND ND ND ND ND ND ND ND
Interleukin 31 (IL31) ND ND ND ND ND ND ND 35.6
Interleukin 33 (IL33) 22.4 22.1 22.6 22.3 23.0 22.7 22.2 22.4
Interleukin 34 (IL34) 29.8 30.1 29.6 30.0 30.3 30.1 29.9 31.0
Interleukin 4 (IL4) ND 37.4 ND ND ND ND ND ND
Interleukin 5 (IL5) 31.3 32.1 32.5 31.4 32.4 31.8 30.6 33.3
Interleukin 6 (IL6) 32.6 33.6 33.5 33.6 33.4 32.2 32.0 31.8
Interleukin 7 (IL7) 29.6 30.0 29.5 29.9 29.9 30.2 30.0 29.6
Interleukin 9 (IL9) ND ND ND ND ND ND ND ND
Integrin alpha M (ITGAM; CD11B) 24.7 24.6 24.4 24.8 24.4 24.0 24.0 23.7
Mannose receptor, C type 1 (MRC1) 26.8 26.3 25.8 26.7 27.6 26.9 26.7 26.4
Nerve growth factor (NGF) 27.9 28.6 28.0 28.0 28.2 28.2 27.7 27.9
Nitric oxide synthase, inducible (NOS2) 29.8 29.6 30.4 29.7 30.6 30.3 28.9 29.3
Neuregulin 1 (NRG1) 22.2 22.5 22.5 22.4 22.8 22.7 22.6 22.7
Platelet factor 4 (PF4; CXCL4) 26.3 24.9 26.5 26.3 26.2 27.7 24.6 26.6
Pro-platelet basic protein (chemokine (C-X-C 
motif) ligand 7 25.9 24.0 26.9 25.6 25.3 28.3 23.3 26.3
Prostaglandin E synthase (PTGES) 27.5 27.4 27.4 27.4 28.2 28.0 27.6 27.7
Prostaglandin-endoperoxide synthase 2      
(COX-2; PTGS2) 30.8 30.8 30.4 30.6 30.8 31.1 28.5 31.3
 Signal Transducer and Activator of 
Transcription protein 4 (STAT4) 32.8 31.7 30.9 33.6 32.9 31.1 30.4 32.9
Toll-like receptor 4 (TLR4) 28.2 27.9 27.7 28.1 28.4 28.4 27.3 28.0
Tumor necrosis factor (TNF) 34.2 32.1 32.1 31.3 31.1 30.2 30.6 30.7
Alpha-taxilin (TXLNA) 23.5 23.6 23.7 23.5 24.3 23.9 23.9 23.7
Chemokine (C motif) ligand 1 (XCL1) 36.7 33.4 35.8 36.6 ND 34.7 35.3 34.9
Housekeeping genes
Beta-actin (ACTB) 17.9 17.9 18.0 17.9 18.3 18.2 17.8 17.9
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) 16.9 17.1 17.0 17.0 17.5 17.4 17.2 17.2
Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) 22.3 22.9 22.8 22.5 23.1 23.2 23.2 22.9
18s (X18S) 13.2 13.2 13.0 13.1 13.3 13.2 13.2 13.2




Appendix Table 5: Raw CT values of genes screened in the sciatic nerve of GPR84 WT 




Gene 1 2 3 4 1 2 3 4
Allograft inflammatory factors -1 (Iba1; AIF) 29.8 30.3 32.3 32.9 31.3 31.0 32.5 30.4
Amphiregulin (AREG) 37.6 36.5 ND ND ND ND ND ND
Artemin (ARTN) 32.4 32.1 33.6 31.6 32.9 35.0 32.9 31.6
Brain-derived neurotrophic factor (BDNF) ND 33.5 ND ND 32.7 32.7 32.8 ND
Betacellulin (BTC) 30.5 30.1 32.1 31.0 28.9 30.9 29.3 29.3
Chemokine (C-C motif) ligand 1 (CCL1) ND ND ND ND ND ND ND ND
Chemokine (C-C motif) ligand 11 (CCL11) 23.7 22.8 24.4 23.9 24.7 25.6 25.6 24.9
Chemokine (C-C motif) ligand 17 (CCL17) 34.8 34.8 34.3 ND ND 32.4 35.6 34.2
Chemokine (C-C motif) ligand 19 (CCL19) 30.5 29.3 31.5 30.9 31.0 33.6 31.7 31.6
Chemokine (C-C motif) ligand 2 (CCL2) 30.2 29.7 30.8 31.9 30.2 30.4 30.3 29.8
Chemokine (C-C motif) ligand 20 (CCL20) ND ND ND ND ND ND ND ND
Chemokine (C-C motif) ligand 21a,b 
(CCL21a,b) 23.6 22.8 23.6 24.6 25.6 26.0 26.9 25.6
Chemokine (C-C motif) ligand 22 (CCL22) 31.7 32.3 32.7 34.4 34.6 30.2 30.4 30.3
Chemokine (C-C motif) ligand 24 (CCL24) 29.5 29.6 30.4 30.2 32.0 33.1 32.9 31.0
Chemokine (C-C motif) ligand 25 (CCL25) 25.4 29.2 31.5 30.8 31.8 30.7 30.8 31.7
Chemokine (C-C motif) ligand 26 (CCL26) ND ND ND ND ND ND ND ND
Chemokine (C-C motif) ligand 27a,b 
(CCL27a,b) 27.0 26.0 27.4 26.9 28.8 28.4 28.7 27.9
Chemokine (C-C motif) ligand 28 (CCL28) 29.4 30.9 32.6 32.4 33.2 32.6 34.7 32.5
Chemokine (C-C motif) ligand 3 (CCL3) 36.9 36.9 ND ND 35.0 33.9 34.0 31.2
Chemokine (C-C motif) ligand 4 (CCL4) 35.7 34.9 35.2 35.2 33.5 32.5 32.9 31.0
Chemokine (C-C motif) ligand 5 (CCL5) 31.3 32.3 31.5 31.7 30.5 30.0 30.9 30.5
Chemokine (C-C motif) ligand 6 (CCL6) 24.1 23.8 24.2 24.3 24.8 24.0 25.3 23.0
Chemokine (C-C motif) ligand 7 (CCL7) 28.5 30.2 30.3 30.6 30.8 31.2 32.8 30.3
Chemokine (C-C motif) ligand 8 (CCL8) 29.1 30.1 30.5 30.3 28.8 28.2 28.3 28.7
Chemokine (C-C motif) ligand 9 (CCL9) 25.7 25.9 26.3 26.6 27.9 27.0 28.2 25.4
T-cell surface glycoprotein CD3 delta chain 
(CD3D) 33.9 ND ND ND ND ND 32.7 34.5
Colony stimulating  factor 1 (macrophage) 
(CSF1) 27.2 25.7 27.3 27.0 27.8 27.6 28.2 27.0
Colony stimulating  factor 1 (macrophage) 
receptor (CSF1R) 25.6 24.6 26.0 25.6 26.7 25.8 26.4 24.8
Colony stimulating  factor 2 (granulocyte-
macrophage) (CSF2) 27.9 36.0 ND ND ND ND 34.6 33.5
Colony stimulating  factor 3 (granulocyte) 
(CSF3) ND ND ND ND 33.6 ND ND 35.0
Chemokine (CX3-C motif) ligand 1 (CX3CL1) 29.6 28.2 30.7 29.6 30.5 30.8 30.7 29.7
Chemokine (C-X-C motif) ligand 1 (CXCL1) 33.7 35.9 33.5 34.9 31.9 33.8 34.3 34.3
Chemokine (C-X-C motif) ligand 10 (CXCL10) 28.3 28.2 32.0 31.5 30.0 30.2 29.8 29.2
Chemokine (C-X-C motif) ligand 11 (CXCL11) 29.7 29.0 31.0 30.2 33.4 31.4 32.6 30.9
Chemokine (C-X-C motif) ligand 12 (CXCL12) 32.0 30.9 31.9 31.7 33.4 33.0 33.1 30.8
Chemokine (C-X-C motif) ligand 13 (CXCL13) 26.7 26.2 26.3 26.6 27.7 29.9 32.6 29.7
Chemokine (C-X-C motif) ligand 14 (CXCL14) 25.4 25.7 27.5 26.8 25.4 27.0 27.0 25.8
Chemokine (C-X-C motif) ligand 16 (CXCL16) 28.8 27.7 29.7 29.1 28.1 27.8 28.3 26.5
Chemokine (C-X-C motif) ligand 17 (CXCL17) 35.5 32.1 34.0 34.9 35.0 33.6 35.1 ND
Chemokine (C-X-C motif) ligand 2 (CXCL2) 34.5 ND ND 34.2 ND 32.2 ND 30.2
Chemokine (C-X-C motif) ligand 3 (CXCL3) 37.6 ND ND ND ND 32.9 32.5 32.4
Chemokine (C-X-C motif) ligand 5 (CXCL5) ND 34.1 ND ND ND 31.8 32.6 29.0
Chemokine (C-X-C motif) ligand 9 (CXCL9) 31.1 29.3 30.7 30.6 30.1 30.4 30.0 30.9
Chemokine (C-X-C motif) receptor 3 (CXCR3) 31.3 31.4 32.5 31.7 30.9 31.4 30.5 30.3
Epstein-Barr virus induced gene 3 (EBI3) 31.5 30.6 33.0 31.7 32.7 31.4 32.4 30.0
Epiregulin (EREG) 35.2 ND ND ND ND 34.1 ND 33.8
Fibroblast growth factor 7 (keratinocyte 
growth factor; FGF7) 25.6 25.8 27.1 26.9 29.4 29.1 28.8 27.6
G-protein receptor 84 (GPR84) ND 36.4 ND ND ND 35.1 37.3 33.6
Histocompatibility 2, class II antigen E beta 
(H2.EB1) 25.3 24.4 26.1 25.7 26.5 26.4 26.3 25.8










Gene 1 2 3 4 1 2 3 4
Heparin-binding EGF-like growth factor 
(HBEGF) 27.1 26.2 27.9 27.1 29.2 29.1 29.4 28.2
Interleukin 10 (IL10) 29.6 35.8 ND ND 35.3 ND ND ND
Interleukin 11 (IL11) 32.2 33.7 ND 34.2 ND 34.9 ND 36.1
Interleukin 12 alpha (IL12a) 33.7 31.3 32.8 34.0 35.5 34.0 35.5 35.3
Interleukin 12 beta (IL12b) ND ND ND ND ND 34.4 ND 35.0
Interleukin 13 (IL13) 32.3 ND ND ND ND ND ND ND
Interleukin 15 (IL15) 29.8 28.6 29.8 29.8 30.2 30.0 30.4 29.6
Interleukin 16 (IL16) 24.3 23.1 24.8 23.9 26.0 26.4 25.7 24.8
Interleukin 17 alpha (IL17a) 33.5 ND ND ND 37.3 ND ND ND
Interleukin 18 (IL18) 29.0 29.8 31.4 30.8 33.4 32.0 32.7 30.6
Interleukin 19 (IL19) ND ND ND ND 34.9 ND ND ND
Interleukin 1 alpha (IL1a) ND ND ND ND 35.6 ND 33.8 31.5
Interleukin 1 beta (IL1b) ND 34.8 35.4 ND 33.3 30.9 31.5 29.6
Interleukin 2 (IL2) 36.9 ND ND ND ND ND ND ND
Interleukin 20 (IL20) ND ND ND ND ND ND ND ND
Interleukin 21 (IL21) ND ND ND ND ND ND ND ND
Interleukin 22 (IL22) ND ND ND ND ND ND ND ND
Interleukin 23 alpha (IL23a) 31.6 32.1 32.7 33.3 33.4 34.4 ND 35.1
Interleukin 24 (IL24) ND 32.9 ND ND ND ND ND ND
Interleukin 25 (IL25) 33.6 34.2 33.3 ND ND 33.7 ND 33.4
Interleukin 27 (IL27) 35.5 ND ND ND 32.9 33.8 34.7 32.9
Interleukin 28 beta (IL28b) ND ND ND ND ND ND ND ND
Interleukin 3 (IL3) ND ND ND ND ND ND ND ND
Interleukin 31 (IL31) 26.9 ND ND ND 37.9 ND ND ND
Interleukin 33 (IL33) 25.2 24.6 25.3 24.9 27.3 27.7 28.1 26.7
Interleukin 34 (IL34) 30.6 30.1 32.8 31.7 33.4 34.0 34.0 32.2
Interleukin 4 (IL4) ND ND ND ND ND ND ND ND
Interleukin 5 (IL5) 32.9 34.3 ND 33.3 ND ND 37.9 ND
Interleukin 6 (IL6) 30.6 36.1 ND ND 34.2 35.4 ND ND
Interleukin 7 (IL7) 31.0 31.9 32.4 33.7 33.6 33.3 34.5 32.9
Interleukin 9 (IL9) ND ND ND ND ND ND ND ND
Integrin alpha M (ITGAM; CD11B) 28.0 27.3 28.9 28.4 28.8 27.5 27.8 25.4
Nerve growth factor (NGF) 27.9 28.3 29.3 29.6 28.5 29.7 31.0 29.9
Nitric oxide synthase, inducible (NOS2) 31.9 31.0 33.5 ND 32.1 31.8 32.0 31.0
Platelet factor 4 (PF4; CXCL4) 26.6 26.6 28.1 27.2 28.8 27.6 28.3 26.9
Pro-platelet basic protein (chemokine (C-X-C 
motif) ligand 7 29.9 28.9 29.3 31.4 30.3 30.9 33.3 31.3
Prostaglandin E synthase (PTGES) 27.9 26.8 29.0 28.4 29.2 30.7 29.9 28.7
Prostaglandin-endoperoxide synthase 2      
(COX-2; PTGS2) 33.6 33.0 33.4 34.1 32.6 34.3 36.7 33.8
 Signal Transducer and Activator of 
Transcription protein 4 (STAT4) 30.3 30.5 32.0 31.2 34.2 33.8 37.5 32.4
Toll-like receptor 4 (TLR4) 27.0 26.5 27.6 27.5 28.5 28.4 29.3 27.4
Tumor necrosis factor (TNF) 33.2 32.1 32.1 32.7 34.2 31.2 31.1 29.1
Alpha-taxilin (TXLNA) 27.4 26.4 28.4 27.9 28.0 27.9 28.0 27.9
Chemokine (C motif) ligand 1 (XCL1) 36.6 ND ND ND 25.3 ND 34.6 37.0
Housekeeping genes
Beta-actin (ACTB) 20.6 19.5 20.7 20.4 21.3 21.3 21.7 20.1
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) 21.5 20.6 22.5 21.9 23.7 19.7 22.6 21.9
Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) 27.6 26.7 28.9 28.3 26.8 28.9 29.1 28.1
18s (X18S) 15.5 14.1 18.0 16.2 15.9 15.6 14.7 15.0




Appendix Table 6: Raw CT values of genes screened in the sciatic nerve of GPR84 KO 




Gene 1 2 3 4 1 2 3 4
Allograft inflammatory factors -1 (Iba1; AIF) 30.3 30.7 31.8 31.2 31.9 30.4 31.9 31.3
Amphiregulin (AREG) ND ND ND ND ND ND ND ND
Artemin (ARTN) 30.7 31.3 34.5 32.3 33.2 33.9 33.8 31.9
Brain-derived neurotrophic factor (BDNF) ND 34.4 ND ND 33.8 34.8 33.4 34.4
Betacellulin (BTC) 30.5 31.9 30.9 32.0 31.1 29.9 30.1 31.0
Chemokine (C-C motif) ligand 1 (CCL1) ND ND ND ND ND ND ND ND
Chemokine (C-C motif) ligand 11 (CCL11) 22.2 22.7 23.1 23.6 26.3 25.0 25.9 25.8
Chemokine (C-C motif) ligand 17 (CCL17) 32.0 33.8 33.9 ND 34.6 36.6 ND 35.1
Chemokine (C-C motif) ligand 19 (CCL19) 28.3 29.4 30.5 31.6 30.9 33.7 32.2 31.1
Chemokine (C-C motif) ligand 2 (CCL2) 28.8 30.0 30.2 30.6 30.5 31.1 31.3 29.6
Chemokine (C-C motif) ligand 20 (CCL20) ND ND ND ND ND ND ND ND
Chemokine (C-C motif) ligand 21a,b 
(CCL21a,b) 23.2 24.4 24.3 27.1 26.2 29.3 26.8 26.4
Chemokine (C-C motif) ligand 22 (CCL22) 29.9 30.9 31.3 31.8 30.7 33.4 32.9 29.6
Chemokine (C-C motif) ligand 24 (CCL24) 28.7 30.0 30.3 31.1 32.2 32.3 32.9 32.0
Chemokine (C-C motif) ligand 25 (CCL25) 29.5 29.6 30.0 30.8 32.6 32.0 32.0 32.1
Chemokine (C-C motif) ligand 26 (CCL26) 36.0 ND ND ND ND ND ND ND
Chemokine (C-C motif) ligand 27a,b 
(CCL27a,b) 25.9 25.9 26.4 26.4 29.8 28.6 28.0 28.6
Chemokine (C-C motif) ligand 28 (CCL28) 30.3 30.8 31.1 31.5 ND 34.0 33.3 35.1
Chemokine (C-C motif) ligand 3 (CCL3) 33.0 35.0 36.6 ND 36.3 35.6 35.6 33.3
Chemokine (C-C motif) ligand 4 (CCL4) 32.2 33.6 33.3 35.1 33.7 33.5 35.3 31.0
Chemokine (C-C motif) ligand 5 (CCL5) 29.5 31.2 31.2 32.8 30.9 31.0 31.8 30.4
Chemokine (C-C motif) ligand 6 (CCL6) 22.2 24.2 25.1 25.8 24.5 25.3 25.2 23.9
Chemokine (C-C motif) ligand 7 (CCL7) 28.1 29.0 29.9 29.7 31.7 32.6 33.2 30.1
Chemokine (C-C motif) ligand 8 (CCL8) 28.6 30.5 30.3 32.5 28.5 28.1 28.7 27.7
Chemokine (C-C motif) ligand 9 (CCL9) 25.0 26.9 27.5 28.0 27.9 27.8 28.7 27.1
T-cell surface glycoprotein CD3 delta chain 
(CD3D) 33.1 35.2 34.4 ND ND ND ND ND
Colony stimulating  factor 1 (macrophage) 
(CSF1) 25.5 25.8 26.4 26.9 28.6 27.7 28.7 27.5
Colony stimulating  factor 1 (macrophage) 
receptor (CSF1R) 24.0 24.6 26.2 26.0 26.3 25.9 26.5 25.6
Colony stimulating  factor 2 (granulocyte-
macrophage) (CSF2) 34.6 ND 34.9 ND ND ND ND ND
Colony stimulating  factor 3 (granulocyte) 
(CSF3) ND ND ND ND ND ND ND ND
Chemokine (CX3-C motif) ligand 1 (CX3CL1) 28.8 28.7 28.6 28.6 30.3 29.5 29.4 29.8
Chemokine (C-X-C motif) ligand 1 (CXCL1) 33.9 33.3 34.9 32.2 34.5 35.4 ND 32.2
Chemokine (C-X-C motif) ligand 10 (CXCL10) 28.7 29.2 29.0 29.8 30.5 29.7 30.7 30.3
Chemokine (C-X-C motif) ligand 11 (CXCL11) 28.4 28.8 29.1 29.4 ND 32.3 32.5 32.8
Chemokine (C-X-C motif) ligand 12 (CXCL12) 29.0 31.3 31.3 32.3 32.9 32.9 32.9 31.4
Chemokine (C-X-C motif) ligand 13 (CXCL13) 24.6 26.4 27.9 28.8 32.3 31.0 30.0 30.3
Chemokine (C-X-C motif) ligand 14 (CXCL14) 24.1 26.4 28.1 27.8 25.9 25.9 26.9 27.1
Chemokine (C-X-C motif) ligand 16 (CXCL16) 26.7 27.9 28.5 29.0 28.3 28.0 28.7 27.6
Chemokine (C-X-C motif) ligand 17 (CXCL17) 32.7 ND ND ND 33.3 35.0 35.0 35.1
Chemokine (C-X-C motif) ligand 2 (CXCL2) 32.8 34.9 34.7 ND 34.1 ND 35.1 31.0
Chemokine (C-X-C motif) ligand 3 (CXCL3) ND ND ND ND 35.0 ND ND 32.5
Chemokine (C-X-C motif) ligand 5 (CXCL5) ND ND ND ND 35.2 ND 35.0 30.1
Chemokine (C-X-C motif) ligand 9 (CXCL9) 30.3 30.9 29.8 31.4 30.9 30.9 30.4 30.1
Chemokine (C-X-C motif) receptor 3 (CXCR3) 29.9 31.0 29.8 33.0 30.9 31.3 31.4 30.5
Epstein-Barr virus induced gene 3 (EBI3) 30.2 30.3 31.0 31.0 33.9 31.6 32.6 31.3
Epiregulin (EREG) ND ND ND ND ND ND ND ND
Fibroblast growth factor 7 (keratinocyte 
growth factor; FGF7) 25.4 25.4 25.4 25.9 26.4 28.6 29.2 28.9
G-protein receptor 84 (GPR84) ND ND ND ND ND ND ND ND
Histocompatibility 2, class II antigen E beta 
(H2.EB1) 24.0 24.9 25.2 25.6 26.6 26.2 26.4 26.1










Gene 1 2 3 4 1 2 3 4
Heparin-binding EGF-like growth factor 
(HBEGF) 26.2 25.9 26.3 26.2 29.9 29.4 28.8 29.2
Interleukin 10 (IL10) ND 36.0 ND ND ND ND ND ND
Interleukin 11 (IL11) 33.2 33.0 33.9 32.7 34.7 ND 36.0 ND
Interleukin 12 alpha (IL12a) 31.6 31.6 31.4 31.9 ND 35.3 31.8 35.5
Interleukin 12 beta (IL12b) ND ND ND 34.8 ND 35.5 ND 34.4
Interleukin 13 (IL13) ND ND ND ND ND ND ND ND
Interleukin 15 (IL15) 28.7 28.8 29.1 29.7 32.2 31.3 29.4 29.8
Interleukin 16 (IL16) 22.9 23.0 23.4 23.4 27.3 26.0 26.7 26.5
Interleukin 17 alpha (IL17a) ND ND ND ND 33.9 ND ND ND
Interleukin 18 (IL18) 28.2 29.9 30.4 30.4 32.6 32.0 32.8 31.9
Interleukin 19 (IL19) ND ND ND ND ND ND ND ND
Interleukin 1 alpha (IL1a) ND ND 33.9 ND 34.5 32.8 34.5 35.8
Interleukin 1 beta (IL1b) 30.1 33.1 32.8 34.8 32.4 33.5 34.6 29.6
Interleukin 2 (IL2) ND ND ND ND ND ND ND ND
Interleukin 20 (IL20) ND ND ND ND ND ND ND ND
Interleukin 21 (IL21) ND ND ND ND ND ND ND ND
Interleukin 22 (IL22) ND ND ND ND ND ND ND ND
Interleukin 23 alpha (IL23a) 30.6 32.2 31.5 31.4 ND ND ND 33.1
Interleukin 24 (IL24) ND ND ND ND ND ND ND ND
Interleukin 25 (IL25) 34.9 33.7 34.2 ND ND ND ND ND
Interleukin 27 (IL27) 33.2 34.6 ND ND ND ND 34.6 34.7
Interleukin 28 beta (IL28b) ND ND ND ND ND ND ND ND
Interleukin 3 (IL3) 37.0 ND ND ND ND ND ND ND
Interleukin 31 (IL31) 36.4 ND 35.6 ND ND ND ND ND
Interleukin 33 (IL33) 24.2 24.8 25.0 25.4 28.8 27.7 28.8 27.8
Interleukin 34 (IL34) 30.2 30.4 31.2 30.4 28.2 32.3 35.2 33.3
Interleukin 4 (IL4) 35.8 ND ND ND ND ND ND ND
Interleukin 5 (IL5) ND 34.3 33.9 ND ND ND ND 34.7
Interleukin 6 (IL6) 32.6 33.8 34.1 35.2 ND 36.3 ND ND
Interleukin 7 (IL7) 29.2 32.9 34.0 36.1 33.9 34.2 33.8 35.2
Interleukin 9 (IL9) ND ND ND ND ND ND ND ND
Integrin alpha M (ITGAM; CD11B) 25.9 27.2 29.1 29.5 27.6 28.3 28.6 26.6
Nerve growth factor (NGF) 27.5 28.5 28.6 28.9 31.0 30.2 30.4 29.8
Nitric oxide synthase, inducible (NOS2) 31.0 32.5 31.9 30.8 33.5 31.5 31.0 31.6
Platelet factor 4 (PF4; CXCL4) 25.2 26.5 27.0 27.4 28.4 28.4 28.0 27.1
Pro-platelet basic protein (chemokine (C-X-C 
motif) ligand 7 27.3 29.8 26.3 29.1 32.1 32.3 33.4 32.2
Prostaglandin E synthase (PTGES) 26.3 26.9 27.3 27.7 31.2 29.3 30.0 29.0
Prostaglandin-endoperoxide synthase 2      
(COX-2; PTGS2) 31.5 33.5 33.5 34.0 36.8 ND 37.2 34.0
 Signal Transducer and Activator of 
Transcription protein 4 (STAT4) 30.1 30.9 29.6 33.2 35.4 34.2 34.5 32.8
Toll-like receptor 4 (TLR4) 26.1 26.9 31.0 27.9 29.6 28.7 29.5 28.0
Tumor necrosis factor (TNF) 30.4 31.1 32.1 34.3 31.8 32.1 33.3 30.4
Alpha-taxilin (TXLNA) 25.9 26.2 26.9 26.9 28.8 28.0 28.1 27.9
Chemokine (C motif) ligand 1 (XCL1) 33.6 37.5 37.5 ND ND 35.1 37.0 37.3
Housekeeping genes
Beta-actin (ACTB) 19.5 19.7 19.8 20.1 22.0 21.5 22.0 21.2
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) 20.5 19.8 20.2 20.9 24.2 21.2 18.5 22.6
Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) 26.3 27.3 27.7 27.8 30.3 29.4 29.4 28.7
18s (X18S) 13.9 14.1 14.4 14.2 15.2 15.2 14.5 14.5




Appendix Table 7: Raw CT values of genes screened in the spinal cord of GPR84 WT 




Gene 1 2 3 4 1 2 3 4
Allograft inflammatory factors -1 (Iba1; AIF) 28.9 28.8 28.5 27.9 27.5 28.7 28.1 28.7
Amphiregulin (AREG) ND 36.7 34.9 ND 33.9 ND ND ND
Artemin (ARTN) 31.8 31.1 31.5 33.3 31.3 32.2 32.6 32.4
Brain-derived neurotrophic factor (BDNF) 28.7 28.4 28.7 29.1 28.8 28.6 28.4 29.3
Betacellulin (BTC) 30.0 29.9 29.7 29.1 28.9 29.8 28.9 29.7
Chemokine (C-C motif) ligand 1 (CCL1) ND ND ND 35.4 ND ND ND ND
Chemokine (C-C motif) ligand 11 (CCL11) 29.6 29.3 27.8 26.4 27.2 30.1 27.2 28.8
Chemokine (C-C motif) ligand 17 (CCL17) 37.4 33.9 34.7 ND ND 34.7 33.9 ND
Chemokine (C-C motif) ligand 19 (CCL19) 29.2 28.2 27.5 27.5 27.9 29.8 28.0 29.0
Chemokine (C-C motif) ligand 2 (CCL2) 30.9 ND 32.3 31.9 29.6 31.3 31.2 31.3
Chemokine (C-C motif) ligand 20 (CCL20) ND ND ND ND ND ND ND ND
Chemokine (C-C motif) ligand 21a,b 
(CCL21a,b) 26.9 25.9 25.8 25.3 26.3 27.4 26.2 26.2
Chemokine (C-C motif) ligand 22 (CCL22) 33.2 31.5 32.3 30.8 30.8 32.4 30.4 32.5
Chemokine (C-C motif) ligand 24 (CCL24) 34.2 35.0 32.6 34.8 30.7 33.6 32.9 34.0
Chemokine (C-C motif) ligand 25 (CCL25) 26.2 26.3 26.6 26.3 26.4 27.1 26.0 27.1
Chemokine (C-C motif) ligand 26 (CCL26) 37.0 ND ND ND ND ND ND ND
Chemokine (C-C motif) ligand 27a,b 
(CCL27a,b) 23.9 23.5 23.6 23.6 23.6 24.2 23.3 24.4
Chemokine (C-C motif) ligand 28 (CCL28) 28.9 29.0 29.1 29.0 28.9 28.9 29.1 29.9
Chemokine (C-C motif) ligand 3 (CCL3) 36.1 35.7 34.2 34.4 35.2 34.9 33.9 34.2
Chemokine (C-C motif) ligand 4 (CCL4) 32.7 34.5 32.2 31.1 31.7 32.7 30.8 32.7
Chemokine (C-C motif) ligand 5 (CCL5) 31.0 31.1 30.3 29.0 30.0 32.1 29.8 30.5
Chemokine (C-C motif) ligand 6 (CCL6) 27.6 26.8 26.3 25.9 26.1 27.4 26.2 26.8
Chemokine (C-C motif) ligand 7 (CCL7) 30.4 33.6 31.4 31.6 29.3 31.0 32.8 31.1
Chemokine (C-C motif) ligand 8 (CCL8) ND 32.3 32.5 33.5 31.7 32.7 31.6 35.0
Chemokine (C-C motif) ligand 9 (CCL9) 29.3 28.0 27.7 27.3 27.9 28.8 27.7 28.6
T-cell surface glycoprotein CD3 delta chain 
(CD3D) 34.6 ND 34.6 32.2 34.5 34.7 34.9 ND
Colony stimulating  factor 1 (macrophage) 
(CSF1) 25.9 25.4 24.9 24.7 24.2 25.8 25.1 25.2
Colony stimulating  factor 1 (macrophage) 
receptor (CSF1R) 24.3 23.7 23.6 23.2 23.0 24.0 23.5 24.1
Colony stimulating  factor 2 (granulocyte-
macrophage) (CSF2) ND ND 35.0 34.9 ND ND ND ND
Colony stimulating  factor 3 (granulocyte) 
(CSF3) 34.4 ND ND ND 29.4 ND ND ND
Chemokine (CX3-C motif) ligand 1 (CX3CL1) 22.5 21.9 22.2 22.0 22.0 22.7 21.7 22.7
Chemokine (C-X-C motif) ligand 1 (CXCL1) 32.8 34.9 ND 33.1 28.8 ND 34.8 34.7
Chemokine (C-X-C motif) ligand 10 (CXCL10) 31.9 32.2 31.0 31.3 29.4 31.6 28.5 31.0
Chemokine (C-X-C motif) ligand 11 (CXCL11) 32.2 30.3 30.4 29.6 30.5 32.2 30.7 31.1
Chemokine (C-X-C motif) ligand 12 (CXCL12) 33.8 34.0 32.0 32.6 32.7 33.3 31.8 32.4
Chemokine (C-X-C motif) ligand 13 (CXCL13) ND 35.1 ND 34.3 32.2 34.3 34.7 ND
Chemokine (C-X-C motif) ligand 14 (CXCL14) 23.7 22.7 22.8 22.2 22.5 23.3 22.5 23.1
Chemokine (C-X-C motif) ligand 16 (CXCL16) 28.1 28.0 27.5 26.9 26.3 28.3 27.3 28.6
Chemokine (C-X-C motif) ligand 17 (CXCL17) ND ND 34.9 34.4 33.9 34.8 33.4 34.9
Chemokine (C-X-C motif) ligand 2 (CXCL2) ND ND 36.1 35.1 31.2 ND ND ND
Chemokine (C-X-C motif) ligand 3 (CXCL3) ND ND ND ND ND ND ND ND
Chemokine (C-X-C motif) ligand 5 (CXCL5) 32.8 31.1 33.5 30.0 31.2 31.8 31.1 31.6
Chemokine (C-X-C motif) ligand 9 (CXCL9) 35.0 35.4 34.2 32.5 35.4 34.9 30.5 33.8
Chemokine (C-X-C motif) receptor 3 (CXCR3) 32.6 ND 33.5 32.5 31.8 33.1 31.5 32.8
Epstein-Barr virus induced gene 3 (EBI3) 32.2 31.3 31.0 32.0 30.7 31.6 31.8 32.1
Epiregulin (EREG) ND ND ND ND ND ND ND ND
Fibroblast growth factor 7 (keratinocyte 
growth factor; FGF7) 28.3 28.6 27.9 27.4 27.7 29.5 27.8 28.6
G-protein receptor 84 (GPR84) 32.0 31.3 31.3 31.2 31.1 31.6 31.0 31.3
Histocompatibility 2, class II antigen E beta 
(H2.EB1) 27.8 27.7 26.8 26.0 26.5 28.0 26.7 28.0










Gene 1 2 3 4 1 2 3 4
Heparin-binding EGF-like growth factor 
(HBEGF) 26.3 25.9 26.2 25.7 25.2 26.8 25.6 26.3
Interleukin 10 (IL10) 35.8 ND ND ND 35.6 ND ND 36.0
Interleukin 11 (IL11) 32.1 32.7 34.8 33.3 33.3 33.5 32.9 34.5
Interleukin 12 alpha (IL12a) 31.1 31.5 31.4 30.7 30.0 32.5 31.1 32.0
Interleukin 12 beta (IL12b) 35.5 ND ND 34.3 33.9 35.9 ND 33.9
Interleukin 13 (IL13) ND ND ND 34.0 ND ND ND ND
Interleukin 15 (IL15) 29.8 29.8 29.6 29.7 28.6 30.0 29.3 29.5
Interleukin 16 (IL16) 27.5 26.7 26.1 25.6 25.9 27.8 26.0 26.6
Interleukin 17 alpha (IL17a) ND ND ND ND ND ND ND ND
Interleukin 18 (IL18) 26.3 25.6 25.5 24.8 25.0 26.1 25.1 25.7
Interleukin 19 (IL19) 33.5 33.6 33.3 32.1 31.3 33.1 33.2 32.6
Interleukin 1 alpha (IL1a) 34.5 32.1 31.9 31.5 30.9 31.8 31.2 31.7
Interleukin 1 beta (IL1b) 32.5 31.9 32.8 31.2 31.3 34.8 32.4 33.4
Interleukin 2 (IL2) ND ND 35.0 ND ND ND ND ND
Interleukin 20 (IL20) ND ND 36.4 ND ND ND ND ND
Interleukin 21 (IL21) 33.8 33.5 33.3 32.0 33.5 33.5 32.6 33.6
Interleukin 22 (IL22) 37.9 37.7 ND 37.9 ND ND ND ND
Interleukin 23 alpha (IL23a) 32.0 31.2 31.3 30.7 30.7 31.0 30.9 31.0
Interleukin 24 (IL24) ND ND ND ND ND ND ND ND
Interleukin 25 (IL25) 32.9 32.2 32.7 34.0 32.1 32.9 31.9 32.3
Interleukin 27 (IL27) ND 34.6 34.5 ND 34.5 ND 34.6 ND
Interleukin 28 beta (IL28b) ND ND ND ND ND ND ND ND
Interleukin 3 (IL3) ND ND ND ND ND ND ND ND
Interleukin 31 (IL31) ND ND ND ND ND ND ND ND
Interleukin 33 (IL33) 23.6 23.1 23.2 22.5 22.5 23.7 22.7 23.3
Interleukin 34 (IL34) 30.8 31.3 30.9 31.0 30.9 32.2 31.1 31.8
Interleukin 4 (IL4) ND ND ND ND ND ND ND ND
Interleukin 5 (IL5) 32.7 33.9 32.7 31.9 32.1 33.2 32.1 ND
Interleukin 6 (IL6) 31.9 33.9 33.3 32.1 31.5 34.7 32.9 32.8
Interleukin 7 (IL7) 31.0 30.7 30.9 30.4 28.8 31.4 30.6 30.7
Interleukin 9 (IL9) ND ND ND ND ND ND ND ND
Integrin alpha M (ITGAM; CD11B) 26.6 26.1 26.1 25.6 25.5 26.8 25.7 26.3
Nerve growth factor (NGF) 29.6 29.7 29.7 28.6 28.7 30.6 29.3 29.6
Nitric oxide synthase, inducible (NOS2) 31.2 30.6 30.6 30.2 29.2 30.9 30.3 31.1
Platelet factor 4 (PF4; CXCL4) 29.5 28.7 28.1 25.8 26.5 28.8 27.5 27.3
Pro-platelet basic protein (chemokine (C-X-C 
motif) ligand 7 31.1 28.3 28.5 25.6 26.0 27.8 27.1 27.0
Prostaglandin E synthase (PTGES) 29.7 28.7 28.4 27.9 27.9 29.6 28.0 28.9
Prostaglandin-endoperoxide synthase 2      
(COX-2; PTGS2) 31.8 31.5 32.6 32.5 28.4 33.2 31.9 32.8
 Signal Transducer and Activator of 
Transcription protein 4 (STAT4) 33.7 32.7 32.4 31.8 33.4 34.2 32.5 34.9
Toll-like receptor 4 (TLR4) 30.4 29.0 28.9 28.7 28.2 29.7 28.9 29.6
Tumor necrosis factor (TNF) 35.1 34.8 33.3 32.1 31.5 ND 33.0 33.5
Alpha-taxilin (TXLNA) 25.7 25.1 25.1 24.5 24.5 25.5 24.5 25.2
Chemokine (C motif) ligand 1 (XCL1) 37.5 36.6 ND 35.1 ND 37.2 35.6 37.5
Housekeeping genes
Beta-actin (ACTB) 19.7 19.2 19.1 18.8 18.5 19.8 18.6 19.3
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) 18.9 18.3 18.5 17.9 18.0 18.8 17.9 18.7
Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) 23.5 23.3 23.3 22.8 23.1 23.8 22.9 23.7
18s (X18S) 14.9 14.6 14.8 14.9 14.8 14.8 14.7 14.8




Appendix Table 8: Raw CT values of genes screened in the spinal cord of GPR84 KO 




Gene 1 2 3 4 1 2 3 4
Allograft inflammatory factors -1 (Iba1; AIF) 27.8 28.2 27.9 28.9 28.0 29.1 27.8 27.6
Amphiregulin (AREG) 33.6 ND ND 34.9 33.8 ND 34.5 33.1
Artemin (ARTN) 31.5 31.0 31.1 31.3 31.6 32.3 30.9 31.8
Brain-derived neurotrophic factor (BDNF) 28.6 28.5 27.8 29.0 28.9 28.9 27.7 28.6
Betacellulin (BTC) 30.0 29.9 29.1 29.9 30.1 30.0 29.6 29.2
Chemokine (C-C motif) ligand 1 (CCL1) ND ND 35.8 ND ND ND ND ND
Chemokine (C-C motif) ligand 11 (CCL11) 28.0 29.7 28.2 28.9 29.3 31.5 27.9 27.8
Chemokine (C-C motif) ligand 17 (CCL17) 34.3 34.7 ND ND ND ND 35.0 35.0
Chemokine (C-C motif) ligand 19 (CCL19) 27.7 28.3 27.8 28.6 28.0 28.9 27.3 28.0
Chemokine (C-C motif) ligand 2 (CCL2) 34.7 32.5 31.0 32.0 29.6 32.2 30.9 29.8
Chemokine (C-C motif) ligand 20 (CCL20) ND ND ND ND ND ND ND ND
Chemokine (C-C motif) ligand 21a,b 
(CCL21a,b) 25.9 25.6 26.4 26.8 26.3 25.4 25.5 26.1
Chemokine (C-C motif) ligand 22 (CCL22) 30.7 30.7 30.6 31.6 32.1 32.5 30.7 30.9
Chemokine (C-C motif) ligand 24 (CCL24) 32.8 32.7 31.6 33.5 32.4 33.9 32.7 32.0
Chemokine (C-C motif) ligand 25 (CCL25) 25.9 26.0 26.1 26.9 26.4 26.7 26.2 26.3
Chemokine (C-C motif) ligand 26 (CCL26) 30.7 ND ND ND ND ND ND ND
Chemokine (C-C motif) ligand 27a,b 
(CCL27a,b) 23.4 23.6 23.4 24.0 23.9 23.8 23.1 23.5
Chemokine (C-C motif) ligand 28 (CCL28) 28.3 28.1 30.2 29.6 29.4 28.5 29.0 29.0
Chemokine (C-C motif) ligand 3 (CCL3) 35.0 34.4 34.4 36.0 35.0 35.1 34.0 34.7
Chemokine (C-C motif) ligand 4 (CCL4) 33.0 32.7 31.5 32.4 31.8 32.8 31.9 31.0
Chemokine (C-C motif) ligand 5 (CCL5) 31.3 29.8 29.5 30.9 30.5 30.7 28.7 28.8
Chemokine (C-C motif) ligand 6 (CCL6) 26.8 27.6 26.2 27.0 26.3 28.0 26.2 26.3
Chemokine (C-C motif) ligand 7 (CCL7) 33.2 32.0 30.8 32.9 29.6 31.0 29.0 28.0
Chemokine (C-C motif) ligand 8 (CCL8) 34.0 31.7 31.8 35.5 31.1 32.8 30.9 30.9
Chemokine (C-C motif) ligand 9 (CCL9) 28.1 28.7 28.3 28.6 28.0 28.9 27.8 28.2
T-cell surface glycoprotein CD3 delta chain 
(CD3D) ND 34.5 34.4 ND 35.0 35.9 33.4 ND
Colony stimulating  factor 1 (macrophage) 
(CSF1) 24.9 25.1 24.5 25.3 25.1 25.5 24.7 24.4
Colony stimulating  factor 1 (macrophage) 
receptor (CSF1R) 23.8 23.9 23.3 24.1 23.5 23.9 23.0 23.0
Colony stimulating  factor 2 (granulocyte-
macrophage) (CSF2) ND ND ND ND ND ND 34.4 ND
Colony stimulating  factor 3 (granulocyte) 
(CSF3) ND ND ND ND 34.6 ND 34.5 ND
Chemokine (CX3-C motif) ligand 1 (CX3CL1) 22.2 22.1 21.8 22.5 22.2 22.5 21.6 21.8
Chemokine (C-X-C motif) ligand 1 (CXCL1) 33.0 ND 34.3 34.2 33.0 35.2 ND 33.4
Chemokine (C-X-C motif) ligand 10 (CXCL10) 31.3 31.4 30.7 30.9 30.5 29.4 29.3 30.6
Chemokine (C-X-C motif) ligand 11 (CXCL11) 31.6 32.2 30.7 30.6 31.9 32.1 30.0 30.6
Chemokine (C-X-C motif) ligand 12 (CXCL12) 32.5 32.7 31.6 31.8 32.8 33.7 31.4 32.1
Chemokine (C-X-C motif) ligand 13 (CXCL13) ND 34.1 33.5 ND 33.5 ND 31.0 32.4
Chemokine (C-X-C motif) ligand 14 (CXCL14) 22.7 22.7 22.6 23.5 22.9 23.1 22.4 22.6
Chemokine (C-X-C motif) ligand 16 (CXCL16) 27.9 27.9 26.9 27.9 27.6 28.9 27.2 27.1
Chemokine (C-X-C motif) ligand 17 (CXCL17) 34.0 34.0 ND 34.0 33.0 33.9 34.0 34.7
Chemokine (C-X-C motif) ligand 2 (CXCL2) ND 34.9 34.0 ND ND 36.8 ND 33.4
Chemokine (C-X-C motif) ligand 3 (CXCL3) 33.2 34.2 ND ND ND 33.1 ND 33.4
Chemokine (C-X-C motif) ligand 5 (CXCL5) 30.8 31.6 30.2 32.8 31.2 31.3 30.9 31.3
Chemokine (C-X-C motif) ligand 9 (CXCL9) 34.4 31.7 33.2 ND 34.7 34.0 31.0 32.6
Chemokine (C-X-C motif) receptor 3 (CXCR3) 34.1 32.9 32.5 32.7 33.4 34.4 31.3 32.2
Epstein-Barr virus induced gene 3 (EBI3) 31.9 32.8 31.1 31.8 31.9 31.6 30.5 30.8
Epiregulin (EREG) ND ND ND 34.9 ND ND ND 34.6
Fibroblast growth factor 7 (keratinocyte 
growth factor; FGF7) 27.8 28.6 27.5 28.6 29.3 29.8 28.0 27.9
G-protein receptor 84 (GPR84) ND ND ND ND ND ND ND ND
Histocompatibility 2, class II antigen E beta 
(H2.EB1) 27.5 27.3 26.6 27.5 27.6 29.6 26.6 26.6










Gene 1 2 3 4 1 2 3 4
Heparin-binding EGF-like growth factor 
(HBEGF) 26.1 26.0 25.5 26.3 26.1 26.6 25.7 25.6
Interleukin 10 (IL10) ND ND ND ND ND ND ND ND
Interleukin 11 (IL11) 32.9 32.2 31.7 33.5 32.9 34.8 34.5 32.7
Interleukin 12 alpha (IL12a) 30.8 30.3 30.8 31.0 31.4 30.7 30.9 31.2
Interleukin 12 beta (IL12b) 35.0 34.2 35.0 33.6 ND ND 34.5 34.0
Interleukin 13 (IL13) ND ND ND ND 34.7 ND ND ND
Interleukin 15 (IL15) 28.8 28.8 29.0 29.9 29.2 30.1 28.7 28.8
Interleukin 16 (IL16) 26.6 27.2 26.1 26.9 27.2 28.3 25.7 25.8
Interleukin 17 alpha (IL17a) ND ND ND ND ND ND ND ND
Interleukin 18 (IL18) 25.7 25.5 25.0 26.0 25.7 25.9 25.0 25.1
Interleukin 19 (IL19) ND 32.5 33.0 ND 32.9 ND 33.2 33.1
Interleukin 1 alpha (IL1a) 31.2 32.7 31.6 32.0 30.8 32.6 31.0 31.1
Interleukin 1 beta (IL1b) 32.5 31.8 32.1 32.7 31.6 32.3 32.2 31.0
Interleukin 2 (IL2) ND ND ND ND 33.4 ND ND ND
Interleukin 20 (IL20) ND ND ND ND ND ND ND ND
Interleukin 21 (IL21) 33.5 32.7 32.6 32.3 33.6 33.0 33.7 32.3
Interleukin 22 (IL22) ND 37.3 ND ND ND ND ND ND
Interleukin 23 alpha (IL23a) 31.5 32.0 30.0 31.4 31.2 ND 30.4 30.5
Interleukin 24 (IL24) ND ND ND ND ND ND ND ND
Interleukin 25 (IL25) 31.7 31.4 32.0 33.5 33.2 32.6 31.0 31.9
Interleukin 27 (IL27) 34.6 ND ND 34.9 34.8 34.3 ND ND
Interleukin 28 beta (IL28b) ND ND ND ND ND ND ND ND
Interleukin 3 (IL3) 30.6 ND ND ND ND ND ND ND
Interleukin 31 (IL31) ND ND ND ND ND ND ND ND
Interleukin 33 (IL33) 23.0 22.9 22.8 23.6 23.1 23.5 22.4 22.6
Interleukin 34 (IL34) 30.7 30.6 30.9 32.0 31.9 31.7 30.8 30.9
Interleukin 4 (IL4) ND ND ND ND ND ND ND ND
Interleukin 5 (IL5) 31.8 32.1 32.8 ND 32.9 32.1 32.4 33.2
Interleukin 6 (IL6) 33.3 33.7 33.1 33.8 33.9 33.7 33.2 32.5
Interleukin 7 (IL7) 30.5 31.3 30.1 31.0 30.8 31.2 30.3 29.9
Interleukin 9 (IL9) ND 37.1 ND ND ND ND ND ND
Integrin alpha M (ITGAM; CD11B) 26.5 26.1 25.7 26.7 25.7 26.4 25.4 25.2
Nerve growth factor (NGF) 29.5 29.8 29.6 29.3 29.3 29.9 28.9 28.8
Nitric oxide synthase, inducible (NOS2) 30.4 30.7 29.5 31.0 30.2 31.6 30.2 30.4
Platelet factor 4 (PF4; CXCL4) 28.5 27.9 27.1 28.1 27.4 27.8 26.4 27.7
Pro-platelet basic protein (chemokine (C-X-C 
motif) ligand 7 29.0 27.4 27.7 27.7 26.7 26.5 25.4 28.1
Prostaglandin E synthase (PTGES) 28.4 28.2 28.0 28.8 28.9 29.7 28.5 28.4
Prostaglandin-endoperoxide synthase 2      
(COX-2; PTGS2) 31.4 31.8 31.3 33.4 30.2 32.6 31.8 32.6
 Signal Transducer and Activator of 
Transcription protein 4 (STAT4) 33.9 33.5 31.4 ND 34.4 33.1 32.9 33.0
Toll-like receptor 4 (TLR4) 29.1 29.3 28.3 29.2 29.3 29.8 28.4 28.7
Tumor necrosis factor (TNF) 32.1 33.2 32.1 32.1 32.7 32.2 31.5 31.5
Alpha-taxilin (TXLNA) 24.8 24.8 24.2 25.4 25.0 25.6 24.4 24.5
Chemokine (C motif) ligand 1 (XCL1) 35.9 34.6 36.5 ND 36.4 ND 35.9 35.8
Housekeeping genes
Beta-actin (ACTB) 19.1 18.9 18.6 19.5 19.0 19.0 18.4 18.6
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) 18.2 18.3 18.0 18.6 18.3 18.5 17.9 18.2
Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) 22.9 23.0 22.6 23.6 23.1 23.9 22.9 23.0
18s (X18S) 14.5 14.5 14.6 14.9 14.7 15.6 14.9 14.9




Appendix Table 9: Raw CT values of genes screened in GPR84 WT B-GEPMs in control 




Gene 1.0 2.0 3.0 4.0 1.0 2.0 3.0 4.0
Allograft inflammatory factors -1 (Iba1; AIF) 24.4 26.9 24.6 24.9 25.8 25.4 25.4 25.5
Amphiregulin (AREG) 33.6 31.9 33.2 38.0 28.9 27.7 29.2 28.4
Artemin (ARTN) 33.9 32.7 33.0 31.0 28.1 27.6 27.8 27.4
Brain-derived neurotrophic factor (BDNF) 33.3 34.4 33.1 32.8 34.0 33.1 38.0 35.2
Betacellulin (BTC) 31.1 32.1 31.3 31.0 33.0 31.5 31.0 31.0
Chemokine (C-C motif) ligand 1 (CCL1) 38.0 38.0 38.0 33.8 38.0 34.1 34.8 38.0
Chemokine (C-C motif) ligand 11 (CCL11) 38.0 38.0 38.0 38.0 38.0 38.0 33.7 35.3
Chemokine (C-C motif) ligand 17 (CCL17) 34.1 38.0 38.0 34.1 30.0 29.7 26.4 28.3
Chemokine (C-C motif) ligand 19 (CCL19) 38.0 38.0 38.0 38.0 32.4 31.4 32.4 32.7
Chemokine (C-C motif) ligand 2 (CCL2) 24.9 26.4 26.2 25.9 22.3 21.0 20.5 22.1
Chemokine (C-C motif) ligand 20 (CCL20) 38.0 32.2 35.0 34.0 30.4 29.7 31.1 30.0
Chemokine (C-C motif) ligand 21a,b 
(CCL21a,b) 38.0 36.8 37.4 34.0 38.0 34.6 35.3 38.0
Chemokine (C-C motif) ligand 22 (CCL22) 32.7 33.0 31.5 33.0 22.8 22.7 20.3 21.1
Chemokine (C-C motif) ligand 24 (CCL24) 23.6 25.7 24.0 24.7 23.3 23.0 22.6 24.2
Chemokine (C-C motif) ligand 25 (CCL25) 26.7 27.6 27.3 27.5 29.9 28.9 28.9 29.2
Chemokine (C-C motif) ligand 26 (CCL26) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Chemokine (C-C motif) ligand 27a,b 
(CCL27a,b) 27.1 27.7 26.8 27.0 28.8 28.3 28.8 28.7
Chemokine (C-C motif) ligand 28 (CCL28) 30.8 31.1 31.5 34.1 33.0 34.7 32.8 33.1
Chemokine (C-C motif) ligand 3 (CCL3) 27.3 26.8 27.7 26.6 20.4 19.4 19.0 19.2
Chemokine (C-C motif) ligand 4 (CCL4) 24.9 25.9 26.0 25.0 18.1 17.0 17.3 17.1
Chemokine (C-C motif) ligand 5 (CCL5) 22.9 23.6 22.9 22.4 16.8 16.3 16.5 16.3
Chemokine (C-C motif) ligand 6 (CCL6) 16.9 17.5 17.1 17.7 18.8 18.3 17.5 18.4
Chemokine (C-C motif) ligand 7 (CCL7) 26.5 27.4 28.1 27.3 23.1 22.1 21.1 23.1
Chemokine (C-C motif) ligand 8 (CCL8) 22.1 25.6 23.4 23.6 24.9 24.2 23.8 25.8
Chemokine (C-C motif) ligand 9 (CCL9) 19.7 20.3 19.6 20.4 17.5 16.9 16.5 16.8
T-cell surface glycoprotein CD3 delta chain 
(CD3D) 33.7 38.0 38.0 38.0 38.0 38.0 33.8 34.6
Colony stimulating  factor 1 (macrophage) 
(CSF1) 23.6 22.9 24.3 23.6 22.3 21.4 21.4 21.3
Colony stimulating  factor 1 (macrophage) 
receptor (CSF1R) 17.7 17.9 17.8 17.7 19.3 18.9 19.1 18.9
Colony stimulating  factor 2 (granulocyte-
macrophage) (CSF2) 32.1 34.7 33.3 34.5 22.6 21.9 20.1 20.6
Colony stimulating  factor 3 (granulocyte) 
(CSF3) 32.4 31.8 33.3 31.9 24.2 23.2 22.8 22.9
Chemokine (CX3-C motif) ligand 1 (CX3CL1) 30.1 31.1 29.9 30.0 28.1 28.4 27.2 27.0
Chemokine (C-X-C motif) ligand 1 (CXCL1) 26.4 27.3 26.6 26.1 18.4 17.5 18.0 17.7
Chemokine (C-X-C motif) ligand 10 (CXCL10) 26.1 27.0 26.5 25.6 19.8 19.3 19.6 19.4
Chemokine (C-X-C motif) ligand 11 (CXCL11) 33.8 35.3 33.5 34.7 30.0 29.8 29.4 29.1
Chemokine (C-X-C motif) ligand 12 (CXCL12) 31.6 32.6 31.3 31.5 32.3 33.3 33.3 31.7
Chemokine (C-X-C motif) ligand 13 (CXCL13) 25.7 29.7 25.9 26.2 25.9 25.9 24.6 24.3
Chemokine (C-X-C motif) ligand 14 (CXCL14) 23.0 25.0 22.9 23.0 24.8 23.8 24.5 23.9
Chemokine (C-X-C motif) ligand 16 (CXCL16) 20.4 21.4 20.4 20.0 20.1 19.1 19.1 19.0
Chemokine (C-X-C motif) ligand 17 (CXCL17) 38.0 38.0 34.7 38.0 38.0 38.0 38.0 38.0
Chemokine (C-X-C motif) ligand 2 (CXCL2) 23.6 24.4 24.6 23.5 16.9 16.0 16.2 15.7
Chemokine (C-X-C motif) ligand 3 (CXCL3) 26.7 27.7 27.0 26.1 17.8 17.3 17.3 16.9
Chemokine (C-X-C motif) ligand 5 (CXCL5) 27.0 27.8 28.4 28.6 23.7 23.6 23.1 22.6
Chemokine (C-X-C motif) ligand 9 (CXCL9) 32.7 34.1 34.9 32.0 29.7 29.0 29.0 28.9
Chemokine (C-X-C motif) receptor 3 (CXCR3) 27.4 29.1 27.7 28.1 28.9 28.7 28.4 28.5
Epstein-Barr virus induced gene 3 (EBI3) 22.9 22.7 22.9 22.9 23.0 22.3 22.0 22.1
Epiregulin (EREG) 30.2 28.7 29.6 29.4 25.9 25.2 25.9 25.0
Fibroblast growth factor 7 (keratinocyte 
growth factor; FGF7) 32.7 32.4 31.9 32.5 33.4 33.3 34.3 34.5
G-protein receptor 84 (GPR84) 25.5 25.8 25.8 24.5 21.7 20.7 20.8 20.1
Histocompatibility 2, class II antigen E beta 
(H2.EB1) 21.6 22.1 20.7 21.0 21.5 21.2 20.9 21.5










Gene 1.0 2.0 3.0 4.0 1.0 2.0 3.0 4.0
Heparin-binding EGF-like growth factor 
(HBEGF) 27.7 27.1 27.6 27.7 27.0 26.4 25.2 26.2
Interleukin 10 (IL10) 31.9 35.7 31.8 33.7 27.4 26.5 25.4 26.2
Interleukin 11 (IL11) 34.1 34.3 33.8 33.1 34.5 32.8 34.4 34.1
Interleukin 12 alpha (IL12a) 30.7 30.6 31.3 30.2 21.7 20.9 20.7 20.4
Interleukin 12 beta (IL12b) 28.7 29.1 29.5 28.2 19.2 18.6 18.5 18.9
Interleukin 13 (IL13) 38.0 38.0 38.0 38.0 36.2 33.0 38.0 34.5
Interleukin 15 (IL15) 24.7 25.8 25.1 25.3 22.5 21.8 22.0 22.1
Interleukin 16 (IL16) 23.4 24.0 23.5 23.9 27.1 26.6 26.2 26.0
Interleukin 17 alpha (IL17a) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Interleukin 18 (IL18) 25.3 25.9 25.6 25.4 24.7 23.9 23.4 23.7
Interleukin 19 (IL19) 33.6 34.8 38.0 38.0 28.9 28.5 28.4 29.0
Interleukin 1 alpha (IL1a) 24.8 24.6 25.8 24.8 18.0 17.4 16.5 16.9
Interleukin 1 beta (IL1b) 25.7 25.8 25.1 24.6 17.0 16.3 15.6 15.6
Interleukin 2 (IL2) 38.0 38.0 38.0 38.0 38.0 38.0 33.9 35.7
Interleukin 20 (IL20) 38.0 38.0 38.0 38.0 35.0 33.0 35.9 34.7
Interleukin 21 (IL21) 32.4 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Interleukin 22 (IL22) 38.0 38.0 38.0 38.0 38.0 38.0 35.4 38.0
Interleukin 23 alpha (IL23a) 33.4 31.4 32.3 31.3 23.4 22.2 21.5 21.6
Interleukin 24 (IL24) 33.3 38.0 38.0 38.0 38.0 38.0 38.0 34.1
Interleukin 25 (IL25) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Interleukin 27 (IL27) 28.3 29.0 28.9 28.3 20.7 19.8 20.1 19.7
Interleukin 28 beta (IL28b) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Interleukin 3 (IL3) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Interleukin 31 (IL31) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Interleukin 33 (IL33) 30.6 31.1 31.6 32.2 29.4 29.5 28.5 27.9
Interleukin 34 (IL34) 38.0 35.7 35.1 34.7 38.0 35.5 38.0 34.6
Interleukin 4 (IL4) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Interleukin 5 (IL5) 33.0 38.0 34.2 34.4 38.0 38.0 34.9 38.0
Interleukin 6 (IL6) 29.5 30.0 30.4 29.1 19.9 19.4 19.0 19.0
Interleukin 7 (IL7) 29.6 29.8 29.4 29.5 28.9 28.5 28.7 28.3
Interleukin 9 (IL9) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Integrin alpha M (ITGAM; CD11B) 18.1 18.8 18.2 18.4 19.9 18.8 19.3 19.1
Nerve growth factor (NGF) 28.3 26.8 29.2 28.3 29.2 27.5 27.3 27.0
Nitric oxide synthase, inducible (NOS2) 31.0 31.7 33.0 31.2 25.7 25.1 24.2 25.3
Platelet factor 4 (PF4; CXCL4) 19.1 22.5 19.4 19.5 20.2 19.6 19.8 20.3
Pro-platelet basic protein (chemokine (C-X-C 
motif) ligand 7 28.5 30.3 27.8 28.6 28.8 28.7 28.3 29.0
Prostaglandin E synthase (PTGES) 23.8 24.1 24.9 24.5 20.9 19.9 19.6 18.7
Prostaglandin-endoperoxide synthase 2      
(COX-2; PTGS2) 29.8 27.0 29.1 28.8 19.4 19.0 18.6 18.6
 Signal Transducer and Activator of 
Transcription protein 4 (STAT4) 28.7 29.7 28.4 28.4 28.8 28.3 28.1 27.9
Toll-like receptor 4 (TLR4) 22.0 23.0 22.3 22.2 23.6 22.9 22.3 22.5
Tumor necrosis factor (TNF) 22.6 22.0 23.1 21.5 16.1 15.5 15.4 15.4
Alpha-taxilin (TXLNA) 23.0 23.8 23.3 23.2 24.9 23.9 24.1 23.9
Chemokine (C motif) ligand 1 (XCL1) 33.1 37.1 35.3 34.3 35.7 34.5 33.9 34.5
Housekeeping genes
Beta-actin (ACTB) 15.9 16.2 16.0 16.1 15.8 15.7 15.7 15.9
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) 17.6 17.8 18.1 18.0 18.7 18.2 18.6 18.4
Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) 21.5 22.8 22.0 21.7 22.7 22.3 22.7 22.8
18s (X18S) 13.2 13.5 13.1 13.3 15.8 13.0 13.1 13.1




Appendix Table 10: Raw CT values of genes screened in GPR84 KO B-GEPMs in control 




Gene 1.0 2.0 3.0 4.0 1.0 2.0 3.0 4.0
Allograft inflammatory factors -1 (Iba1; AIF) 24.5 23.3 25.0 24.9 25.1 27.1 26.8 26.1
Amphiregulin (AREG) 33.4 31.4 34.6 38.0 27.0 30.9 30.5 29.4
Artemin (ARTN) 32.9 32.3 35.0 32.9 28.1 29.5 29.0 27.7
Brain-derived neurotrophic factor (BDNF) 33.7 35.0 34.4 33.7 32.8 38.0 32.6 35.1
Betacellulin (BTC) 33.0 31.0 31.0 30.6 33.6 31.5 29.4 31.3
Chemokine (C-C motif) ligand 1 (CCL1) 38.0 38.0 38.0 34.1 38.0 38.0 38.0 35.3
Chemokine (C-C motif) ligand 11 (CCL11) 38.0 38.0 38.0 38.0 38.0 33.4 34.8 34.7
Chemokine (C-C motif) ligand 17 (CCL17) 38.0 38.0 38.0 35.1 31.9 30.2 30.1 28.1
Chemokine (C-C motif) ligand 19 (CCL19) 38.0 38.0 38.0 38.0 38.0 38.0 35.0 38.0
Chemokine (C-C motif) ligand 2 (CCL2) 24.9 25.6 26.4 25.7 22.1 22.9 22.3 22.5
Chemokine (C-C motif) ligand 20 (CCL20) 32.1 34.9 38.0 38.0 28.8 32.9 30.4 29.5
Chemokine (C-C motif) ligand 21a,b 
(CCL21a,b) 38.0 34.1 38.0 33.2 38.0 38.0 38.0 35.2
Chemokine (C-C motif) ligand 22 (CCL22) 30.0 31.7 32.4 31.8 25.4 22.5 22.1 20.2
Chemokine (C-C motif) ligand 24 (CCL24) 24.5 22.7 24.6 24.7 23.4 24.0 23.7 24.2
Chemokine (C-C motif) ligand 25 (CCL25) 27.3 26.2 27.6 27.7 28.3 29.8 29.9 29.0
Chemokine (C-C motif) ligand 26 (CCL26) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Chemokine (C-C motif) ligand 27a,b 
(CCL27a,b) 27.4 26.8 27.1 27.3 28.7 29.6 29.3 28.6
Chemokine (C-C motif) ligand 28 (CCL28) 38.0 31.6 31.8 31.8 32.9 34.0 33.1 35.3
Chemokine (C-C motif) ligand 3 (CCL3) 26.5 26.0 27.4 26.9 19.6 20.8 20.0 19.7
Chemokine (C-C motif) ligand 4 (CCL4) 25.5 24.5 26.4 26.4 16.8 19.1 18.6 18.0
Chemokine (C-C motif) ligand 5 (CCL5) 22.0 22.1 24.0 23.6 16.8 18.0 17.7 16.8
Chemokine (C-C motif) ligand 6 (CCL6) 16.6 16.5 17.5 17.3 17.8 18.8 18.8 18.4
Chemokine (C-C motif) ligand 7 (CCL7) 25.4 28.1 27.8 27.0 24.0 23.2 22.8 23.6
Chemokine (C-C motif) ligand 8 (CCL8) 23.9 21.8 23.4 23.0 23.0 25.3 24.5 24.1
Chemokine (C-C motif) ligand 9 (CCL9) 19.3 19.5 20.0 20.1 17.1 17.7 17.2 17.0
T-cell surface glycoprotein CD3 delta chain 
(CD3D) 34.3 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Colony stimulating  factor 1 (macrophage) 
(CSF1) 24.5 23.8 24.4 24.0 22.5 22.7 22.2 21.1
Colony stimulating  factor 1 (macrophage) 
receptor (CSF1R) 18.1 17.3 18.1 18.2 18.5 20.0 20.0 19.0
Colony stimulating  factor 2 (granulocyte-
macrophage) (CSF2) 31.2 33.7 38.0 38.0 24.6 22.7 21.9 21.0
Colony stimulating  factor 3 (granulocyte) 
(CSF3) 30.8 32.7 33.7 33.4 24.7 24.6 24.1 23.8
Chemokine (CX3-C motif) ligand 1 (CX3CL1) 32.8 29.9 29.9 30.0 28.9 28.9 28.0 27.0
Chemokine (C-X-C motif) ligand 1 (CXCL1) 26.6 26.5 28.1 27.8 18.3 20.7 20.0 18.0
Chemokine (C-X-C motif) ligand 10 (CXCL10) 25.3 25.2 26.8 26.2 18.8 19.8 19.6 19.0
Chemokine (C-X-C motif) ligand 11 (CXCL11) 38.0 34.5 38.0 38.0 31.0 29.6 29.6 29.0
Chemokine (C-X-C motif) ligand 12 (CXCL12) 33.8 31.5 31.1 31.0 31.6 34.0 32.8 33.3
Chemokine (C-X-C motif) ligand 13 (CXCL13) 27.0 26.3 26.6 25.6 27.3 26.8 25.8 27.1
Chemokine (C-X-C motif) ligand 14 (CXCL14) 23.9 22.5 22.9 23.4 22.8 24.8 24.9 24.3
Chemokine (C-X-C motif) ligand 16 (CXCL16) 21.4 20.0 21.3 21.0 19.2 20.8 20.2 19.3
Chemokine (C-X-C motif) ligand 17 (CXCL17) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Chemokine (C-X-C motif) ligand 2 (CXCL2) 24.5 23.2 25.0 25.4 16.1 18.3 17.8 16.6
Chemokine (C-X-C motif) ligand 3 (CXCL3) 25.5 25.8 28.0 28.3 17.4 19.5 19.2 17.6
Chemokine (C-X-C motif) ligand 5 (CXCL5) 25.5 28.5 28.5 27.0 23.7 24.8 24.4 22.7
Chemokine (C-X-C motif) ligand 9 (CXCL9) 31.8 32.0 33.6 30.8 29.5 29.9 29.1 28.4
Chemokine (C-X-C motif) receptor 3 (CXCR3) 27.6 27.3 27.8 27.7 27.8 29.7 29.7 29.1
Epstein-Barr virus induced gene 3 (EBI3) 22.7 22.4 23.8 23.7 23.1 23.9 23.6 21.8
Epiregulin (EREG) 29.9 30.0 30.6 29.8 24.3 26.7 26.5 25.1
Fibroblast growth factor 7 (keratinocyte 
growth factor; FGF7) 32.6 31.4 34.0 33.8 37.6 38.0 38.0 35.6
G-protein receptor 84 (GPR84) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Histocompatibility 2, class II antigen E beta 
(H2.EB1) 20.3 20.8 21.5 21.2 21.3 22.4 22.6 21.6









Gene 1.0 2.0 3.0 4.0 1.0 2.0 3.0 4.0
Heparin-binding EGF-like growth factor 
(HBEGF) 28.4 28.1 28.4 28.2 27.4 28.0 27.1 27.1
Interleukin 10 (IL10) 30.1 32.5 32.2 32.3 26.6 27.2 27.8 26.9
Interleukin 11 (IL11) 36.5 33.6 33.5 34.0 33.7 38.0 38.0 34.0
Interleukin 12 alpha (IL12a) 29.1 30.1 32.1 31.8 21.7 22.2 21.9 20.6
Interleukin 12 beta (IL12b) 28.8 27.5 30.2 30.1 19.0 19.9 19.7 19.0
Interleukin 13 (IL13) 38.0 38.0 38.0 38.0 34.8 38.0 38.0 38.0
Interleukin 15 (IL15) 24.7 24.5 25.9 25.6 22.5 23.0 22.9 22.2
Interleukin 16 (IL16) 23.8 22.7 23.9 23.8 27.0 27.8 27.7 26.6
Interleukin 17 alpha (IL17a) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Interleukin 18 (IL18) 25.1 24.6 25.8 25.9 24.8 25.5 24.9 23.6
Interleukin 19 (IL19) 35.0 33.6 38.0 34.8 28.4 29.4 30.4 29.5
Interleukin 1 alpha (IL1a) 24.8 24.8 25.6 25.9 18.0 18.1 17.8 17.2
Interleukin 1 beta (IL1b) 25.8 24.9 26.9 26.8 16.9 17.9 17.4 16.2
Interleukin 2 (IL2) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Interleukin 20 (IL20) 38.0 38.0 38.0 38.0 34.6 34.8 38.0 35.8
Interleukin 21 (IL21) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Interleukin 22 (IL22) 38.0 38.0 38.0 38.0 38.0 36.9 38.0 35.3
Interleukin 23 alpha (IL23a) 38.0 32.1 32.0 33.3 23.2 24.4 23.9 22.0
Interleukin 24 (IL24) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Interleukin 25 (IL25) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Interleukin 27 (IL27) 28.8 28.0 29.6 29.2 20.3 21.5 21.2 20.0
Interleukin 28 beta (IL28b) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Interleukin 3 (IL3) 38.0 38.0 38.0 38.0 37.9 38.0 38.0 38.0
Interleukin 31 (IL31) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 36.5
Interleukin 33 (IL33) 30.6 32.3 32.2 30.8 28.5 29.5 28.9 27.8
Interleukin 34 (IL34) 38.0 33.5 36.0 38.0 38.0 38.0 36.1 35.9
Interleukin 4 (IL4) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Interleukin 5 (IL5) 34.7 33.8 38.0 33.3 38.0 38.0 38.0 38.0
Interleukin 6 (IL6) 28.7 29.2 31.4 30.9 19.9 21.3 20.9 19.1
Interleukin 7 (IL7) 29.5 29.2 29.7 29.7 29.3 29.7 30.2 28.5
Interleukin 9 (IL9) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0
Integrin alpha M (ITGAM; CD11B) 18.5 17.8 18.5 19.1 18.2 20.1 20.3 19.3
Nerve growth factor (NGF) 27.8 29.2 28.9 28.7 28.6 28.8 27.9 27.0
Nitric oxide synthase, inducible (NOS2) 31.0 31.5 32.5 32.0 26.0 24.3 24.4 24.5
Platelet factor 4 (PF4; CXCL4) 19.3 18.5 19.6 19.7 19.3 21.4 21.3 20.6
Pro-platelet basic protein (chemokine (C-X-C 
motif) ligand 7 27.4 28.3 28.8 28.7 28.3 28.9 29.8 28.9
Prostaglandin E synthase (PTGES) 25.5 24.0 25.9 25.8 20.1 21.7 21.4 19.5
Prostaglandin-endoperoxide synthase 2      
(COX-2; PTGS2) 28.0 28.9 29.6 29.9 19.5 20.1 19.5 18.9
 Signal Transducer and Activator of 
Transcription protein 4 (STAT4) 28.5 28.1 29.5 29.0 28.2 28.3 28.7 28.0
Toll-like receptor 4 (TLR4) 22.2 21.8 22.7 22.6 23.3 24.2 23.7 22.9
Tumor necrosis factor (TNF) 23.4 21.9 23.3 23.5 15.3 16.2 15.9 15.5
Alpha-taxilin (TXLNA) 23.3 22.3 23.5 23.7 24.0 25.5 25.1 24.3
Chemokine (C motif) ligand 1 (XCL1) 37.1 33.7 37.2 34.0 35.3 36.9 35.1 34.3
Housekeeping genes
Beta-actin (ACTB) 16.1 15.5 16.2 16.3 15.8 16.5 16.4 16.0
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) 17.5 17.2 18.2 18.3 18.1 19.1 19.2 18.8
Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) 22.3 20.8 22.5 22.3 22.0 24.5 24.2 23.5
18s (X18S) 13.1 13.4 13.1 13.0 13.2 13.7 13.4 13.1




Appendix Table 11: FC values of genes profiled in the sciatic nerve and spinal cord at 






7 days post 
PNL
21 days post 
PNL 
7 days post 
PNL
21 days post 
PNL 
3 hours post 
LPS
Allograft inflammatory factors -1 (Iba1; AIF) 4.3** 1.2 1.1 1.2 1.0
Amphiregulin (AREG) 12.2 ND ND -1.1 64.0*
Arginase-1 (ARG-1) 5.7 X -1.2 X X
Artemin (ARTN) 4.5* -1.3 1.1 -1.2 38.5**
Brain-derived neurotrophic factor (BDNF) 7.9* 8.3 1.1 -1.1 -2.5
Betacellulin (BTC) 4.1* 2.8 -1.1 1.3 1.1
Chemokine (C-C motif) ligand 1 (CCL1) -1.3 ND ND ND ND
Chemokine (C-C motif) ligand 11 (CCL11) -3.0* -2.4 1.0 1.0 4.3
Chemokine (C-C motif) ligand 17 (CCL17) -3.0 1.5 -1.4 -1.1 224.2**
Chemokine (C-C motif) ligand 19 (CCL19) -2.1* -2.3 -1.6 -1.5 71.0***
Chemokine (C-C motif) ligand 2 (CCL2) 1.9 1.6 4.2 5.4 27.2***
Chemokine (C-C motif) ligand 20 (CCL20) ND ND ND ND 28.7
Chemokine (C-C motif) ligand 21a,b 
(CCL21a,b) -2.9* -4.5 1.0 -1.5 1.4
Chemokine (C-C motif) ligand 22 (CCL22) 3.8* 3.1 -1.2 1.4 2360.1***
Chemokine (C-C motif) ligand 24 (CCL24) -3.6* -4.2 -1.3 2.5 3.0*
Chemokine (C-C motif) ligand 25 (CCL25) -1.8* -3.5 1.0 -1.3 -3.0***
Chemokine (C-C motif) ligand 26 (CCL26) X ND X ND ND
Chemokine (C-C motif) ligand 27a,b 
(CCL27a,b) -3.0** -2.6 -1.1 -1.2 -2.1**
Chemokine (C-C motif) ligand 28 (CCL28) X -3.2 X -1.1 -2.2
Chemokine (C-C motif) ligand 3 (CCL3) 10.2** 17.8 -1.2 1.5 249.5***
Chemokine (C-C motif) ligand 4 (CCL4) 8.3** 8.0 -1.2 1.6 341.3***
Chemokine (C-C motif) ligand 5 (CCL5) 5.8* 2.8 1.0 -1.2 114.4***
Chemokine (C-C motif) ligand 6 (CCL6) 2.4 1.0 1.0 -1.0 -1.5
Chemokine (C-C motif) ligand 7 (CCL7) 1.6 -2.2 15.8* 1.6 41.4***
Chemokine (C-C motif) ligand 8 (CCL8) 7.6 3.3 1.2 2.4 -1.5
Chemokine (C-C motif) ligand 9 (CCL9) 1.8 -1.7 1.3 -1.1 10.7***
T-cell surface glycoprotein CD3 delta chain 
(CD3D) 2.5 2.6 -2.3 -1.6 ND
Colony stimulating  factor 1 (macrophage) 
(CSF1) -1.7* -1.5 1.0 1.1 5.1**
Colony stimulating  factor 1 (macrophage) 
receptor (CSF1R) X -1.2 X 1.0 -1.9**
Colony stimulating  factor 2 (granulocyte-
macrophage) (CSF2) -1.4 -1.8 ND ND 6884.0***
Colony stimulating  factor 3 (granulocyte) 
(CSF3) 4.4 ND ND ND 689.8***
Colony stimulating  factor 3 (granulocyte) 
receptor (CSF3R) 6.9* X 1.1 X X
Chemokine (CX3-C motif) ligand 1 (CX3CL1) 1.4 -1.6 -1.1 -1.1 7.8**
Chemokine (C-X-C motif) ligand 1 (CXCL1) -1.7 2.2 -1.9 1.5 517.8***
Chemokine (C-X-C motif) ligand 10 (CXCL10) 1.8 1.3 1.7 2.7 140.6***
Chemokine (C-X-C motif) ligand 11 (CXCL11) -7.4* -3.7 -1.2 -1.4 35.1***
Chemokine (C-X-C motif) ligand 12 (CXCL12) 2.5 -1.6 -1.1 1.4 -1.5
Chemokine (C-X-C motif) ligand 13 (CXCL13) -11.7** -9.9 2.7 2.9 4.2
Chemokine (C-X-C motif) ligand 14 (CXCL14) 1.3 1.2 -1.2 1.0 -1.4
Chemokine (C-X-C motif) ligand 16 (CXCL16) 5.5** 2.6 -1.3 1.0 3.0
Chemokine (C-X-C motif) ligand 17 (CXCL17) -6.2 -2.1 -1.4 4.2 ND
Chemokine (C-X-C motif) ligand 2 (CXCL2) 20.0** 3.5 -1.4 1.4 289.9***









7 days post 
PNL
21 days post 
PNL 
7 days post 
PNL
21 days post 
PNL 
3 hours post 
LPS
Chemokine (C-X-C motif) ligand 3 (CXCL3) 226.2** 18.1 2.0 ND 959.8***
Chemokine (C-X-C motif) ligand 5 (CXCL5) 445.9** 21.2 -1.4 1.3 33.7***
Chemokine (C-X-C motif) ligand 9 (CXCL9) 3.5* 1.3 6.0 1.5 25.4**
Chemokine (C-X-C motif) receptor 3 (CXCR3) 1.7 2.3 -1.5 3.5 -1.1
Epstein-Barr virus induced gene 3 (EBI3) 1.5 1.2 -1.1 1.0 1.8
Epiregulin (EREG) 55.3* 2.9 ND ND 19.7**
Fibroblast growth factor 7 (keratinocyte 
growth factor; FGF7) -3.5** -4.5 1.1 -1.3 -2.2
G-protein receptor 84 (GPR84) 51.3** 3.6 2.6 1.1 30.8***
Histocompatibility 2, class II antigen E beta 
(H2.EB1) X -1.6 X -1.2 1.4
Heparin-binding EGF-like growth factor 
(HBEGF) -3.3** -3.2* -1.1 1.0 3.2*
Interleukin 10 (IL10) 3.0 -3.4 2.1 1.5 153.2**
Interleukin 11 (IL11) 1.1 -4.0 -1.7 -1.2 1.2
Interleukin 12 alpha (IL12a) -3.0* -3.7 -1.2 -1.2 1121.8***
Interleukin 12 beta (IL12b) 7.1 ND -1.4 2.0 1399.8***
Interleukin 13 (IL13) -2.1 ND -2.7 ND 7.7
Interleukin 15 (IL15) -1.6* -1.3 -1.3 1.3 11.1***
Interleukin 16 (IL16) -4.1** -2.8 -1.1 -1.1 -5.4***
Interleukin 17 alpha (IL17a) ND ND ND ND ND
Interleukin 18 (IL18) -1.3 -3.2 -1.2 1.1 4.0**
Interleukin 19 (IL19) ND ND -1.4 1.4 219.6*
Interleukin 1 alpha (IL1a) 103.3** 11.5 2.0 2.1 288.4***
Interleukin 1 beta (IL1b) 24.9* 42.8 1.9 -1.8 749.5***
Interleukin 2 (IL2) ND ND ND ND ND
Interleukin 20 (IL20) ND ND -2.1 ND 13.1*
Interleukin 21 (IL21) -1.6 ND -1.8 -1.1 ND
Interleukin 22 (IL22) ND ND ND -1.1 ND
Interleukin 23 alpha (IL23a) -3.0* -6.0 -1.1 1.3 1227.4***
Interleukin 24 (IL24) ND ND 9.0 ND ND
Interleukin 25 (IL25) -5.7 -1.7 1.5 1.6 ND
Interleukin 27 (IL27) 3.2 16.4 1.9 1.0 475.3***
Interleukin 28 beta (IL28b) ND ND ND ND ND
Interleukin 3 (IL3) ND ND ND ND ND
Interleukin 31 (IL31) ND ND ND ND ND
Interleukin 33 (IL33) 2.3** -4.7 -1.1 1.0 7.5**
Interleukin 34 (IL34) 4.5* -3.6 -1.6 -1.5 -1.2
Interleukin 4 (IL4) ND ND ND ND ND
Interleukin 5 (IL5) -1.5 -8.7 -1.1 -2.1 -3.9
Interleukin 6 (IL6) 1.8 -1.4 1.5 -1.1 1785.4***
Interleukin 7 (IL7) -1.5 -2.1 1.1 1.3 2.6**
Interleukin 9 (IL9) ND ND ND ND ND
Integrin alpha M (ITGAM; CD11B) 4.6* 2.0 1.6 1.0 -1.4
Mannose receptor, C type 1 (MRC1) 1.5 X -1.2 X X
Nerve growth factor (NGF) 1.0 -1.8 1.0 -1.1 1.7
Nitric oxide synthase, inducible (NOS2) 3.8** 4.3 -1.2 1.2 130.0***
Neuregulin 1 (NRG1) 1.1 X -1.2 X X
Platelet factor 4 (PF4; CXCL4) 2.7* -1.5 1.1 1.4 1.4
Pro-platelet basic protein (chemokine (C-X-C 
motif) ligand 7 -1.9 -2.6 1.4 2.6 1.4
Prostaglandin E synthase (PTGES) 1.6 -2.6 -1.2 1.0 30.1***
Prostaglandin-endoperoxide synthase 2 (COX-
2; PTGS2) 1.8 -1.5 -1.1 1.4 1120.5**
 Signal Transducer and Activator of 
Transcription protein 4 (STAT4) 1.2 -9.4 -1.1 -2.2 1.8
Toll-like receptor 4 (TLR4) -1.0 -2.0 -1.0 1.1 -1.1
Table 11
WT





























7 days post 
PNL
21 days post 
PNL 
7 days post 
PNL
21 days post 
PNL 
3 hours post 
LPS
Tumor necrosis factor (TNF) 6.8** 2.6 2.2 -1.1 134.6***
Alpha-taxilin (TXLNA) 1.0 -1.1 1.0 1.1 -1.4**
Chemokine (C motif) ligand 1 (XCL1) 4.7 17.2 1.3 -1.2 1.5
Table 11
WT




Appendix Table 12: FC values of genes profiled in the sciatic nerve and spinal cord at 






7 days post 
PNL
21 days post 
PNL 
7 days post 
PNL
21 days post 
PNL 
3 hours post 
LPS
Allograft inflammatory factors -1 (Iba1; AIF) 9.2** 2.3 1.5* 1.1 -2.2*
Amphiregulin (AREG) ND ND -1.6 2.6 49.0*
Arginase-1 (ARG-1) 20.7** X 1.1 X X
Artemin (ARTN) 2.4 1.4 -1.1 -1.3 43.2***
Brain-derived neurotrophic factor (BDNF) 7.0** 23.0 -1.2 1.0 1.2
Betacellulin (BTC) 2.0 5.0* 1.3 1.0 1.6
Chemokine (C-C motif) ligand 1 (CCL1) 8.0 ND ND ND ND
Chemokine (C-C motif) ligand 11 (CCL11) -4.1 -2.5 -1.8 -1.3 11.3
Chemokine (C-C motif) ligand 17 (CCL17) 1.8 -1.1 1.4 -1.1 243.7**
Chemokine (C-C motif) ligand 19 (CCL19) -2.0 -1.5 -1.5 1.1 ND
Chemokine (C-C motif) ligand 2 (CCL2) 4.9* 1.7 5.4* 4.0 15.6***
Chemokine (C-C motif) ligand 20 (CCL20) ND ND ND ND 66.6*
Chemokine (C-C motif) ligand 21a,b 
(CCL21a,b) -1.9 -1.9 1.9 1.3 ND
Chemokine (C-C motif) ligand 22 (CCL22) 3.9 1.8 -1.4 -1.4 798.4**
Chemokine (C-C motif) ligand 24 (CCL24) -2.2* -1.7 -1.1 1.0 2.1
Chemokine (C-C motif) ligand 25 (CCL25) -1.8 -1.6 -1.2 1.0 -2.5**
Chemokine (C-C motif) ligand 26 (CCL26) X ND X ND ND
Chemokine (C-C motif) ligand 27a,b 
(CCL27a,b) -3.3* -2.1** -1.0 1.1 -2.3**
Chemokine (C-C motif) ligand 28 (CCL28) X -6.4 X 1.1 1.2
Chemokine (C-C motif) ligand 3 (CCL3) 25.7*** 4.0 -1.2 1.2 165.1***
Chemokine (C-C motif) ligand 4 (CCL4) 32.0** 3.3 1.2 1.5 307.5***
Chemokine (C-C motif) ligand 5 (CCL5) 6.5* 3.2 2.3 1.7 82.2**
Chemokine (C-C motif) ligand 6 (CCL6) 3.8* 2.2 1.2 1.2 -1.6*
Chemokine (C-C motif) ligand 7 (CCL7) 7.6* -2.4 21.5* 7.5 21.3**
Chemokine (C-C motif) ligand 8 (CCL8) 21.0* 13.4 3.8 3.7 -1.4
Chemokine (C-C motif) ligand 9 (CCL9) 4.2* 1.4 -1.1 1.2 9.3***
T-cell surface glycoprotein CD3 delta chain 
(CD3D) 5.9* -2.5 3.9 1.7 ND
Colony stimulating  factor 1 (macrophage) 
(CSF1) -1.9* -1.4 1.1 1.1 6.9**
Colony stimulating  factor 1 (macrophage) 
receptor (CSF1R) X 1.6 X 1.4 -1.6**
Colony stimulating  factor 2 (granulocyte-
macrophage) (CSF2) 3.5 -1.1 ND ND 11030**
Colony stimulating  factor 3 (granulocyte) 
(CSF3) 5.7 ND 1.2 ND 531.1***
Colony stimulating  factor 3 (granulocyte) 
receptor (CSF3R) 13.6*** X 1.6 X X
Chemokine (CX3-C motif) ligand 1 (CX3CL1) -1.1 1.3 1.0 1.1 9.0*
Chemokine (C-X-C motif) ligand 1 (CXCL1) 1.9 1.0 -1.8 1.1 428.9***
Chemokine (C-X-C motif) ligand 10 (CXCL10) 5.5* 1.3 2.0 2.2 158.4***
Chemokine (C-X-C motif) ligand 11 (CXCL11) -9.6* -11.1 -1.7 1.2 268.9***
Chemokine (C-X-C motif) ligand 12 (CXCL12) 1.5 1.0 -1.1 -1.2 -1.3
Chemokine (C-X-C motif) ligand 13 (CXCL13) -20.1* -5.5 3.1 4.7 1.3
Chemokine (C-X-C motif) ligand 14 (CXCL14) 1.9 3.2 -1.2 1.1 -1.2
Chemokine (C-X-C motif) ligand 16 (CXCL16) 7.3** 2.6 1.0 1.0 3.5**
Chemokine (C-X-C motif) ligand 17 (CXCL17) -1.9 12.1 1.7 2.2 ND
Chemokine (C-X-C motif) ligand 2 (CXCL2) 55.9** 4.3 -2.0 -1.2 261.1***
Table 12
KO








7 days post 
PNL
21 days post 
PNL 
7 days post 
PNL
21 days post 
PNL 
3 hours post 
LPS
Chemokine (C-X-C motif) ligand 3 (CXCL3) 184.4** 12.4 ND 1.2 597.2***
Chemokine (C-X-C motif) ligand 5 (CXCL5) 882.3** 31.2 -1.5 1.2 18.5*
Chemokine (C-X-C motif) ligand 9 (CXCL9) 9.8* 2.9 4.5 2.5 11.8**
Chemokine (C-X-C motif) receptor 3 (CXCR3) 3.1* 2.7 7.0 1.2 -1.7
Epstein-Barr virus induced gene 3 (EBI3) 1.1 -1.2 1.4 1.7 1.7
Epiregulin (EREG) 30.5* ND ND ND 35.6***
Fibroblast growth factor 7 (keratinocyte 
growth factor; FGF7) -3.8* -2.4 -1.5 -1.5 -12.1**
G-protein receptor 84 (GPR84) ND ND ND ND ND
Histocompatibility 2, class II antigen E beta 
(H2.EB1) X 1.1 X -1.3 -1.2
Heparin-binding EGF-like growth factor 
(HBEGF) -5.7* -3.1** 1.1 1.0 3.1*
Interleukin 10 (IL10) 5.2 ND 2.2 ND 42.2**
Interleukin 11 (IL11) -1.7* -3.9 -1.1 -2.1 -1.7
Interleukin 12 alpha (IL12a) -3.0 -3.9 -1.5 -1.2 959.5***
Interleukin 12 beta (IL12b) 26.2* 4.7 1.0 -3.1 1385.0***
Interleukin 13 (IL13) ND ND ND ND ND
Interleukin 15 (IL15) -1.4 1.0 1.1 1.0 9.5***
Interleukin 16 (IL16) -6.3* -3.7 -1.5 1.0 -8.0***
Interleukin 17 alpha (IL17a) ND ND ND ND ND
Interleukin 18 (IL18) 1.5 -2.1 -1.1 1.1 2.6
Interleukin 19 (IL19) ND ND -3.1 2.2 100.0**
Interleukin 1 alpha (IL1a) 91.0** 17.3 2.1 1.5 302.5***
Interleukin 1 beta (IL1b) 79.9*** 3.2 1.8 1.4 823.4***
Interleukin 2 (IL2) 1.0 ND ND ND ND
Interleukin 20 (IL20) ND ND ND ND 7.6*
Interleukin 21 (IL21) ND ND -1.2 -1.2 ND
Interleukin 22 (IL22) ND ND ND ND ND
Interleukin 23 alpha (IL23a) -7.3 -14.3 -1.5 -2.3 2374.0**
Interleukin 24 (IL24) ND ND 5.7 ND ND
Interleukin 25 (IL25) -3.7 -2.4 1.1 1.1 ND
Interleukin 27 (IL27) 6.8 2.2 -1.8 1.1 470.0***
Interleukin 28 beta (IL28b) ND ND ND ND ND
Interleukin 3 (IL3) ND ND ND ND ND
Interleukin 31 (IL31) ND 1.4 ND ND ND
Interleukin 33 (IL33) -2.8 -3.7 1.0 1.2 11.5**
Interleukin 34 (IL34) -8.7 -1.1 -1.1 -1.2 ND
Interleukin 4 (IL4) ND ND ND ND ND
Interleukin 5 (IL5) -16.2*** 1.3 1.0 2.1 -5.0
Interleukin 6 (IL6) 14.3* -4.4 2.4 1.2 1438.0***
Interleukin 7 (IL7) -1.6 1.2 1.1 1.2 1.8
Interleukin 9 (IL9) ND ND ND ND ND
Integrin alpha M (ITGAM; CD11B) 6.4** 3.2 1.8* 1.6 -1.2
Mannose receptor, C type 1 (MRC1) 2.2 X -1.2 X X
Nerve growth factor (NGF) 1.1 -1.4 1.3 1.3 2.5
Nitric oxide synthase, inducible (NOS2) 5.3* 2.2 1.3 -1.1 204.2**
Neuregulin 1 (NRG1) 1.3 X 1.0 X X
Platelet factor 4 (PF4; CXCL4) 3.7 1.1 1.0 1.6 -1.5
Pro-platelet basic protein (chemokine (C-X-C 
motif) ligand 7 1.4 -7.1 1.0 2.5 1.0
Prostaglandin E synthase (PTGES) -2.2 -2.5 -1.1 -1.4 41.1***
Prostaglandin-endoperoxide synthase 2 (COX-
2; PTGS2) 2.2 -3.7 1.4 1.2 1292.0***
 Signal Transducer and Activator of 
Transcription protein 4 (STAT4) 1.9 -3.4 1.6 1.9 2.3*
Toll-like receptor 4 (TLR4) 1.5 1.4 1.2 1.0 -1.4
Table 12
KO













7 days post 
PNL
21 days post 
PNL 
7 days post 
PNL
21 days post 
PNL 
3 hours post 
LPS
Tumor necrosis factor (TNF) 18.3** 3.0 4.1 1.4 266.6***
Alpha-taxilin (TXLNA) -1.6* -1.2 -1.1 1.0 -1.7*
Chemokine (C motif) ligand 1 (XCL1) 19.8* 2.5 1.1 -1.1 1.8
Table 12
KO
Sciatic nerve Spinal cord
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